



US009102692B2

(12) **United States Patent**
Taka et al.

(10) **Patent No.:** US 9,102,692 B2
(45) **Date of Patent:** Aug. 11, 2015

(54) **AMINOPYRAZOLE DERIVATIVE**

(71) Applicants: **Chugai Seiyaku Kabushiki Kaisha**,
Tokyo (JP); **F. Hoffmann-La Roche AG**,
Basel (CH)

(72) Inventors: **Naoki Taka**, Shizuoka (JP); **Masayuki Ohmori**, Shizuoka (JP); **Kyoko Takami**, Shizuoka (JP); **Masayuki Matsushita**, Kanagawa (JP); **Tadakatsu Hayase**, Kanagawa (JP); **Ikumi Hyodo**, Kanagawa (JP); **Masami Kochi**, Kanagawa (JP); **Hiroki Nishii**, Kanagawa (JP); **Hirosato Ebiki**, Kanagawa (JP); **Yoshito Nakanishi**, Kanagawa (JP); **Toshiyuki Mio**, Kanagawa (JP); **Lisha Wang**, Shanghai (CN); **Weili Zhao**, Shanghai (CN)

(73) Assignees: **Chugai Seiyaku Kabushiki Kaisha**,
Tokyo (JP); **F. Hoffmann-La Roche AG**,
Basel (CH)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: 14/297,790

(22) Filed: Jun. 6, 2014

(65) **Prior Publication Data**

US 2014/0315856 A1 Oct. 23, 2014

Related U.S. Application Data

(62) Division of application No. 13/389,146, filed as application No. PCT/JP2010/063315 on Aug. 5, 2010.

(30) **Foreign Application Priority Data**

Aug. 7, 2009 (JP) 2009-184822

(51) **Int. Cl.**

A61K 31/4184 (2006.01)
C07F 7/08 (2006.01)
A61K 31/437 (2006.01)
A61K 31/4439 (2006.01)
A61K 31/444 (2006.01)
A61K 31/454 (2006.01)

(Continued)

(52) **U.S. Cl.**

CPC C07F 7/0809 (2013.01); A61K 31/4184 (2013.01); A61K 31/437 (2013.01); A61K 31/444 (2013.01); A61K 31/4439 (2013.01); A61K 31/454 (2013.01); A61K 31/4709 (2013.01); A61K 31/496 (2013.01); A61K 31/501 (2013.01); A61K 31/5377 (2013.01); C07D 401/14 (2013.01); C07D 403/14 (2013.01); C07D 405/14 (2013.01); C07D 409/14 (2013.01); C07D 413/14 (2013.01); C07D 471/04 (2013.01); C07D 491/056 (2013.01)

(58) **Field of Classification Search**

USPC 514/394
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

6,316,466 B1	11/2001	Goldstein et al.
8,829,199 B2	9/2014	Taka et al.

(Continued)

FOREIGN PATENT DOCUMENTS

CN	102099335	6/2011
FR	2831537	5/2003

(Continued)

OTHER PUBLICATIONS

Byron et al., "Inhibition of activated fibroblast growth factor receptor 2 in endometrial cancer cells induces cell death despite PTEN abrogation," *Cancer Res.*, 68(17):6902-7 (2008).

(Continued)


Primary Examiner — Laura L. Stockton

(74) *Attorney, Agent, or Firm* — Fish & Richardson P.C.

(57) **ABSTRACT**

A method for treating cancer that includes administering a pharmaceutically effective amount of a composition containing a compound represented by formula (I) or a pharmaceutically acceptable salt thereof. In the formula, A represents a 5- to 10-membered heteroaryl group, or a C₆₋₁₀ aryl group; R₁ and R₂ independently represent H, OH, X, CN, NO₂, a C₁₋₄ haloalkyl group, a C₁₋₆ alkyl group, or the like <R₁ and R₂ together form a (substituted) 3- to 10-membered heterocycl group or a (substituted) 5- to 10-membered heteroaryl group>; R₃ represents H, a C₁₋₅ alkyl group, a C₆₋₁₀ aryl group, a C₁₋₅ alkyl group, or a C₁₋₄ haloalkyl group; and R₄ represents H, X, a C₁₋₃ alkyl group, a C₁₋₄ haloalkyl group, OH, CN, NO₂, or the like.

(I)



- (51) **Int. Cl.**
- | | |
|---------------------|-----------|
| <i>A61K 31/4709</i> | (2006.01) |
| <i>A61K 31/496</i> | (2006.01) |
| <i>A61K 31/501</i> | (2006.01) |
| <i>A61K 31/5377</i> | (2006.01) |
| <i>C07D 401/14</i> | (2006.01) |
| <i>C07D 403/14</i> | (2006.01) |
| <i>C07D 405/14</i> | (2006.01) |
| <i>C07D 409/14</i> | (2006.01) |
| <i>C07D 471/04</i> | (2006.01) |
| <i>C07D 491/056</i> | (2006.01) |
| <i>C07D 413/14</i> | (2006.01) |
- (56) **References Cited**
- U.S. PATENT DOCUMENTS
- | | | |
|-----------------|--------|-----------------|
| 2005/0049288 A1 | 3/2005 | Fryszman et al. |
| 2009/0197866 A1 | 8/2009 | Cherrier et al. |
| 2012/0208811 A1 | 8/2012 | Taka et al. |
- FOREIGN PATENT DOCUMENTS
- | | |
|-------------------|---------|
| JP 2002-513784 | 5/2002 |
| JP 2003-50945 | 3/2003 |
| JP 2007-521278 | 8/2007 |
| JP 2011-528686 | 11/2011 |
| WO WO 94/13643 | 6/1994 |
| WO WO 99/57101 | 11/1999 |
| WO WO 01/12600 | 2/2001 |
| WO WO 01/21591 | 3/2001 |
| WO WO 03/035065 | 5/2003 |
| WO WO 2004/096792 | 11/2004 |
| WO WO 2005/009973 | 2/2005 |
| WO WO 2006/134318 | 12/2006 |
| WO WO 2007/077435 | 7/2007 |
| WO WO 2010/010017 | 1/2010 |
- OTHER PUBLICATIONS
- Cappellen et al., "Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas," *Nat. Genet.*, 23(1):18-20 (1999).
- Cheng et al., "Novel agents for the treatment of pancreatic adenocarcinoma. Highlights from the "2011 ASCO Annual Meeting," Chicago, IL, USA; Jun. 3-7, 2011," *JOP*, 12(4):334-338.
- Elbauomy Elsheikh et al., "FGFR1 amplification in breast carcinomas: a chromogenic *in situ* hybridisation analysis," *Breast Cancer Res.*, 9(2):R23 (2007).
- Eswarakumar et al., "Cellular signaling by fibroblast growth factor receptors," *Cytokine Growth Factor Rev.*, 16(2):139-49 (2005).
- Fonseca et al., "Clinical and biologic implications of recurrent genomic aberrations in myeloma," *Blood*, 101(11):4569-75 (2003).
- Golub et al., "Molecular classification of cancer: class discovery and class prediction by gene expression monitoring," *Science*, 286:531-537 (1999).
- Heiskanen et al., "CGH, cDNA and tissue microarray analyses implicate FGFR2 amplification in a small subset of breast tumors," *Anal. Cell Pathol.*, 22(4):229-34 (2001).
- MacDonald et al., "The 8p11 myeloproliferative syndrome: a distinct clinical entity caused by constitutive activation of FGFR1," *Acta Haematol.*, 107(2):101-7 (2002).
- Peng et al., "Alterations of chromosomal copy number during progression of diffuse-type gastric carcinomas: metaphase- and array-based comparative genomic hybridization analyses of multiple samples from individual," *J. Pathol.*, 201(3):439-50 (2003).
- Rand et al., "Sequence survey of receptor tyrosine kinases reveals mutations in glioblastomas," *Proc. Natl. Acad. Sci. USA*, 102(40):14344-9 (2005).
- Wang et al., "Antisense targeting of basic fibroblast growth factor and fibroblast growth factor receptor-1 in human melanomas blocks intratumoral angiogenesis and tumor growth," *Nat. Med.*, 3(8):887-93 (1997).
- Zhao et al., "Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis," *Cancer Res.*, 65(13):5561-70 (2005).
- International Search Report for App. Ser. No. PCT/JP2010/063315, mailed Sep. 7, 2010, 8 pages.
- International Preliminary Report on Patentability for App. Ser. No. PCT/JP2010/063315, dated Mar. 13, 2012, 9 pages.
- Supplementary European Search Report for App. Ser. No. EP 10 80 6527, dated Feb. 15, 2013, 3 pages.
- Search Report and Written Opinion issued in corresponding Singapore App. Ser. No. 201200851-2, dated Apr. 17, 2013, 19 pages.

1

AMINOPYRAZOLE DERIVATIVE**CROSS-REFERENCE TO RELATED APPLICATIONS**

This application is a divisional of U.S. application Ser. No. 13/389,146, filed on Feb. 6, 2012, which is the National Stage of International Application Serial No. PCT/JP2010/063315, filed on Aug. 5, 2010, which claims the benefit of Japanese Application Serial No. 2009-184822, filed on Aug. 7, 2009. The contents of all foregoing applications are hereby incorporated by reference in their entireties.

TECHNICAL FIELD

The present invention relates to aminopyrazole derivatives and uses thereof.

BACKGROUND ART

Most of currently promising molecular-targeted drugs against cancer are receptor tyrosine kinase inhibitors such as erlotinib and lapatinib. Many of them are highly effective against cancers with mutation, amplification, or overexpression of target genes. However, such molecular-targeted agents cannot exert efficacy against cancers in which genes that are not their targets are altered. Thus, there is still no established therapeutic method that is effective against such cancers. Inhibitors against novel genes altered in cancer are expected to make a great contribution to treatment of cancer patients on whom conventional drugs have no effect.

Fibroblast growth factor receptors (FGFRs) are kinases belonging to the receptor tyrosine kinase family. FGFR1, FGFR2, FGFR3, and FGFR4 constitute the FGFR family. The ligand is fibroblast growth factor (FGF), and 22 types of structurally similar proteins form a family. It is known that each FGFR is activated upon overexpression, gene amplification, mutation, or translocation, and serves as a cause of cancer. The FGFR signal follows the MAPK pathway or PI3K/AKT pathway. In cancer, the signal is known to be involved in cell growth, angiogenesis, cell migration, invasion, metastasis, and such (Non-patent Document 1).

The FGFR1 gene is known to be amplified in breast cancer and non-small cell lung cancer (Non-patent Documents 2 and 3); mutated in glioblastoma (Non-patent Document 4); translocated to generate a fusion protein in acute myelocytic leukemia (Non-patent Document 5); and overexpressed in pancreatic cancer, bladder cancer, prostatic cancer, and esophageal cancer. Furthermore, FGFR1 is known to be expressed in neovessels and greatly contribute to angiogenesis (Non-patent Document 6). The FGFR2 gene is known to be amplified in stomach cancer and breast cancer (Non-patent Documents 7 and 8); mutated in endometrial cancer (Non-patent Document 9); and overexpressed in prostatic cancer, esophageal cancer, ovarian cancer, pancreatic cancer, brain tumor, and colon cancer. The FGFR3 gene is known to be translocated in multiple myeloma (Non-patent Document 10); mutated in bladder cancer (Non-patent Document 11); and overexpressed in ovarian cancer, non-small cell lung cancer, and hepatocellular carcinoma. Finally, FGFR4 is known to be mutated in lung cancer, ovarian cancer, prostatic cancer, etc.; and overexpressed in thyroid cancer, ovarian cancer, etc.

As described above, all FGFR family kinases have been strongly suggested to be involved in cancer. Thus, the inhibi-

2

tion of the FGFR family kinases in cancer tissues may be a promising therapeutic method for treating the above types of cancer.

PRIOR ART DOCUMENTS

- [Non-patent Document 1] Cytokine & Growth Factor Reviews 16 (2005) 139-149
- [Non-patent Document 2] Breast Cancer Research 2007, 9:R23
- [Non-patent Document 3] Cancer Res 2005; 65(13): 5561-70
- [Non-patent Document 4] PNAS (2005), 102(40), 14344-14349.
- [Non-patent Document 5] Acta Haematol 2002; 107:101-107
- [Non-patent Document 6] Nature Medicine 3, 887-89, 1997
- [Non-patent Document 7] J Pathol. 2003 November; 201(3): 439-50
- [Non-patent Document 8] Anal Cell Pathol. 2001; 22(4):229-34
- [Non-patent Document 9] Cancer Res 2008; 68(17):6902-7
- [Non-patent Document 10] Blood. 2003; 101: 4569-4575
- [Non-patent Document 11] Nat Genet. 1999 September; 23(1):18-20.


SUMMARY OF THE INVENTION**Problems to be Solved by the Invention**

An objective of the present invention is to provide low molecular weight compounds capable of inhibiting fibroblast growth factor receptor (FGFR) family kinases in cancer tissues.

Means for Solving the Problems

Specifically, the present invention includes the following:

[1] A compound represented by following general formula (I), or a pharmaceutically acceptable salt thereof:



wherein R₁, R₂, R₃, and R₄ each independently represents the group listed below:

R₁ represents hydrogen, hydroxy, halogen, cyano, nitro, C₁₋₄ haloalkyl, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, C₆₋₁₀ aryl, C₁₋₄ alkyl, —OR₅, —NR₆R₇, —(CR₈R₉)_nZ₁, —C(O)NR₁₂R₁₃, —SR₁₄, —SOR₁₅, —SO₂R₁₆, —NR₁₇SO₂R₁₈, COOH, C₆₋₁₀ aryl which is optionally substituted by one or more groups independently selected from group P, 5- to 10-membered heteroaryl or 3- to 10-membered heterocycl which is optionally substituted by one or more groups independently selected from group Q, —COR₁₉, —COOR₂₀, —OC(O)R₂₁, —NR₂₂C(O)R₂₃, —NR₂₄C(S)R₂₅, —C(S)NR₂₆R₂₇, —SO₂NR₂₈R₂₉, —OSO₂R₃₀, —SO₃R₃₁, or —Si(R₃₂)₃;

R₂ represents hydrogen, hydroxy, halogen, cyano, nitro, C₁₋₄ haloalkyl, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, C₆₋₁₀ aryl C₁₋₄ alkyl, —OR₅, —NR₆R₇, —(CR₈R₉)_nZ₁, —C(O)NR₁₂R₁₃, —SR₁₄, —SOR₁₅, —SO₂R₁₆, —NR₁₇SO₂R₁₈, COOH, C₆₋₁₀ aryl which is optionally substituted by one or more groups independently selected from group P, 5- to 10-membered heteroaryl or 3- to 10-membered heterocycl which is optionally substituted by one or more groups independently selected from group Q, —COR₁₉, —COOR₂₀, —OC(O)R₂₁, —NR₂₂C(O)R₂₃, —NR₂₄C(S)R₂₅, —C(S)NR₂₆R₂₇, —SO₂NR₂₈R₂₉, —OSO₂R₃₀, —SO₃R₃₁, or —Si(R₃₂)₃; or R₁ and R₂, together with an atom linked thereto, form 3- to 10-membered heterocycl or 5- to 10-membered heteroaryl, wherein the heterocycl or heteroaryl is optionally substituted by halogen;

R₃ represents hydrogen, C₁₋₅ alkyl, C₆₋₁₀ aryl C₁₋₆ alkyl, or C₁₋₄ haloalkyl;

R₄ represents hydrogen, halogen, C₁₋₃ alkyl, C₁₋₄ haloalkyl, hydroxy, cyano, nitro, C₁₋₄ alkoxy, —(CH₂)_nZ₁, —NR₆R₇, —OR₅, —C(O)NR₁₂R₁₃, —SR₁₄, —SOR₁₅, —SO₂R₁₆, NR₁₇SO₂R₁₈, COOH, —COR₁₉, —COOR₂₀, —OC(O)R₂₁, —NR₂₂C(O)R₂₃, —NR₂₄C(S)R₂₅, —C(S)NR₂₆R₂₇, —SO₂NR₂₈R₂₉, —OSO₂R₃₀, —SO₃R₃₁, or —Si(R₃₂)₃;

A represents a 5- to 10-membered heteroaryl ring or C₆₋₁₀ aryl ring;

R₅ represents C₁₋₅ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkyl C₁₋₃ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₄ haloalkyl, C₁₋₃ alkoxy C₁₋₄ alkyl, C₁₋₄ alkoxy C₁₋₄ alkyl, C₁₋₄ aminoalkyl, C₁₋₄ alkylamino C₁₋₄ alkyl, di(C₁₋₄ alkyl)amino C₁₋₄ alkyl, C₆₋₁₀ aryl, C₆₋₁₀ aryl C₁₋₃ alkyl, or 3- to 10-membered heterocycl C₁₋₃ alkyl, 3- to 10-membered heterocycl, 5- to 10-membered heteroaryl, 5- to 10-membered heteroaryl C₁₋₃ alkyl, C₁₋₆ monohydroxy alkyl, C₁₋₆ dihydroxy alkyl, or C₁₋₆ trihydroxy alkyl which is optionally substituted by one or more groups independently selected from group Q;

R₆ and R₇, which are the same or different, each represents hydrogen, C₁₋₄ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₄ haloalkyl, C₁₋₃ alkoxy C₁₋₄ alkyl, C₆₋₁₀ aryl C₁₋₃ alkyl, 3- to 10-membered heterocycl C₁₋₃ alkyl, 5- to 10-membered heteroaryl C₁₋₃ alkyl, C₁₋₆ monohydroxy alkyl, C₁₋₆ dihydroxy alkyl, C₁₋₆ trihydroxy alkyl, 3- to 10-membered heterocycl, C₁₋₄ aminoalkyl, C₁₋₄ alkylamino C₁₋₄ alkyl, di(C₁₋₄ alkyl)amino C₁₋₄ alkyl, or cyano(C₁₋₃ alkyl); or R₆ and R₇, together with a nitrogen atom linked thereto, form 3- to 10-membered heterocycl or 5- to 10-membered heteroaryl; n represents 1 to 3;

R₈ and R₉, which are the same or different, each represents hydrogen, C₁₋₄ alkyl, or halogen; or alternatively, R₈ and R₉, together with a carbon atom linked thereto, form a 50 cycloaliphatic ring;

Z₁ represents hydrogen, NR₁₀R₁₁, —OH, or 3- to 10-membered heterocycl or 5- to 10-membered heteroaryl which is optionally substituted by one or more groups independently selected from group Q;

R₁₀ and R₁₁, which are the same or different, each represents C₁₋₄ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₄ haloalkyl, C₁₋₃ alkoxy C₁₋₄ alkyl, cyano(C₁₋₃ alkyl), or C₁₋₃ alkylsulfonyl C₁₋₄ alkyl; or alternatively, R₁₀ and R₁₁, together with a nitrogen atom linked thereto, form 3- to 10-membered heterocycl or 5- to 10-membered heteroaryl;

R₁₂ and R₁₃, which are the same or different, each represents hydrogen, C₁₋₄ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₄ haloalkyl, C₁₋₃ alkoxy C₁₋₄ alkyl, C₆₋₁₀ aryl, 5- to 10-membered heteroaryl, 3- to 10-membered heterocycl, C₆₋₁₀ aryl C₁₋₄ alkyl, 3- to 10-membered heterocycl C₁₋₃ alkyl, 5- to 10-membered heteroaryl C₁₋₃ alkyl, cyano(C₁₋₃ alkyl), C₁₋₃

alkylsulfonyl C₁₋₄ alkyl, 3- to 10-membered cycloaliphatic ring, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocycl; or alternatively, R₁₂ and R₁₃, together with a nitrogen atom linked thereto, form 3- to 10-membered heterocycl or 5- to 10-membered heteroaryl which is optionally substituted by one or more groups independently selected from group Q;

R₁₄ represents C₁₋₄ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₄ haloalkyl, C₆₋₁₀ aryl which is optionally substituted by one or more groups independently selected from group P, or 5- to 10-membered heteroaryl or 3- to 10-membered heterocycl which is optionally substituted by one or more groups independently selected from group Q;

R₁₅ represents C₁₋₄ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₄ haloalkyl, C₆₋₁₀ aryl which is optionally substituted by one or more groups independently selected from group P, or 5- to 10-membered heteroaryl or 3- to 10-membered heterocycl which is optionally substituted by one or more groups independently selected from group Q;

R₁₆ represents C₁₋₄ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₄ haloalkyl, C₆₋₁₀ aryl which is optionally substituted by one or more groups independently selected from group P, or 5- to 10-membered heteroaryl or 3- to 10-membered heterocycl which is optionally substituted by one or more groups independently selected from group Q;

R₁₇ represents hydrogen or C₁₋₄ alkyl;

R₁₈ represents C₁₋₄ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₄ haloalkyl, C₆₋₁₀ aryl which is optionally substituted by one or more groups independently selected from group P, or 5- to 10-membered heteroaryl or 3- to 10-membered heterocycl which is optionally substituted by one or more groups independently selected from group Q;

R₁₉ represents hydrogen, C₁₋₄ alkyl, C₃₋₇ cycloalkyl, C₁₋₄ haloalkyl, C₆₋₁₀ aryl, or 5- to 10-membered heteroaryl or 3- to 10-membered heterocycl which is optionally substituted by one or more groups independently selected from group Q;

R₂₀ represents C₁₋₄ alkyl, C₃₋₇ cycloalkyl, C₁₋₄ haloalkyl, C₆₋₁₀ aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocycl;

R₂₁ represents C₁₋₄ alkyl, C₃₋₇ cycloalkyl, C₁₋₄ haloalkyl, C₆₋₁₀ aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocycl;

R₂₂ represents hydrogen, C₁₋₄ alkyl, or C₁₋₄ haloalkyl;

R₂₃ represents hydrogen, C₁₋₄ alkyl, C₃₋₇ cycloalkyl, C₁₋₄ haloalkyl, C₆₋₁₀ aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocycl;

R₂₄ represents hydrogen, C₁₋₄ alkyl, or C₁₋₄ haloalkyl;

R₂₅ represents C₁₋₄ alkyl, C₃₋₇ cycloalkyl, C₁₋₄ haloalkyl, C₆₋₁₀ aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocycl;

R₂₆ and R₂₇, which are the same or different, each represents hydrogen, C₁₋₄ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₄ haloalkyl, C₁₋₃ alkoxy C₁₋₄ alkyl, C₆₋₁₀ aryl, 5- to 10-membered heteroaryl, 3- to 10-membered heterocycl, C₆₋₁₀ aryl

55 C₁₋₄ alkyl, 3- to 10-membered heterocycl C₁₋₃ alkyl, 5- to 10-membered heteroaryl C₁₋₃ alkyl, cyano(C₁₋₃ alkyl), C₁₋₃ alkylsulfonyl C₁₋₄ alkyl, or 3- to 10-membered cycloaliphatic ring; or alternatively, R₂₆ and R₂₇, together with a nitrogen atom linked thereto, form 3- to 10-membered heterocycl or 5- to 10-membered heteroaryl;

R₂₈ and R₂₉, which are the same or different, each represents hydrogen, C₁₋₄ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₄ haloalkyl, C₁₋₃ alkoxy C₁₋₄ alkyl, C₆₋₁₀ aryl, 5- to 10-membered heteroaryl, 3- to 10-membered heterocycl, C₆₋₁₀ aryl

65 C₁₋₄ alkyl, 3- to 10-membered heterocycl C₁₋₃ alkyl, 5- to 10-membered heteroaryl C₁₋₃ alkyl, cyano(C₁₋₃ alkyl), C₁₋₃ alkylsulfonyl C₁₋₄ alkyl, or 3- to 10-membered cycloaliphatic

5

ring; or alternatively, R₂₈ and R₂₉, together with a nitrogen atom linked thereto, form 3- to 10-membered heterocycl or 5- to 10-membered heteroaryl;

R₃₀ represents C₁₋₄ alkyl, C₃₋₇ cycloalkyl, C₁₋₄ haloalkyl, C₆₋₁₀ aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocycl;

R₃₁ represents C₁₋₄ alkyl, C₃₋₇ cycloalkyl, C₁₋₄ haloalkyl, C₆₋₁₀ aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocycl;

R₃₂ represents C₁₋₄ alkyl or C₆₋₁₀ aryl;

<Group P>

halogen, C₁₋₄ alkyl, C₁₋₄ haloalkyl, —OH, C₁₋₃ alkoxy, C₁₋₃ haloalkoxy, 3- to 10-membered heterocyclamino, —SO₂R₁₆, —CN, —NO₂, and 3- to 10-membered heterocycl;

<Group Q>

halogen, C₁₋₄ alkyl, C₁₋₄ haloalkyl, —OH, C₁₋₃ alkoxy, C₁₋₆ monohydroxy alkyl, C₁₋₆ dihydroxy alkyl, C₁₋₆ trihydroxy alkyl, 3- to 10-membered heterocycl amino, —SO₂R₁₆, —CN, —NO₂, C₃₋₇ cycloalkyl, —COR₁₉, and 3- to 10-membered heterocycl which is optionally substituted by C₁₋₄ alkyl.

[2] The compound of [1] or a pharmaceutically acceptable salt thereof, wherein A represents benzene, indole, azaindole, benzofuran, benzothiophene, benzothiazole, quinoline, or pyrrole.

[3] The compound of [1] or [2], or a pharmaceutically acceptable salt thereof, wherein R₃ represents hydrogen, C₁₋₄ alkyl, C₆₋₁₀ aryl C₁₋₄ alkyl, or C₁₋₃ perfluoroalkyl.

[4] The compound of any one of [1] to [3], or a pharmaceutically acceptable salt thereof, wherein R₄ represents hydrogen, halogen, C₁₋₃ alkyl, C₁₋₃ perfluoroalkyl, cyano, methanesulfonyl, hydroxyl, alkoxy, or amino.

[5] The compound of [1] or a pharmaceutically acceptable salt thereof, which is selected from the group consisting of:

- (1) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1H-indol-2-yl]-methanone;
- (2) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-pyrrolidin-1-ylmethyl-1H-indol-2-yl]-methanone;
- (3) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(4-hydroxy-piperidin-1-ylmethyl)-1H-indol-2-yl]-methanone;
- (4) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1H-pyrrolo[3,2-c]pyridin-2-yl]-methanone;
- (5) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-piperazin-1-ylmethyl-1H-indol-2-yl]-methanone;
- (6) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(2-morpholin-4-yl-ethoxy)-1H-indol-2-yl]-methanone;
- (7) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(tetrahydro-pyran-4-yloxy)-1H-indol-2-yl]-methanone;
- (8) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-chloro-1H-indol-2-yl]-methanone;
- (9) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-bromo-1H-indol-2-yl]-methanone;
- (10) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-iodo-1H-indol-2-yl]-methanone;
- (11) 2-[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazole-4-carbonyl]-1H-indole-5-carboxylic acid (2,2,2-trifluoro-ethyl)-amide;
- (12) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-bromo-5-fluoro-1H-indol-2-yl]-methanone;
- (13) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-ethynyl-1H-indol-2-yl]-methanone;

6

- (14) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(2-fluoro-phenyl)-1H-indol-2-yl]-methanone;
- (15) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(3-fluoro-phenyl)-1H-indol-2-yl]-methanone;
- (16) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(4-fluoro-phenyl)-1H-indol-2-yl]-methanone;
- (17) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(2-chloro-phenyl)-1H-indol-2-yl]-methanone;
- (18) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(3-chloro-phenyl)-1H-indol-2-yl]-methanone;
- (19) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(4-chloro-phenyl)-1H-indol-2-yl]-methanone;
- (20) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(2-trifluoromethyl-phenyl)-1H-indol-2-yl]-methanone;
- (21) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(3-trifluoromethyl-phenyl)-1H-indol-2-yl]-methanone;
- (22) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(4-trifluoromethyl-phenyl)-1H-indol-2-yl]-methanone;
- (23) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-bromo-1H-indol-2-yl]-methanone;
- (24) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(3-fluoro-pyridin-2-yl)-1H-indol-2-yl]-methanone;
- (25) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(methyl-1H-indol-2-yl)-methanone];
- (26) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(4,4-difluoro-piperidine-1-carbonyl)-1H-indol-2-yl]-methanone;
- (27) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(3,3-difluoro-piperidine-1-carbonyl)-1H-indol-2-yl]-methanone;
- (28) 2-[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazole-4-carbonyl]-1H-indole-5-carboxylic acid (2,2,2-trifluoro-ethyl)-amide;
- (29) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(5-trifluoromethyl-pyridin-2-yl)-1H-indol-2-yl]-methanone;
- (30) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(6-trifluoromethyl-pyridin-2-yl)-1H-indol-2-yl]-methanone;
- (31) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(5-chloro-pyridin-2-yl)-1H-indol-2-yl]-methanone;
- (32) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(4-methyl-pyridin-2-yl)-1H-indol-2-yl]-methanone;
- (33) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(3-chloro-4-fluoro-phenyl)-1H-indol-2-yl]-methanone;
- (34) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(3-trifluoromethyl-pyridin-2-yl)-1H-indol-2-yl]-methanone;
- (35) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(4-trifluoromethyl-pyridin-2-yl)-1H-indol-2-yl]-methanone;
- (36) [5-amino-1-(6-fluoro-2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1H-indol-2-yl]-methanone;

- (37) 2-[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazole-4-carbonyl]-1H-indole-6-carboxylic acid;
- (38) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-hydroxymethyl-1H-indol-2-yl]-methanone;
- (39) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-{6-[2-(4-methyl-piperazin-1-yl)-ethoxy]-1H-indol-2-yl}-methanone;
- (40) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(3-methyl-oxetan-3-ylmethoxy)-1H-indol-2-yl]-methanone;
- (41) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(3-fluoro-piperidin-1-ylmethyl)-1H-indol-2-yl]-methanone;
- (42) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-{[bis(2-methoxy-ethyl)amino]-methyl}-1H-indol-2-yl]-methanone;
- (43) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-{6-[(methyl-prop-2-ynyl-amino)methyl]-1H-indol-2-yl}-methanone;
- (44) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(3,3-difluoro-pyrrolidin-1-ylmethyl)-1H-indol-2-yl]-methanone;
- (45) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(2,5-dimethyl-pyrrolidin-1-ylmethyl)-1H-indol-2-yl]-methanone;
- (46) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(3,3-difluoro-piperidin-1-ylmethyl)-1H-indol-2-yl]-methanone;
- (47) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-((S)-3-methyl-morpholin-4-ylmethyl)-1H-indol-2-yl]-methanone;
- (48) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-bromo-1H-indol-2-yl]-methanone;
- (49) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-iodo-1H-indol-2-yl]-methanone;
- (50) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1H-pyrrolo[3,2-b]pyridin-2-yl]-methanone;
- (51) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-bromo-6-trifluoromethyl-1H-indol-2-yl]-methanone;
- (52) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-iodo-1H-indol-2-yl]-methanone;
- (53) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-methyl-1H-indol-2-yl]-methanone;
- (54) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-isopropyl-1H-indol-2-yl]-methanone;
- (55) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(2-fluoro-phenyl)-1H-indol-2-yl]-methanone;
- (56) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-benzyl-1H-indol-2-yl]-methanone;
- (57) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(2-trifluoromethyl-phenyl)-1H-indol-2-yl]-methanone;
- (58) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(3-fluorophenyl)-1H-indol-2-yl]-methanone;
- (59) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(3-trifluoromethyl-phenyl)-1H-indol-2-yl]-methanone;
- (60) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-ethynyl-1H-indol-2-yl]-methanone;
- (61) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5H-[1,3]dioxolo[4,5-f]indol-6-yl]-methanone;

- (62) [5-amino-1-(7-fluoro-2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1H-indol-2-yl]-methanone;
- (63) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(4-trifluoromethyl-phenyl)-1H-indol-2-yl]-methanone;
- (64) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-butoxy-1H-indol-2-yl]-methanone;
- (65) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(1-methyl-piperidin-4-yl)-1H-indol-2-yl]-methanone;
- (66) N-[2-[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazole-4-carbonyl]-1H-indol-6-yl]-methane-sulfonamide;
- (67) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(6-morpholin-4-yl-pyridin-3-yl)-1H-indol-2-yl]-methanone;
- (68) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-butyl-1H-indol-2-yl]-methanone;
- (69) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(1-methyl-1H-pyrazol-4-yl)-1H-indol-2-yl]-methanone;
- (70) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(5-methoxy-pyridin-3-yl)-1H-indol-2-yl]-methanone;
- (71) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(2-methoxy-pyridin-3-yl)-1H-indol-2-yl]-methanone;
- (72) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-cyclopropyl-1H-indol-2-yl]-methanone;
- (73) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(2-methoxy-phenyl)-1H-indol-2-yl]-methanone;
- (74) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-phenyl-1H-indol-2-yl]-methanone;
- (75) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(5-methanesulfonyl-pyridin-3-yl)-1H-indol-2-yl]-methanone;
- (76) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-isopropyl-1H-indol-2-yl]-methanone;
- (77) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-pyridin-2-yl-1H-indol-2-yl]-methanone;
- (78) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-cyclopropyl-1H-indol-2-yl]-methanone;
- (79) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-pyridazin-3-yl-1H-indol-2-yl]-methanone;
- (80) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-isopropoxy-1H-indol-2-yl]-methanone;
- (81) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(2-methoxy-ethoxy)-1H-indol-2-yl]-methanone;
- (82) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-cyclopropylmethoxy-1H-indol-2-yl]-methanone;
- (83) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[2,2-difluoro-5H-[1,3]dioxolo[4,5-f]indol-6-yl]-methanone;
- (84) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(3-chloro-pyridin-2-yl)-1H-indol-2-yl]-methanone;
- (85) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(5-fluoro-pyridin-2-yl)-1H-indol-2-yl]-methanone;
- (86) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(6-morpholin-4-yl-pyridazin-3-yl)-1H-indol-2-yl]-methanone;

- (87) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-chloro-6-cyclopropylmethoxy-1H-indol-2-yl]-methanone;
- (88) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(2,4-difluoro-phenyl)-1H-indol-2-yl]-methanone;
- (89) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-pyridazin-4-yl-1H-indol-2-yl]-methanone;
- (90) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[3-fluoro-1H-indol-2-yl]-methanone;
- (91) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(1-isopropyl-piperidin-4-yl)-6-trifluoromethyl-1H-indol-2-yl]-methanone;
- (92) 2-[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazole-4-carbonyl]-1H-indole-6-carbonitrile;
- (93) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(1,2,3,6-tetrahydro-pyridin-4-yl)-1H-indol-2-yl]-methanone;
- (94) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-piperidin-4-yl-1H-indol-2-yl]-methanone;
- (95) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-((R)-3-fluoro-pyrrolidin-1-ylmethyl)-1H-indol-2-yl]-methanone;
- (96) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-fluoro-5-piperidin-4-yl-1H-indol-2-yl]-methanone;
- (97) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-fluoro-5-(1-methyl-piperidin-4-yl)-1H-indol-2-yl]-methanone;
- (98) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(1-isopropyl-piperidin-4-yl)-1H-indol-2-yl]-methanone;
- (99) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-fluoro-5-(1-isopropyl-piperidin-4-yl)-1H-indol-2-yl]-methanone;
- (100) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-pyridin-3-yl-1H-indol-2-yl]-methanone;
- (101) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(6-morpholin-4-ylpyridin-3-yl)-1H-indol-2-yl]-methanone;
- (102) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-pyridin-3-yl-1H-indol-2-yl]-methanone;
- (103) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(6-piperazin-1-yl-pyridin-3-yl)-1H-indol-2-yl]-methanone;
- (104) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(6-hydroxy-pyridin-3-yl)-1H-indol-2-yl]-methanone;
- (105) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-fluoro-5-(4-methyl-piperazin-1-ylmethyl)-1H-indol-2-yl]-methanone;
- (106) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-fluoro-5-pyrrolidin-1-ylmethyl-1H-indol-2-yl]-methanone;
- (107) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(1-methyl-piperidin-4-yl)-1H-indol-2-yl]-methanone;
- (108) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(4-morpholin-4-yl-phenyl)-1H-indol-2-yl]-methanone;
- (109) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(3,4,5,6-tetrahydro-2H-[1,2']bipyridin-5'-yl)-1H-indol-2-yl]-methanone;

- (110) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(6-piperazin-1-yl-pyridin-3-yl)-1H-indol-2-yl]-methanone;
- (111) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(6-methoxy-pyridin-3-yl)-1H-indol-2-yl]-methanone;
- (112) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-((S)-3-methyl-morpholin-4-ylmethyl)-1H-indol-2-yl]-methanone;
- (113) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-((R)-3-fluoro-pyrrolidin-1-ylmethyl)-1H-indol-2-yl]-methanone;
- (114) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(2,5-dimethyl-pyrrolidin-1-ylmethyl)-1H-indol-2-yl]-methanone;
- (115) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(3-fluoro-piperidin-1-ylmethyl)-1H-indol-2-yl]-methanone;
- (116) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(3,3-difluoro-piperidin-1-ylmethyl)-1H-indol-2-yl]-methanone;
- (117) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-{6-[2-(4-methyl-piperazin-1-yl)pyridin-4-yl]-1H-indol-2-yl}-methanone;
- (118) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-pyridin-4-yl-1H-indol-2-yl]-methanone;
- (119) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(4-fluoropiperidin-1-ylmethyl)-1H-indol-2-yl]-methanone;
- (120) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(4,4-difluoro-piperidin-1-ylmethyl)-1H-indol-2-yl]-methanone;
- (121) [5-amino-1-(2-difluoromethyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(1-methyl-piperidin-4-yl)-1H-indol-2-yl]-methanone;
- (122) [5-amino-1-(2-difluoromethyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1H-indol-2-yl]-methanone;
- (123) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(3,3-difluoro-pyrrolidin-1-ylmethyl)-1H-indol-2-yl]-methanone;
- (124) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(1-cyclopentyl-piperidin-4-yl)-1H-indol-2-yl]-methanone;
- (125) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(1-cyclohexyl-piperidin-4-yl)-1H-indol-2-yl]-methanone;
- (126) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-bromo-1H-pyrrol-2-yl]-methanone;
- (127) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1H-pyrrol-2-yl]-methanone;
- (128) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-phenyl-1H-pyrrol-2-yl]-methanone;
- (129) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-(3-chloro-phenyl)-1H-pyrrol-2-yl]-methanone;
- (130) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-(4-fluoro-phenyl)-1H-pyrrol-2-yl]-methanone;
- (131) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-(3-fluoro-phenyl)-1H-pyrrol-2-yl]-methanone;
- (132) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-morpholin-4-ylmethyl-1H-indol-2-yl]-methanone;
- (133) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-(2-morpholin-4-yl-ethylamino)-1H-indol-2-yl]-methanone;

11

- (134) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(4-methyl-piperazine-1-carbonyl)-1H-indol-2-yl]-methanone;
- (135) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(2-morpholin-4-yl-ethylamino)-1H-indol-2-yl]-methanone;
- (136) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(piperazine-1-carbonyl)-1H-indol-2-yl]-methanone;
- (137) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-(2-methoxy-ethylamino)-1H-indol-2-yl]-methanone;
- (138) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-(2-hydroxy-1-hydroxymethyl-ethylamino)-1H-indol-2-yl]-methanone;
- (139) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-(2-pyridin-4-yl-ethylamino)-1H-indol-2-yl]-methanone;
- (140) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(2-methoxy-ethylamino)-1H-indol-2-yl]-methanone;
- (141) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-morpholin-4-yl-1H-indol-2-yl]-methanone;
- (142) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-morpholin-4-yl-1H-indol-2-yl]-methanone;
- (143) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-morpholin-4-ylmethyl-1H-indol-2-yl]-methanone;
- (144) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-morpholin-4-ylmethyl-1H-indol-2-yl]-methanone;
- (145) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(morpholine-4-carbonyl)-1H-indol-2-yl]-methanone;
- (146) [5-amino-1-(2-isopropyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1H-indol-2-yl]-methanone;
- (147) [5-amino-1-(2-propyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1H-indol-2-yl]-methanone;
- (148) [5-amino-1-(1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1H-indol-2-yl]-methanone;
- (149) [5-amino-1-(2-trifluoromethyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1H-indol-2-yl]-methanone;
- (150) [5-amino-1-(2-ethyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1H-indol-2-yl]-methanone;
- (151) [5-amino-1-(2-benzyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1H-indol-2-yl]-methanone;
- (152) 1-(4-{2-[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazole-4-carbonyl]-1H-indol-5-ylmethyl}-piperazin-1-yl)-ethanone;
- (153) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(4-methanesulfonyl-piperazin-1-ylmethyl)-1H-indol-2-yl]-methanone;
- (154) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-piperazin-1-ylmethyl-1H-indol-2-yl]-methanone;
- (155) 1-(4-{2-[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazole-4-carbonyl]-1H-indol-6-ylmethyl}piperazin-1-yl)-ethanone;
- (156) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(4-methyl-piperazin-1-ylmethyl)-1H-indol-2-yl]-methanone;
- (157) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(4-methyl-piperazin-1-ylmethyl)-1H-indol-2-yl]-methanone;

12

- (158) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-pyrrolidin-1-ylmethyl-1H-indol-2-yl]-methanone;
- (159) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-fluoro-1H-indol-2-yl]-methanone;
- (160) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-fluoro-1H-indol-2-yl]-methanone;
- (161) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-fluoro-1H-indol-2-yl]-methanone;
- (162) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1H-pyrrolo[2,3-b]pyridin-2-yl]-methanone;
- (163) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-fluoro-6-morpholin-4-ylmethyl-1H-indol-2-yl]-methanone;
- (164) 2-[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazole-4-carbonyl]-1H-indole-5-carboxylic acid;
- (165) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-methoxy-1H-indol-2-yl]-methanone;
- (166) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4,6-dimethoxy-1H-indol-2-yl]-methanone;
- (167) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-methoxy-1H-indol-2-yl]-methanone;
- (168) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-methoxy-1H-indol-2-yl]-methanone;
- (169) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4,6-dimethyl-1H-indol-2-yl]-methanone;
- (170) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-tert-butyl-1H-indol-2-yl]-methanone;
- (171) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-isopropyl-1H-indol-2-yl]-methanone;
- (172) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-benzyloxy-1H-indol-2-yl]-methanone;
- (173) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-benzyloxy-1H-indol-2-yl]-methanone;
- (174) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5,6-dimethoxy-1H-indol-2-yl]-methanone;
- (175) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-tert-butyl-1H-indol-2-yl]-methanone;
- (176) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-fluoro-4-trifluoromethyl-1H-indol-2-yl]-methanone;
- (177) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-phenoxy-1H-indol-2-yl]-methanone;
- (178) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-methylsulfanyl-1H-indol-2-yl]-methanone;
- (179) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-tert-butyl-1H-indol-2-yl]-methanone;
- (180) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-methyl-1H-indol-2-yl]-methanone;
- (181) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-ethyl-1H-indol-2-yl]-methanone;
- (182) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-fluoro-6-trifluoromethyl-1H-indol-2-yl]-methanone;
- (183) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-fluoro-5-methoxy-1H-indol-2-yl]-methanone;
- (184) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-chloro-5-methoxy-1H-indol-2-yl]-methanone;
- (185) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-chloro-6-methoxy-1H-indol-2-yl]-methanone;

13

- (186) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-isopropoxy-1H-indol-2-yl]-methanone;
 (187) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-benzylxy-1H-indol-2-yl]-methanone;
 (188) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-isopropoxy-1H-indol-2-yl]-methanone;
 (189) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[2,3-dihydro-6H-[1,4]dioxino[2,3-f]indol-7-yl]-methanone;
 (190) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4,6-di-tert-butyl-1H-indol-2-yl]-methanone;
 (191) 2-[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazole-4-carbonyl]-1H-indole-4-carbonitrile;
 (192) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-imidazol-1-yl-1H-indol-2-yl]-methanone;
 (193) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-trifluoromethylsulfanyl-1H-indol-2-yl]-methanone;
 (194) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-methylsulfanyl-1H-indol-2-yl]-methanone;
 (195) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-methanesulfonyl-1H-indol-2-yl]-methanone;
 (196) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(4,4-difluoro-piperidin-1-ylmethyl)-1H-indol-2-yl]-methanone;
 (197) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(4-fluoro-piperidin-1-ylmethyl)-1H-indol-2-yl]-methanone;
 (198) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(oxetan-3-yloxy)-1H-indol-2-yl]-methanone;
 (199) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-hydroxy-1H-indol-2-yl]-methanone;
 (200) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-methanesulfonyl-1H-indol-2-yl]-methanone;
 (201) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4,5-dibromo-1H-pyrrol-2-yl]-methanone;
 (202) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4,5-diphenyl-1H-pyrrol-2-yl]-methanone;
 (203) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4,5-dipyridin-3-yl-1H-pyrrol-2-yl]-methanone;
 (204) [5-amino-1-(2-methyl-3H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-chloro-1H-indol-2-yl]-methanone;
 (205) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-chloro-1H-indol-2-yl]-methanone;
 (206) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1H-indol-3-yl]-methanone;
 (207) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1H-indol-6-yl]-methanone;
 (208) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-bromo-6-fluoro-1H-indol-2-yl]-methanone;
 (209) [5-amino-1-(2-ethyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-bromo-6-fluoro-1H-indol-2-yl]-methanone;
 (210) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-trifluoromethyl-1H-indol-2-yl]-methanone;
 (211) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-trifluoromethoxy-1H-indol-2-yl]-methanone;

14

- 5 (212) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4,6-dichloro-1H-indol-2-yl]-methanone;
 (213) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-bromo-4-fluoro-1H-indol-2-yl]-methanone;
 10 (214) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-trifluoromethoxy-1H-indol-2-yl]-methanone;
 (215) [5-amino-1-(2-ethyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-trifluoromethoxy-1H-indol-2-yl]-methanone;
 (216) [5-amino-1-(2-ethyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-trifluoromethyl-1H-indol-2-yl]-methanone;
 15 (217) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5,6-dichloro-1H-indol-2-yl]-methanone;
 (218) [5-amino-1-(2-ethyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-bromo-5-fluoro-1H-indol-2-yl]-methanone;
 (219) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4,5-dichloro-1H-indol-2-yl]-methanone;
 20 (220) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4,6-difluoro-1H-indol-2-yl]-methanone;
 (221) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(3-chloro-pyridin-4-yl)-1H-indol-2-yl]-methanone;
 25 (222) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(6-methyl-pyridine-3-yl)-1H-indol-2-yl]-methanone;
 (223) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(5-fluoro-pyridin-3-yl)-1H-indol-2-yl]-methanone;
 30 (224) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(2-trifluoromethyl-pyridin-3-yl)-1H-indol-2-yl]-methanone;
 (225) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(5-chloro-2-methoxy-pyridin-3-yl)-1H-indol-2-yl]-methanone;
 (226) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(5-chloro-pyridin-3-yl)-1H-indol-2-yl]-methanone;
 35 (227) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-thiophen-3-yl-1H-indol-2-yl]-methanone;
 (228) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(4-chloropyridin-3-yl)-1H-indol-2-yl]-methanone;
 (229) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-thiophen-2-yl-1H-indol-2-yl]-methanone;
 40 (230) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(3-fluoro-pyridin-4-yl)-1H-indol-2-yl]-methanone;
 (231) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(2-trifluoromethyl-pyridin-4-yl)-1H-indol-2-yl]-methanone;
 (232) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(3,3-difluoro-pyrrolidine-1-carbonyl)-1H-indol-2-yl]-methanone;
 45 (233) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(2,6-dimethyl-morpholine-4-carbonyl)-1H-indol-2-yl]-methanone;
 (234) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-([1,4']bipiperidinyl-1'-carbonyl)-1H-indol-2-yl]-methanone;
 50 (235) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-{4-(2,2,2-trifluoro-ethyl)-piperazine-1-carbonyl}-1H-indol-2-yl]-methanone;

15

- (236) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-{5-[4-(2-hydroxy-ethyl)-piperazine-1-carbonyl]-1H-indol-2-yl}-methanone;
- (237) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(3,3,4,4-tetrafluoro-pyrrolidine-1-carbonyl)-1H-indol-2-yl]-methanone;
- (238) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-((R)-3-fluoro-pyrrolidine-1-carbonyl)-1H-indol-2-yl]-methanone;
- (239) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-((S)-3-fluoro-pyrrolidine-1-carbonyl)-1H-indol-2-yl]-methanone;
- (240) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-(4-methoxy-phenyl)-1H-pyrrol-2-yl]-methanone;
- (241) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-(3-methoxy-phenyl)-1H-pyrrol-2-yl]-methanone;
- (242) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4,5-bis-(3-fluoro-phenyl)-1H-pyrrol-2-yl]-methanone;
- (243) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4,5-bis-(4-methoxy-phenyl)-1H-pyrrol-2-yl]-methanone;
- (244) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-(2,4-difluoro-phenyl)-1H-pyrrol-2-yl]-methanone;
- (245) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-(4-trifluoromethoxy-phenyl)-1H-pyrrol-2-yl]-methanone;
- (246) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4,5-bis-(3-methoxy-phenyl)-1H-pyrrol-2-yl]-methanone;
- (247) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-benzofuran-2-yl-methanone;
- (248) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-benzo[b]thiophen-2-yl-methanone;
- (249) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-benzothiazol-2-yl-methanone;
- (250) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-fluoro-phenyl]-methanone;
- (251) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[3-chloro-phenyl]-methanone;
- (252) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-quinolin-3-yl-methanone;
- (253) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-quinolin-7-yl-methanone; and
- (254) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-quinolin-6-yl-methanone.

[6] A pharmaceutical composition comprising the compound of any one of [1] to [5], or a pharmaceutically acceptable salt thereof; and a carrier.

[7] An agent for inhibiting FGFR activity, which comprises as an active ingredient the compound of any one of [1] to [5], or a pharmaceutically acceptable salt thereof

[8] An agent for preventing or treating cancer, which comprises as an active ingredient the compound of any one of [1] to [5], or a pharmaceutically acceptable salt thereof

[9] The agent for preventing or treating cancer of [8], wherein the cancer is at least one selected from the group consisting of:
breast cancer, acute myelocytic leukemia, pancreatic cancer, bladder cancer, prostatic cancer, esophageal cancer, angiogenesis, stomach cancer, uterine body cancer, ovarian cancer, brain tumor, colon cancer, multiple myeloma, hepatocarcinoma, pulmonary cancer, and thyroid cancer.

16


[10] A method for preventing or treating cancer, comprising administering a pharmaceutically effective amount of a composition comprising the compound of any one of [1] to [5] or a pharmaceutically acceptable salt thereof to a patient in need of prevention or treatment of cancer.

[11] Use of the compound of any one of [1] to [5] or a pharmaceutically acceptable salt thereof in the production of an agent for preventing or treating cancer.

[12] The compound of any one of [1] to [5] or a pharmaceutically acceptable salt thereof, for use in preventing or treating cancer.

The present invention also includes the following.

[101] A compound represented by following general formula (I), or a pharmaceutically acceptable salt thereof:



wherein R₁, R₂, R₃, and R₄ each independently represents the group listed below:

R₁ represents hydrogen, hydroxy, halogen, cyano, nitro, C₁₋₄ haloalkyl, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₆₋₁₀ aryl C₁₋₄ alkyl, —OR₅, —NR₆R₇, —(CR₈R₉)_nZ₁, —C(O)NR₁₂R₁₃, —SR₁₄, —SO₂R₁₆, —NR₁₇SO₂R₁₈, COOH, C₆₋₁₀ aryl which is optionally substituted by one or more groups selected from group P, 5- to 10-membered heteroaryl or 3- to 10-membered heterocycl which is optionally substituted by one or more groups selected from group Q, —COR₁₉, —COOR₂₀, —OC(O)R₂₁, —NR₂₂C(O)R₂₃, —NR₂₄C(S)R₂₅, —C(S)NR₂₆R₂₇, —SO₂NR₂₈R₂₉, —OSO₂R₃₀, —SO₃R₃₁, or —Si(R₃₂)₃;

R₂ represents hydrogen, hydroxy, halogen, cyano, nitro, C₁₋₄ haloalkyl, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₆₋₁₀ aryl C₁₋₄ alkyl, —OR₅, —NR₆R₇, —(CR₈R₉)_nZ₁, —C(O)NR₁₂R₁₃, —SO₂R₁₆, —NR₁₇SO₂R₁₈, COOH, C₆₋₁₀ aryl which is optionally substituted by one or more groups selected from group P, 5- to 10-membered heteroaryl or 3- to 10-membered heterocycl which is optionally substituted by one or more groups selected from group Q, —COR₁₉, —COOR₂₀, —OC(O)R₂₁, —NR₂₂C(O)R₂₃, —NR₂₄C(S)R₂₅, —C(S)NR₂₆R₂₇, —SO₂NR₂₈R₂₉, —OSO₂R₃₀, —SO₃R₃₁, or —Si(R₃₂)₃; or

R₁ and R₂, together with an atom linked thereto, form 3- to 10-membered heterocycl or 5- to 10-membered heteroaryl, wherein the heterocycl or heteroaryl is optionally substituted by halogen;

R₃ represents hydrogen, C₁₋₅ alkyl, C₆₋₁₀ aryl C₁₋₆ alkyl, or C₁₋₄ haloalkyl;

R₄ represents hydrogen, halogen, C₁₋₃ alkyl, C₁₋₄ haloalkyl, hydroxy, cyano, nitro, C₁₋₄ alkoxy, —(CH₂)_nZ₁, —NR₆R₇, —OR₅, —C(O)NR₁₂R₁₃, —SR₁₄, —SOR₁₅, —SO₂R₁₆,

NR₁₇SO₂R₁₈, COOH, —COR₁₉, —COOR₂₀, —OC(O)R₂₁, NR₂₂C(O)R₂₃, —NR₂₄C(S)R₂₅, —C(S)NR₂₆R₂₇, —SO₂NR₂₈R₂₉, —OSO₂R₃₀, —SO₃R₃₁, or —Si(R₃₂)₃;

A represents a 5- to 10-membered heteroaryl ring or C₆₋₁₀ aryl ring;

R₅ represents C₁₋₅ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkyl C₁₋₃ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₄ haloalkyl, C₁₋₃ alkoxy C₂₋₄ alkyl, C₁₋₃ alkoxy C₂₋₄ alkoxy C₂₋₄ alkyl, C₂₋₄ amio-noalkyl, C₁₋₄ alkylamino C₂₋₄ alkyl, di(C₁₋₄ alkyl)amino C₂₋₄ alkyl, C₆₋₁₀ aryl, C₆₋₁₀ aryl C₁₋₃ alkyl, or 3- to 10-membered heterocycl C₁₋₃ alkyl, 3- to 10-membered heterocycl, 5- to 10-membered heteroaryl, 5- to 10-membered heteroaryl C₁₋₃ alkyl, C₁₋₆ monohydroxy alkyl, C₁₋₆ dihydroxy alkyl, or C₁₋₆ trihydroxy alkyl which is optionally substituted by one or more groups selected from group Q;

R₆ and R₇, which are the same or different, each represents hydrogen, C₁₋₄ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₄ haloalkyl, C₁₋₃ alkoxy C₂₋₄ alkyl, C₆₋₁₀ aryl C₁₋₃ alkyl, 3- to 10-membered heterocycl C₁₋₃ alkyl, 5- to 10-membered heteroaryl C₁₋₃ alkyl, C₂₋₆ monohydroxy alkyl, C₂₋₆ dihydroxy alkyl, C₂₋₆ trihydroxy alkyl, 3- to 10-membered heterocycl, C₂₋₄ aminoalkyl, C₁₋₄ alkylamino C₂₋₄ alkyl, di(C₁₋₄ alkyl)amino C₂₋₄ alkyl, or cyano(C₁₋₃ alkyl); or R₆ and R₇, together with a nitrogen atom linked thereto, form 3- to 10-membered heterocycl or 5- to 10-membered heteroaryl; n represents 1 to 3;

R₈ and R₉, which are the same or different, each represents hydrogen, C₁₋₄ alkyl, or halogen; or alternatively, R₈ and R₉, together with a carbon atom linked thereto, form a cycloaliphatic ring; Z₁ represents hydrogen, NR₁₀R₁₁, hydroxyl, or 3- to 10-membered heterocycl or 5- to 10-membered heteroaryl which is optionally substituted by one or more groups independently selected from group Q;

R₁₀ and R₁₁, which are the same or different, each represents C₁₋₄ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₄ haloalkyl, C₁₋₃ alkoxy C₂₋₄ alkyl, cyano(C₁₋₃ alkyl), or C₁₋₃ alkylsulfonyl C₂₋₄ alkyl; or alternatively, R₁₀ and R₁₁, together with a nitrogen atom linked thereto, form 3- to 10-membered heterocycl or 5- to 10-membered heteroaryl;

R₁₂ and R₁₃, which are the same or different, each represents hydrogen, C₁₋₄ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₄ haloalkyl, C₁₋₃ alkoxy C₂₋₄ alkyl, C₆₋₁₀ aryl, 5- to 10-membered heteroaryl, 3- to 10-membered heterocycl, C₆₋₁₀ aryl C₁₋₄ alkyl, 3- to 10-membered heterocycl C₁₋₃ alkyl, 5- to 10-membered heteroaryl C₁₋₃ alkyl, cyano(C₁₋₃ alkyl), C₁₋₃ alkylsulfonyl C₂₋₄ alkyl, 3- to 10-membered cycloaliphatic ring, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocycl; or alternatively, R₁₂ and R₁₃, together with a nitrogen atom linked thereto, form 3- to 10-membered heterocycl or 5- to 10-membered heteroaryl which is optionally substituted by one or more groups selected from group Q; R₁₄ represents C₁₋₄ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₄ haloalkyl, C₆₋₁₀ aryl which is optionally substituted by one or more groups selected from group P, or 5- to 10-membered heteroaryl or 3- to 10-membered heterocycl which is optionally substituted by one or more groups selected from group Q;

R₁₅ represents C₁₋₄ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₄ haloalkyl, C₆₋₁₀ aryl which is optionally substituted by one or more groups selected from group P, or 5- to 10-membered heteroaryl or 3- to 10-membered heterocycl which is optionally substituted by one or more groups selected from group Q;

R₁₆ represents C₁₋₄ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₄ haloalkyl, C₆₋₁₀ aryl which is optionally substituted by one or more groups selected from group P, or 5- to 10-membered heteroaryl or 3- to 10-membered heterocycl which is optionally substituted by one or more groups selected from group Q;

R₁₇ represents hydrogen or C₁₋₄ alkyl;

R₁₈ represents C₁₋₄ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₄ haloalkyl, C₆₋₁₀ aryl which is optionally substituted by one or more groups selected from group P, or 5- to 10-membered heteroaryl or 3- to 10-membered heterocycl which is optionally substituted by a group(s) selected from group Q; R₁₉ represents hydrogen, C₁₋₄ alkyl, C₃₋₇ cycloalkyl, C₁₋₄ haloalkyl, C₆₋₁₀ aryl, or 5- to 10-membered heteroaryl or 3- to 10-membered heterocycl which is optionally substituted by one or more groups selected from group Q;

R₂₀ represents C₁₋₄ alkyl, C₃₋₇ cycloalkyl, C₁₋₄ haloalkyl, C₆₋₁₀ aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocycl;

R₂₁ represents C₁₋₄ alkyl, C₃₋₇ cycloalkyl, C₁₋₄ haloalkyl, C₆₋₁₀ aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocycl;

R₂₂ represents hydrogen, C₁₋₄ alkyl, or C₁₋₄ haloalkyl;

R₂₃ represents hydrogen, C₁₋₄ alkyl, C₃₋₇ cycloalkyl, C₁₋₄ haloalkyl, C₆₋₁₀ aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocycl;

R₂₄ represents hydrogen, C₁₋₄ alkyl, or C₁₋₄ haloalkyl;

R₂₅ represents C₁₋₄ alkyl, C₃₋₇ cycloalkyl, C₁₋₄ haloalkyl, C₆₋₁₀ aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocycl;

R₂₆ and R₂₇, which are the same or different, each represents hydrogen, C₁₋₄ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₄ haloalkyl, C₁₋₃ alkoxy C₂₋₄ alkyl, C₆₋₁₀ aryl, 5- to 10-membered heteroaryl, 3- to 10-membered heterocycl, C₆₋₁₀ aryl C₁₋₄ alkyl, 3- to 10-membered heterocycl C₁₋₃ alkyl, 5- to 10-membered heteroaryl C₁₋₃ alkyl, cyano(C₁₋₃ alkyl), C₁₋₃ alkylsulfonyl C₂₋₄ alkyl, or 3- to 10-membered cycloaliphatic ring; or alternatively, R₂₆ and R₂₇, together with a nitrogen atom linked thereto, form 3- to 10-membered heterocycl or 5- to 10-membered heteroaryl;

R₂₈ and R₂₉, which are the same or different, each represents hydrogen, C₁₋₄ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₄ haloalkyl, C₁₋₃ alkoxy C₂₋₄ alkyl, C₆₋₁₀ aryl, 5- to 10-membered heteroaryl, 3- to 10-membered heterocycl, C₆₋₁₀ aryl C₁₋₄ alkyl, 3- to 10-membered heterocycl C₁₋₃ alkyl, 5- to 10-membered heteroaryl C₁₋₃ alkyl, cyano(C₁₋₃ alkyl), C₁₋₃ alkylsulfonyl C₂₋₄ alkyl, or 3- to 10-membered cycloaliphatic ring; or alternatively, R₂₈ and R₂₉, together with a nitrogen atom linked thereto, form 3- to 10-membered heterocycl or 5- to 10-membered heteroaryl;

R₃₀ represents C₁₋₄ alkyl, C₃₋₇ cycloalkyl, C₁₋₄ haloalkyl, C₆₋₁₀ aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocycl;

R₃₁ represents C₁₋₄ alkyl, C₃₋₇ cycloalkyl, C₁₋₄ haloalkyl, C₆₋₁₀ aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocycl;

R₃₂ represents C₁₋₄ alkyl or C₆₋₁₀ aryl;

<Group P>

hydrogen, halogen, C₁₋₄ alkyl, C₁₋₄ haloalkyl, —OH, C₁₋₃ alkoxy, 3- to 10-membered heterocyclamino, —SO₂R₁₆, —CN, —NO₂, and 3- to 10-membered heterocycl;

<Group Q>

hydrogen, halogen, C₁₋₄ alkyl, C₁₋₄ haloalkyl, —OH, C₁₋₃ alkoxy, 3- to 10-membered heterocycl amine, —SO₂R₁₆, —CN, —NO₂, C₃₋₇ cycloalkyl, —COR₁₉, and 3- to 10-membered heterocycl.

[102] The compound of [101] or a pharmaceutically acceptable salt thereof, wherein A represents indole, azaindole, or pyrrole.

[103] The compound of [101] or [102], or a pharmaceutically acceptable salt thereof, wherein R₃ represents hydrogen, C₁₋₄ alkyl, C₆₋₁₀ aryl C₁₋₄ alkyl, or C₁₋₃ perfluoroalkyl.

[104] The compound of any one of [101] to [103], or a pharmaceutically acceptable salt thereof, wherein R₄ represents hydrogen, halogen, C₁₋₃ alkyl, C₁₋₃ perfluoroalkyl, cyano, methanesulfonyl, hydroxyl, alkoxy, or amino.

19

[105] The compound of [101] or a pharmaceutically acceptable salt thereof, which is selected from the group consisting of:

- (1) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1H-indol-2-yl]-methanone;
- (2) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-pyrrolidin-1-ylmethyl-1H-indol-2-yl]-methanone;
- (3) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(4-hydroxy-piperidin-1-ylmethyl)-1H-indol-2-yl]-methanone;
- (4) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1H-pyrrolo[3,2-c]pyridin-2-yl]-methanone;
- (5) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-piperazin-1-ylmethyl-1H-indol-2-yl]-methanone;
- (6) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(2-morpholin-4-yl-ethoxy)-1H-indol-2-yl]-methanone;
- (7) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(tetrahydro-pyran-4-yloxy)-1H-indol-2-yl]-methanone;
- (8) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-chloro-1H-indol-2-yl]-methanone;
- (9) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-bromo-1H-indol-2-yl]-methanone;
- (10) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-iodo-1H-indol-2-yl]-methanone;
- (11) 2-[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazole-4-carbonyl]-1H-indole-5-carbonitrile;
- (12) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-bromo-5-fluoro-1H-indol-2-yl]-methanone;
- (13) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-ethynyl-1H-indol-2-yl]-methanone;
- (14) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(2-fluoro-phenyl)-1H-indol-2-yl]-methanone;
- (15) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(3-fluoro-phenyl)-1H-indol-2-yl]-methanone;
- (16) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(4-fluoro-phenyl)-1H-indol-2-yl]-methanone;
- (17) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(2-chloro-phenyl)-1H-indol-2-yl]-methanone;
- (18) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(3-chloro-phenyl)-1H-indol-2-yl]-methanone;
- (19) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(4-chloro-phenyl)-1H-indol-2-yl]-methanone;
- (20) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(2-trifluoromethyl-phenyl)-1H-indol-2-yl]-methanone;
- (21) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(3-trifluoromethyl-phenyl)-1H-indol-2-yl]-methanone;
- (22) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(4-trifluoromethyl-phenyl)-1H-indol-2-yl]-methanone;
- (23) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-bromo-1H-indol-2-yl]-methanone;
- (24) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(3-fluoro-pyridin-2-yl)-1H-indol-2-yl]-methanone;

20

- (25) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-methyl-1H-indol-2-yl]-methanone;
- (26) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(4,4-difluoro-piperidine-1-carbonyl)-1H-indol-2-yl]-methanone;
- (27) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(3,3-difluoro-piperidine-1-carbonyl)-1H-indol-2-yl]-methanone;
- (28) 2-[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazole-4-carbonyl]-1H-indole-5-carboxylic acid (2,2,2-trifluoro-ethyl)-amide;
- (29) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(5-trifluoromethyl-pyridin-2-yl)-1H-indol-2-yl]-methanone;
- (30) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(6-trifluoromethyl-pyridin-2-yl)-1H-indol-2-yl]-methanone;
- (31) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(5-chloro-pyridin-2-yl)-1H-indol-2-yl]-methanone;
- (32) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(4-methyl-pyridin-2-yl)-1H-indol-2-yl]-methanone;
- (33) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(3-chloro-4-fluoro-phenyl)-1H-indol-2-yl]-methanone;
- (34) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(3-trifluoromethyl-pyridin-2-yl)-1H-indol-2-yl]-methanone;
- (35) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(4-trifluoromethyl-pyridin-2-yl)-1H-indol-2-yl]-methanone;
- (36) [5-amino-1-(6-fluoro-2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1H-indol-2-yl]-methanone;
- (37) 2-[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazole-4-carbonyl]-1H-indole-6-carboxylic acid;
- (38) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-hydroxymethyl-1H-indol-2-yl]-methanone;
- (39) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(2-(4-methyl-piperazin-1-yl)-ethoxy)-1H-indol-2-yl]-methanone;
- (40) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(3-methyl-oxetan-3-ylmethoxy)-1H-indol-2-yl]-methanone;
- (41) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(3-fluoro-piperidin-1-ylmethyl)-1H-indol-2-yl]-methanone;
- (42) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-[(bis(2-methoxy-ethyl)amino)-methyl]-1H-indol-2-yl]-methanone;
- (43) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-[(methyl-prop-2-ynyl-amino)methyl]-1H-indol-2-yl]-methanone;
- (44) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(3,3-difluoro-pyrrolidin-1-ylmethyl)-1H-indol-2-yl]-methanone;
- (45) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(2,5-dimethyl-pyrrolidin-1-ylmethyl)-1H-indol-2-yl]-methanone;
- (46) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(3,3-difluoro-piperidin-1-ylmethyl)-1H-indol-2-yl]-methanone;
- (47) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-((S)-3-methyl-morpholin-4-ylmethyl)-1H-indol-2-yl]-methanone;

21

- (48) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(6-bromo-1H-indol-2-yl)-methanone;
 (49) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-iodo-1H-indol-2-yl]-methanone;
 (50) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1H-pyrrolo[3,2-b]pyridin-2-yl]-methanone;
 (51) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-bromo-6-trifluoromethyl-1H-indol-2-yl]-methanone;
 (52) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-iodo-1H-indol-2-yl]-methanone;
 (53) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-methyl-1H-indol-2-yl]-methanone;
 (54) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-isopropyl-1H-indol-2-yl]-methanone;
 (55) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(2-fluoro-phenyl)-1H-indol-2-yl]-methanone;
 (56) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-benzyl-1H-indol-2-yl]-methanone;
 (57) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(2-trifluoromethyl-phenyl)-1H-indol-2-yl]-methanone;
 (58) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(3-fluorophenyl)-1H-indol-2-yl]-methanone;
 (59) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(3-trifluoromethyl-phenyl)-1H-indol-2-yl]-methanone;
 (60) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-ethynyl-1H-indol-2-yl]-methanone;
 (61) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5H-[1,3]dioxolo[4,5-f]indol-6-yl]-methanone;
 (62) [5-amino-1-(7-fluoro-2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1H-indol-2-yl]-methanone;
 (63) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(4-trifluoromethyl-phenyl)-1H-indol-2-yl]-methanone;
 (64) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-butoxy-1H-indol-2-yl]-methanone;
 (65) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(1-methyl-piperidin-4-yl)-1H-indol-2-yl]-methanone;
 (66) N-[2-[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazole-4-carbonyl]-1H-indol-6-yl]-methanesulfonamide;
 (67) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(6-morpholin-4-yl-pyridin-3-yl)-1H-indol-2-yl]-methanone;
 (68) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-butyl-1H-indol-2-yl]-methanone;
 (69) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(1-methyl-1H-pyrazol-4-yl)-1H-indol-2-yl]-methanone;
 (70) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(5-methoxy-pyridin-3-yl)-1H-indol-2-yl]-methanone;
 (71) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(2-methoxy-pyridin-3-yl)-1H-indol-2-yl]-methanone;
 (72) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-cyclopropyl-1H-indol-2-yl]-methanone;
 (73) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(2-methoxy-phenyl)-1H-indol-2-yl]-methanone;

22

- (74) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-phenyl-1H-indol-2-yl]-methanone;
 (75) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(5-methanesulfonyl-pyridin-3-yl)-1H-indol-2-yl]-methanone;
 (76) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-isopropyl-1H-indol-2-yl]-methanone;
 (77) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-pyridin-2-yl-1H-indol-2-yl]-methanone;
 (78) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-cyclopropyl-1H-indol-2-yl]-methanone;
 (79) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-pyridazin-3-yl-1H-indol-2-yl]-methanone;
 (80) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-isopropoxy-1H-indol-2-yl]-methanone;
 (81) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(2-methoxy-ethoxy)-1H-indol-2-yl]-methanone;
 (82) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-cyclopropylmethoxy-1H-indol-2-yl]-methanone;
 (83) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[2,2-difluoro-5H-[1,3]dioxolo[4,5-f]indol-6-yl]-methanone;
 (84) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(3-chloro-pyridin-2-yl)-1H-indol-2-yl]-methanone;
 (85) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(5-fluoro-pyridin-2-yl)-1H-indol-2-yl]-methanone;
 (86) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(6-morpholin-4-yl-pyridazin-3-yl)-1H-indol-2-yl]-methanone;
 (87) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-chloro-6-cyclopropylmethoxy-1H-indol-2-yl]-methanone;
 (88) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(2,4-difluoro-phenyl)-1H-indol-2-yl]-methanone;
 (89) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-pyridazin-4-yl-1H-indol-2-yl]-methanone;
 (90) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[3-fluoro-1H-indol-2-yl]-methanone;
 (91) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(1-isopropyl-piperidin-4-yl)-6-trifluoromethyl-1H-indol-2-yl]-methanone;
 (92) 2-[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazole-4-carbonyl]-1H-indole-6-carbonitrile;
 (93) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(1,2,3,6-tetrahydro-pyridin-4-yl)-1H-indol-2-yl]-methanone;
 (94) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-piperidin-4-yl-1H-indol-2-yl]-methanone;
 (95) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-((R)-3-fluoro-pyrrolidin-1-ylmethyl)-1H-indol-2-yl]-methanone;
 (96) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-fluoro-5-piperidin-4-yl-1H-indol-2-yl]-methanone;
 (97) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-fluoro-5-(1-methyl-piperidin-4-yl)-1H-indol-2-yl]-methanone;

- (98) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(1-isopropyl-piperidin-4-yl)-1H-indol-2-yl]-methanone;
- (99) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-fluoro-5-(1-isopropyl-piperidin-4-yl)-1H-indol-2-yl]-methanone;
- (100) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-pyridin-3-yl-1H-indol-2-yl]-methanone;
- (101) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(6-morpholin-4-ylpyridin-3-yl)-1H-indol-2-yl]-methanone;
- (102) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-pyridin-3-yl-1H-indol-2-yl]-methanone;
- (103) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(6-piperazin-1-yl-pyridin-3-yl)-1H-indol-2-yl]-methanone;
- (104) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(6-hydroxy-pyridin-3-yl)-1H-indol-2-yl]-methanone;
- (105) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-fluoro-5-(4-methyl-piperazin-1-ylmethyl)-1H-indol-2-yl]-methanone;
- (106) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-fluoro-5-pyrrolidin-1-ylmethyl-1H-indol-2-yl]-methanone;
- (107) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(1-methyl-piperidin-4-yl)-1H-indol-2-yl]-methanone;
- (108) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(4-morpholin-4-yl-phenyl)-1H-indol-2-yl]-methanone;
- (109) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(3,4,5,6-tetrahydro-2H-[1,2']bipyridin-5'-yl)-1H-indol-2-yl]-methanone;
- (110) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(6-piperazin-1-yl-pyridin-3-yl)-1H-indol-2-yl]-methanone;
- (111) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(6-methoxy-pyridin-3-yl)-1H-indol-2-yl]-methanone;
- (112) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-((S)-3-methyl-morpholin-4-ylmethyl)-1H-indol-2-yl]-methanone;
- (113) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-((R)-3-fluoro-pyrrolidin-1-ylmethyl)-1H-indol-2-yl]-methanone;
- (114) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(2,5-dimethyl-pyrrolidin-1-ylmethyl)-1H-indol-2-yl]-methanone;
- (115) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(3-fluoro-piperidin-1-ylmethyl)-1H-indol-2-yl]-methanone;
- (116) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(3,3-difluoro-piperidin-1-ylmethyl)-1H-indol-2-yl]-methanone;
- (117) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-{6-[2-(4-methyl-piperazin-1-yl)pyridin-4-yl]-1H-indol-2-yl}-methanone;
- (118) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-pyridin-4-yl-1H-indol-2-yl]-methanone;
- (119) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(4-fluoropiperidin-1-ylmethyl)-1H-indol-2-yl]-methanone;
- (120) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(4,4-difluoro-piperidin-1-ylmethyl)-1H-indol-2-yl]-methanone;

- (121) [5-amino-1-(2-difluoromethyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(1-methyl-piperidin-4-yl)-1H-indol-2-yl]-methanone;
- (122) [5-amino-1-(2-difluoromethyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1H-indol-2-yl]-methanone;
- (123) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(3,3-difluoro-pyrrolidin-1-ylmethyl)-1H-indol-2-yl]-methanone;
- (124) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(1-cyclopentyl-piperidin-4-yl)-1H-indol-2-yl]-methanone;
- (125) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(1-cyclohexyl-piperidin-4-yl)-1H-indol-2-yl]-methanone;
- (126) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-bromo-1H-pyrrol-2-yl]-methanone;
- (127) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1H-pyrrol-2-yl]-methanone;
- (128) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-phenyl-1H-pyrrol-2-yl]-methanone;
- (129) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-(3-chloro-phenyl)-1H-pyrrol-2-yl]-methanone;
- (130) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-(4-fluoro-phenyl)-1H-pyrrol-2-yl]-methanone;
- (131) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-(3-fluoro-phenyl)-1H-pyrrol-2-yl]-methanone;
- (132) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-morpholin-4-ylmethyl-1H-indol-2-yl]-methanone;
- (133) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-(2-morpholin-4-yl-ethylamino)-1H-indol-2-yl]-methanone;
- (134) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(4-methyl-piperazine-1-carbonyl)-1H-indol-2-yl]-methanone;
- (135) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(2-morpholin-4-yl-ethylamino)-1H-indol-2-yl]-methanone;
- (136) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(piperazine-1-carbonyl)-1H-indol-2-yl]-methanone;
- (137) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-(2-methoxy-ethylamino)-1H-indol-2-yl]-methanone;
- (138) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-(2-hydroxy-1-hydroxymethyl-ethylamino)-1H-indol-2-yl]-methanone;
- (139) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-(2-pyridin-4-yl-ethylamino)-1H-indol-2-yl]-methanone;
- (140) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(2-methoxy-ethylamino)-1H-indol-2-yl]-methanone;
- (141) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-morpholin-4-yl-1H-indol-2-yl]-methanone;
- (142) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-morpholin-4-yl-1H-indol-2-yl]-methanone;
- (143) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-morpholin-4-ylmethyl-1H-indol-2-yl]-methanone;

25

- (144) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-morpholin-4-ylmethyl-1H-indol-2-yl]-methanone;
- (145) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(morpholine-4-carbonyl)-1H-indol-2-yl]-methanone;
- (146) [5-amino-1-(2-isopropyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1H-indol-2-yl]-methanone;
- (147) [5-amino-1-(2-propyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1H-indol-2-yl]-methanone;
- (148) [5-amino-1-(1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1H-indol-2-yl]-methanone;
- (149) [5-amino-1-(2-trifluoromethyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1H-indol-2-yl]-methanone;
- (150) [5-amino-1-(2-ethyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1H-indol-2-yl]-methanone;
- (151) [5-amino-1-(2-benzyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1H-indol-2-yl]-methanone;
- (152) 1-[4-{2-[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazole-4-carbonyl]-1H-indol-5-ylmethyl}-piperazin-1-yl]-ethanone;
- (153) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(4-methanesulfonyl-piperazin-1-ylmethyl)-1H-indol-2-yl]-methanone;
- (154) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-piperazin-1-ylmethyl-1H-indol-2-yl]-methanone;
- (155) 1-[4-{2-[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazole-4-carbonyl]-1H-indol-6-ylmethyl}piperazin-1-yl]-ethanone;
- (156) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(4-methyl-piperazin-1-ylmethyl)-1H-indol-2-yl]-methanone;
- (157) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(4-methyl-piperazin-1-ylmethyl)-1H-indol-2-yl]-methanone;
- (158) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-pyrrolidin-1-ylmethyl-1H-indol-2-yl]-methanone;
- (159) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-fluoro-1H-indol-2-yl]-methanone;
- (160) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-fluoro-1H-indol-2-yl]-methanone;
- (161) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-fluoro-1H-indol-2-yl]-methanone;
- (162) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1H-pyrrolo[2,3-b]pyridin-2-yl]-methanone;
- (163) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-fluoro-6-morpholin-4-ylmethyl-1H-indol-2-yl]-methanone;
- (164) 2-[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazole-4-carbonyl]-1H-indole-5-carboxylic acid;
- (165) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-methoxy-1H-indol-2-yl]-methanone;
- (166) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4,6-dimethoxy-1H-indol-2-yl]-methanone;
- (167) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-methoxy-1H-indol-2-yl]-methanone;
- (168) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-methoxy-1H-indol-2-yl]-methanone;
- (169) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4,6-dimethyl-1H-indol-2-yl]-methanone;
- (170) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-tert-butyl-1H-indol-2-yl]-methanone;

26

- (171) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-isopropyl-1H-indol-2-yl]-methanone;
- (172) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-benzyloxy-1H-indol-2-yl]-methanone;
- (173) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-benzyloxy-1H-indol-2-yl]-methanone;
- (174) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5,6-dimethoxy-1H-indol-2-yl]-methanone;
- (175) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-tert-butyl-1H-indol-2-yl]-methanone;
- (176) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-fluoro-4-trifluoromethyl-1H-indol-2-yl]-methanone;
- (177) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-phenoxy-1H-indol-2-yl]-methanone;
- (178) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-methylsulfanyl-1H-indol-2-yl]-methanone;
- (179) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-tert-butyl-1H-indol-2-yl]-methanone;
- (180) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-methyl-1H-indol-2-yl]-methanone;
- (181) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-ethyl-1H-indol-2-yl]-methanone;
- (182) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-fluoro-6-trifluoromethyl-1H-indol-2-yl]-methanone;
- (183) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-fluoro-5-methoxy-1H-indol-2-yl]-methanone;
- (184) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-chloro-5-methoxy-1H-indol-2-yl]-methanone;
- (185) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-chloro-6-methoxy-1H-indol-2-yl]-methanone;
- (186) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-isopropoxy-1H-indol-2-yl]-methanone;
- (187) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-benzyloxy-1H-indol-2-yl]-methanone;
- (188) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-isopropoxy-1H-indol-2-yl]-methanone;
- (189) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[2,3-dihydro-6H-[1,4]dioxino[2,3-f]indol-7-yl]-methanone;
- (190) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4,6-di-tert-butyl-1H-indol-2-yl]-methanone;
- (191) 2-[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazole-4-carbonyl]-1H-indole-4-carbonitrile;
- (192) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-imidazol-1-yl-1H-indol-2-yl]-methanone;
- (193) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-trifluoromethylsulfanyl-1H-indol-2-yl]-methanone;
- (194) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-methylsulfanyl-1H-indol-2-yl]-methanone;
- (195) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-methanesulfonyl-1H-indol-2-yl]-methanone;
- (196) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(4,4-difluoro-piperidin-1-ylmethyl)-1H-indol-2-yl]-methanone;

- (197) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(4-fluoro-piperidin-1-ylmethyl)-1H-indol-2-yl]-methanone;
- (198) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(oxetan-3-yloxy)-1H-indol-2-yl]-methanone;
- (199) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-hydroxy-1H-indol-2-yl]-methanone;
- (200) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-methanesulfonyl-1H-indol-2-yl]-methanone;
- (201) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4,5-dibromo-1H-pyrrol-2-yl]-methanone;
- (202) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4,5-diphenyl-1H-pyrrol-2-yl]-methanone; and
- (203) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4,5-dipyridin-3-yl-1H-pyrrol-2-yl]-methanone.

[106] A pharmaceutical composition comprising the compound of any one of [101] to [105], or a pharmaceutically acceptable salt thereof; and a carrier.

[107] An agent for inhibiting FGFR activity, which comprises as an active ingredient the compound of any one of [101] to [105], or a pharmaceutically acceptable salt thereof

[108] An agent for preventing or treating cancer, which comprises as an active ingredient the compound of any one of [101] to [105], or a pharmaceutically acceptable salt thereof

[109] The agent for preventing or treating cancer of [108], wherein the cancer is at least one selected from the group consisting of:

breast cancer, acute myelocytic leukemia, pancreatic cancer, bladder cancer, prostatic cancer, esophageal cancer, angiogenesis, stomach cancer, uterine body cancer, ovarian cancer, brain tumor, colon cancer, multiple myeloma, hepatocarcinoma, pulmonary cancer, and thyroid cancer.

[110] A method for preventing or treating cancer, comprising administering a pharmaceutically effective amount of a composition comprising the compound of any one of [101] to [105] or a pharmaceutically acceptable salt thereof to a patient in need of prevention or treatment of cancer.

[111] Use of the compound of any one of [101] to [105] or a pharmaceutically acceptable salt thereof in the production of an agent for preventing or treating cancer.

[112] The compound of any one of [101] to [105] or a pharmaceutically acceptable salt thereof, for preventing or treating cancer.

Effects of the Invention

The compounds of the present invention and pharmaceutically acceptable salts thereof have the activity of inhibiting FGFR family kinases in cancer tissues. Furthermore, the compounds of the present invention can exert efficacy on novel genes (non-target genes) altered in cancer, and thus can prevent and/or treat cancers against which no effective therapy has been available.

MODE FOR CARRYING OUT THE INVENTION

The present invention relates to aminopyrazole derivatives and uses thereof. The present inventors for the first time synthesized compounds represented by formula (I) shown above or pharmaceutically acceptable salts thereof and discovered that the compounds or salts thereof had the activity of inhibiting the FGFR family kinases.

Herein, the “alkyl” refers to a monovalent group derived from an aliphatic hydrocarbon by removing an arbitrary hydrogen atom. It contains no heteroatom nor unsaturated carbon-carbon bond in the backbone, and has a subset of hydrocarbyl or hydrocarbon group structures which contain hydrogen and carbon atoms. The alkyl group includes linear and branched structures. Preferred alkyl groups include alkyl groups with one to six carbon atoms (C_{1-6} ; hereinafter, “ $C_{p,q}$ ” means that the number of carbon atoms is p to q), C_{1-5} alkyl groups, C_{1-4} alkyl groups, and C_{1-3} alkyl groups.

Specifically, the alkyl includes, for example, methyl group, ethyl group, n-propyl group, isopropyl group, n-butyl group, isobutyl group, s-butyl group, t-butyl group, pentyl group, isopentyl group, 2,3-dimethylpropyl group, 3,3-dimethylbutyl group, and hexyl group.

Herein, “alkenyl” refers to a monovalent hydrocarbon group having at least one double bond (two adjacent SP₂ carbon atoms), and includes those of linear and branched forms. Depending on the configuration of the double bond and substituents (if any), the geometry of the double bond can be of entgegen (E) or zusammen (Z), or cis or trans configuration. Preferred alkenyl groups include C_{2-6} alkenyl groups.

Specifically, the alkenyl includes, for example, vinyl group, allyl group, 1-propenyl group, 2-propenyl group, 1-but enyl group, 2-but enyl group (including cis and trans), 3-but enyl group, pentenyl group, and hexenyl group.

Herein, “alkynyl” refers to a monovalent hydrocarbon group having at least one triple bond (two adjacent SP carbon atoms), and includes those of linear and branched forms. Preferred alkynyl groups include C_{2-6} alkynyl groups.

Specifically, the alkynyl includes, for example, ethynyl group, 1-propynyl group, propargyl group, 3-butynyl group, pentynyl group, and hexynyl group.

The alkenyl and alkynyl may each have one or more double bonds or triple bonds.

Herein, “cycloalkyl” refers to a saturated or partially saturated cyclic monovalent aliphatic hydrocarbon group, and includes monocyclic groups, bicyclo rings, and spiro rings. Preferred cycloalkyl includes C_{3-7} cycloalkyl groups. Specifically, the cycloalkyl group includes, for example, cyclopropyl group, cyclobutyl group, cyclopentyl group, cyclohexyl group, and cycloheptyl group.

Herein, “cycloalkylalkyl” refers to a group in which an arbitrary hydrogen atom of an “alkyl” defined above is substituted with a “cycloalkyl” defined above. Preferred cycloalkylalkyl groups include C_{3-7} cycloalkyl C_{1-3} alkyl, and specifically includes, for example, cyclopropylmethyl group and cyclopropylethyl group.

Herein, “hetero atom” refers to a nitrogen atom (N), oxygen atom (O), or sulfur atom (S).

Herein, “halogen atom” refers to a fluorine atom, chlorine atom, bromine atom, or iodine atom.

Herein, “haloalkyl” refers to a group in which preferably one to nine, more preferably one to five identical or different “halogen atoms” defined above are linked to an “alkyl” defined above.

Specifically, the haloalkyl includes, for example, chloromethyl group, dichloromethyl group, trichloromethyl group, fluoromethyl group, difluoromethyl group, perfluoroalkyl group (such as trifluoromethyl group and —CF₂CF₃), and 2,2,2-trifluoroethyl group.

Herein, “alkoxy” refers to an oxy group linked with an “alkyl” defined above. Preferred alkoxy includes C_{1-4} alkoxy groups and C_{1-3} alkoxy groups. Specifically, alkoxy includes, for example, methoxy group, ethoxy group, 1-propoxy group, 2-propoxy group, n-butoxy group, i-butoxy group, sec-butoxy group, and tert-butoxy group.

29

Herein, "haloalkoxy" refers to a group in which preferably one to nine, more preferably one to five identical or different halogen atoms defined above are linked to an "alkoxy" defined above.

Specifically, the haloalkoxy includes, for example, chlormethoxy group, trichloromethoxy group, and trifluoromethoxy group.

Herein, "aryl" refers to a monovalent aromatic hydrocarbon ring. The aryl preferably includes C₆₋₁₀ aryl. Specifically, the aryl includes, for example, phenyl group and naphthyl groups (for example, 1-naphthyl group and 2-naphthyl group).

Herein, "alicyclic ring" refers to a monovalent non-aromatic hydrocarbon ring. The alicyclic ring may have unsaturated bonds within its ring, and may be a multicyclic group having two or more rings. The carbon atoms constituting the ring may be oxidized to form a carbonyl. The number of atoms constituting an alicyclic ring preferably ranges from three to ten (3- to 10-membered aliphatic ring). The alicyclic ring includes, for example, cycloalkyl rings, cycloalkenyl rings, and cycloalkynyl rings.

Herein, "heteroaryl" refers to a monovalent aromatic heterocyclic group in which the ring-constituting atoms include preferably one to five hetero atoms. The heteroaryl may be partially saturated, and may be a monocyclic or condensed ring (for example, a bicyclic heteroaryl condensed with a benzene ring or monocyclic heteroaryl ring). The number of ring-constituting atoms preferably ranges from five to ten (5- to 10-membered heteroaryl).

Specifically, the heteroaryl includes, for example, furyl group, thienyl group, pyrrolyl group, imidazolyl group, pyrazolyl group, thiazolyl group, isothiazolyl group, oxazolyl group, isooxazolyl group, oxadiazolyl group, thiadiazolyl group, triazolyl group, tetrazolyl group, pyridyl group, pyrimidyl group, pyridazinyl group, pyrazinyl group, triazinyl group, benzofuranyl group, benzothienyl group, benzothiadiazolyl group, benzothiazolyl group, benzoxazolyl group, benzoxadiazolyl group, benzoimidazolyl group, indolyl group, isoindolyl group, azaindolyl group, indazolyl group, quinolyl group, isoquinolyl group, cinnolinyl group, quinazolinyl group, quinoxalinyl group, benzodioxolyl group, indolidinyl group, and imidazopyridyl group.

Herein, "heterocycl" refers to a non-aromatic monovalent heterocyclic group in which the ring-constituting atoms include preferably one to five hetero atoms. The heterocycl may contain double or triple bonds in its ring. The carbon atoms may be oxidized to form carbonyl. The ring may be a monocyclic or condensed ring. The number of the ring-constituting atoms preferably ranges from three to ten (3- to 10-membered heterocycl).

Specifically, the heterocycl includes, for example, oxetanyl group, dihydrofuryl group, tetrahydrofuryl group, dihydropyranyl group, tetrahydropyranyl group, tetrahydropyridyl group, morpholinyl group, thiomorpholinyl group, pyrrolidinyl group, piperidinyl group, piperazinyl group, pyrazolidinyl group, imidazolinyl group, imidazolidinyl group, oxazolidinyl group, isooxazolidinyl group, thiazolidinyl group, isothiazolidinyl group, thiadiazolidinyl group, azetidinyl group, oxazolidone group, benzodioxanyl group, benzoxazolyl group, dioxolanyl group, and dioxanyl group.

Herein, "arylalkyl" refers to a group in which an arbitrary hydrogen atom in an "alkyl" defined above is substituted with an "aryl" defined above. The arylalkyl preferably includes C₆₋₁₀ aryl C₁₋₄ alkyl and C₆₋₁₀ aryl C₁₋₃ alkyl. Specifically, the arylalkyl includes, for example, benzyl group, phenethyl group, and naphthylmethyl group.

30

Herein, "heteroarylalkyl" refers to a group in which an arbitrary hydrogen atom in an alkyl defined above is substituted with a "heteroaryl" defined above. The heteroarylalkyl preferably includes 5- to 10-membered heteroaryl C₁₋₃ alkyl. Specifically, the heteroarylalkyl includes, for example, pyrrolylmethyl group, imidazolylmethyl group, thienylmethyl group, pyridylmethyl group, pyrimidylmethyl group, quinolylmethyl group, and pyridylethyl group.

Herein, "heterocyclalkyl" refers to a group in which an arbitrary hydrogen atom in an "alkyl" defined above is substituted with a "heterocycl" defined above. The heterocyclalkyl preferably includes 3- to 10-membered heterocycl C₁₋₃ alkyl. Specifically, the heterocyclalkyl includes, for example, morpholinylmethyl group, morpholinylethyl group, thiomorpholinylmethyl group, pyrrolidinylmethyl group, piperidinylmethyl group, piperazinylmethyl group, piperazinylethyl group, and oxetanymethyl group.

Herein, "monohydroxyalkyl" refers to a group in which an arbitrary hydrogen atom in an "alkyl" defined above is substituted with a hydroxyl group. The monohydroxyalkyl preferably includes C₁₋₆ monohydroxyalkyl and C₂₋₆ monohydroxyalkyl. Specifically, the monohydroxyalkyl includes, for example, hydroxymethyl group, 1-hydroxyethyl group, and 2-hydroxyethyl group.

Herein, "dihydroxyalkyl" refers to a group in which two arbitrary hydrogen atoms in an "alkyl" defined above are substituted with two hydroxyl groups. The dihydroxyalkyl preferably includes C₁₋₆ dihydroxyalkyl and C₂₋₆ dihydroxyalkyl. Specifically, the dihydroxyalkyl includes, for example, 1,2-dihydroxyethyl group, 1,2-dihydroxypropyl group, and 1,3-dihydroxypropyl group.

Herein, "trihydroxyalkyl" refers to a group in which three arbitrary hydrogen atoms in an "alkyl" defined above are substituted with three hydroxyl groups. The trihydroxyalkyl preferably includes C₁₋₆ trihydroxyalkyl and C₂₋₆ trihydroxyalkyl.

Herein, "alkoxyalkyl" refers to a group in which an arbitrary hydrogen atom in an "alkyl" defined above is substituted with an "alkoxy" defined above. The alkoxyalkyl preferably includes C₁₋₃ alkoxy C₁₋₄ alkyl and C₁₋₃ alkoxy C₂₋₄ alkyl. Specifically, the alkoxyalkyl includes, for example, methoxyethyl.

Herein, "alkoxyalkoxyalkyl" refers to a group in which an arbitrary hydrogen atom in the terminal alkyl of an "alkoxyalkyl" defined above is substituted with an "alkoxy" defined above. The alkoxyalkoxyalkyl preferably includes C₁₋₃ alkoxy C₁₋₄ alkoxy C₁₋₄ alkyl and C₁₋₃ alkoxy C₂₋₄ alkoxy C₂₋₄ alkyl.

Herein, "aminoalkyl" refers to a group in which an arbitrary hydrogen atom in an "alkyl" defined above is substituted with an amino group. The aminoalkyl group preferably includes C₁₋₄ aminoalkyl and C₂₋₄ aminoalkyl.

Herein, "alkylamino" refers to an amino group linked with an "alkyl" defined above. The alkylamino preferably includes C₁₋₄ alkylamino.

Herein, "dialkylamino" refers to an amino group linked with two "alkyls" defined above. The two alkyl groups may be same or different. The dialkylamino preferably includes di(C₁₋₄ alkyl)amino.

Herein, "alkylaminoalkyl" refers to a group in which an arbitrary hydrogen atom in an "alkyl" defined above is substituted with an "alkylamino" defined above. The alkylaminoalkyl preferably includes C₁₋₄ alkylamino C₁₋₄ alkyl and C₁₋₄ alkylamino C₂₋₄ alkyl.

Herein, "dialkylaminoalkyl" refers to a group in which an arbitrary hydrogen atom in an "alkyl" defined above is substituted with a "dialkylamino" defined above. The dialkyl-

larninoalkyl preferably includes di(C₁₋₄ alkyl)amino C₁₋₄ alkyl and di(C₁₋₄ alkyl)amino C₂₋₄ alkyl.

Herein, “heterocycllamino” refers to an amino group linked with a “heterocycl” defined above. The heterocycllamino preferably includes 3- to 10-membered heterocycllamino.

Herein, “cyanoalkyl” refers to a group in which an arbitrary hydrogen atom in an “alkyl” defined above is substituted with a cyano group. The cyanoalkyl preferably includes cyano (C₁₋₃ alkyl).

Herein, “alkylsulfonyl” refers to a sulfonyl group linked with an “alkyl” defined above (i.e. alkyl-SO₂—). The alkylsulfonyl preferably includes C₁₋₃ alkylsulfonyl. Specifically, the alkylsulfonyl includes methylsulfonyl, ethylsulfonyl, n-propylsulfonyl, and i-propylsulfonyl.

Herein, “alkylsulfonylalkyl” refers to a group in which an arbitrary hydrogen atom in an “alkyl” defined above is substituted with an “alkylsulfonyl” defined above. The alkylsulfonylalkyl preferably includes C₁₋₃ alkylsulfonyl C₁₋₄ alkyl and C₁₋₃ alkylsulfonyl C₂₋₄ alkyl.

The compounds of the present invention include free forms and pharmaceutically acceptable salts thereof. Such “salts” include, for example, inorganic acid salts, organic acid salts, inorganic base salts, organic base salts, and acidic or basic amino acid salts.

Preferred inorganic acid salts include, for example, hydrochloride, hydrobromide, sulfate, nitrate, and phosphate. Preferred organic salts include, for example, acetate, succinate, fumarate, maleate, tartrate, citrate, lactate, malate, stearate, benzoate, methanesulfonate, and p-toluenesulfonate. A particularly preferred salt in the present invention is malate.

Preferred inorganic base salts include, for example, alkali metal salts such as sodium salts and potassium salts; alkali earth metal salts such as calcium salts and magnesium salts; aluminum salts; and ammonium salts. Preferred organic base salts include, for example, diethylamine salts, diethanolamine salts, meglumine salts, and N,N-dibenzylethylenediamine salts.

Preferred acidic amino acid salts include, for example, aspartate and glutamate. Preferred basic amino acid salts include, for example, arginine salts, lysine salts, and ornithine salts.

When the compounds of the present invention are left standing in the atmosphere, they may absorb moisture to adsorb water or form hydrates. Such hydrates are also included in the salts of the present invention.

Furthermore, the compounds of the present invention may absorb other solvents to form solvates. Such solvates are also included in the salts of the present invention.

All structurally possible isomers (geometric isomers, optical isomers, stereoisomers, tautomers, etc.) of the compounds of the present invention and mixtures of such isomers are included in the present invention.

The compounds of the present invention may have polymorphic crystalline forms. Such polymorphs are all included in the present invention.

The compounds of the present invention include prodrugs thereof. The prodrugs refer to derivatives of the compounds of the present invention which have a chemically or metabolically degradable group, and upon administration to the living body, revert to the original compounds and exhibit the original drug efficacy. The prodrugs include non-covalent complexes and salts.

The compounds of the present invention include those in which one or more atoms within the molecule have been replaced with isotopes. Herein, the isotope refers to an atom which has the same atomic number (proton number) but is

different in mass number (sum of protons and neutrons). The target atoms to be replaced with an isotope in the compounds of the present invention, include, for example, hydrogen atom, carbon atom, nitrogen atom, oxygen atom, phosphorus atom, sulfur atom, fluorine atom, and chlorine atom. Their isotopes include ²H, ³H, ¹³C, ¹⁴C, ¹⁵N, ¹⁷O, ¹⁸O, ³¹P, ³²P, ³⁵S, ¹⁸F and ³⁶Cl.

In particular, radioisotopes such as ³H and ¹⁴C, which decay emitting radiation, are useful in in vivo tissue distribution study etc. of pharmaceuticals or compounds.

Stable isotopes do not decay, are almost constant in abundance, and emit no radiation. For this reason, stable isotopes can be used safely. The compounds of the present invention can be converted into isotope-substituted compounds according to conventional methods by replacing reagents used in synthesis with reagents containing corresponding isotopes.

Preferably, the compounds of the present invention represented by formula (I) shown above are as follows:

R₁ shown above preferably represents hydrogen, hydroxy, halogen, cyano, nitro, C₁₋₄ haloalkyl, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, C₆₋₁₀ aryl C₁₋₄ alkyl, —OR₅, —NR₆R₇, —(CR₈R₉)_nZ₁, —C(O)NR₁₂R₁₃, —SR₁₄, —SOR₁₅, —SO₂R₁₆, —NR₁₇SO₂R₁₈, COOH, C₆₋₁₀ aryl which is optionally substituted with one or more groups independently selected from group P, 5- to 10-membered heteroaryl or 3- to 10-membered heterocycl each of which is optionally substituted with one or more groups independently selected from group Q, —COR₁₉, —COOR₂₀, —OC(O)R₂₁, —NR₂₂C(O)R₂₃, —NR₂₄C(S)R₂₅, —C(S)NR₂₆R₂₇, —SO₂NR₂₈R₂₉, —OSO₂R₃₀, —SO₃R₃₁, or —Si(R₃₂)₃.

R₁ shown above more preferably represents hydrogen, hydroxy, halogen, cyano, C₁₋₄ haloalkyl, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₃₋₇ cycloalkyl, C₆₋₁₀ aryl C₁₋₄ alkyl, —OR₅, —NR₆R₇, —(CR₈R₉)_nZ₁, —C(O)NR₁₂R₁₃, —SR₁₄, —SO₂R₁₆, —NR₁₇SO₂R₁₈, COOH, C₆₋₁₀ aryl which is optionally substituted with one or more groups independently selected from group P, or 5- to 10-membered heteroaryl or 3- to 10-membered heterocycl each of which is optionally substituted with one or more groups independently selected from group Q. Specifically, the above 5- to 10-membered heteroaryl is particularly preferably an imidazolyl group, thienyl group, pyridyl group, pyridazinyl group, or pyrazolyl group. The above 3- to 10-membered heterocycl is particularly preferably a morpholinyl group, tetrahydropyridyl group, or piperidinyl group.

R₂ shown above preferably represents hydrogen, hydroxy, halogen, cyano, nitro, C₁₋₄ haloalkyl, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, C₆₋₁₀ aryl C₁₋₄ alkyl, —OR₅, —NR₆R₇, —(CR₈R₉)_nZ₁, —C(O)NR₁₂R₁₃, —SR₁₄, —SOR₁₅, —SO₂R₁₆, —NR₁₇SO₂R₁₈, COOH, C₆₋₁₀ aryl which is optionally substituted with one or more groups independently selected from group P, 5- to 10-membered heteroaryl or 3- to 10-membered heterocycl each of which is optionally substituted with one or more groups independently selected from group Q, —COR₁₉, —COOR₂₀, —OC(O)R₂₁, —NR₂₂C(O)R₂₃, —NR₂₄C(S)R₂₅, —C(S)NR₂₆R₂₇, —SO₂NR₂₈R₂₉, —OSO₂R₃₀, —SO₃R₃₁, or —Si(R₃₂)₃.

R₂ shown above more preferably represents hydrogen, halogen, C₁₋₄ haloalkyl, C₁₋₆ alkyl, —OR₅, C₆₋₁₀ aryl which is optionally substituted with one or more groups independently selected from group P, or 5- to 10-membered heteroaryl which is optionally substituted with one or more groups independently selected from group Q. Specifically, this 5- to 10-membered heteroaryl is particularly preferably a pyridyl group.

R₁ and R₂ shown above can preferably be taken together with the atoms to which they are attached to form 3- to 10-membered heterocycl or 5- to 10-membered heteroaryl.

33

The heterocycl or heteroaryl may have a halogen atom as a substituent. Specifically, the 3- to 10-membered heterocycl formed together with the atoms to which R₁ and R₂ are attached, is particularly preferably a dioxolanyl group or dioxanyl group.

R₃ shown above preferably represents hydrogen, C₁₋₅ alkyl, C₆₋₁₀ aryl C₁₋₆ alkyl, or C₁₋₄ haloalkyl, more preferably hydrogen, C₁₋₄ alkyl, C₆₋₁₀ aryl C₁₋₄ alkyl, or C₁₋₃ perfluoroalkyl, and particularly preferably C₁ alkyl.

R₄ shown above preferably represents hydrogen, halogen, C₁₋₃ alkyl, C₁₋₄ haloalkyl, hydroxy, cyano, nitro, C₁₋₄ alkoxy, —(CH₂)_nZ₁, —NR₆R₇, —OR₅, —C(O)NR₁₂R₁₃, —SR₁₄, —SOR₁₅, —SO₂R₁₆, NR₁₇SO₂R₁₈, COOH, —COR₁₉, —COOR₂₀, —OC(O)R₂₁, —NR₂₂C(O)R₂₃, —NR₂₄C(S)R₂₅, —C(S)NR₂₆R₂₇, —SO₂NR₂₈R₂₉, —OSO₂R₃₀—SO₃R₃₁, or —Si(R₃₂)₃.

R₄ shown above more preferably represents hydrogen, halogen, C₁₋₃ alkyl, C₁₋₃ perfluoroalkyl, cyano, methanesulfonyl, hydroxyl, alkoxy, or amino, and particularly preferably hydrogen or halogen.

Ring A shown above is represented by the following formula:



(herein, it may be simply referred to as "A"). Ring A is preferably a 5- to 10-membered heteroaryl ring or C₆₋₁₀ aryl ring, more preferably benzene, indole, azaindole, benzofuran, benzothiophene, benzothiazole, quinoline, or pyrrole, and particularly preferably indole or pyrrole.

R₅ shown above preferably represents C₁₋₅ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkyl C₁₋₃ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₄ haloalkyl, C₁₋₃ alkoxy C₁₋₄ alkyl, C₁₋₃ alkoxy C₁₋₄ alkoxy C₁₋₄ alkyl, C₁₋₄ amino alkyl, C₁₋₄ alkylamino C₁₋₄ alkyl, di(C₁₋₄ alkyl)amino C₁₋₄ alkyl, C₆₋₁₀ aryl, C₆₋₁₀ aryl C₁₋₃ alkyl, or 3- to 10-membered heterocycl C₁₋₃ alkyl, 3- to 10-membered heterocycl, 5- to 10-membered heteroaryl, or 5- to 10-membered heteroaryl C₁₋₃ alkyl, each of which is optionally substituted with one or more groups independently selected from group Q, C₁₋₆ monohydroxyalkyl, C₁₋₆ dihydroxyalkyl, or C₁₋₆ trihydroxyalkyl.

R₅ shown above more preferably represents C₁₋₅ alkyl, C₃₋₇ cycloalkyl C₁₋₃ alkyl, C₁₋₄ haloalkyl, C₁₋₃ alkoxy C₁₋₄ alkyl, C₆₋₁₀ aryl, C₆₋₁₀ aryl C₁₋₃ alkyl, or 3- to 10-membered heterocycl C₁₋₃ alkyl or 3- to 10-membered heterocycl each of which is optionally substituted with one or more groups independently selected from group Q. Specifically, the above 3- to 10-membered heterocyclalkyl is particularly preferably a piperazinylethyl group, oxetanymethyl group, or morpholinylethyl group. The above 3- to 10-membered heterocycl is particularly preferably an oxetanyl group or tetrahydropyranyl group.

R₆ and R₇ shown above may be the same or different, and each preferably represents hydrogen, C₁₋₄ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₄ haloalkyl, C₁₋₃ alkoxy C₂₋₄ alkyl, C₆₋₁₀ aryl C₁₋₃ alkyl, 3- to 10-membered heterocycl C₁₋₃ alkyl, 5- to 10-membered heteroaryl C₁₋₃ alkyl, C₁₋₆ monohydroxyalkyl, C₁₋₆ dihydroxyalkyl, C₁₋₆ trihydroxyalkyl, 3- to 10-membered heterocycl, C₁₋₄ aminoalkyl, C₁₋₄ alkylamino C₁₋₄ alkyl, di(C₁₋₄ alkyl)amino C₁₋₄ alkyl, or cyano(C₁₋₃ alkyl).

R₆ and R₇ shown above more preferably each independently represent hydrogen, C₁₋₃ alkoxy C₁₋₄ alkyl, 3- to 10-membered heterocycl C₁₋₃ alkyl, 5- to 10-membered

34

heteroaryl C₁₋₃ alkyl, or C₁₋₆ dihydroxyalkyl. Specifically, the 3- to 10-membered heterocyclalkyl is particularly preferably a morpholinylethyl group, and the 5- to 10-membered heteroarylalkyl is particularly preferably a pyridylethyl group.

Alternatively, R₆ and R₇ shown above can preferably be taken together with the nitrogen atoms to which they are attached to form 3- to 10-membered heterocycl or 5- to 10-membered heteroaryl.

¹⁰ "n" shown above represents an integer from 1 to 3. Preferably, n is 1.

R₈ and R₉ shown above preferably may be the same or different, and each represents hydrogen, C₁₋₄ alkyl, or halogen, and more preferably hydrogen.

Alternatively, R₈ and R₉ shown above can preferably be taken together with the carbon atoms to which they are attached to form an alicyclic ring.

Z₁ shown above preferably represents hydrogen, NR₁₀R₁₁, —OH, or 3- to 10-membered heterocycl or 5- to 10-membered heteroaryl each of which is optionally substituted with one or more groups independently selected from group Q, more preferably NR₁₀R₁₁ or —OH, or 3- to 10-membered heterocycl which is optionally substituted with one or more groups independently selected from group Q. Specifically, the above 3- to 10-membered heterocycl is particularly preferably a pyrrolidinyl group, piperazinyl group, piperidinyl group, or morpholinyl group.

²⁰ R₁₀ and R₁₁ shown above preferably may be the same or different, and each preferably represents C₁₋₄ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₄ haloalkyl, C₁₋₃ alkoxy C₁₋₄ alkyl, cyano(C₁₋₃ alkyl), or C₁₋₃ alkylsulfonyl C₁₋₄ alkyl, more preferably C₁₋₄ alkyl, C₂₋₆ alkynyl, or C₁₋₃ alkoxy C₂₋₄ alkyl.

Alternatively, R₁₀ and R₁₁ shown above can preferably be taken together with the nitrogen atoms to which they are attached to form 3- to 10-membered heterocycl or 5- to 10-membered heteroaryl.

R₁₂ and R₁₃ shown above preferably may be the same or different, and each represents hydrogen, C₁₋₄ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₄ haloalkyl, C₁₋₃ alkoxy C₁₋₄ alkyl, C₆₋₁₀ aryl, 5- to 10-membered heteroaryl, 3- to 10-membered heterocycl, C₆₋₁₀ aryl C₁₋₄ alkyl, 3- to 10-membered heterocycl C₁₋₃ alkyl, 5- to 10-membered heteroaryl C₁₋₃ alkyl, cyano(C₁₋₃ alkyl), C₁₋₃ alkylsulfonyl C₁₋₄ alkyl, or 3- to 10-membered alicyclic ring, more preferably hydrogen, C₁₋₄ alkyl, or C₁₋₄ haloalkyl.

Alternatively, R₁₂ and R₁₃ shown above preferably can be taken together with the nitrogen atoms to which they are attached to form 3- to 10-membered heterocycl or 5- to 10-membered heteroaryl each of which is optionally substituted with one or more groups independently selected from group Q, and particularly preferably 3- to 10-membered heterocyclalkyl. Specifically, piperazinyl group, morpholinyl group, pyrrolidinyl group, and piperidinyl group are more preferred.

⁴⁰ R₁₄ shown above preferably represents C₁₋₄ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₄ haloalkyl, C₆₋₁₀ aryl which is optionally substituted with one or more groups independently selected from group P, or 5- to 10-membered heteroaryl or 3- to 10-membered heterocycl each of which is optionally substituted with one or more groups independently selected from group Q, and more preferably represents C₁₋₄ alkyl or C₁₋₄ haloalkyl.

⁶⁰ R₁₅ shown above preferably represents C₁₋₄ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₄ haloalkyl, C₆₋₁₀ aryl which is optionally substituted with one or more groups independently selected from group P, or 5- to 10-membered heteroaryl or 3-

to 10-membered heterocycl each of which is optionally substituted with one or more groups independently selected from group Q.

R₁₆ shown above preferably represents C₁₋₄ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₄ haloalkyl, C₆₋₁₀ aryl which is optionally substituted with one or more groups independently selected from group P, or 5- to 10-membered heteroaryl or 3- to 10-membered heterocycl each of which is optionally substituted with one or more groups independently selected from group Q, and more preferably represents C₁₋₄ alkyl.

R₁₇ shown above preferably represents hydrogen or C₁₋₄ alkyl, and more preferably hydrogen.

R₁₈ shown above preferably represents C₁₋₄ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₄ haloalkyl, C₆₋₁₀ aryl which is optionally substituted with one or more groups independently selected from group P, or 5- to 10-membered heteroaryl or 3- to 10-membered heterocycl each of which is optionally substituted with one or more groups independently selected from group Q, and more preferably represents C₁₋₄ alkyl.

R₁₉ shown above preferably represents hydrogen, C₁₋₄ alkyl, C₃₋₇ cycloalkyl, C₁₋₄ haloalkyl, C₆₋₁₀ aryl, or 5- to 10-membered heteroaryl or 3- to 10-membered heterocycl each of which is optionally substituted with one or more groups independently selected from group Q, and more preferably represents hydrogen, or 5- to 10-membered heteroaryl or 3- to 10-membered heterocycl each of which is optionally substituted with one or more groups independently selected from group Q. Specifically, this 3- to 10-membered heterocycl is more preferably a piperazinyl group, morpholinyl group, pyrrolidinyl group, or piperidinyl group.

R₂₀ shown above preferably represents C₁₋₄ alkyl, C₃₋₇ cycloalkyl, C₁₋₄ haloalkyl, C₆₋₁₀ aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocycl.

R₂₁ shown above preferably represents C₁₋₄ alkyl, C₃₋₇ cycloalkyl, C₁₋₄ haloalkyl, C₆₋₁₀ aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocycl.

R₂₂ shown above preferably represents hydrogen, C₁₋₄ alkyl, or C₁₋₄ haloalkyl.

R₂₃ shown above preferably represents hydrogen, C₁₋₄ alkyl, C₃₋₇ cycloalkyl, C₁₋₄ haloalkyl, C₆₋₁₀ aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocycl.

R₂₄ shown above preferably represents hydrogen, C₁₋₄ alkyl, or C₁₋₄ haloalkyl.

R₂₅ shown above preferably represents C₁₋₄ alkyl, C₃₋₇ cycloalkyl, C₁₋₄ haloalkyl, C₆₋₁₀ aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocycl.

R₂₆ and R₂₇ shown above preferably may be the same or different, and each represents hydrogen, C₁₋₄ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₄ haloalkyl, C₁₋₃ alkoxy C₁₋₄ alkyl, C₆₋₁₀ aryl, 5- to 10-membered heteroaryl, 3- to 10-membered heterocycl, C₆₋₁₀ aryl C₁₋₄ alkyl, 3- to 10-membered heteroaryl C₁₋₃ alkyl, 5- to 10-membered heteroaryl C₁₋₃ alkyl, cyano(C₁₋₃ alkyl), C₁₋₃ alkylsulfonyl C₁₋₄ alkyl, or 3- to 10-membered alicyclic ring.

Alternatively, R₂₆ and R₂₇ shown above can preferably be taken together with the nitrogen atoms to which they are attached to form 3- to 10-membered heterocycl or 5- to 10-membered heteroaryl.

R₂₈ and R₂₉ shown above preferably may be the same or different, and each represents hydrogen, C₁₋₄ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₄ haloalkyl, C₁₋₃ alkoxy C₁₋₄ alkyl, C₆₋₁₀ aryl, 5- to 10-membered heteroaryl, 3- to 10-membered heterocycl, C₆₋₁₀ aryl C₁₋₄ alkyl, 3- to 10-membered heteroaryl C₁₋₃ alkyl, 5- to 10-membered heteroaryl C₁₋₃ alkyl, cyano(C₁₋₃ alkyl), C₁₋₃ alkylsulfonyl C₁₋₄ alkyl, or 3- to 10-membered alicyclic ring.

Alternatively, R₂₈ and R₂₉ shown above preferably can be taken together with the nitrogen atoms to which they are attached to form 3- to 10-membered heterocycl or 5- to 10-membered heteroaryl.

R₃₀ shown above preferably represents C₁₋₄ alkyl, C₃₋₇ cycloalkyl, C₁₋₄ haloalkyl, C₆₋₁₀ aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocycl.

R₃₁ shown above preferably represents C₁₋₄ alkyl, C₃₋₇ cycloalkyl, C₁₋₄ haloalkyl, C₆₋₁₀ aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocycl.

R₃₂ shown above preferably represents C₁₋₄ alkyl, or C₆₋₁₀ aryl.

Preferred substituents included in group P defined above are halogen, C₁₋₄ alkyl, C₁₋₄ haloalkyl, —OH, C₁₋₃ alkoxy, C₁₋₃ haloalkoxy, 3- to 10-membered heterocyclamino, —SO₂R, —CN, —NO₂, and 3- to 10-membered heterocycl; and more preferably halogen, C₁₋₄ haloalkyl, C₁₋₃ alkoxy, C₁₋₃ haloalkoxy, and 3- to 10-membered heterocycl. Specifically, this 3- to 10-membered heterocycl is particularly preferably a morpholinyl group.

Preferred substituents included in group Q defined above are halogen, C₁₋₄ alkyl, C₁₋₄ haloalkyl, —OH, C₁₋₃ alkoxy, C₁₋₆ monohydroxyalkyl, C₁₋₆ dihydroxyalkyl, C₁₋₆ trihydroxyalkyl, 3- to 10-membered heterocyclamino, —SO₂R, —CN, —NO₂, C₃₋₂ cycloalkyl, —COR₁₉, and 3- to 10-membered heterocycl which is optionally substituted with C₁₋₄ alkyl; and more preferably halogen, C₁₋₄ alkyl, C₁₋₄ haloalkyl, —OH, C₁₋₃ alkoxy, C₁₋₆ monohydroxyalkyl, —SO₂R₁₆, C₃₋₇ cycloalkyl, —COR₁₉, and 3- to 10-membered heterocycl which is optionally substituted with C₁₋₄ alkyl. Specifically, this 3- to 10-membered heterocycl is more preferably a piperazinyl group, piperidinyl group, or morpholinyl group.

Specifically, the compounds of the present invention include, for example:

- (1) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1H-indol-2-yl]-methanone;
- (2) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-pyrrolidin-1-ylmethyl-1H-indol-2-yl]-methanone;
- (3) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(4-hydroxy-piperidin-1-ylmethyl)-1H-indol-2-yl]-methanone;
- (4) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1H-pyrrolo[3,2-c]pyridin-2-yl]-methanone;
- (5) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-piperazin-1-ylmethyl-1H-indol-2-yl]-methanone;
- (6) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(2-morpholin-4-yl-ethoxy)-1H-indol-2-yl]-methanone;
- (7) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(tetrahydro-pyran-4-yloxy)-1H-indol-2-yl]-methanone;
- (8) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-chloro-1H-indol-2-yl]-methanone;
- (9) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-bromo-1H-indol-2-yl]-methanone;
- (10) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-iodo-1H-indol-2-yl]-methanone;
- (11) 2-[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazole-4-carbonyl]-1H-indole-5-carbonitrile;
- (12) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-bromo-5-fluoro-1H-indol-2-yl]-methanone;
- (13) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-ethynyl-1H-indol-2-yl]-methanone;

- (14) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(2-fluoro-phenyl)-1H-indol-2-yl]-methanone;
- (15) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(3-fluoro-phenyl)-1H-indol-2-yl]-methanone;
- (16) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(4-fluoro-phenyl)-1H-indol-2-yl]-methanone;
- (17) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(2-chloro-phenyl)-1H-indol-2-yl]-methanone;
- (18) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(3-chloro-phenyl)-1H-indol-2-yl]-methanone;
- (19) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(4-chloro-phenyl)-1H-indol-2-yl]-methanone;
- (20) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(2-trifluoromethyl-phenyl)-1H-indol-2-yl]-methanone;
- (21) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(3-trifluoromethyl-phenyl)-1H-indol-2-yl]-methanone;
- (22) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(4-trifluoromethyl-phenyl)-1H-indol-2-yl]-methanone;
- (23) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-bromo-1H-indol-2-yl]-methanone;
- (24) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(3-fluoro-pyridin-2-yl)-1H-indol-2-yl]-methanone;
- (25) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(methyl-1H-indol-2-yl)-methanone];
- (26) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(4,4-difluoro-piperidine-1-carbonyl)-1H-indol-2-yl]-methanone;
- (27) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(3,3-difluoro-piperidine-1-carbonyl)-1H-indol-2-yl]-methanone;
- (28) 2-[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-carbonyl]-1H-indole-5-carboxylic acid (2,2,2-trifluoro-ethyl)-amide;
- (29) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(5-trifluoromethyl-pyridin-2-yl)-1H-indol-2-yl]-methanone;
- (30) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(6-trifluoromethyl-pyridin-2-yl)-1H-indol-2-yl]-methanone;
- (31) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(5-chloro-pyridin-2-yl)-1H-indol-2-yl]-methanone;
- (32) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(4-methyl-pyridin-2-yl)-1H-indol-2-yl]-methanone;
- (33) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(3-chloro-4-fluoro-phenyl)-1H-indol-2-yl]-methanone;
- (34) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(3-trifluoromethyl-pyridin-2-yl)-1H-indol-2-yl]-methanone;
- (35) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(4-trifluoromethyl-pyridin-2-yl)-1H-indol-2-yl]-methanone;
- (36) [5-amino-1-(6-fluoro-2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1H-indol-2-yl]-methanone;

- (37) 2-[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazole-4-carbonyl]-1H-indole-6-carboxylic acid;
- (38) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-hydroxymethyl-1H-indol-2-yl]-methanone;
- (39) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-[2-(4-methyl-piperazin-1-yl)-ethoxy]-1H-indol-2-yl]-methanone;
- (40) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(3-methyl-oxetan-3-ylmethoxy)-1H-indol-2-yl]-methanone;
- (41) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(3-fluoro-piperidin-1-ylmethyl)-1H-indol-2-yl]-methanone;
- (42) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-[{bis(2-methoxy-ethyl)-amino}-methyl]-1H-indol-2-yl]-methanone;
- (43) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-[(methyl-prop-2-ynyl-amino)-methyl]-1H-indol-2-yl]-methanone;
- (44) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(3,3-difluoro-pyrrolidin-1-ylmethyl)-1H-indol-2-yl]-methanone;
- (45) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(2,5-dimethyl-pyrrolidin-1-ylmethyl)-1H-indol-2-yl]-methanone;
- (46) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(3,3-difluoro-piperidin-1-ylmethyl)-1H-indol-2-yl]-methanone;
- (47) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-((S)-3-methyl-morpholin-4-ylmethyl)-1H-indol-2-yl]-methanone;
- (48) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-bromo-1H-indol-2-yl]-methanone;
- (49) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-iodo-1H-indol-2-yl]-methanone;
- (50) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1H-pyrrolo[3,2-b]pyridin-2-yl]-methanone;
- (51) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-bromo-6-trifluoromethyl-1H-indol-2-yl]-methanone;
- (52) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-iodo-1H-indol-2-yl]-methanone;
- (53) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-methyl-1H-indol-2-yl]-methanone;
- (54) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-isopropyl-1H-indol-2-yl]-methanone;
- (55) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(2-fluoro-phenyl)-1H-indol-2-yl]-methanone;
- (56) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-benzyl-1H-indol-2-yl]-methanone;
- (57) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(2-trifluoromethyl-phenyl)-1H-indol-2-yl]-methanone;
- (58) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(3-fluorophenyl)-1H-indol-2-yl]-methanone;
- (59) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(3-trifluoromethyl-phenyl)-1H-indol-2-yl]-methanone;
- (60) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-ethynyl-1H-indol-2-yl]-methanone;
- (61) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5H-[1,3]dioxolo[4,5-f]indol-6-yl]-methanone;

- (62) [5-amino-1-(7-fluoro-2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1H-indol-2-yl]-methanone;
 (63) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(4-trifluoromethyl-phenyl)-1H-indol-2-yl]-methanone;
 (64) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(butoxy-1H-indol-2-yl)-methanone;
 (65) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(1-methyl-piperidin-4-yl)-1H-indol-2-yl]-methanone;
 (66) N-[2-[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazole-4-carbonyl]-1H-indol-6-yl]-methane-sulfonamide;
 (67) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(6-morpholin-4-yl-pyridin-3-yl)-1H-indol-2-yl]-methanone;
 (68) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(butyl-1H-indol-2-yl)-methanone;
 (69) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(1-methyl-1H-pyrazol-4-yl)-1H-indol-2-yl]-methanone;
 (70) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(5-methoxy-pyridin-3-yl)-1H-indol-2-yl]-methanone;
 (71) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(2-methoxy-pyridin-3-yl)-1H-indol-2-yl]-methanone;
 (72) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(cyclopropyl-1H-indol-2-yl)-methanone;
 (73) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(2-methoxy-phenyl)-1H-indol-2-yl]-methanone;
 (74) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(phenyl-1H-indol-2-yl)-methanone;
 (75) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(5-methanesulfonyl-pyridin-3-yl)-1H-indol-2-yl]-methanone;
 (76) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(isopropyl-1H-indol-2-yl)-methanone;
 (77) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(pyridin-2-yl-1H-indol-2-yl)-methanone;
 (78) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(cyclopropyl-1H-indol-2-yl)-methanone;
 (79) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(pyridazin-3-yl-1H-indol-2-yl)-methanone;
 (80) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(isopropoxy-1H-indol-2-yl)-methanone;
 (81) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(2-methoxy-ethoxy)-1H-indol-2-yl]-methanone;
 (82) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(cyclopropylmethoxy-1H-indol-2-yl)-methanone;
 (83) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[2,2-difluoro-5H-[1,3]dioxolo[4,5-f]indol-6-yl]-methanone;
 (84) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(3-chloro-pyridin-2-yl)-1H-indol-2-yl]-methanone;
 (85) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(5-fluoro-pyridin-2-yl)-1H-indol-2-yl]-methanone;
 (86) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(6-morpholin-4-yl-pyridazin-3-yl)-1H-indol-2-yl]-methanone;

- (87) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-chloro-6-cyclopropylmethoxy-1H-indol-2-yl]-methanone;
 (88) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(2,4-difluoro-phenyl)-1H-indol-2-yl]-methanone;
 (89) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(pyridazin-4-yl-1H-indol-2-yl)-methanone;
 (90) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[3-fluoro-1H-indol-2-yl]-methanone;
 (91) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(1-isopropyl-piperidin-4-yl)-6-trifluoromethyl-1H-indol-2-yl]-methanone;
 (92) 2-[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazole-4-carbonyl]-1H-indole-6-carbonitrile;
 (93) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(1,2,3,6-tetrahydro-pyridin-4-yl)-1H-indol-2-yl]-methanone;
 (94) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(piperidin-4-yl-1H-indol-2-yl)-methanone;
 (95) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-((R)-3-fluoro-pyrrolidin-1-ylmethyl)-1H-indol-2-yl]-methanone;
 (96) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-fluoro-5-(1-methyl-piperidin-4-yl)-1H-indol-2-yl]-methanone;
 (97) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-fluoro-5-(1-methyl-piperidin-4-yl)-1H-indol-2-yl]-methanone;
 (98) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(1-isopropyl-piperidin-4-yl)-1H-indol-2-yl]-methanone;
 (99) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-fluoro-5-(1-isopropyl-piperidin-4-yl)-1H-indol-2-yl]-methanone;
 (100) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(pyridin-3-yl-1H-indol-2-yl)-methanone;
 (101) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(6-morpholin-4-yl-pyridin-3-yl)-1H-indol-2-yl]-methanone;
 (102) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(pyridin-3-yl-1H-indol-2-yl)-methanone;
 (103) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(6-piperazin-1-yl-pyridin-3-yl)-1H-indol-2-yl]-methanone;
 (104) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(6-hydroxy-pyridin-3-yl)-1H-indol-2-yl]-methanone;
 (105) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-fluoro-5-(4-methyl-piperazin-1-ylmethyl)-1H-indol-2-yl]-methanone;
 (106) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-fluoro-5-(pyrrolidin-1-ylmethyl)-1H-indol-2-yl]-methanone;
 (107) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(1-methyl-piperidin-4-yl)-1H-indol-2-yl]-methanone;
 (108) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(4-morpholin-4-yl-phenyl)-1H-indol-2-yl]-methanone;
 (109) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(3,4,5,6-tetrahydro-2H-[1,2']bipyridin-5-yl)-1H-indol-2-yl]-methanone;

- (110) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(6-piperazin-1-yl-pyridin-3-yl)-1H-indol-2-yl]-methanone;
- (111) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(6-methoxy-pyridin-3-yl)-1H-indol-2-yl]-methanone;
- (112) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-((S)-3-methyl-morpholin-4-ylmethyl)-1H-indol-2-yl]-methanone;
- (113) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-((R)-3-fluoro-pyrrolidin-1-ylmethyl)-1H-indol-2-yl]-methanone;
- (114) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(2,5-dimethyl-pyrrolidin-1-ylmethyl)-1H-indol-2-yl]-methanone;
- (115) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(3-fluoro-piperidin-1-ylmethyl)-1H-indol-2-yl]-methanone;
- (116) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(3,3-difluoro-piperidin-1-ylmethyl)-1H-indol-2-yl]-methanone;
- (117) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-[2-(4-methyl-piperazin-1-yl)pyridin-4-yl]-1H-indol-2-yl]-methanone;
- (118) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-pyridin-4-yl-1H-indol-2-yl]-methanone;
- (119) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(4-fluoropiperidin-1-ylmethyl)-1H-indol-2-yl]-methanone;
- (120) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(4,4-difluoro-piperidin-1-ylmethyl)-1H-indol-2-yl]-methanone;
- (121) [5-amino-1-(2-difluoromethyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(1-methyl-piperidin-4-yl)-1H-indol-2-yl]-methanone;
- (122) [5-amino-1-(2-difluoromethyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1H-indol-2-yl]-methanone;
- (123) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(3,3-difluoro-pyrrolidin-1-ylmethyl)-1H-indol-2-yl]-methanone;
- (124) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(1-cyclopentyl-piperidin-4-yl)-1H-indol-2-yl]-methanone;
- (125) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(1-cyclohexyl-piperidin-4-yl)-1H-indol-2-yl]-methanone;
- (126) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-bromo-1H-pyrrol-2-yl]-methanone;
- (127) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1H-pyrrol-2-yl]-methanone;
- (128) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-phenyl-1H-pyrrol-2-yl]-methanone;
- (129) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-(3H-pyrrol-2-yl)-methanone;
- (130) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-(4-fluoro-phenyl)-1H-pyrrol-2-yl]-methanone;
- (131) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-(3-fluoro-phenyl)-1H-pyrrol-2-yl]-methanone;
- (132) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-morpholin-4-ylmethyl-1H-indol-2-yl]-methanone;
- (133) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-(2-morpholin-4-yl-ethylamino)-1H-indol-2-yl]-methanone;

- (134) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(4-methyl-piperazine-1-carbonyl)-1H-indol-2-yl]-methanone;
- (135) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(2-morpholin-4-yl-ethylamino)-1H-indol-2-yl]-methanone;
- (136) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(piperazine-1-carbonyl)-1H-indol-2-yl]-methanone;
- (137) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-(2-methoxy-ethylamino)-1H-indol-2-yl]-methanone;
- (138) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-(2-hydroxy-1-hydroxymethyl-ethylamino)-1H-indol-2-yl]-methanone;
- (139) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-(2-pyridin-4-yl-ethylamino)-1H-indol-2-yl]-methanone;
- (140) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(2-methoxy-ethylamino)-1H-indol-2-yl]-methanone;
- (141) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-morpholin-4-yl-1H-indol-2-yl]-methanone;
- (142) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-morpholin-4-yl-1H-indol-2-yl]-methanone;
- (143) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-morpholin-4-ylmethyl-1H-indol-2-yl]-methanone;
- (144) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-morpholin-4-ylmethyl-1H-indol-2-yl]-methanone;
- (145) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(morpholine-4-carbonyl)-1H-indol-2-yl]-methanone;
- (146) [5-amino-1-(2-isopropyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1H-indol-2-yl]-methanone;
- (147) [5-amino-1-(2-propyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1H-indol-2-yl]-methanone;
- (148) [5-amino-1-(1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1H-indol-2-yl]-methanone;
- (149) [5-amino-1-(2-trifluoromethyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1H-indol-2-yl]-methanone;
- (150) [5-amino-1-(2-ethyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1H-indol-2-yl]-methanone;
- (151) [5-amino-1-(2-benzyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1H-indol-2-yl]-methanone;
- (152) 1-(4-{2-[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazole-4-carbonyl]-1H-indol-5-ylmethyl}-piperazin-1-yl)-ethanone;
- (153) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(4-methanesulfonyl-piperazin-1-ylmethyl)-1H-indol-2-yl]-methanone;
- (154) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-piperazin-1-ylmethyl-1H-indol-2-yl]-methanone;
- (155) 1-(4-{2-[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazole-4-carbonyl]-1H-indol-6-ylmethyl}-piperazin-1-yl)-ethanone;
- (156) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(4-methyl-piperazin-1-ylmethyl)-1H-indol-2-yl]-methanone;
- (157) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(4-methyl-piperazin-1-ylmethyl)-1H-indol-2-yl]-methanone;

- (158) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-pyrrolidin-1-ylmethyl-1H-indol-2-yl]-methanone;
- (159) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-fluoro-1H-indol-2-yl]-methanone;
- (160) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-fluoro-1H-indol-2-yl]-methanone;
- (161) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-fluoro-1H-indol-2-yl]-methanone;
- (162) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1H-pyrrolo[2,3-b]pyridin-2-yl]-methanone;
- (163) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-fluoro-6-morpholin-4-ylmethyl-1H-indol-2-yl]-methanone;
- (164) 2-[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazole-4-carbonyl]-1H-indole-5-carboxylic acid;
- (165) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-methoxy-1H-indol-2-yl]-methanone;
- (166) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4,6-dimethoxy-1H-indol-2-yl]-methanone;
- (167) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-methoxy-1H-indol-2-yl]-methanone;
- (168) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-methoxy-1H-indol-2-yl]-methanone;
- (169) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4,6-dimethyl-1H-indol-2-yl]-methanone;
- (170) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-tert-butyl-1H-indol-2-yl]-methanone;
- (171) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-isopropyl-1H-indol-2-yl]-methanone;
- (172) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-benzyloxy-1H-indol-2-yl]-methanone;
- (173) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-benzyloxy-1H-indol-2-yl]-methanone;
- (174) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5,6-dimethoxy-1H-indol-2-yl]-methanone;
- (175) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-tert-butyl-1H-indol-2-yl]-methanone;
- (176) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-fluoro-4-trifluoromethyl-1H-indol-2-yl]-methanone;
- (177) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-phenoxy-1H-indol-2-yl]-methanone;
- (178) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-methylsulfanyl-1H-indol-2-yl]-methanone;
- (179) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-tert-butyl-1H-indol-2-yl]-methanone;
- (180) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-methyl-1H-indol-2-yl]-methanone;
- (181) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-ethyl-1H-indol-2-yl]-methanone;
- (182) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-fluoro-6-trifluoromethyl-1H-indol-2-yl]-methanone;
- (183) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-fluoro-5-methoxy-1H-indol-2-yl]-methanone;
- (184) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-chloro-5-methoxy-1H-indol-2-yl]-methanone;
- (185) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-chloro-6-methoxy-1H-indol-2-yl]-methanone;

- (186) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-isopropoxy-1H-indol-2-yl]-methanone;
- (187) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-benzyloxy-1H-indol-2-yl]-methanone;
- 5 (188) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-isopropoxy-1H-indol-2-yl]-methanone;
- (189) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[2,3-dihydro-6H-[1,4]dioxino[2,3-f]indol-7-yl]-methanone;
- 10 (190) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4,6-di-tert-butyl-1H-indol-2-yl]-methanone;
- (191) 2-[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazole-4-carbonyl]-1H-indole-4-carbonitrile;
- 15 (192) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-imidazol-1-yl-1H-indol-2-yl]-methanone;
- (193) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-trifluoromethylsulfanyl-1H-indol-2-yl]-methanone;
- 20 (194) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-methylsulfanyl-1H-indol-2-yl]-methanone;
- (195) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-methanesulfonyl-1H-indol-2-yl]-methanone;
- (196) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(4,4-difluoro-piperidin-1-ylmethyl)-1H-indol-2-yl]-methanone;
- 25 (197) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(4-fluoro-piperidin-1-ylmethyl)-1H-indol-2-yl]-methanone;
- (198) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(oxetan-3-yloxy)-1H-indol-2-yl]-methanone;
- 30 (199) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-hydroxy-1H-indol-2-yl]-methanone;
- (200) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-methanesulfonyl-1H-indol-2-yl]-methanone;
- (201) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4,5-dibromo-1H-pyrrol-2-yl]-methanone;
- (202) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4,5-diphenyl-1H-pyrrol-2-yl]-methanone; and
- (203) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4,5-dipyridin-3-yl-1H-pyrrol-2-yl]-methanone.
- (204) [5-amino-1-(2-methyl-3H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-chloro-1H-indol-2-yl]-methanone;
- (205) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-chloro-1H-indol-2-yl]-methanone;
- (206) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1H-indol-3-yl]-methanone;
- 55 (207) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1H-indol-6-yl]-methanone;
- (208) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-bromo-6-fluoro-1H-indol-2-yl]-methanone;
- (209) [5-amino-1-(2-ethyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-bromo-6-fluoro-1H-indol-2-yl]-methanone;
- (210) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-trifluoromethyl-1H-indol-2-yl]-methanone;
- 60 (211) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-trifluoromethoxy-1H-indol-2-yl]-methanone;

- (212) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4,6-dichloro-1H-indol-2-yl]-methanone;
 (213) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-bromo-4-fluoro-1H-indol-2-yl]-methanone;
 (214) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-trifluoromethoxy-1H-indol-2-yl]-methanone;
 (215) [5-amino-1-(2-ethyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-trifluoromethoxy-1H-indol-2-yl]-methanone;
 (216) [5-amino-1-(2-ethyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-trifluoromethyl-1H-indol-2-yl]-methanone;
 (217) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5,6-dichloro-1H-indol-2-yl]-methanone;
 (218) [5-amino-1-(2-ethyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-bromo-5-fluoro-1H-indol-2-yl]-methanone;
 (219) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4,5-dichloro-1H-indol-2-yl]-methanone;
 (220) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4,6-difluoro-1H-indol-2-yl]-methanone;
 (221) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(3-chloro-pyridin-4-yl)-1H-indol-2-yl]-methanone;
 (222) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(6-methyl-pyridine-3-yl)-1H-indol-2-yl]-methanone;
 (223) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(5-fluoro-pyridin-3-yl)-1H-indol-2-yl]-methanone;
 (224) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(2-trifluoromethyl-pyridin-3-yl)-1H-indol-2-yl]-methanone;
 (225) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(5-chloro-2-methoxy-pyridin-3-yl)-1H-indol-2-yl]-methanone;
 (226) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(5-chloro-pyridin-3-yl)-1H-indol-2-yl]-methanone;
 (227) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-thiophen-3-yl-1H-indol-2-yl]-methanone;
 (228) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(4-chloropyridin-3-yl)-1H-indol-2-yl]-methanone;
 (229) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-thiophen-2-yl-1H-indol-2-yl]-methanone;
 (230) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(3-fluoro-pyridin-4-yl)-1H-indol-2-yl]-methanone;
 (231) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(2-trifluoromethyl-pyridin-4-yl)-1H-indol-2-yl]-methanone;
 (232) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(3,3-difluoro-pyrrolidine-1-carbonyl)-1H-indol-2-yl]-methanone;
 (233) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(2,6-dimethyl-morpholine-4-carbonyl)-1H-indol-2-yl]-methanone;
 (234) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-([1,4']bipiperidinyl-1'-carbonyl)-1H-indol-2-yl]-methanone;
 (235) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-[4-(2,2,2-trifluoro-ethyl)-piperazine-1-carbonyl]-1H-indol-2-yl]-methanone;

- (236) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-[4-(2-hydroxy-ethyl)-piperazine-1-carbonyl]-1H-indol-2-yl]-methanone;
 (237) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(3,3,4,4-tetrafluoro-pyrrolidine-1-carbonyl)-1H-indol-2-yl]-methanone;
 (238) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-((R)-3-fluoro-pyrrolidine-1-carbonyl)-1H-indol-2-yl]-methanone;
 (239) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-((S)-3-fluoro-pyrrolidine-1-carbonyl)-1H-indol-2-yl]-methanone;
 (240) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-(4-methoxy-phenyl)-1H-pyrrol-2-yl]-methanone;
 (241) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-(3-methoxy-phenyl)-1H-pyrrol-2-yl]-methanone;
 (242) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4,5-bis-(3-fluoro-phenyl)-1H-pyrrol-2-yl]-methanone;
 (243) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4,5-bis-(4-methoxy-phenyl)-1H-pyrrol-2-yl]-methanone;
 (244) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-(2,4-difluoro-phenyl)-1H-pyrrol-2-yl]-methanone;
 (245) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-(4-trifluoromethoxy-phenyl)-1H-pyrrol-2-yl]-methanone;
 (246) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4,5-bis-(3-methoxy-phenyl)-1H-pyrrol-2-yl]-methanone;
 (247) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-benzofuran-2-yl-methanone;
 (248) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-benzo[b]thiophen-2-yl-methanone;
 (249) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-benzothiazol-2-yl-methanone;
 (250) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-fluoro-phenyl]-methanone;
 (251) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[3-chloro-phenyl]-methanone;
 (252) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-quinolin-3-yl-methanone;
 (253) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-quinolin-7-yl-methanone; and
 (254) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-quinolin-6-yl-methanone.

The above compounds represented by formula (I) of the present invention and pharmaceutically acceptable salts thereof are useful as compounds that have an activity of inhibiting kinases of the fibroblast growth factor receptor (FGFR) family. Thus, the compounds are useful in preventing and/or treating cancer (for example, breast cancer, acute myelocytic leukemia, pancreatic cancer, bladder cancer, prostatic cancer, esophageal cancer, angiogenesis, stomach cancer, uterine body cancer, ovarian cancer, brain tumor (including glioblastoma), colon cancer, multiple myeloma, hepatocarcinoma, pulmonary cancer (including small cell and non-small cell lung cancers), and thyroid cancer).

The compounds of the present invention and salts thereof can be formulated into tablets, powders, fine granules, granules, coated tablets capsules, syrups, troches, inhalants, suppositories, injections, ointments, eye ointments, eye drops, nasal drops, ear drops, cataplasms, lotions, and the like by conventional methods. For the formulation, conventional

excipients, binders, lubricants, colorants, flavoring agents, and if needed, stabilizers, emulsifiers, absorbefacients, surfactants, pH adjusting agents, preservatives, antioxidants, and the like can be used. The compounds of the present invention are formulated by combining ingredients that are generally used as materials for pharmaceutical preparations, using conventional methods.

For example, to produce oral formulations, the compounds of the present invention or pharmaceutically acceptable salts thereof are combined with excipients, and if needed, binders, disintegrating agents, lubricants, colorants, flavoring agents, and the like; and then formulated into powders, fine granules, granules, tablets, coated tablets, capsules, and the like by conventional methods.

The ingredients include, for example, animal and vegetable oils such as soybean oils, beef tallow, and synthetic glycerides; hydrocarbons such as liquid paraffin, squalane, and solid paraffin; ester oils such as octyldodecyl myristate and isopropyl myristate; higher alcohols such as cetostearyl alcohol and behenyl alcohol; silicon resins; silicon oils; surfactants such as polyoxyethylene fatty acid esters, sorbitan fatty acid esters, glycerin fatty acid esters, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene hydrogenated castor oils, and polyoxyethylene/polyoxypropylene block copolymers; water-soluble polymers such as hydroxyethyl cellulose, polyacrylic acids, carboxyvinyl polymers, polyethylene glycol, polyvinylpyrrolidone, and methyl cellulose; lower alcohols such as ethanol and isopropanol; polyalcohols such as glycerin, propylene glycol, dipropylene glycol, and sorbitol; saccharides such as glucose and sucrose; inorganic powders such as silicic anhydride, magnesium aluminum silicate, and aluminum silicate; and purified water.

Excipients include, for example, lactose, cornstarch, sucrose, glucose, mannitol, sorbit, crystalline cellulose, and silicon dioxide.

Binders include, for example, polyvinyl alcohol, polyvinyl ether, methyl cellulose, ethyl cellulose, Arabic gum, tragacanth, gelatin, shellac, hydroxypropyl methyl cellulose, hydroxypropyl cellulose, polyvinylpyrrolidone, polypropylene glycol/polyoxyethylene block polymer, and meglumine.

Disintegrating agents include, for example, starch, agar, gelatin powder, crystalline cellulose, calcium carbonate, sodium bicarbonate, calcium citrate, dextran, pectin, and calcium carboxymethyl cellulose.

Lubricants include, for example, magnesium stearate, talc, polyethylene glycol, silica, and hardened vegetable oil.

Colorants approved for use as additives for pharmaceuticals are used. Flavoring agents used include, for example, cacao powder, menthol, aromatic powder, peppermint oil, borneol, and cinnamon powder.

Of course, these tablets and granules may be coated with sugar, or if needed, other appropriate coatings. Alternatively, when liquid preparations such as syrups and injections are produced, the compounds of the present invention or pharmaceutically acceptable salts thereof are combined with pH adjusting agents, solubilizers, isotonizing agents, or such, and if needed, solubilizing agents, stabilizers, and such, and then formulated using conventional methods.

Methods for producing external preparations are not limited, and they can be produced by conventional methods. Various conventional materials for pharmaceuticals, quasi-drugs, cosmetics, and the like can be used as base materials in the production. Specifically, the base materials used include, for example, animal and vegetable oils, mineral oils, ester oils, waxes, higher alcohols, fatty acids, silicon oils, surfactants, phospholipids, alcohols, polyalcohols, water-soluble polymers, clay minerals, and purified water. Furthermore, as

necessary, it is possible to add pH adjusting agents, antioxidants, chelating agents, preservatives, colorants, flavoring agents, and such. However, the base materials for external preparations of the present invention are not limited thereto.

Furthermore, if needed, the preparations may be combined with components that have an activity of inducing differentiation, or components such as blood flow-enhancing agents, antimicrobial agents, antiphlogistic agents, cell-activating agents, vitamins, amino acids, humectants, and keratolytic agents. The above-described base materials can be added at an amount that provides a concentration typically selected in the production of external preparations.

When the compounds of the present invention, salts, or hydrates thereof are administered, their dosage forms are not particularly limited, and they may be administered orally or parenterally by conventionally used methods. They can be formulated and administered as tablets, powders, granules, capsules, syrups, troches, inhalants, suppositories, injections, ointments, eye ointments, eye drops, nasal drops, ear drops, cataplasms, lotions, and the like.

The dosage of pharmaceuticals of the present invention can be appropriately selected depending on the severity of symptom, age, sex, weight, administration method, type of salt, specific type of disease, and such.

The dosage considerably varies depending on the type of disease, severity of symptom, age, sex, sensitivity to the agent, and such of the patient. Typically, the agent is administered to an adult once or several times a day at a daily dose of about 0.03 to 1000 mg, preferably 0.1 to 500 mg, and more preferably 0.1 to 100 mg. When an injection is used, the daily dose is typically about 1 to 3000 µg/kg, preferably about 3 to 1000 µg/kg.

When the compounds of the present invention are produced, material compounds and various reagents may form salts, hydrates, or solvates. The type varies depending on the starting material, solvent used, and such, and is not particularly limited as long as the reactions are not inhibited.

The solvents to be used vary depending on the starting material, reagent, and such, and as a matter of course, they are not particularly limited as long as they can dissolve starting materials to some extent without inhibiting the reactions.

Various isomers (for example, geometric isomers, optical isomers based on asymmetric carbons, rotational isomers, stereoisomers, and tautomers) can be purified and isolated by conventional separation methods such as recrystallization, diastereomer salt methods, enzyme-based resolution methods, various chromatographic methods (for example, thin-layer chromatography, column chromatography, high performance liquid chromatography, and gas chromatography).

When a compound of the present invention is obtained in a free form, it can be converted by conventional methods into a salt or hydrate thereof that may be formed from the compound of the present invention. When a compound of the present invention is obtained as a salt or hydrate thereof, it can be converted by conventional methods into a free form of the compound of the present invention.

The compounds of the present invention can be purified and isolated using conventional chemical methods such as extraction, concentration, distilling off, crystallization, filtration, re-crystallization, and various chromatographic methods.

All the prior art documents cited in this specification are incorporated herein by reference.

The general methods for producing the compounds of the present invention and working examples are described below.

The compounds of the present invention can be synthesized by various methods. Some of them are illustrated with

49

reference to the schemes shown below. The schemes are for illustrative purposes, and the present invention is not limited to the chemical reactions and conditions shown therein. In the schemes shown below, some substituents may be omitted for clarity, but this is not intended to limit the disclosure of the schemes. Representative compounds of the present invention can be synthesized using appropriate intermediates, known compounds, and reagents.

Production of the Compound Represented by Formula (I)

Scheme A shows a method for producing the compound represented by formula (I).

In the schemes and general production methods below, the definitions of R₁ and others are shown in each scheme or general production method. R₃₃ to R₃₇ are defined as follows:

R₃₃ represents an alkyl group.


R₃₄ and R₃₅ each represent an alkyl group. Alternatively, a plurality of R₃₄ or a plurality of R₃₅ together form a ring.

R₃₆ represents an alkyl group. Alternatively, a plurality of R₃₆ together form a ring.


R₃₇ represents an alkyl or aryl group.

The compound of formula (I) in which R₁, R₂, R₃, and R₄ are defined as in the compound represented by general formula (I) shown above can be produced by the method described below.

Scheme A



50



10

5

-continued

2-Ketoacetonitrile of formula (2) is obtained through a reaction between the carboxylic acid ester represented by formula (1) and acetonitrile anion which is generated by allowing a base to act on acetonitrile.

The compound represented by formula (1) is commercially available or can be prepared by methods known in the art. For example, aryl/heteroaryl carboxylic acid esters of formula (1) such as indole-2-carboxylic acid ethyl ester, benzofuran-2-carboxylic acid ethyl ester, benzoisophenone-2-carboxylic acid methyl ester, pyrrole-2-carboxylic acid methyl ester, and quinoline-6-carboxylic acid methyl ester, are commercially available. Other compounds can be prepared by heating corresponding carboxylic acids in alcohol (R₃₃OH) in the presence of an acid (for example, sulfuric acid). Alternatively, the methyl ester of formula (1), in which R₃₃ is a methyl group, can be prepared through a reaction with trimethylsilyldiazomethane or diazomethane in a solvent (for example, dichloromethane or methanol).

The compound of formula (2) can be prepared by methods known in the art. It can be prepared by treating acetonitrile with a base (for example, lithium diisopropylamide or n-butyl lithium) and then reacting the resultant acetonitrile anion with aryl/heteroaryl carboxylic acid ester.

The compound of formula (3) can be prepared by methods known in the art. 2-Keto-3-dimethylamino-acrylonitrile of formula (3) can be prepared by reacting 2-ketoacetonitrile of formula (2) with N,N-dimethylformamide dimethyl acetal in a solvent (for example, toluene or tetrahydrofuran).

The compound of formula (4) can be prepared by methods known in the art. 2-Keto-3-alkoxy-acrylonitrile of formula (4) can be prepared by reacting 2-ketoacetonitrile of formula (2) and trialkyl orthoformate in a solvent (for example, acetonitrile, chloroform, or acetic anhydride) under heat.

The compound of formula (I) can be prepared by methods known in the art. 5-Amino-ketopyrazole of formula (I) can be prepared by reacting 2-keto-3-dimethylamino-acrylonitrile of formula (3) with benzimidazol-5-yl hydrazine of formula (5) in the presence or absence of a base (for example, triethylamine or pyridine) in a solvent (for example, ethanol or N,N-dimethylacetamide); or reacting 2-keto-3-alkoxy-acrylonitrile of formula (4) with benzimidazol-5-yl hydrazine of formula (5) or a compound in which the hydrazine in formula (5) has been protected (for example, N-benzhydrylidene-N'-(2-methyl-1H-benzimidazol-5-yl)-hydrazine, N'-(2-methyl-1H-benzimidazol-5-yl)-hydrazine carboxylic acid tert-butyl ester, or N-tert-butoxycarbonyl-N'-(2-methyl-1H-benzimidazol-5-yl)-hydrazine carboxylic acid tert-butyl ester), in the presence or absence of a base (for example, triethylamine or pyridine) in a solvent (for example, ethanol or N,N-dimethylacetamide).

When compounds with ring A having an NH group such as indole or pyrrole are synthesized, in some cases, an ester of formula (1) is used to form an aminopyrazole ring through the

51

reactions of formula (3) or (4) and formula (5), and then deprotection is carried out to give formula (I) with ring A having an NH group.



Protecting groups for indole include arylsulfonyl groups (for example, benzenesulfonyl group and toluenesulfonyl group).
5

Formula (1) in which ring A is an indole ring protected by an arylsulfonyl group can be obtained by reacting formula (I) in which ring A is an unprotected indol with arylsulfonyl chloride (for example, benzyl halide or p-methoxybenzyl halide) in a solvent (for example, tetrahydrofuran or dimethylformamide) in the presence of a base (for example, sodium hydride or diisopropylethylamine).

Protecting groups for pyrrole include benzyl groups (for example, benzyl group and p-methoxybenzyl group). Formula (1) in which A is a pyrrole ring protected by a benzyl group can be obtained by reacting formula (I) in which A is an unprotected pyrrole with benzyl halide (for example, benzyl chloride, benzyl bromide, or 4-methoxybenzyl bromide) in a solvent (for example, tetrahydrofuran or dimethylformamide).

If the compound of formula (1) with desired R₁ or R₂ is not commercially available, it is possible to synthesize an ester of formula (1) having desired R₁ or R₂ by any one of methods (a) to (y) described below, and then synthesize formula (I) by the same method as in scheme A. Alternatively, the compound of formula (I) with a convertible substituent at R₁ or R₂ can be synthesized and then converted into the compound with desired substituent R₁ or R₂.

The conversion of substituent R₁ or R₂ can be achieved by any one of methods (a) to (y) described below.




60
65

65

52

-continued



10 Method (a)



When R₁ is an ether (—OR₅), the compound of formula (I) can be prepared through Mitsunobu reaction between alcohol (R₅OH) and the compound of formula (6) in which R₁ is a hydroxyl group, or through etherification in the presence of a base between the compound of formula (6) in which R₁ is a hydroxyl group and R₅X having leaving group X, such as halogen or alkylsulfonyloxy group.
15

Alternatively, an ester of formula (1) in which R₁ is ether (—OR₅) can be prepared through Mitsunobu reaction between alcohol (R₅OH) and an ester of formula (7) in which R₁ has a hydroxyl group, or through etherification in the presence of a base between the ester of formula (7) and R₅X having leaving group X, such as halogen or alkylsulfonyloxy group.
20

The ester of formula (1) in which R₁ is ether (—OR₅) can be used to prepare the compound of formula (I) in which R₁ is ether (—OR₅) by the same method as in scheme A.

In general, Mitsunobu reaction can be carried out using alcohol (R₅OH) and a compound having a hydroxyl group, in a solvent (for example, tetrahydrofuran or dioxane) in the presence of an azo compound (for example, diethyl azodicarboxylate or diisopropyl azodicarboxylate), phosphine (for example, triphenylphosphine or tri-n-butylphosphine).
25

In general, etherification can be carried out by heating a compound having a hydroxyl group and R₅X having leaving group X such as halogen or alkylsulfonyloxy group, in a solvent (for example, dimethylformamide or tetrahydrofuran) in the presence of a base (for example, sodium hydride or potassium carbonate).
30




60
65

65

7

Method (b)

The compound of formula (I) in which R_1 is an amino group (NR_6R_7) can be prepared by reacting the compound of formula (8) having halogen with an amine (NR_6R_7) at room temperature or under heat in the presence of a base (for example, cesium carbonate, sodium tert-butoxide, or potassium phosphate) and a ligand (for example, N,N-dimethylglycine, 1,10-phenanthroline, or tri-tert-butylphosphine) in a solvent (for example, dimethylsulfoxide, dimethylformamide, toluene, or dioxane) using a copper catalyst (for example, copper iodide) or palladium catalyst (for example, palladium acetate).




Method (c)

The compound of formula (I) in which R_1 is an aminomethyl group ($-(CR_8R_9)_nZ_1$, $R_8=R_9=H$) can be prepared through reductive amination between amine (NHR_8R_9) and the compound of formula (9) having an aldehyde group. Alternatively, an ester of formula (1) in which R_1 is an aminomethyl group ($-(CR_8R_9)_nZ_1$, $R_8=R_9=H$) can be prepared through reductive amination between amine (NHR_8R_9) and an ester of formula (10) having an aldehyde group. The compound of formula (I) in which R_1 is an aminomethyl group ($-(CR_8R_9)_nZ_1$, $R_8=R_9=H$) can be obtained by the same method as in scheme A using the ester of formula (1) in which R_1 is an aminomethyl group ($-(CR_8R_9)_nZ_1$, $R_8=R_9=H$).

In general, reductive amination can be carried out with aldehyde and amine (NHR_8R_9) using a reducing agent (for

example, sodium triacetoxyborohydride, sodium cyanoborohydride, or sodium borohydride) in a solvent (for example, dichloromethane, 1,2-dichloroethane, or methanol), in the presence of an acid (for example, acetic acid) in some cases, at from 0° C. to room temperature.




Method (d)

The compound of formula (I) in which R_1 is an amide ($CONR_{12}R_{13}$) can be prepared by reacting the carboxylic acid of formula (11) with an amine ($NHR_{12}R_{13}$) in the presence of a condensation agent.




In general, amide synthesis is achieved by converting carboxylic acid into acyl halide or activated ester using a halogenating agent (for example, thionyl chloride or oxalyl chloride) or an activator (for example, ethyl chloroformate), respectively, and then reacting it with an amine ($NHR_{12}R_{13}$) in a solvent (for example, tetrahydrofuran, dimethylformamide, or dichloromethane).

Alternatively, amide synthesis is achieved by synthesizing an active ester from carboxylic acid using a condensation agent (for example, dicyclohexylcarbodiimide) in the presence of a base (for example, triethylamine) in a solvent (for example, tetrahydrofuran, dimethylformamide, or dichloromethane), and then treating the resulting active ester with an amine ($NHR_{12}R_{13}$).



55

-continued

**Method (e)**






The compound of formula (I) in which R₁ is sulfide (—SR₁₄) can be prepared by reacting thiol with the compound of formula (8) having halogen in the presence of a base (for example, cesium carbonate, lithium hexamethyldisilazide or potassium phosphate) and a catalyst (for example, copper iodide, or palladium acetate) in a solvent (for example, dimethylsulfoxide or 1,2-dimethoxyethane) under heat.

The ester of formula (1) in which R₁ is sulfide (—SR₁₄) can be prepared by reacting thiol with the ester of formula (12) having halogen in the presence of a base (for example, cesium carbonate, lithium hexamethyldisilazide or potassium phosphate) and a catalyst (for example, copper iodide, or palladium acetate) in a solvent (for example, dimethylsulfoxide or 1,2-dimethoxyethane) with heating.

Alternatively, the ester of formula (1) can be prepared by reacting the ester of formula (12) with a base (for example, n-butyl lithium) at a low temperature (-80 to 0° C.) in a solvent (for example, diethyl ether or tetrahydrofuran), and then reacting it with alkylsulfide or dialkyldisulfide. The ester of formula (1) in which R₁ is sulfide (—SR₁₄) can be used to prepare the compound of formula (I) in which R₁ is sulfide (—SR₁₄) by the same method as in scheme A.

15 Method (f)

The compound of formula (I) in which R₁ is sulfoxide (—SO₂R₁₅) can be prepared by treating the compound of formula (13) having a sulfide group (—SR₁₅) with an oxidizing agent (for example, m-chloroperbenzoic acid, oxon, or hydrogen peroxide) in a solvent (for example, dichloromethane, methanol, or water).




**60 Method (g)**

The compound of formula (I) in which R₁ is sulfone (—SO₂R₁₆) can be prepared by treating the compound of formula (14) having sulfide (—SR₁₆) with an oxidizing agent (for example, m-chloroperbenzoic acid, oxon, or hydrogen peroxide) in a solvent (for example, dichloromethane, methanol, or water).


The ester of formula (1) in which R₁ is sulfone (—SO₂R₁₆) can be prepared by treating the sulfide of formula (15) with an

57

oxidizing agent (for example, m-chloroperbenzoic acid, oxon, or hydrogen peroxide) in a solvent (for example, dichloromethane, methanol, or water). The ester of formula (1) in which as R_1 is sulfone ($-\text{SO}_2\text{R}_{16}$) can be used to prepare the compound of formula (I) in which R_1 is sulfone ($-\text{SO}_2\text{R}_{16}$) by the same method as in scheme A.







The compound of formula (I) in which R₁ is alkylsulfonamide ($-\text{NR}_{17}\text{SO}_2\text{R}_{18}$) can be prepared by reacting the compound of formula (8) in which R₁ is halogen with alkyl or arylsulfonamide ($\text{HNR}_{17}\text{SO}_2\text{R}_{18}$) in the presence of a metal such as copper. Alternatively, it can be prepared by reacting the compound of formula (16) having an amino group ($-\text{NHR}_{17}$) with an alkyl or arylsulfonyl halide.




In general, the synthesis from a halogen compound is achieved by reacting a halogen compound with alkyl or aryl-
45 sulfonamide in the presence of a base (for example, cesium carbonate or potassium phosphate), a catalyst (for example, palladium acetate or copper iodide), and, in some cases, a ligand (for example, tri-*t*-butylphosphine or N,N-dimethylglycine) in a solvent (for example, dioxane, toluene, or dimethylformamide) with heating.
50

In general, the synthesis from an amine compound is achieved by reacting an amine compound with alkyl or aryl-sulfonyl halide in the presence of a base (for example, triethylamine) in a solvent (for example, dichloromethane).




59

-continued



5

10

**Method (i)**


The compound of formula (I) in which R₁ is aryl or heteroaryl can be prepared through Suzuki coupling reaction between the compound of formula (8) having halogen and aryl boronic acid, heteroaryl boronic acid, aryl boronic acid ester, or heteroaryl boronic acid ester.

Alternatively, the ester of formula (1) in which R₁ is aryl or heteroaryl can be prepared through Suzuki coupling reaction between the ester of formula (12) having halogen and aryl boronic acid, heteroaryl boronic acid, aryl boronic acid ester, or heteroaryl boronic acid ester. The ester of formula (1) in which R₁ is aryl or heteroaryl can be used to prepare the compound of formula (I) in which R₁ is aryl or heteroaryl by the same method as in scheme A.

In general, Suzuki coupling reaction is conducted by heating aryl halide or heteroaryl halide together with aryl boronic acid, heteroaryl boronic acid, aryl boronic acid ester, or heteroaryl boronic acid ester in the presence of a base (for example, potassium phosphate or cesium carbonate) and a catalyst (for example, palladium acetate or tetrakis(triphenylphosphine) in a solvent (for example, dioxane or toluene).

60

-continued





15 Method (j)

The compound of formula (I) in which R₁ is a cyano group can be prepared by reacting the compound of formula (8) having halogen (X) with a cyanide such as copper cyanide.

In general, cyanidation is carried out by heating a halogen compound, alkylsulfonyloxy compound, or arylsulfonyloxy compound together with a cyanidating agent (for example, copper (I) cyanide or potassium cyanide) in a solvent (for example, dimethylformamide or N-methylpyrrolidone).

20

25

**Method (k)**


The compound of formula (I) in which R₁ is an alkyl group can be prepared through Suzuki reaction between the compound of formula (8) having halogen and alkylboronic acid, alkylboronic acid ester, or a boron trifluoride-alkyl complex.

65

61

The ester of formula (1) in which R₁ is an alkyl group can be prepared through Suzuki reaction between the ester of formula (12) having halogen and alkylboronic acid, alkylboronic acid ester, or a boron trifluoride-alkyl complex. The ester of formula (1) in which R₁ is an alkyl group can be used to prepare the compound of formula (I) in which R₁ is an alkyl group by the same method as in scheme A.

In general, Suzuki reaction is conducted by heating a mixture of a halogen compound, a boron derivative (for example, alkylboronic acid, alkyl boronic acid ester, or boron trifluoride-alkyl complex), and a base (for example, potassium carbonate or potassium phosphate) in a solvent (for example, xylene, toluene, dimethylformamide, dioxane, or tetrahydrofuran) in the presence of a palladium catalyst (for example, palladium acetate) and, in some cases, a ligand (for example, triphenylphosphine).



Method (1)


The compound of formula (I) in which R₁ is a perfluoroalkyl group can be prepared by reacting the compound of formula (8) having halogen with a perfluoroalkylating agent.

The ester of formula (12) in which R₁ is a perfluoroalkyl group can be prepared by reacting the ester of formula (11) having halogen with a perfluoroalkylating agent. The ester of formula (1) in which R₁ is a perfluoroalkyl group can be used to prepare the compound of formula (I) in which R₁ is a perfluoroalkyl group by the same method as in scheme A.

In general, perfluoroalkylation is achieved by reacting a halogen compound, copper (for example, copper or copper (I) iodide), a perfluoroalkylating agent (such as potassium perfluoroalkyl carboxylate, triethylsilyl perfluoroalkyl, or per-

62

fluoroalkyl iodide) in a solvent (for example, dimethylsulfoxide or dimethylformamide) under heat.






Method (m)

The compound of formula (I) in which R₁ is an alkynyl group can be prepared through Sonogashira reaction of the compound of formula (8) having halogen.

The ester of formula (1) in which R₁ is an alkynyl group can be prepared through Sonogashira reaction of the ester of formula (12) having halogen. The ester of formula (1) in which R₁ is an alkynyl group can be used to prepare the compound of formula (I) in which R₁ is an alkynyl group by the same method as in scheme A.

In general, Sonogashira reaction is conducted by reacting aryl halide or heteroaryl halide with an alkynylating agent (for example, trimethylsilylacetylene) in the presence of a base (for example, triethylamine or potassium carbonate), a copper catalyst (for example, copper (I) iodide), and a palladium catalyst (for example, bis(triphenylphosphine)palladium dichloride) in a solvent (for example, tetrahydrofuran or toluene) under heat.







Method (n)

The compound of formula (I) in which R₁ is a carboxyl group can be prepared through a reaction for introducing carbon monoxide into the compound of formula (8) having halogen.

The ester of formula (1) in which R₁ is a carboxyl group can be prepared through a reaction for introducing carbon monoxide into the ester of formula (12) having halogen. The ester of formula (1) in which R₁ is a carboxyl group can be protected at the carboxyl group (for example, tert-butyl ester) and then used to prepare the compound of formula (I) in which R₁ is a carboxyl group by the same method as in scheme A.

In general, the introduction of carbon monoxide is achieved by reacting aryl halide or heteroaryl halide in the presence of a base (for example, triethylamine or sodium carbonate), a palladium catalyst (for example, palladium acetate), and a ligand (for example, triphenylphosphine) in a solvent (for example, dimethylsulfoxide or water) under a carbon monoxide atmosphere. Alternatively, the introduction is achieved by reacting aryl halide or heteroaryl halide with a base (for example, n-butyl lithium) in a solvent (for example, diethyl ether or tetrahydrofuran) at a low temperature (-80 to 0° C.), and then reacting carbon monoxide therewith.





15 Math 1

The compound of formula (I) in which R₁ is a hydroxyl group can be prepared through dealkylation of the compound of formula (18) having a methoxy group or benzylloxy group.

In general, demethylation of methoxy group is achieved by reacting a mixture of a methoxy compound and a solvent (for example, dichloromethane) with a Lewis acid (for example, boron trifluoride or aluminum chloride). Alternatively, the demethylation is achieved by reacting the methoxy compound in the presence of pyridine hydrochloride with heating.

In general, debenzylation of benzyloxy group is achieved through a reaction in the presence of a catalyst (for example, palladium carbon or palladium hydroxide) in a solvent (for example, methanol) under a hydrogen atmosphere.



65

Method (p)

The compound of formula (I) in which R₁ is an aliphatic heterocycl can be prepared through Suzuki coupling reaction of the compound of formula (8) having halogen with aliphatic heterocycl boronic acid or aliphatic heterocycl boronic acid ester.

The ester of formula (1) in which R₁ is an aliphatic heterocycl can be prepared through Suzuki coupling reaction of the ester of formula (12) having halogen with aliphatic heterocycl boronic acid or aliphatic heterocycl boronic acid ester. The resulting ester of formula (1) in which R₁ is an aliphatic heterocycl can be used to prepare the compound of formula (I) in which R₁ is an aliphatic heterocycl by the same method as in scheme A.

In general, Suzuki coupling reaction of aliphatic heterocycl is achieved by reacting aryl halide or heteroaryl halide with aliphatic heterocycl boronic acid or aliphatic heterocycl boronic acid ester in the presence of a base (for example, potassium phosphate) and a palladium catalyst (for example, tetrakis(triphenylphosphine)palladium) in a solvent (for example, dioxane or water) under heat.

5

10

15

20

25

25

30

35

40

45



50

55

60

65

66



Method (q)

The compound of formula (I) in which R₁ is acyloxy (—OC(O)R₂₁) can be prepared through acylation between the compound of formula (6) in which R₁ is a hydroxy group and acyl halide or carboxylic anhydride.


In general, acylation of hydroxyl group is achieved by reacting a hydroxy compound and acyl halide or anhydrous carboxylic acid in the presence of a base (for example, triethylamine) in a solvent (for example, dichloromethane or pyridine).

Method (r)

The compound of formula (I) having carbamide (—NR₂₂C(O)R₂₃) as R₁ can be prepared by acylation of the compound of formula (19) having an amino group (—NHR₂₂).



The ester of formula (1) having carbamide (—NR₂₂C(O)R₂₃) as R₁ can be prepared by acylation of the ester of formula (20) having an amino group (—NHR₂₂).

In general, acylation of an amino group is achieved by reacting an amine compound with acyl halide or carboxylic anhydride in the presence of a base (for example, triethylamine) in a solvent (for example, dichloromethane or pyridine). Alternatively, acylation is achieved by reacting an amine compound with carboxylic acid in the presence of a base (for example, triethylamine) and a condensation agent (for example, dicyclohexylcarbodiimide) in a solvent (for example, tetrahydrofuran or dichloromethane).



acetate or tetrakis(triphenylphosphine) palladium), a base (for example, sodium carbonate or triethylamine), and a reducing agent (for example, triethylsilane) in a solvent (for example, tetrahydrofuran or N,N-dimethylformamide), in a carbon monoxide atmosphere under ambient or elevated pressure. Meanwhile, in ketone synthesis, the reaction for introducing a carbonyl source is achieved using aldehyde, enol ether derivative, hydrazone derivative, or the like, instead of carbon monoxide, as a carbonyl source.

Alternatively, the reaction is achieved by halogen/metal exchange of a halogen compound using a base (for example, tert-butyl lithium), followed by reaction with a carbonyl source (for example, N,N-dimethylformamide, N,N-dimethylalkylamide, or carboxylic acid ester).



Method (t)

The compound of formula (I) having thioamide (—NR₂₄C(S)R₂₅) as R₁ can be prepared by treating the compound of formula (21) having amide (—NR₂₄C(O)R₂₅) with a sulfurizing agent (for example, Lawesson's reagent). Alternatively, the compound of formula (I) can be prepared by a reaction between the compound of formula (22) having an amino group (NHR₂₄) and thiocarboxylic acid ester.

In general, thiocarbonylation is achieved by reacting, with heating, a carbamide compound with a sulfurizing agent (for example, Lawesson's reagent) in a solvent (for example, toluene).

The reaction between the compound of formula (22) having an amino group (NHR₂₄) and thiocarboxylic acid ester is achieved by reacting, with heating, an amine compound with thiocarboxylic acid ester in a solvent (for example, methanol).


Method (s)

The compound of formula (I) having aldehyde (C(O)R₁₉; R₁₉=H) or ketone (C(O)R₁₉; R₁₉ is other than H) as R₁ can be prepared by a reaction for introducing a carbonyl source into the compound of formula (8) having halogen.

In general, in aldehyde synthesis, the reaction for introducing a carbonyl source is achieved by heating a halogen compound in the presence of a catalyst (for example, palladium

69


70

**Method (u)**


The compound of formula (I) having thioamide ($-\text{C}(\text{S})\text{NR}_{26}\text{R}_{27}$) as R_1 can be prepared by treating the compound of formula (23) having amide ($-\text{C}(\text{O})\text{NR}_{26}\text{R}_{27}$) with a sulfurizing agent (for example, Lawesson's reagent). Alternatively, the compound of formula (I) can be prepared by a reaction 35 between a thioisocyanate derivative and the compound of formula (8) having halogen.

In general, thiocarbonylation is achieved by reacting, with heating, a carbamide compound with a sulfurizing agent (for example, Lawesson's reagent) in a solvent (for example, toluene).

In general, the reaction with a thioisocyanate derivative is carried out by treatment of a halogen compound with a base (for example, t-butyl lithium) in a solvent (for example, tetrahydrofuran or diethyl ether) at a low temperature (for example, -80 to 0°C .), and then reaction with a thioisocyanate derivative.


**Method (v)**

The compound of formula (I) having sulfonamide ($-\text{SO}_2\text{NR}_{28}\text{R}_{29}$) as R_1 can be prepared by conversion of the compound of formula (24) having sulfonic acid into sulfonyl halide using a halogenating agent (for example, thionyl chloride or phosphorus oxychloride), followed by reaction with 50 amine ($\text{NHR}_{28}\text{R}_{29}$) in the presence of a base (for example, triethylamine) in a solvent (for example, dichloromethane or pyridine).






72

Alternatively, the compound of formula (I) can be prepared by reacting the compound of formula (24) having sulfonic acid as R₁ with a halogen compound (R₃₁X) in a solvent (for example, acetonitrile).



Method (w)

The compound of formula (I) having sulfonic acid ester (—OSO₂R₃₀) as R₁ can be prepared by reacting the compound of formula (6) having a hydroxyl group with sulfonyl halide (R₃₀SO₂X) or sulfonic acid anhydride ((R₃₀SO₂)O) in the presence of a base (for example, triethylamine, pyridine, or sodium hydride) in a solvent (for example, dichloromethane or dimethylformamide).



Method (x)

The compound of formula (I) having sulfonic acid ester (—SO₃R₃₁) as R₁ can be prepared by reacting the compound of formula (25) having sulfonyl halide as R₁ with alcohol (R₃₁OH) in the presence of a base (for example, triethylamine or 4-dimethylaminopyridine) in a solvent (for example, dichloromethane or diethyl ether).


55

60

65

Alternatively, the compound of formula (I) can be prepared by reacting the compound of formula (24) having sulfonic acid as R₁ with alcohol (R₃₁OH) in the presence of a base (for example, triethylamine, 4-dimethylaminopyridine, or sodium hydride) or a catalyst (for example, cobalt chloride), in a solvent (for example, dichloromethane or diethyl ether).


-continued




73

Method (y)

The compound of formula (I) having a trialkylsilyl group ($-\text{Si}(\text{R}_{32})_3$) as R_1 can be prepared by treatment of the compound of formula (8) having halogen with a base (for example, n-butyl lithium) in a solvent (for example, tetrahydrofuran) at a low temperature (-80 to 0°C), followed by treatment with trialkyl halide ($\text{XSi}(\text{R}_{32})_3$).




The ester of formula (1) having indole as ring A is commercially available, or can be prepared by methods well-known in the art, for example, methods (1) to (3) described below.



Method (1)


The indole of formula (27) having an alkoxy carbonyl group ($\text{C}(\text{O})\text{OR}_{33}$) can be prepared by alkoxy carbonylation of the indole compound of formula (26) which is protected by an alkylsulfonyl or aryl sulfonyl group.

In general, alkoxy carbonylation is achieved by reacting a base (for example, lithium diisopropyl amide) with the indole compound of formula (26) which is protected by an alkylsulfonyl or aryl sulfonyl group, in a solvent (for example, tetrahydrofuran), and then reacting this with a carbonyl source (for example, ethyl chloroformate).




74

-continued



Method (2)


The indole of formula (29) having an alkoxy carbonyl group ($\text{C}(\text{O})\text{OR}_{33}$) can be prepared as follows: pyruvate ester is reacted with the hydrazine derivative of formula (28) in a solvent (for example, methanol or ethanol) under an acidic condition (for example, in hydrochloric acid or acetic acid) to produce a hydrazone derivative; and this hydrazone derivative is reacted in a solvent (for example, ethanol, dichloromethane, or toluene) under an acidic condition (for example, in hydrochloric acid or methanesulfonic acid).



Method (3)


The indole of formula (29) having an alkoxy carbonyl group ($\text{C}(\text{O})\text{OR}_{33}$) can be prepared by heating the o-ethynyl aniline derivative of formula (30) in the presence of a catalyst (for example, copper acetate) in a solvent (for example, dichloroethane) as described in Hiroya, K. et al. (J. Org. Chem., 69, 1126, (2004)) or Hiroya, K. et al. (Tetrahedron Letters, 43, 1277, (2002)).

55




The ester of formula (1) having azaindole as ring A is commercially available, or can be prepared by methods well-known in the art, for example, by methods (4) to (7) described below.

75



Method (4)


The azaindole of formula (32) having an alkoxy carbonyl group ($\text{C}(\text{O})\text{OR}_{33}$) can be prepared as follows: pyruvate ester is reacted with the aminohalopyridine of formula (31) in a solvent (for example, pyridine) as described in Lachance, N. et al., Synthesis, 15, 2571, (2005); and the resulting enamine is heated in the presence of a palladium catalyst (for example, tetrakis(triphenylphosphine)palladium) and a base (for example, dicyclohexylmethylamine)



Method (5)


The azaindole of formula (32) having an alkoxy carbonyl group ($\text{C}(\text{O})\text{OR}_{33}$) can be prepared as described in Romanelli, M. N. et al., Arkivoc, 286, (2004) by synthesis of the intermediate of formula (34) by reacting oxalic acid ester with the methylnitropyridine of formula (33) in the presence of a base (sodium ethoxide or such) in a solvent (for example, ethanol); followed by catalytic reduction under a hydrogen atmosphere.

76



Method (6)


The azaindole of formula (32) having an alkoxy carbonyl group ($\text{C}(\text{O})\text{OR}_{33}$) can be prepared by thermal decomposition of the 2-azido-3-pyridine acrylic acid ester of formula (35) in a solvent (for example, mesitylene) by heating as described in Roy, P. J. et al., Synthesis, 16, 2751, (2005).



Method (7)


The azaindole of formula (37) having an alkoxy carbonyl group ($\text{C}(\text{O})\text{OR}_{33}$) can be prepared by alkoxy carbonylation of the azaindole compound of formula (36) which is protected by an alkylsulfonyl group or aryl sulfonate group.

In general, alkoxy carbonylation of azaindole at position 2 is achieved as follows: a base (for example, lithium diisopropyl amide) is reacted with the azaindole compound of formula (36) which is protected by an alkylsulfonyl group or aryl sulfonate group, in a solvent (for example, tetrahydrofuran); and then this is reacted with a carbonyl source (for example, ethyl chloroformate).




The ester of formula (1) in which A is a pyrrole ring, and either one or both of R_1 and R_2 are aryl or heteroaryl group(s) can be prepared by Suzuki coupling reaction between the monobromopyrrole of formula (38) or dibromopyrrole of

formula (39), and aryl boronic acid, heteroaryl boronic acid, aryl boronic acid ester, or heteroaryl boronic acid ester.



The benzimidazolyl-5-hydrazine of formula (5) is commercially available, or can be prepared by methods well-known in the art, for example, by methods (8) to (11) described below.



The benzimidazolyl-5-hydrazine of formula (5) can be prepared by methods well-known in the art.

Method (8)

The 5-nitrobenzimidazole of formula (41) is prepared by reacting the 4-nitro-1,2-phenylenediamine of formula (40) with carboxylic acid (R₃COOH), aldehyde (R₃CHO), ortho-carboxylic acid triester (R₃C(OR)₃), or acyl halide (R₃COX) under an acidic condition (for example, in hydrochloric acid or sulfuric acid), or in the presence of Lewis acid (for example, boron trifluoride/diethyl ether complex or dichlorooxozirconium (IV)), in a solvent (for example, methanol or xylene).

The aniline derivative of formula (42) is prepared by catalytic reduction of the prepared compound of formula (41) under a hydrogen atmosphere in the presence of a catalyst (for example, palladium carbon or palladium hydroxide) in a solvent (for example, methanol or ethanol).

The 5-benzimidazolyl-5-hydrazine of formula (5) is prepared by subsequent diazotization under an acidic condition (for example, in hydrochloric acid) and reduction using tin (II) chloride or such (for example, tin (II) chloride). Mean-

while, the 5-nitrobenzimidazole of formula (41) can also be prepared by nitration of the benzimidazole of formula (43).

Functional groups can be modified, for example, by methods described in "Smith and March, March's Advanced Organic Chemistry (Fifth ed., John Wiley & Sons, 2001)" or "Richard C. Larock, Comprehensive Organic Transformations (VCH Publishers, Inc., 1989)". Compounds used as a material for the production may be those commercially available, or as necessary, may be produced by conventional methods.

(Method 9)

Alternatively, the compound of formula (46) was prepared by introducing a protecting group into the benzimidazole moiety of the 5-halobenzimidazole of formula (44) in the reaction system. The protecting group used is preferably a

group that can be readily and selectively removed for deprotection in subsequent steps. Methods of selection of protecting groups and deprotection are described, for example, in Greene and Wuts, Protective Groups in Organic Synthesis (third ed., John Wiley & Sons, 1999). The methods are appropriately used depending on the reaction condition. For example, a dimethoxymethyl group, trimethylsilyl group, p-methoxybenzyl group, tetrahydropyranyl group, formyl group, benzenesulfonyl group or such can be introduced as a protecting group under acidic or basic conditions. When a protecting group is introduced, acids are preferably used in a range of about 1% to about 1 equivalent. The acids include inorganic acids such as hydrochloric acid; sulfuric acid or sulfonic acids such as toluenesulfonic acid; carboxylic acids such as acetic acid, propionic acid, and benzoic acid; salts of strong acids such as pyridinium toluenesulfonate; and substances that generate hydrochloric acid in the reaction system, such as trimethylsilyl chloride. In addition to the above Brønsted acids, Lewis acids such as metal halides including zinc chloride, magnesium chloride, and lithium chloride are also effectively used in the reaction for introducing protecting

groups. When a protecting group is introduced, bases are preferably used at one equivalent or more; or in some cases, at an excess amount such as about three equivalents. The bases preferably used include metal hydrides such as sodium hydride and potassium hydride; metal carbonates such as potassium carbonate and cesium carbonate; and metal alcohohates such as potassium t-butoxide and sodium t-butoxide.

Then, a base was added for halogen/metal exchange reaction to produce an intermediate in which the halogen group of formula (46) is replaced with a metal. Alkyl lithium or alkyl magnesium halide is preferably used as the base. More preferred bases include lower alkyl magnesium halides such as isopropyl magnesium chloride, isopropyl magnesium bromide, sec-butyl magnesium chloride, and cyclohexyl magnesium chloride. Solvents that ensure the stability of metal reagents in the reaction system are preferably used in the halogen/metal exchange reaction. The solvents include, for example, ether solvents such as diethyl ether, dimethoxy ethane, and tetrahydrofuran. A reaction temperature that ensures the stability of metal reagents in the reaction system is preferred. Considering known halogen/metal exchange reactions described in documents, the preferred temperature ranges from about -80° C. to room temperature, more preferably from about -78° C. to 15° C. The bases used herein are in solutions commercially available, or prepared using alkyl halides and metal lithium or metal magnesium. An intermediate resulting from replacement of the halogen group of formula (46) with a metal is treated with an azodicarboxylic acid derivative (for example, azodicarboxylic acid di-tert-butyl ester or azodicarboxylic acid diethyl ester) to obtain the compound of formula (47). Then, the benzimidazole-protecting group is removed for deprotection to provide the protected hydrazine of formula (45). The protected hydrazine of formula (45) can be purified and isolated from the reaction solution as a free form or a salt with an appropriate acid. The appropriate acids include not only inorganic acids such as hydrochloric acid, hydrobromic acid, and sulfuric acid, but also any acids that are effective in the crystallization and purification. The acids include, for example, sulfonic acids such as methanesulfonic acid and toluenesulfonic acid, and carboxylic acids such as acetic acid, benzoic acid, malic acid, maleic acid, and fumaric acid. Finally, the hydrazine-protecting group is removed for deprotection to provide the benzimidazolyl hydrazine of formula (5). The deprotection may be carried out under known acidic or basic conditions described in documents. Acids used in the deprotection include not only inorganic acids such as hydrochloric acid, hydrobromic acid, and sulfuric acid, but also strong acids including carboxylic acids such as trifluoroacetic acid and pentafluoropropionic acid, and sulfonic acids such as methanesulfonic acid and toluenesulfonic acid. As necessary, the reaction solution can be diluted with an appropriate solvent, and the deprotection can be carried out. The solvents preferably used herein include amide solvents such as DMF, DMA, and NMP. The benzimidazolyl hydrazine of formula (5) of interest can be produced by treatment in such a solvent at a temperature ranging from about ice-cold temperature to the boiling point of the solvent. Meanwhile, bases suitably used in the deprotection include alkyl metal hydroxides such as sodium hydroxide and potassium hydroxide, alkyl metal carbonates such as sodium carbonate and potassium carbonate. The benzimidazolyl hydrazine of formula (5) of interest can be produced by treatment in the presence of such a base in alcohol such as methanol or ethanol at a temperature ranging from about ice-cold temperature to the boiling point of the solvent.

(Method 10)

Alternatively, the benzimidazole moiety of the 5-halobenzimidazole of formula (44) is protected with an above-described protecting group in the reaction system to provide the compound of formula (46). This is then heated in the presence of a hydrazine derivative (for example, di-tert-butyloxycarbonyl hydrazine), a base (for example, cesium carbonate or potassium carbonate), a transition metal catalyst (for example, palladium acetate, copper iodide, or copper bromide), a ligand (for example, triphenylphosphine, N,N-dimethyl glycine, or N,N'-dimethyl ethylene diamine), in a solvent (for example, N,N-dimethylacetamide). Thus, the compound of formula (47) is obtained. Then, the benzimidazole-protecting group is removed for deprotection to provide the protected hydrazine of formula (45). Finally, the hydrazine-protecting group is removed for deprotection by the method as described above to provide the benzimidazolyl hydrazine of formula (5).

Method (11)


Alternatively, the boronic acid derivative of formula (48) and a hydrazine derivative (for example, di-tert-butyloxycarbonyl hydrazine or azodicarboxylic acid di-tert-butyl ester) is stirred in the presence of a base (for example, tetramethyl ethylene diamine), a copper catalyst (for example, copper iodide, copper fluoride, or copper acetate) in a solvent (for example, methanol, tetrahydrofuran, or 1,2-dimethoxyethane) under a nitrogen atmosphere or in the air, at a temperature ranging from about room temperature to the boiling point of the solvent. Thus, the protected hydrazine of formula (45) is obtained. Finally, the hydrazine-protecting group is removed for deprotection by the method as described above to provide the benzimidazolyl hydrazine of formula (5).

EXAMPLES

The present invention is more specifically described below with reference to the Examples and test examples, but it is not to be construed as being limited thereto. All the starting materials and reagents were obtained from commercial suppliers or synthesized by known methods. Typically, ¹H-NMR spectra were obtained by measurement, with or without Me₄Si as an internal reference, using EX270 (JEOL), Mercury300 (Varian), ECP-400 (JEOL), or 400-MR (Varian) (s=singlet; d=doublet; t=triplet; brs=broad singlet; m=multiple). Mass spectrometric measurements were carried out using the mass spectrometer LCQ Classic (Thermo Electron), ZQ2000 (Waters), or ZMD4000 (Waters). Microwaves were generated using Initiator™ (Biotege).

Example 1

Synthesis of [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(1H-indol-2-yl)-methanone



81


An aqueous solution (1.67 ml) of 4 M sodium hydroxide was added to an ethanol solution (17 ml) of [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-1H-indol-2-yl methanone (87 mg). The resulting mixture was stirred at room temperature for 2 hours. The reaction mixture was poured into water. The resulting solid was collected by filtration, washed with water, and dried to give [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-1H-indol-2-yl methanone (40 mg, 63%).

¹H-NMR (DMSO-D₆) δ: 12.47 (1H, s), 11.70 (1H, s), 8.32 (1H, s), 7.70 (1H, d, J=8.0 Hz), 7.66-7.55 (2H, m), 7.50-7.45 (2H, m), 7.31-7.23 (2H, m), 7.10-7.06 (1H, m), 7.01 (2H, brs), 2.53 (3H, s)

ESI (LC-MS positive mode) m/z 357 [(M+H)⁺]

Example 1A

Synthesis of [5-amino-1-(2-methyl-3H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-1H-indol-2-yl-methanone L-malate



Predetermined amounts of L-malic acid (68 g, 0.507 mol) and [5-amino-1-(2-methyl-3H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-1H-indol-2-yl-methanone hydrate (190 g, 0.507 mol) were dissolved in dimethyl sulfoxide (0.418 l, 2.2 v/w) and acetone (0.418 l, 2.2 v/w). Then, the resulting solution was filtered using a Kiriyma rohto (No. 4 paper filter), and placed into a 10-1 separable flask with a jacket. The reaction solution was heated at 50° C. for dissolution.

A predetermined amount of L-malic acid (544.4 g, 4.06 mol) was dissolved in acetone (1.25 l, 6.6 v/w) and acetic acid (0.418 l, 2.2 v/w). Then, the resulting solution was filtered using a Kiriyma rohto (No. 4 paper filter), and placed into a 10-1 separable flask with a jacket while keeping the inner temperature at 45° C. or higher. The seed crystal (0.95 g, 0.5%) was suspended in acetone (7.5 ml), and then this was placed into a 10-1 separable flask with a jacket.

After seven hours, the suspension was cooled to 25° C. The crystals were collected by filtration using a Kiriyma rohto, and washed twice with acetone (0.85 l, 5 v/w). The resulting wet powder was placed into a 10-1 separable flask with a jacket.

Acetone (2.85 l, 15 v/w) was added into the flask, and the suspension was stirred for three hours at 50° C. The resulting crystals were collected by filtration using a Kiriyma rohto, and washed twice with acetone (0.85 l, 5 v/w).

The resulting wet powder was dried for three hours under reduced pressure at an outer temperature of 40° C. to provide [5-amino-1-(2-methyl-3H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-1H-indol-2-yl-methanone L-malate (556.9 g, 73%).


¹H-NMR (DMSO-D₆) δ: 11.69 (1H, s), 8.31 (1H, s), 8.25-7.00 (10H, m), 4.25-4.22 (1H, m), 3.33 (2H, brs), 2.69-2.32 (9H, m)

FAB positive mode m/z 157.1, 232.1, 289.2, 357.2 [(M+H)⁺]

82

Example 1B

Synthesis of [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-1H-indol-2-yl-methanone hydrochloride




[5-Amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-1H-indol-2-yl-methanone (194 mg) was dissolved in dimethylformamide (1.94 ml). An aqueous solution of 2 M hydrochloric acid (300 µl) was divided into five portions and separately added dropwise thereto at 25° C. 2-Propanol (4 ml) was divided into three portions and separately added to the reaction solution at five-minute intervals. The resulting precipitate was collected by filtration, and washed with 2-propanol (1 ml). Then, the powder was dried under reduced pressure at 40° C. This yielded an opalescent powder (188 mg, 88%).

11.72 (1H, s), 8.39 (1H, s), 7.96 (1H, d, J=2.1 Hz), 7.92 (1H, d, J=8.7 Hz), 7.71 (1H, t, J=2.1 Hz), 7.68 (1H, t, J=2.1 Hz), 7.51 (1H, s), 7.48 (1H, d, J=2.1 Hz), 7.28 (1H, d, J=7.6 Hz), 7.23 (3H, s), 7.09 (1H, t, J=7.6 Hz), 2.82 (3H, s).

ESI (LC-MS positive mode) m/z 357 [(M+H)⁺]

Example 1C

Synthesis of [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-1H-indol-2-yl-methanone 1-methanesulfonate monohydrate



An aqueous solution (64.9 ml) of 2 M methanesulfonic acid was added to a dimethylformamide solution (420 ml) of [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-1H-indol-2-yl-methanone (42 g). This was stirred at room temperature for 20 minutes. Then, methyl-t-butyl ether (105 ml) was added to the reaction solution. 3.0 mg of a seed crystal was added thereto, and this was stirred at room temperature. After confirmation of crystal precipitation, methyl-t-butyl ether (105 ml) was divided into four portions and

separately added to the reaction solution at 15-minute intervals. The reaction solution was stirred at room temperature for 1.5 hours. The resulting crystals were collected by filtration using a Kiriyama roto. The solid collected by filtration was washed three times with methyl-t-butyl ether (210 ml), and dried to provide [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(1H-indol-2-yl)-methanone 1-methanesulfonate monohydrate (42.68 g, 84%).

¹H-NMR (DMSO-D₆) δ: 11.70 (1H, s), 8.39 (1H, s), 7.99 (1H, d, J=1.6 Hz), 7.94 (1H, d, J=8.8 Hz), 7.74-7.68 (2H, m), 7.51-7.46 (2H, m), 7.29-7.18 (3H, m), 7.11-7.06 (1H, m), 2.84 (3H, s), 2.37 (3H, s)

ESI (LC-MS positive mode) m/z 357 [(M+H)⁺]

The compounds of Examples 2 to 35 listed in Table 1 were synthesized by the same method as in Example 1.

TABLE 1

Exam- ple	Structure	Compound name	m/z	¹ H-NMR
2		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazolo[4-yl]-[6-pyridin-1-ylmethyl-1H-indol-2-yl]-methanone	440	¹ H-NMR (DMSO-D ₆) δ: 12.46 (1.0H, d, J = 3.9 Hz), 11.82 (1.0H, s), 8.30 (1.0H, d, J = 4.9 Hz), 7.61 (3.0H, m), 7.41 (2.0H, m), 7.29 (1.0H, t, J = 7.3 Hz), 7.10-6.90 (3.0H, m), 3.86 (2.0H, s), 2.54 (3H, s), 2.40-2.42 (2.0H, m), 1.71 (4.0H, m).
3		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazolo[4-yl]-[6-(4-hydroxy-piperidin-1-ylmethyl)-1H-indol-2-yl]-methanone	470	¹ H-NMR (CD ₃ OD) δ: 8.27 (1.0H, s), 7.70-7.60 (3.0H, m), 7.44 (1.0H, s), 7.40-7.35 (2.0H, m), 7.11 (1.0H, dd, J = 8.1, 1.2 Hz), 3.64 (3.0H, m), 2.90-2.80 (2.0H, m), 2.61 (3.0H, s), 2.30-2.20 (2.0H, m), 1.90-1.80 (2.0H, m), 1.65-1.50 (2.0H, m).
4		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazolo[4-yl]-[1H-pyrrrol[3,2-c]pyridin-2-yl]-methanone	358	¹ H-NMR (CD ₃ OD) δ: 9.02-8.98 (1H, m), 8.31 (1H, s), 8.25 (1H, d, J = 5.9 Hz), 7.70-7.65 (2H, m), 7.59-7.56 (1H, m), 7.51 (1H, d, J = 5.9 Hz), 7.39 (1H, dd, J = 8.8, 2.0 Hz), 2.82 (3H, s).
5		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazolo[4-yl]-[6-piperazin-1-ylmethyl-1H-indol-2-yl]-methanone	455	¹ H-NMR (CD ₃ OD) δ: 8.27 (1.0H, s), 7.74-7.68 (3.0H, m), 7.48-7.40 (2.0H, m), 7.36 (1.0H, d, J = 1.0 Hz), 7.13 (1.0H, br s), 7.32-7.28 (2.0H, m), 3.25-3.20 (4.0H, m), 2.77-2.70 (4.0H, m), 2.66 (3.0H, s).
6		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazolo[4-yl]-[6-(2-morpholin-4-yl-ethoxy)-1H-indol-2-yl]-methanone	486	¹ H-NMR (DMSO-D ₆) δ: 12.45 (1.0H, br s), 11.50 (1.0H, br s), 8.27 (1.0H, s), 7.60-7.55 (3.0H, m), 7.40 (1.0H, br s), 7.32-7.28 (1.0H, m), 6.93 (3.0H, br s), 6.75 (1.0H, dd, J = 8.8, 2.4 Hz), 4.11 (2.0H, t, J = 5.9 Hz), 3.60 (4.0H, t, J = 4.6 Hz), 3.34-3.28 (4.0H, m), 2.73 (2.0H, t, J = 5.9 Hz), 2.53 (3.0H, s).

TABLE 1-continued

Example	Structure	Compound name	m/z	1H-NMR
7		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(tetrahydro-pyran-4-yloxy)-1H-indol-2-yl]-methanone	457	1H-NMR (DMSO-D6) δ: 12.46 (1.0H, br s), 11.44 (1.0H, br s), 8.27 (1.0H, s), 7.61-7.57 (3.0H, m), 7.39 (1.0H, br s), 7.29 (1.0H, d, J = 8.3 Hz), 6.98-6.95 (3.0H, m), 6.79 (1.014, d, J = Hz), 4.59-4.63 (1.0H, m), 3.90-3.86 (2.0H, m), 3.53-3.43 (2.0H, m), 2.53 (3.014, s), 2.02-1.99 (2.0H, m), 1.68-1.59 (2.0H, m).
8		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-chloro-1H-indol-2-yl]-methanone	391, 393	1H-NMR (DMSO-D6) δ: 12.49 (1H, s), 12.10 (1H, s), 8.32 (1H, d, J = 3.6 Hz), 7.66 (1H, dd, J = 4.9, 3.3 Hz), 7.58 (1H, t, J = 4.0 Hz), 7.47 (1H, d, J = 7.9 Hz), 7.32-7.31 (3H, m), 7.26 (1H, t, J = 7.7 Hz), 7.19 (1H, s), 7.16 (1H, s), 2.54 (3H, s).
9		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-bromo-1H-indol-2-yl]-methanone	435, 437	1H-NMR (DM80-D6) δ: 12.48 (1H, s), 11.93 (1H, s), 8.28 (1H, s), 7.88 (1H, d, J = 1.5 Hz), 7.63-7.59 (2H, m), 7.47-7.44 (2H, m), 7.37 (1H, dd, J = 8.6, 1.9 Hz), 7.29 (1H, dd, J = 8.6, 1.9 Hz), 7.04 (2H, s), 2.54 (3H, s).
10		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-iodo-1H-indol-2-yl]-methanone	483	1H-NMR(DMSO-D6) δ: 12.23 (1.0H, s), 8.22 (1.0H, s), 7.64-7.57 (2.0H, m), 7.54-7.48 (2.0H1, m), 7.29 (1.0H, dd, J = 8.3, 1.9 Hz), 7.10-6.96 (3.0H, m), 3.16 (2H, s), 2.63 (3H, s)

TABLE 1-continued

Exam- ple	Structure	Compound name	m/z	1H-NMR
11		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-carbonyl]-1H-indole-5-carbonitrile	382	1H-NMR (DMSO-D6) δ: 12.46 (1.0H, s), 12.26 (1.0H, s), 8.30 (8.23 (2.0H, m), 7.60 (5.0H, m), 7.28 (1.0H, d, J = 8.4 Hz), 7.05 (2.0H, m), 2.52 (3.0H, s),
12		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-bromo-5-fluoro-1H-indol-2-yl]-methanone	453, 455	1H-NMR (DMSO-D6) δ: 12.16 (1.0H, s), 8.28 (1.0H, s), 7.73 (1.0H, m), 7.63-7.60 (3H, m), 7.44 (1.0H, s), 7.27 (1.0H, m), 7.05 (2.0H, br s), 2.53 (3.0H, s),
13		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-ethynyl-1H-indol-2-yl]-methanone	381	1H-NMR (DMSO-D6) δ: 12.45 (1.0H, s), 11.91 (1.0H, s), 8.29 (1.1H, s), 7.86 (1.0H, s) 7.61 (2.0H, m), 7.48 (2.0H, m), 7.34-7.28 (2.0H, m), 7.01-6.90 (2H, m), 3.99 (1.0H, s), 2.54 (3.0H, s),
14		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(2-fluoro-phenyl)-1H-indol-2-yl]-methanone	451	1H-NMR (DMSO-D6) δ: 8.35 (1H, s), 7.79 (1H, d, J = 8.6 Hz), 7.63-7.68 (6H, m), 7.52 (1H, s), 7.42-7.26 (3H, m), 7.05 (2H, br s), 2.54 (3H, s),

TABLE 1-continued

Exam- ple	Structure	Compound name	m/z	1H-NMR
15		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazolo[4-yl]-[6-(3-fluoro-phenyl)-1H-indol-2-yl]-methanone	451	1H-NMR (DMSO-D6) δ: 12.48 (1H, s), 11.86 (1H, s), 8.34 (1H, s), 7.80 (1H, d, J = 8.6 Hz), 7.73 (2H, br s), 7.65-7.42 (25H, m), 7.30 (1H, d, J = 6.9 Hz), 7.02 (2H, br s), 2.64 (3H, s).
16		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazolo[4-yl]-[6-(4-fluoro-phenyl)-1H-indol-2-yl]-methanone	451	1H-NMR (DMSO-D6) δ: 12.50 (1H, s), 11.82 (1H, s), 8.34 (1H, s), 7.31-7.65 (5H, m), 7.60 (1H, br s), 7.43-7.27 (5H, m), 7.63 (2H, br s), 2.54 (3H, s).
17		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazolo[4-yl]-[6-(2-chloro-phenyl)-1H-indol-2-yl]-methanone	467, 469	1H-NMR (DMSO-D6) δ: 12.49 (1H, s), 11.84 (1H, s), 8.35 (1H, d, J = 3.1 Hz), 7.77 (1H, d, J = 8.2 Hz), 7.66 (1H, t, J = 4.2 Hz), 7.59-7.57 (3H, m), 7.53-7.50 (2H, br s), 7.49-7.39 (2H, m), 7.30 (1H, d, J = 6.8 Hz), 7.14 (1H, dd, J = 8.1, 1.3 Hz), 7.04 (2H, d, J = 14.5 Hz), 2.54 (3H, s).

TABLE 1-continued

Exam- ple	Structure	Compound name	m/z	1H-NMR
18		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(3-chlorophenyl)-1H-indol-2-yl]-methane	467, 469	1H-NMR (DMSO-D6) δ: 12.49 (1H, s), 11.86 (1H, s), 8.34 (1H, d, $J = 5.0$ Hz), 7.80 (1H, d, $J = 8.4$ Hz), 7.72 (3H, m), 7.68-7.66 (3H, m), 7.58 (1H, d, $J = 8.4$ Hz), 7.51 (1H, d, $J = 7.6$ Hz), 7.43 (1H, d, $J = 7.9$ Hz), 7.30 (1H, dd, $J = 8.6, 4.1, 1.8$ Hz), 7.06 (2H, d, $J = 14.0$ Hz), 2.54 (3H, s).
19		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(4-chlorophenyl)-1H-indol-2-yl]-methane	467, 469	1H-NMR (DMSO-D6) δ: 12.49 (1H, s), 11.85 (1H, s), 8.34 (1H, s), 7.79 (2H, d, $J = 8.1$ Hz), 7.75-7.71 (2H, m), 7.72-7.68 (1H, m), 7.64-7.60 (1H, m), 7.54 (2H, d, $J = 8.1$ Hz), 7.51 (1H, d, $J = 2.0$ Hz), 7.41 (1H, dd, $J = 8.4, 1.6$ Hz), 7.30 (1H, dd, $J = 8.7, 1.5$ Hz), 7.05 (2H, br s), 2.54 (3H, s).
20		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(2-trifluoromethyl-phenyl)-1H-indol-2-yl]-methane	501	1H-NMR (CD3OD) δ: 8.32 (1H, s), 7.96 (1H, s), 7.85 (1H, d, $J = 8.7$ Hz), 7.77 (1H, t, $J = 8.6$ Hz), 7.68-7.52 (5H, m), 7.42 (1H, dt, $J = 13.3, 5.4$ Hz), 7.06 (2H, d, $J = 3.7$ Hz), 2.65 (3H, s).

TABLE 1-continued

Example	Structure	Compound name	m/z	1H-NMR
21		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazolo[4,3-y]-[6-(3-trifluoromethyl-phenyl)-1H-indol-2-yl]-methanone	501	1H-NMR (CD3OD) δ: 8.29(1H, s), 7.94(2H, br s), 7.83 (1H, dd, J = 8.4, 0.7 Hz), 7.76-7.75 (1H, m), 7.67 (1H, br s), 7.65-7.62 (H, m), 7.43 (1H, d, J = 1.6 Hz), 7.40-7.39 (2H, m), 7.36 (1H, d, J = 2.0 Hz), 2.61 (3H, s).
22		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazolo[4,3-y]-[6-(4-trifluoromethyl-phenyl)-1H-indol-2-yl]-methanone	501	1H-NMR (CD3OD) δ: 8.31(1H, s), 7.89 (2H, d, J = 8.1 Hz), 7.85 (1H, dd, J = 8.3, 0.7 Hz), 7.81-7.80 (1H, m), 7.75 (2H, d, J = 8.1 Hz), 7.69-7.65 (2H, m), 7.46 (1H, dd, J = 8.4, 1.6 Hz), 7.43 (2H, d, J = 0.8 Hz), 7.39 (2H, dd, J = 8.5, 2.1 Hz), 2.62 (3H, s).
23		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazolo[4,3-y]-[4-bromo-1H-indol-2-yl]-methanone	435, 437	1H-NMR (DMSO-D6) δ: 13.0-11.5 (1H, s), 11.2-10.5 (1H, s), 8.28 (1H, s), 7.60 (2H, t, J = 4.3 Hz), 7.49 (1H, d, J = 8.4 Hz), 7.29-7.25 (2H, m), 7.14 (2H, t, J = 9.1 Hz), 3.17 (2H, s), 2.53 (3H, s).

TABLE 1-continued

Example	Structure	Compound name	m/z	¹ H-NMR
24		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(3-fluoro-pyridin-2-yl)-1H-indol-2-yl]-methanone	452	¹ H-NMR (DMSO-D6) δ: 12.49 (1H, s), 11.94 (1H, d, J = 2.2 Hz), 8.57 (1H, td, J = 3.0, 1.5 Hz), 8.36 (1H, s), 8.13 (1H, s), 7.87-7.81 (2H, m), 7.73 (1H, dt, J = 8.6, 1.5 Hz), 7.54-7.52 (2H, m), 7.52 (1H, d, J = 1.5 Hz), 7.49-7.45 (1H, m), 7.31 (1H, dd, J = 8.6, 1.9 Hz), 7.06 (2H, s), 2.54 (3H, s).
25		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(methyl-1H-indol-2-yl)-methanone]	371	¹ H-NMR (DMSO-D6) δ: 12.44 (1.0H, d, J = 3.7 Hz), 11.53 (1.0H, d, J = 1.6 Hz), 8.28 (1.0H, d, J = 4.7 Hz), 7.67-7.62 (1.0H, m), 7.59-7.54 (2.0H, m), 7.39 (1.1H, s), 7.32-7.24 (2.0H, m), 7.03-6.84 (3.0H, m), 2.53 (3.0H, s), 2.41 (3.0H, s).
26		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(4-difluoro-piperidine-1-carbonyl)-1H-indol-2-yl]-methanone	504	¹ H-NMR (DMSO-D6) δ: 12.42 (1.0H, s), 11.88 (1.0H, s), 8.28 (1.0H, s), 7.80 (1.0H, d, J = 1.2 Hz), 7.65-7.45 (4.0H, m), 7.32 (1.0H, dd, J = 8.4, 1.6 Hz), 7.26 (1.0H, m), 7.05-6.90 (2.0H, m), 3.70-3.55 (4.0H, m), 2.51 (3H, s), 2.10-1.95 (4.0H, m).

TABLE 1-continued

Exam- ple	Structure	Compound name	m/z	1H-NMR
27		[5-amino-1-(2-methyl-1H-pyrazol-5-yl)-1H-pyrazole-1-carbonyl]-1H-indol-2-yl]-methanone	504	1H-NMR (DMSO-D6) δ: 12.42 (1.0H, s), 11.90 (1.0H, s), 8.28 (1.0H, s), 7.74 (1.0H, d, J = 0.8 Hz), 7.66-7.45 (4.0H, m), 7.30-7.23 (2.0H, m), 6.99 (2.0H, m), 3.84 (2.0H, m), 3.51 (2.0H, m), 2.51 (3.0H, s), 2.20-2.00 (2.0, m), 1.74-1.60 (2.0H, s).
28		2-[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazole-4-carbonyl]-1H-indole-5-carboxylic acid (2,2-trifluoroethyl)amide	482	1H-NMR (DMSO-D6) δ: 12.43 (1.0H, s), 11.98 (1.0H, s), 8.98 (1.0H, d, J = 6.5 Hz), 8.31 (2.0H, m), 7.79 (1.0H, dd, J = 8.7, 1.7 Hz), 7.70-7.50 (4.0H, m), 7.28 (1.0H, m), 7.05-6.90 (2.0H, m), 4.15-4.00 (2.0H, m), 2.52 (3.0H, s).
29		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazole-4-yl]-[6-(5-trifluoromethyl-pyridin-2-yl)-1H-indol-2-yl]-methanone	502	1H-NMR (DMSO-D6) δ: 12.49 (1.0H, s), 12.02 (1.0H, d, J = 1.6 Hz), 9.06 (1H, d, J = 1.1 Hz), 8.35 (2H, s), 8.28 (1H, dd, J = 8.8, 2.2 Hz), 8.21 (1H, d, J = 8.2 Hz), 7.91 (1H, dd, J = 8.2, 1.6 Hz), 7.84 (1H, d, J = 8.2 Hz), 7.64-7.62 (2H, m), 7.53 (1H, d, J = 1.1 Hz), 7.31 (1H, dd, J = 8.2, 2.2 Hz), 7.07 (2H, s), 2.54 (3H, s).

TABLE 1-continued




Exam- ple	Structure	Compound name	m/z	1H-NMR
30		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(6-trifluoromethyl-pyridin-2-yl)-1H-indol-2-yl]-methanone	502	1H-NMR (DMSO-D6) δ: 12.48 (1H, s), 11.94 (1H, d, J = 2.2 Hz), 8.34-8.31 (3H, m), 8.18 (1H, t, J = 7.7 Hz), 7.88-7.84 (3H, m), 7.65-7.58 (2H, m), 7.52 (1H, d, J = 1.6 Hz), 7.31-7.30 (1H, m), 7.06 (2H, d, J = 22.0 Hz), 2.54 (3H, s).
31		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(5-chloro-pyridin-2-yl)-1H-indol-2-yl]-methanone	468, 470	1H-NMR (DMSO-D6) δ: 12.48 (1H, s), 11.95 (1H, s), 8.72 (1H, dd, J = 2.2, 1.1 Hz), 8.34 (1H, s), 8.25 (1H, s), 8.04-7.99 (2H, m), 7.82-7.80 (2H, m), 7.63 (2H, s), 7.51 (1H, s), 7.30 (1H, dd, J = 8.5, 1.9 Hz), 7.05 (2H, d, J = 6.6 Hz), 2.54 (3H, s).
32		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(4-methyl-pyridin-2-yl)-1H-indol-2-yl]-methanone	448	1H-NMR (COSOD) δ: 8.46 (1H, dd, J = 5.2, 0.4 Hz), 8.31 (1H, s), 8.05-8.04 (1H, m), 7.93 (1H, dd, J = 8.0, 1.7 Hz), 7.84 (1H, dd, J = 8.4, 0.7 Hz), 7.77-7.76 (1H, m), 7.69-7.67 (2H, m), 7.43 (1H, d, J = 0.8 Hz), 7.39 (1H, dd, J = 8.6, 2.0 Hz), 7.22-7.13 (1H, m), 2.62 (3H, s), 2.48 (3H, s).


TABLE 1-continued

Example	Structure	Compound name	m/z	1H-NMR
33		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazolo[4,3-e]indol-2-yl]-[6-(3-chloro-4-fluoro-phenyl)-1H-indol-2-yl)methanone	484, 486	1H-NMR (DMSO-D6) δ: 12.48 (1H, s), 11.85 (1H, s), 8.34 (1H, s), 7.87 (1H, dd, J = 7.1, 2.2 Hz), 7.79 (1H, d, J = 8.2 Hz), 7.74-7.66 (2H, m), 7.65-7.58 (2H, m), 7.57-7.49 (2H, m), 7.41 (1H, d, J = 8.2 Hz), 7.30 (1H, d, J = 8.2 Hz), 7.04 (2H, s), 2.54 (3H, s).
34		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazolo[4,3-e]indol-2-yl]-[6-(3-trifluoromethyl-pyridin-2-yl)-1H-indol-2-yl)methanone	502	1H-NMR (DMSO-D6) δ: 12.48 (1H, s), 11.96 (1H, s), 8.95 (1H, d, J = 4.9 Hz), 8.35-8.34 (2H, m), 8.26 (1H, s), 7.93 (1H, dd, J = 8.5, 1.4 Hz), 7.82 (1H, d, J = 8.2 Hz), 7.70 (1H, d, J = 5.5 Hz), 7.62-7.60 (2H, m), 7.52 (1H, s), 7.30 (1H, dd, 3 = 8.5, 1.9 Hz), 7.06 (2H, s), 2.54 (3H, s).
35		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazolo[4,3-e]indol-2-yl]-[6-(4-trifluoromethyl-pyridin-2-yl)-1H-indol-2-yl)methanone	502	1H-NMR (DMSO-D6) δ: 12.47 (1H, s), 11.90 (1H, d, J = 1.6 Hz), 8.92 (1H, d, 1 = 3.8 Hz), 8.35-8.31 (2H, m), 7.78 (1H, d, J = 8.2 Hz), 7.67-7.60 (4H, m), 7.53 (1H, d, J = 1.6 Hz), 7.30 (1H, d, J = 8.2 Hz), 7.19 (1H, d, J = 8.2 Hz), 7.04 (2H, d, J = 10.4 Hz), 2.54 (3H, s).

105

Example 36

Synthesis of [5-amino-1-(6-fluoro-2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(1H-indol-2-yl)-methanone



[5-Amino-1-(6-fluoro-2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-1-benzenesulfonyl-1H-indol-2-yl) methanone (114 mg, 0.22 mmol) was dissolved in isopropanol (2.2 ml), and an aqueous solution of 1 M sodium hydroxide (2.2

106

ml) was added thereto. The resulting mixture was heated at 90° C. with stirring under a nitrogen atmosphere for two hours. After the reaction mixture was cooled to room temperature, water and a saturated aqueous solution of sodium dihydrogen phosphate were added thereto. The product was extracted with ethyl acetate. The organic layer was isolated, washed with an saturated aqueous solution of sodium chloride, and dried over magnesium sulfate. The desiccant was removed by filtration. The filtrate was concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (amino silica gel; dichloromethane/methanol=100/5) to give [5-amino-1-(6-fluoro-2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(1H-indol-2-yl) methanone as a yellow solid (75 mg, 89.8%).

¹⁵ ¹H-NMR (DMSO-D₆) δ: 12.60 (1.0H, brs), 11.70 (1.0H, brs), 8.31 (1.0H, s), 7.69 (1.0H, d, J=7.6 Hz), 7.62 (1.0H, d, J=6.8 Hz), 7.55 (1.0H, d, J=10.7 Hz), 7.50-7.45 (2.0H, m), 7.25 (1.0H, dd, J=7.6, 7.6 Hz), 7.08 (1.0H, dd, J=7.6, 7.6 Hz), 7.02 (2.0H, brs), 2.53 (3.0H, s)

²⁰ ESI (LC-MS positive mode) m/z 375 [(M+H)⁺]

The compounds of Examples 37 to 63 listed in Table 2 were synthesized by the same method as in Examples 36.

TABLE 2

Exam- ple	Structure	Compound name	m/z	¹ H-NMR
37		2-[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazole-4-carbonyl]-1H-indole-6-carboxylic acid	401	¹ H-NMR (DMSO-D ₆) δ: 12.74 (1H, br s), 12.06 (1H, s), 8.36 (1H, s), 8.15 (1H, s), 7.78-7.76 (3H, m), 7.65 (1H, dd, J = 8.4, 1.4 Hz), 7.62 (1H, dd, J = 2.2, 0.8 Hz), 7.49 (1H, br s), 7.17 (2H, br s), 2.57 (3H, s).
38		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-hydroxymethyl-1H-indol-2-yl]-methanone	387	¹ H-NMR (CD ₃ OD) δ: 8.32 (1H, s), 7.89 (1H, d, J = 2.2 Hz), 7.85 (1H, d, J = 8.8 Hz), 7.70-7.69 (2H, m), 7.49 (1H, s), 7.36 (1H, s), 7.11 (1H, dd, J = 8.2, 1.1 Hz), 4.72 (2H, s), 2.83 (3H, s).
39		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-[2-(4-methyl-piperazin-1-yl)-ethoxy]-1H-indol-2-yl]-methanone	499	¹ H-NMR (DMSO-D ₆) δ: 12.51 (1.0H, br s), 11.49 (1.0H, br s), 8.27 (1.0H, s), 7.61-7.66 (10H, m), 7.40 (1.0H, br s), 7.29 (1.0H, dd, J = 8.3, 2.0 Hz), 6.94-6.93 (3.0H, m), 6.74 (1.0H, dd, J = 8.8, 2.0 Hz), 4.09 (2.0H, t, J = 5.8 Hz), 3.32-3.30 (4.0H, m), 2.72 (2.0H, t, J = 5.8 Hz), 2.53 (3.0H, s), 2.34-2.32 (4.0H, br m), 2.16 (3.0H, s).

TABLE 2-continued

Example	Structure	Compound name	m/z	1H-NMR
40		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(3-methyl-oxetan-3-yl)methoxy]-1H-indol-2-yl]-methanone	457	1H-NMR (DMSO-D6) δ: 12.54 (1.0H, br s), 11.55 (1.0H, br s), 8.28 (1.0H, s), 7.61-7.57 (3.0H, m), 7.41 (1.0H, br s), 7.28 (1.0H, dd, J = 8.3, 2.0 Hz), 6.97-6.96 (3.0H, m), 6.79 (1.0H, dd, J = 8.8, 2.4 Hz), 4.55 (2.0H, d, J = 5.9 Hz), 4.33 (2.0H, d, J = 5.9 Hz), 4.08 (2.0H, s), 2.53 (3.0H, s), 1.40 (3.0H, s).
41		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(3-fluoro-piperidin-1-yl)methyl]-1H-indol-2-yl]-methanone	472	1H-NMR (DMSO-D6) δ: 12.48 (1.0H, br s), 11.65 (1.0H, br s), 8.30 (1.0H, s), 7.64-7.62 (3.0H, m), 7.43 (1.0H, br s), 7.40 (1.0H, br s), 7.29 (1.0H, dd, J = 8.3, 1.0 Hz), 7.04-7.02 (3.0H, m), 4.69-4.57 (1.0H, m), 3.59 (2.0H, s), 2.74-2.67 (1.0H, m), 2.63 (3.0H, m), 2.51-2.49 (1.0H, m), 2.46-2.33 (1.0H, m) 2.28-2.23 (1.0H, m), 1.83-1.72 (2.0H, m), 1.55-1.43 (2.0H, m).
42		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-[(bis(2-methoxy-ethyl)-amino)methyl]-1H-indol-2-yl]-methanone	502	1H-NMR (DMSO-D6) δ: 12.49 (1.0H, br s), 11.62 (1.0H, br s), 8.30 (1.0H, s), 7.62-7.60 (3.0H, m), 7.41 (1.0H, br s), 7.41 (1.0H, br s), 7.29 (1.0H, dd, J = 8.3 Hz), 7.05 (1.0H, d, J = 7.8 Hz), 6.99 (1.0H, br s), 6.97 (1.0H, br s), 3.73 (2.0H, s), 3.42 (4.0H, t, J = 6.1 Hz), 3.22 (3.0H, s), 3.22 (3.0H, s), 2.66 (4.0H, t, J = 6.1 Hz), 2.53 (3.0H, s).
43		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-[(methyl-prop-2-ynyl-amino)methyl]-1H-indol-2-yl]-methanone	438	1H-NMR (CD3OD) δ: 8.27 (1.0H, s) 7.71-7.65 (3.0H, m), 7.47 (1.0H, s), 7.40-7.36 (2.0H, m), 7.13 (1.0H, dd, J = 8.7, 1.2 Hz), 3.73 (2.0H, s), 3.32-3.30 (2.0H, m), 2.73 (1.0H, t, J = 2.4 Hz), 2.62 (3.0H, s), 2.38 (3.0H, s).

TABLE 2-continued

Exam- ple	Structure	Compound name	m/z	1H-NMR
44		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(3,3-difluoro-pyrrolidin-1-ylmethyl)-1H-indol-2-yl]-methanone	476	1H-NMR (DMSO-D6) δ: 12.47 (1.0H, br s), 11.67 (1.0H, br s), 8.30 (1.0H, s), 7.65-7.63 (3.0H, m), 7.43 (1.0H, br s), 7.42 (1.0H, br s), 7.29 (1.0H, dd, J = 8.5, 1.7 Hz), 7.06-6.99 (3.0H, m), 3.71 (2.0H, s), 2.87 (2.0H, t, J = 13.4 Hz), 2.71 (2.0H, t, J = 7.1 Hz), 2.53 (3.0H, s), 2.33-2.20 (2.0H, m).
45		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(2,5-dimethyl-pyrrolidin-1-ylmethyl)-1H-indol-2-yl]-methanone	468	1H-NMR (DMSO-D6) δ: 12.47 (1.0H, br s), 11.56 (1.0H, br s), 8.29 (1.0H, s), 7.65-7.59 (3.0H, m), 7.46-7.41 (2.0H, m), 7.30 (1.0H, d, J = 8.8 Hz), 7.11-6.97 (3.0H, m), 3.93-3.51 (2.0H, m), 3.02-2.94 (1.0H, m), 2.63-2.57 (1.0H, m), 2.53 (3.0H, s) 2.00-1.93 (1.0H, m), 1.81-1.76 (1.0H, m), 1.36-1.28 (2.0H, m), 0.97 (3.0H, d, J = 6.1 Hz), 0.96 (3.0H, d, J = 6.1 Hz).
46		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(3,3-piperidin-1-ylmethyl)-1H-indol-2-yl]-methanone	490	1H-NMR (DMSO-D6) δ: 12.47 (1.0H, br s), 11.67 (1.0H, br s), 8.30 (1.0H, s), 7.65-7.62 (3.0H, m), 7.43 (1.0H, br s), 7.41 (1.0H, br s), 7.29 (1.0H, dd, J = 8.8, 2.0 Hz), 7.06-7.00 (3.0H, m), 3.96 (2.0H, s), 2.64 (2.0H, t, J = 12.2 Hz), 2.53 (3.0H, s), 2.44-2.42 (2.0H, m), 1.93-1.83 (2.0H, m), 1.69-1.63 (2.0H, m).

TABLE 2-continued

Example	Structure	Compound name	<i>m/z</i>	¹ H-NMR
47		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-((S)-3-methyl-1-morpholin-4-ylmethyl)-1H-indol-2-yl]-methanone	470	¹ H-NMR (DMSO-D ₆) δ: 12.47 (1.0H, br s), 11.62 (1.0H, br s), 8.30 (1.0H, s), 7.64-7.58 (3.0H, m), 7.42 (1.0H, br s), 7.42 (1.0H, br s), 7.29 (1.0H, d, J = 8.8 Hz), 7.07-6.98 (3.0H, m), 4.12-4.09 (1.0H, br m), 3.66-3.60 (2.0H, m), 3.48-3.40 (1.0H, m), 3.20-3.14 (3.0H, m), 2.53 (3.0H, s), 2.44-2.40 (1.0H, m), 2.14-2.07 (1.0H, m), 1.05-1.04 (3.0H, br m).
48		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-bromo-1H-indol-2-yl]-methanone	435, 437	¹ H-NMR (DMSO-D ₆) δ: 12.48 (1.0H, s), 11.86 (1.0H, s), 8.32 (1H, d, J = 3.1 Hz), 7.68 (1H, d, J = 3.6 Hz), 7.65 (2H, br s), 7.58-7.56 (1H, m), 7.50 (1H, br s), 7.30-7.28 (1H, m), 7.22 (1H, dd, J = 8.6, 1.6 Hz), 7.05 (2H, d, J = 14.2 Hz), 2.53 (3H, s).
49		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-iodo-1H-indol-2-yl]-methanone	483	¹ H-NMR (DMSO-D ₆) δ: 12.45 (1.0H, s), 11.87 (1.0H, s), 8.26 (1.1H, d, J = 4.7 Hz), 8.06 (1.0H, d, J = 1.8 Hz), 7.65 (1.0H, d, J = 8.4 Hz), 7.56 (1.0H, t, J = 4.1 Hz), 7.50 (1.0H, dd, J = 8.6, 1.6 Hz), 7.39 (1.0H, s), 7.33 (1.0H, d, J = 8.6 Hz), 7.28 (1.0H, m), 7.01 (2.0H, m), 2.53 (3.0H, d, J = 1.0 Hz).
50		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1H-pyrazolo[3,2-b]pyridin-2-yl]-methanone	358	¹ H-NMR (CD ₃ OD) δ: 9.02-8.98 (1H, m), 8.31 (1H, s), 8.25 (1H, d, J = 5.9 Hz), 7.70-7.65 (2H, m), 7.59-7.56 (1H, m), 7.51 (1H, d, J = 5.9 Hz), 7.39 (1H, dd, J = 8.8, 2.0 Hz), 2.82 (3H, s).

TABLE 2-continued

Exam- ple	Structure	Compound name	m/z	1H-NMR
51		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-bromo-6-trifluoromethyl-1H-indol-2-yl]-methanone	503, 505	1H-NMR (DMSO-D6) δ: 12.49 (1.0H, br s), 8.30 (1.0H, s), 8.17 (1.0H, s), 7.94 (1.0H, s), 7.62-7.52 (3.0H, m), 7.29 (1.0H, dd, J = 8.5, 1.7 Hz), 7.12 (2.0H, br s), 2.53 (3.0H, s),
52		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-iodo-1H-indol-2-yl]-methanone	483	1H-NMR (DMSO-D6) δ: 12.43 (1.0H, s), 11.77 (1.0H, s), 8.30 (1.0H, s), 7.86 (1.0H, s), 7.58 (3.0H, m), 7.46 (1.0H, s), 7.36 (1.0H, dd, J = 8.4, 1.6 Hz), 7.29 (1.0H, m), 7.05-6.90 (2.0H, m), 2.53 (3.0H, s).
53		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-methyl-1H-indol-2-yl]-methanone	371	1H-NMR (DMSO-D6) δ: 12.47 (1.0H, br s), 11.66 (1.0H, br s), 8.40 (1.0H, s), 7.62-7.60 (2.0H, m), 7.46 (1.0H, s), 7.30-7.28 (2.0H, m), 7.14 (1.0H, dd, J = 7.3, 7.3 Hz), 6.99 (2.0H, br s), 6.86 (1.0H, d, J = 7.3 Hz), 2.57 (3.0H, s), 2.53 (3.0H, s),
54		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-isopropyl-1H-indol-2-yl]-methanone	399	1H-NMR (DMSO-D6) δ: 12.47 (1.0H, br s), 11.69 (1.0H, br s), 8.23 (1.0H, s), 7.64-7.59 (2.0H, m), 7.29 (1.0H, dd, J = 8.3, 1.5 Hz), 7.25 (1.0H, br s), 7.15 (1.0H, br s), 7.04-6.97 (3.0H, m), 6.55 (1.0H, d, J = 8.0 Hz), 4.79-4.73 (1.0H, m), 2.53 (3.0H, s), 1.38 (6.0H, d, J = 2.9 Hz),

TABLE 2-continued

Exam- ple	Structure	Compound name	m/z	$^{1}\text{H-NMR}$
55		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(2-fluoro-phenyl)-1H-indol-2-yl]-methanone	451	$^{1}\text{H-NMR}$ (DMSO-D ₆) δ : 12.45 (1H, br s), 11.82 (1H, s), 8.32 (1H, d, J = 4.9 Hz), 7.85 (1H, s), 7.65-7.63 (1H, m), 7.38-7.52 (4H, m), 7.44-7.42 (1H, m), 7.39-7.35 (1H, m), 7.31-7.28 (3H, m), 7.04 (1H, br s), 6.99 (1H, br s), 2.52 (3H, s).
56		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-benzyl-1H-indol-2-yl]-methanone	447	$^{1}\text{H-NMR}$ (DMSO-D ₆) δ : 12.47 (1H, br s), 11.62 (1H, br s), 8.29 (1H, s), 7.69-7.53 (2H, m), 7.52-7.48 (1H, m), 7.42-7.36 (2H, m), 7.32-7.23 (5H, m), 7.20-7.12 (2H, m), 7.06-6.93 (2H, m), 4.02 (2H, s), 2.53 (3H, s).
57		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(2-trifluoromethyl-phenyl)-1H-indol-2-yl]-methanone		$^{1}\text{H-NMR}$ (DMSO-D ₆) δ : 12.48 (1H, br s), 11.82 (1H, s), 8.31 (1H, s), 7.83-7.81 (1H, m), 7.72-7.70 (1H, m), 7.60-7.57 (4H, m), 7.52-7.50 (2H, m), 7.45 (1H, d, J = 7.2 Hz), 7.28 (1H, dd, J = 8.4, 2.0 Hz), 7.19-7.17 (1H, m), 7.01 (2H, br s), 2.52 (3H, s).
58		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(3-fluorophenyl)-1H-indol-2-yl]-methanone	451	$^{1}\text{H-NMR}$ (DMSO-D ₆) δ : 12.47 (1H, s), 11.81 (1H, s), 8.30 (1H, s), 7.99 (1H, s), 7.61-7.46 (8H, m), 7.28 (1H, dd, J = 8.4, 1.8 Hz), 7.16-7.12 (1H, m), 7.01 (2H, br s), 2.62 (3H, s).

TABLE 2-continued

Exam- ple	Structure	Compound name	m/z	1H-NMR
59		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(3-trifluoromethyl-phenyl)-1H-indol-2-yl]-methanone	501	1H-NMR (DMSO-d6) δ: 12.48 (1H, brs), 11.84 (1H, s), 8.29 (1H, s), 8.06 (1H, d, J = 1.3 Hz), 8.02-8.00 (1H, m), 7.97 (1H, s), 7.72-7.68 (6H, m), 7.51 (1H, s), 7.28 (1H, dd, J = 8.4, 2.2 Hz), 7.02 (2H, s), 2.52 (3H, s).
60		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-ethyl-1H-indol-2-yl]-methanone	381	1H-NMR (DMSO-d6) δ: 12.47 (1.0H, brs), 12.01 (1.0H, br s), 8.24 (1.0H, s), 7.62-7.60 (2.0H, m), 7.57-7.53 (1.0H, m), 7.31-7.24 (4.0H m), 7.03 (2.0H, br s), 4.44 (1.0H, s), 2.53 (3.0H, s).
61		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1,3-dioxolo[4,5-f]indol-6-yl]-methanone	401	1H-NMR (DMSO-D6) δ: 12.46 (1H, s), 11.52 (1H, s), 8.23 (1H, s), 7.59-7.58 (2H, m), 7.32 (1H, s), 7.27 (1H, dd, J = 8.6, 2.0 Hz), 7.97 (1H, s), 8.92 (2H, br s), 8.90 (1H, s), 5.99 (2H, s), 2.52 (3H, s).


TABLE 2-continued

Exam- ple	Structure	Compound name	m/z	1H-NMR
62		[5-amino-1-(7-fluoro-2-methyl-1H-benzimidazol-5-yl)-1H-pyrazolo[4-yl](1H-indol-2-yl)methanone	375	1H-NMR (DMSO-D ₆) δ: 12.81 (1.0H, s), 11.68 (1.0H, s), 8.33 (1.0H, s), 7.70 (1.0H, d, J = 8.0 Hz), 7.50-7.40 (3.0H, m), 7.30-7.22 (1.0H, m), 7.18 (1.0H, d, J = 11.2 Hz), 7.09 (3.0H, m), 2.55 (3.0H, s).
63		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazolo[4-yl][5-(4-trifluoromethylphenyl)-1H-indol-2-yl)methanone	501	1H-NMR (DMSO-D ₆) δ: 12.46 (1H, d, J = 5.3 Hz), 11.85 (1H, s), 8.31 (1H, d, J = 5.3 Hz), 8.05 (1H, s), 7.82 (2H, d, J = 8.4 Hz), 7.80 (2H, d, J = 8.4 Hz), 7.63-7.57 (4H, m), 7.53 (1H, s), 7.30-7.27 (1H, m), 7.08 (1H, s), 7.00 (1H, s), 2.52 (3H, s).

123

Example 64

Synthesis of [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(5-butoxy-1H-indol-2-yl)-methanone



A mixture consisting of [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-butoxy-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone (70 mg), dioxane (3 ml), and an aqueous solution of 5 M sodium hydroxide (300

124

μ l) was stirred under reflux for two hours. The reaction mixture was cooled in an ice bath, and acidified with an aqueous solution of 5 M hydrochloric acid. The solvent was distilled off under reduced pressure. Water was added to the residue obtained by concentration under reduced pressure. The solid was collected by filtration, washed with water, and dried to give [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-butoxy-1H-indol-2-yl]-methanone (35 mg, 65%).

¹⁰ $^1\text{H-NMR}$ (DMSO-D₆) δ : 12.45 (1H, s), 11.54 (1H, d, J=1.8 Hz), 8.25 (1H, s), 7.65-7.63 (1H, brm), 7.57-7.55 (1H, brm), 7.36 (1H, d, J=8.8 Hz), 7.32 (1H, d, J=1.8 Hz), 7.30-7.28 (1H, brm), 7.12 (1H, d, J=2.4 Hz), 7.01 (1H, brs), 6.95 (1H, brs), 6.90 (1H, dd, J=8.8, 2.4 Hz), 3.98 (2H, t, J=6.4 Hz), 2.53 (3H, s), 1.76-1.69 (2H, m), 1.51-1.44 (2H, m), 0.95 (3H, t, J=7.3 Hz)

ESI (LC-MS positive mode) m/z 429 [(M+H)⁺]

The compounds of Examples 65 to 89, and 204 to 239 listed in Table 3 were synthesized by the same method as in Example 64.

TABLE 3

Exam- ple	Structure	Compound name	m/z	¹ H-NMR
65		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(1-methyl-piperidin-4-yl)-1H-indol-2-yl] methanone	454	¹ H-NMR (DMSO-D ₆) δ: 12.45 (1H, s), 11.56 (1H, br. J = 1.8 Hz), 8.28 (1H, s), 7.66-7.62 (1H, br. m), 7.60-7.55 (1H, br. m), 7.50 (1H, d, J = 1.8 Hz), 7.40 (1H, d, J = 8.5 Hz), 7.37 (1H, d, J = 1.8 Hz), 7.29 (1H, d, J = 8.5 Hz), 7.16 (1H, dd, J = 8.5, 1.8 Hz), 7.00 (1H br. s), 6.95 (1H, br. s), 2.89-2.87 (2H, m), 2.55-2.51 (1H, br. m), 2.53 (3H, s), 2.20 (3H, s), 2.01-1.95 (2H, m), 1.82-1.65 (4H, m).
66		N-[2-[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(6-nmorpholin-4-yl-pyridin-3-yl)-1H-indol-2-yl]-methanesulfonamide	450	¹ H-NMR (DMSO-D ₆) δ: 12.45 (1H, s), 11.65 (1H, s), 9.67 (1H, s), 8.28 (1H, s), 7.57-7.64 (3H, m), 7.42 (2H, s), 7.29 (1H, s), 7.02-6.93 (3H, m), 2.95 (3H, s), 2.53 (3H, s).
67		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(6-nmorpholin-4-yl-pyridin-3-yl)-1H-indol-2-yl]-methanone	519	¹ H-NMR (DMSO-D ₆) δ: 12.48 (1H, s), 11.73 (1H, s), 8.49 (1H, d, J = 2.4 Hz), 8.33 (1H, s), 7.90 (1H, dd, J = 9.2, 2.4 Hz), 7.78 (1H, d, J = 7.9 Hz), 7.85-7.58 (3H, m), 7.48 (1H, s), 7.37 (1H, dd, J = 8.5, 1.2 Hz), 7.30 (1H, dd, J = 8.5, 1.8 Hz), 7.01 (2H, s), 6.96 (1H, d, J = 8.5 Hz), 3.78-3.70 (4H, m), 3.54-3.47 (4H, m), 2.54 (3H, s).
68		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-butyl-1H-indol-2-yl]-methanone	413	¹ H-NMR (DMSO-D ₆) δ: 12.46 (1H, s), 11.64 (1H, s), 8.28 (1H, s), 7.59-7.57 (3H, m), 7.38 (1H, d, J = 1.4 Hz), 7.28 (1H, dd, J = 8.4, 2.0 Hz), 7.25 (1H, s), 6.96 (2H, s), 6.93 (1H, dd, J = 8.3, 1.5 Hz), 2.68-2.65 (2H, m), 2.52 (3H, s), 1.62-1.55 (2H, m), 1.34-1.30 (2H, m), 0.90 (3H, s), 0.90 (3H, s), J = 7.3 Hz,

TABLE 3-continued




Example	Structure	Compound name	m/z	1H-NMR
69		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(1-methyl-1H-pyrazol-4-yl)-1H-indol-2-yl]-methanone	437	1H-NMR (DMSO-D6) δ: 12.49 (1H, s), 11.68 (1H, s), 8.31 (1H, s), 8.14 (1H, s), 8.84 (1H, s), 7.67 (1H, d, J = 8.5 Hz), 7.62 (1H, dd, J = 8.5, 1.8 Hz), 6.99 (2H, s), 3.89 (3H, s), 2.54 (3H, s).
70		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(5-methoxy-pyridin-3-yl)-1H-indol-2-yl]-methanone	464	1H-NMR (DMSO-D6) δ: 11.87 (1H, s), 8.51 (1H, d, J = 1.8 Hz), 8.38 (1H, s), 8.31 (1H, d, J = 3.1 Hz), 7.83 (1H, d, J = 8.5 Hz), 7.79-7.72 (3H, m), 7.64 (1H, t, J = 2.1 Hz), 7.53 (1H, d, J = 1.8 Hz), 7.49-7.45 (2H, m), 7.14 (2H, s), 3.94 (3H, s), 2.66 (3H, s).
71		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(2-methoxy-pyridin-3-yl)-1H-indol-2-yl]-methanone	464	1H-NMR (DMSO-D6) δ: 11.87 (1H, s), 8.51 (1H, d, J = 1.8 Hz), 8.36 (1H, s), 8.31 (1H, d, J = 3.1 Hz), 7.83 (1H, d, J = 6.5 Hz), 7.79-7.72 (3H, m), 7.64 (1H, t, J = 2.1 Hz), 7.53 (1H, d, J = 1.8 Hz), 7.49-7.45 (2H, m), 7.14 (2H, s), 3.94 (3H, s), 2.65 (3H, s).

TABLE 3-continued

Exam- ple	Structure	Compound name	m/z	1H-NMR
72		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-cyclopropyl-1H-indol-2-yl]-methanone	397	1H-NMR (DMSO-D6) δ: 12.46 (1H, s), 11.49 (1H, s), 8.27 (1H, d), 7.59 (1H, br s), 7.56 (1H, s), 7.64 (1H, s), 7.27 (1H, dd, $J = 8.5, 2.1$ Hz), 7.16 (1H, s), 6.95 (2H, br s), 8.80 (1H, dd, $J = 8.4, 1.8$ Hz), 2.62 (3H, a), 2.04-1.97 (1H, m), 0.96 (2H, dd, $J = 9.5, 6.2, 3.0$ Hz), 0.69-0.65 (2H, m).
73		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(2-methoxy-phenyl)-1H-indol-2-yl]-methanone	463	1H-NMR (DMSO-D6) δ: 12.49 (1H, s), 11.71 (1H, s), 8.34 (1H, d), 7.75-7.55 (4H, m), 7.48 (1H, s), 7.40-7.28 (3H, m), 7.20 (1H, d, $J = 8.5$ Hz), 7.13 (1H, d, $J = 8.5$ Hz), 7.09-6.98 (3H, m), 3.78 (3H, s), 2.54 (3H, s).
74		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-phenyl-1H-indol-2-yl]-methanone	433	1H-NMR (DMSO-D6) δ: 12.49 (1H, s), 11.80 (1H, s), 8.34 (1H, s), 7.79 (1H, d, $J = 8.5$ Hz), 7.73-7.60 (5H, s), 7.52-7.47 (3H, m), 7.41 (1H, dd, $J = 8.5, 1.2$ Hz), 7.37 (1H, t, $J = 7.3$ Hz), 7.30 (1H, dd, $J = 8.2, 2.1$ Hz), 7.04 (2H, s), 2.54 (3.14, s).

TABLE 3-continued

Exam- ple	Structure	Compound name	m/z	1H-NMR
75		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(5-nethanesulfonyl)-pyridin-3-yl]-1H-indol-2-yl]-methanone	512	1H-NMR (DMSO-D6) δ: 12.48 (1H, s), 11.97 (1H, s), 9.26 (1H, s), 9.06 (1H, s), 8.55 (1H, s), 8.35 (1H, d, J = 3.7 Hz), 7.93-7.84 (2H, m), 7.70-7.51 (4H, m), 7.31 (1H, t, J = 7.0 Hz), 7.09 (1H, s), 7.03 (1H, s), 3.44 (3H, s), 2.54 (3H, s).
76		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-isopropyl-1H-indol-2-yl]-methanone	399	1H-NMR (DMSO-D6) δ: 12.46 (114, s), 11.64 (1H, s), 8.27 (OH, s), 7.60-7.58 (3H, m), 7.38 (1H, d, J = 1.6 Hz), 7.29-7.26 (2H, m), 7.00 (1H, dd, J = 8.5, 1.5 Hz), 6.96 (2H, br s), 3.01-2.94 (1H, s), 2.52 (3H, s), 1.26 (3H, s), 1.24 (3H, s).
77		+5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-pyridin-2-yl-1H-indol-2-yl]-methanone	434	1H-NMR (DMSO-D6) δ: 12.49 (1H, s), 11.91 (1H, s), 8.68 (1H, d, J = 4.9 Hz), 8.54 (1H, s), 8.26 (1H, s), 7.97 (1H, d, J = 7.9 Hz), 7.91-7.97 (1H, m), 7.81 (2H, q, J = 8.5 Hz), 7.63 (2H, s), 7.50 (1H, s), 7.36-7.28 (2H, m), 7.04 (2H, s), 2.54 (3H, s).

TABLE 3-continued

Exam- ple	Structure	Compound name	m/z	1H-NMR
78		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-cyclopropyl-1H-indol-2-yl]-methanone	397	1H-NMR (DMSO-D6) δ: 12.46 (1H, s), 11.66 (1H, s), 8.27 (1H, s), 7.64-7.57 (2H, br m), 7.57 (1H, s), 7.36 (1H, d, J = 8.6 Hz), 7.33 (1H, d, J = 1.6 Hz), 7.28 (1H, dd, J = 8.2, 2.1 Hz), 7.00 (1H, dd, J = 8.5, 1.5 Hz), 6.99 (2H, br s), 2.53 (3H, s), 2.03-1.97 (1H, m), 0.95-0.90 (2H, m), 0.68-0.64 (2H, m).
79		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-pyridazin-3-yl-1H-indol-2-yl]-methanone	435	1H-NMR (DMSO-D6) δ: 12.49 (1H, s), 12.03 (1H, s), 9.20 (1H, dd, J = 4.9, 1.5 Hz), 8.35 (2H, d, J = 8.0 Hz), 8.24 (1H, d, J = 1.8 Hz), 7.87 (2H, s), 7.78 (1H, dd, J = 6.5, 4.9 Hz), 7.63 (1H, s), 7.54 (2H, s), 7.31 (1H, dd, J = 8.0, 1.5 Hz), 7.06 (2H, s), 2.54 (3H, s).
80		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-isopropoxy-1H-indol-2-yl]-methanone	415	1H-NMR (DMSO-D6) δ: 12.46 (1H, s), 11.62 (1H, d, J = 1.8 Hz), 8.26 (1H, s), 7.66-7.55 (2H, br m), 7.36 (1H, d, J = 8.9 Hz), 7.32 (1H, d, J = 1.8 Hz), 7.29 (1H, dd, J = 9.6, 1.8 Hz), 7.13 (1H, d, J = 2.2 Hz), 6.99 (2H, br s), 6.99 (1H, dd, J = 8.9, 2.2 Hz), 4.38-4.52 (1H, m), 2.53 (3H, s), 1.29 (6H, d, J = 6.1 Hz).
81		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(2-methoxy-ethoxy)-1H-indol-2-yl]-methanone	431	1H-NMR (DMSO-D6) δ: 12.46 (1H, s), 11.56 (1H, d, J = 1.2 Hz), 8.27 (1H, s), 7.64-7.57 (2H, br m), 7.37 (1H, d, J = 9.1 Hz), 7.33 (1H, d, J = 1.2 Hz), 7.29 (1H, dd, J = 8.5, 1.8 Hz), 7.13 (1H, d, J = 2.4 Hz), 6.99 (2H, br s), 6.92 (1H, dd, J = 9.1, 2.4 Hz), 4.11-4.08 (2H, m), 3.70-3.68 (2H, m), 3.33 (3H, s), 2.53 (3H, s).

TABLE 3-continued

Example	Structure	Compound name	m/z	1H-NMR
82		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-5-cyclopropylmethoxy-1H-indol-2-yl)-methanone	427	1H-NMR (DMSO-D6) δ: 12.46 (1H, s), 11.54 (1H, s), 8.26 (1H, s), 7.65-7.55 (2H, br m), 7.36 (1H, d, J = 8.8 Hz), 7.31 (1H, s), 7.28 (1H, dd, J = 8.2, 2.2 Hz), 7.09 (1H, d, J = 2.5 Hz), 6.98 (2H, s), 6.92 (1H, dd, J = 8.8, 2.5 Hz), 3.82 (2H, d, J = 7.1 Hz), 2.53 (3H, s), 1.28-1.20 (1H, m), 0.60-0.56 (2H, m), 0.37-0.31 (2H, m).
83		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-2,2-difluoro-5H-[1,3]dioxolo[4,5-f]-indol-6-yl)-methanone	437	1H-NMR (DMSO-D6) δ: 12.46 (1H, s), 11.96 (1H, s), 8.28 (1H, s), 7.65-7.55 (2H, br m), 7.60 (1H, d, J = 1.9 Hz), 7.36 (1H, s), 7.28 (1H, dd, J = 8.5, 1.9 Hz), 7.01 (2H, br s), 2.53 (3H, s).
84		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(3-chloro-pyridin-2-yl)-1H-indol-2-yl]-methanone	468, 470	1H-NMR (DMSO-D6) δ: 12.48 (1H, s), 11.90 (1H, s), 8.66 (1H, dd, J = 4.7, 1.4 Hz), 8.36 (1H, s), 8.07 (1H, dd, J = 8.0, 1.4 Hz), 7.84 (1H, s), 7.79 (1H, d, J = 8.2 Hz), 7.64 (2H, s), 7.63 (1H, s), 7.46-7.41 (2H, m), 7.31 (1H, dd, J = 8.5, 1.9 Hz), 7.05 (2H, s), 2.63 (3H, t, J = 5.5 Hz).

TABLE 3-continued




Example	Structure	Compound name	m/z	1H-NMR
85		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(5-fluoro-pyridin-2-yl)-1H-indol-2-yl]-methanone	452	1H-NMR (DMSO-D6) δ: 12.48 (1H, s), 11.92 (1H, s), 8.68 (1H, d, J = 2.7 Hz), 8.36 (1H, s), 8.21 (1H, d, J = 1.1 Hz), 8.06 (1H, dd, J = 8.8, 4.4 Hz), 7.85-7.79 (3H, m), 7.63 (2H, s), 7.50 (1H, s), 7.31 (1H, dd, J = 8.5, 1.9 Hz), 7.05 (2H, s), 2.56 (3H, s).
86		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(6-norpholin-4-yl-pyridazin-3-yl)-1H-indol-2-yl]-methanone	520	1H-NMR (DMSO-D6) δ: 12.47 (1H, d, J = 5.5 Hz), 11.90 (1H, d, J = 2.2 Hz), 8.34 (1H, d, J = 4.9 Hz), 8.17 (1H, s), 7.98 (1H, d, J = 9.3 Hz), 7.82-7.74 (2H, m), 7.68-7.64 (1H, m), 7.60-7.56 (1H, m), 7.50 (1H, s), 7.38 (1H, d, J = 9.3 Hz), 7.33-7.28 (1H, m), 7.07 (1H, s), 7.01 (1H, s), 3.80-3.74 (4H, m), 3.65-3.60 (4H, m), 2.53 (3H, s).
87		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-chloro-6-cyclopropylmethoxy-1H-indol-2-yl]-methanone	461, 463	1H-NMR (DMSO-d6) δ: 12.46 (1H, s), 11.66 (1H, s), 8.25 (1H, s), 7.72 (1H, s), 7.62-7.38 (2H, m), 7.37 (1H, d, J = 1.3 Hz), 7.28 (1H, dd, J = 8.2, 1.3 Hz), 7.02 (1H, s), 6.97 (2H, s), 3.92 (2H, d, J = 7.1 Hz), 2.53 (3H, s), 1.35-1.25 (1H, m), 0.64-0.59 (2H, m), 0.44-0.39 (2H, m).

TABLE 3-continued

Example	Structure	Compound name	m/z	1H-NMR
88		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(2,4-difluoro-phenyl)-1H-indol-2-yl]-methanone	469	1H-NMR (DMSO-D6) δ: 12.51 (1H, s), 11.88 (1H, s), 8.35 (1H, s), 7.79 (1H, d, J = 7.7 Hz), 7.62 (4H, s), 7.52 (1H, s), 7.46-7.16 (4H, m), 7.05 (2H, s), 2.54 (3H, s).
89		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-pyridazin-4-yl-1H-indol-2-yl]-methanone	435	1H-NMR (DMSO-D6) δ: 12.48 (1H, s), 12.04 (1H, s), 9.67-9.64 (1H, m), 9.27 (1H, d, J = 5.6 Hz), 8.35 (1H, d, J = 4.4 Hz), 8.02 (1H, dd, J = 5.5, 2.7 Hz), 7.96 (1H, s), 7.89 (1H, d, J = 8.8 Hz), 7.67-7.55 (4H, m), 7.30 (1H, t, J = 6.3 Hz), 7.10 (1H, s), 7.04 (1H, s), 2.54 (3H, s).
204		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-chloro-1H-indol-2-yl]-methanone	391	1H-NMR (CDCl3) δ: 11.18 (1H, br s), 8.28 (1H, m), 7.70-7.68 (1H, m), 7.60 (2H, m), 7.46 (2H, m), 7.29-7.27 (1H, m), 7.01 (2H, m), 2.52 (3H, s)
205		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-chloro-1H-indol-2-yl]-methanone	391	1H-NMR (CDCl3) δ: 11.91 (s, 1H), 8.30 (s, 1H), 7.71 (m, 3H), 7.45 (m, 4H), 7.26 (m, 1H), 7.09 (s, 2H), 2.62 (s, 3H).

TABLE 3-continued

Exam- ple	Structure	Compound name	m/z	1H-NMR
206		[5-amino-1-(2-methyl-1H-benzimidazo[5,1-y]-1H-pyrazo[4,y]-1(1H-indol-3-y)-methanone	357	11.92 (s, 1H), 8.32 (m, 1H), 8.25 (d, J = 7.6 Hz, 1H), 8.20 (s, 1H), 7.77 (m, 2H), 7.51 (m, 2H), 7.18 (m, 2H), 6.97 (s, 2H), 2.67 (s, 3H).
207		[5-amino-1-(2-methyl-1H-benzimidazo[5,1-y]-1H-pyrazo[4,y]-1(5-bromo-o-6-fluoro-1H-indol-2-y)-methanone	357	12.42 (s, 1H), 11.36 (s, 1H), 7.91 (s, 1H), 7.85 (m, 1H), 7.66 (d, J = 8.3 Hz, 1H), 7.58 (m, 3H), 7.48 (d, J = 8 Hz, 1H), 7.29 (d, J = 8.7 Hz, 1H), 6.95 (br s, 2H), 6.54 (s, 1H), 2.53 (s, 3H).
208		[5-amino-1-(2-methyl-1H-benzimidazo[5,1-y]-1H-pyrazo[4,y]-1(5-bromo-o-6-fluoro-1H-indol-2-y)-methanone	453	12.49 (s, 1H), 11.97 (s, 1H), 8.27 (s, 1H), 8.01 (d, J = 7 Hz, 1H), 7.62 (m, 2H), 7.36 (d, J = 9.6 Hz, 1H), 7.29 (d, J = 7.6 Hz, 1H), 7.02 (br s, 2H), 2.54 (s, 3H)
209		[5-amino-1-(2-ethyl-1H-benzimidazo[5,1-y]-1H-pyrazo[4,y]-1(5-bromo-o-6-fluoro-1H-indol-2-y)-methanone	467	12.48 (s, 1H), 11.98 (s, 1H), 8.27 (d, J = 4.5 Hz, 1H), 8.01 (d, J = 6.8 Hz, 1H), 7.67 (m, 1H), 7.57 (s, 1H), 7.46 (s, 1H), 7.37 (d, J = 9.4 Hz, 1H), 7.29 (t, J = 7.7 Hz, 1H), 7.03 (m, 2H), 2.86 (m, 2H), 1.34 (m, 3H)

TABLE 3-continued

Exam- ple	Structure	Compound name	m/z	1H-NMR
210		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazo[4-yl]-[5-trifluoromethyl-1H-indol-2-yl]-methanone	425	12.15 (s, 1H), 8.33 (s, 1H), 8.10 (s, 1H), 7.74 (m, 2H), 7.67 (d, J = 8.5 Hz, 1H), 7.52 (s, 1H), 7.54 (d, J = 8.5 Hz, 1H), 7.45 (d, J = 8.6 Hz, 1H), 7.13 (m, 2H), 2.65 (s, 3H)
211		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazo[4-yl]-[5-(4-fluoromethoxy)-1H-indol-2-yl]-methanone	441	12.48 (s, 1H), 11.99 (s, 1H), 8.29 (d, J = 4.8 Hz, 1H), 7.66 (d, J = 8.6 Hz, 2H), 7.56 (d, J = 9.3 Hz, 1H), 7.52 (s, 2H), 7.27 (m, 2H), 7.16 (m, 1H), 7.05 (m, 2H), 2.53 (s, 3H)
212		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazo[4-yl]-[4-(6-dichloro-1H-indol-2-yl)-methanone	425	12.47 (s, 1H), 12.21 (s, 1H), 8.33 (d, J = 5.6 Hz, 1H), 7.95 (br s, 1H), 7.65 (d, J = 7.8 Hz, 1H), 7.56 (d, J = 6.9 Hz, 1H), 7.48 (s, 1H), 7.37 (s, 1H), 7.28 (m, 1H), 7.22 (m, 1H), 7.09 (s, 1H), 7.03 (s, 1H), 2.53 (s, 3H)
213		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazo[4-yl]-[6-bromo-4-fluoro-1H-indol-2-yl]-methanone	453	12.16 (s, 1H), 8.38 (s, 1H), 7.65 (m, 2H), 7.50 (d, J = 5.3 Hz, 2H), 7.34 (m, 1H), 7.13 (m, 1H), 7.09 (m, 2H), 2.57 (s, 3H)

TABLE 3-continued

Exam- ple	Structure	Compound name	m/z	1H-NMR
214		[5-amino-1-(2-methyl-1H-benzimidazo[5,1-f]pyrazo[4,3-g][6-trifluoromethoxy-1H-indol-2-yl]-methanone	441	12.5 (s, 1H), 11.93 (s, 1H), 8.31 (s, 1H), 7.80 (d, J = 8.7 Hz, 1H), 7.62 (s, 2H), 7.55 (s, 1H), 6.81 (m, 3H), 2.53 (s, 3H).
215		[5-amino-1-(2-ethyl-1H-benzimidazo[5,1-f]pyrazo[4,3-g][6-trifluoromethoxy-1H-indol-2-yl]-methanone	455	12.50 (s, 1H), 11.98 (s, 1H), 8.29 (s, 1H), 7.67 (s, 1H), 7.63 (br s, 1H), 7.57 (d, J = 8.9 Hz, 1H), 7.51 (m, 1H), 7.29 (d, J = 8.3 Hz, 1H), 7.23 (d, J = 8.4 Hz, 1H), 7.04 (s, 1H), 2.87 (m, 2H), 1.48 (m, 3H)
216		[5-amino-1-(2-ethyl-1H-benzimidazo[5,1-f]pyrazo[4,3-g][6-trifluoromethyl-1H-indol-2-yl]-methanone	439	12.16 (s, 1H), 8.33 (br s, 1H), 8.10 (br s, 1H), 7.73 (m, 2H), 7.67 (d, J = 8.2 Hz, 1H), 7.62 (s, 1H), 7.54 (d, J = 8.3 Hz, 1H), 7.43 (m, 1H), 7.12 (br s, 3H), 2.96 (m, 2H), 1.37 (m, 3H)

TABLE 3-continued

Exam- ple	Structure	Compound name	m/z	1H-NMR
217		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazo[4,5-y]-[5,6-dichloro-1H-indol-2-yl]-methanone	425	11.98 (s, 1H), 8.30 (s, 1H), 7.96 (s, 1H), 7.70 (m, 3H), 7.46 (s, 1H), 7.42 (d, J = 8.8 Hz, 1H), 7.11 (s, 2H), 2.67 (s, 3H).
218		[5-amino-1-(2-ethyl-1H-benzimidazol-5-yl)-1H-pyrazo[4,5-y]-[6-bromo-5-fluoro-1H-indol-2-yl]-methanone	467	11.91 (s, 1H), 8.28 (s, 1H), 7.74 (d, J = 6 Hz, 1H), 7.64 (d, J = 9 Hz, 3H), 7.46 (s, 1H), 7.31 (d, J = 7.8 Hz, 1H), 7.06 (br s, 2H), 2.89 (q, J = 7.2 Hz, 2H), 1.35 (t, J = 7.2 Hz, 3H).
219		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazo[4,5-y]-[4,5-dichloro-1H-indol-2-yl]-methanone	425	12.46 (s, 2H), 7.66 (m, 1H), 7.57 (d, J = 7.6 Hz, 1H), 7.49 (m, 1H), 7.43 (d, J = 8.7 Hz, 1H), 7.30 (t, J = 6.6 Hz, 1H), 7.05 (m, 2H), 2.53 (s, 3H)
220		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazo[4,5-y]-[4,6-difluoro-1H-indol-2-yl]-methanone	393	12.40 (m, 1H), 12.12 (s, 1H), 8.37 (s, 1H), 7.62 (s, 2H), 7.49 (s, 1H), 7.29 (m, 1H), 7.07 (m, 3H), 6.94 (m, 1H), 2.54 (s, 3H).

TABLE 3-continued




Exam- ple	Structure	Compound name	m/z	1H-NMR
221		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazo[4-yl]-[6-O-chloropyridin-4-yl]-1H-indol-2-yl]-methanone	468	11.95 (bs, 1H), 8.75 (s, 1H), 8.59 (d, 1H, $J = 4$ Hz), 8.41 (bs, 1H), 7.95 (m, 1H), 7.89 (m, 1H), 7.82 (d, 1H, $J = 12$ Hz), 7.66 (m, 1H), 7.64 (m, 1H), 7.54 (m, 2H), 7.22 (m, 2H), 6.86 (s, 1H), 6.63 (s, 1H), 2.8 (s, 3H), 2.18 (s, 3H)
222		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazo[4-yl]-[6-(6-methylpyridine-3-yl)-1H-indol-2-yl]-methanone	448	8.73 (1H, m), 8.30 (1H, m), 8.07-8.04 (1H, m), 7.86-7.84 (2H, m), 7.75 (1H, m), 7.68 (2H, m), 7.42-7.39 (4H, m), 2.62 (3H, s), 2.59 (3H, s)
223		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazo[4-yl]-[6-(6-fluoropyridin-3-yl)-1H-indol-2-yl]-methanone	452	11.95 (s, 1H), 8.009 (m, 1H), 7.80 (m, 2H), 7.70 (m, 1H), 7.54 (m, 2H), 7.38 (d, 1H, $J = 12$ Hz), 7.17 (bs, 1H), 2.85 (s, 1H), 2.65 (m, 1H), 2.55 (s, 3H)

TABLE 3-continued

Exam- ple	Structure	Compound name	m/z	1H-NMR
224		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazo[4-yl]-[6-(2-trifluoromethyl-pyridin-3-yl)-1H-indol-2-yl]-methanone	502	8.30 (s, 2H), 8.17 (m, 1H), 8.06 (t, 1H, <i>J</i> = 8 Hz), 7.86 (q, 2H, <i>J</i> = 12 Hz), 7.67 (d, 3H, <i>J</i> = 8 Hz), 7.40 (m, 2H), 2.61 (m, 3H),
225		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazo[4-3,5-yl]-[6-(5-chloropyridin-3-yl)-1H-indol-2-yl]-methanone	498	8.30 (1H, s), 8.09 (1H, d, <i>J</i> = 2.8 Hz), 7.78 (2H, m), 7.59 (3H, m), 7.42 (2H, m), 7.28 (1H, m), 5.78 (2H, m), 3.96 (3H, s), 2.63 (3H, s), 2.02 (3H, m)
226		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazo[4-3,5-yl]-[6-(5-chloropyridin-3-yl)-1H-indol-2-yl]-methanone	468	12.55 (bs, 1H), 11.95 (bs, 1H), 8.87 (m, 1H), 8.62 (d, 1H, <i>J</i> = 2.4 Hz), 8.34 (s, 1H), 8.23 (t, 1H, <i>J</i> = 2 Hz), 7.82 (d, 1H, <i>J</i> = 8 Hz), 7.78 (s, 1H), 7.60 (m, 3H), 7.52 (m, 1H), 7.47 (d, 1H, <i>J</i> = 8 Hz), 7.28 (m, 1H), 7.05 (m, 1H), 2.54 (s, 3H)
227		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazo[4-4,5-yl]-[6-thiophen-3-yl-1H-indol-2-yl]-methanone	439	12.55 (bs, 1H), 11.74 (s, 1H), 8.32 (s, 1H), 7.82 (m, 1H), 7.71 (m, 2H), 7.66 (m, 1H), 7.60 (m, 2H), 7.54 (d, 1H, <i>J</i> = 4 Hz), 7.3 (m, 1H), 2.54 (s, 3H)

TABLE 3-continued




Exam- ple	Structure	Compound name	m/z	1H-NMR
228		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazo[4-yl]-[6-(4-chloropyridin-3-yl)-1H-indol-2-yl]-methanone	468	11.87 (s, 1H), 8.61 (m, 2H), 8.51 (m, 2H), 8.36 (bs, 1H), 7.78 (m, 3H), 7.66 (m, 1H), 7.51 (m, 3H), 7.15 (m, 3H), 3.04 (s, 2H), 2.68 (s, 3H), 1.47 (bs, 1H), 1.16 (m, 6H)
229		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazo[4-yl]-[6-(4-thiophen-2-yl-1H-indol-2-yl)-methanone	439	11.75 (s, 1H), 8.35 (s, 1H), 7.75 (m, 4H), 7.48 (m, 5H), 7.14 (m, 3H), 3.08 (s, 1H), 2.65 (s, 3H),
230		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazo[4-yl]-[6-(3-fluoropyridin-4-yl)-1H-indol-2-yl]-methanone	452	12.59 (s, 1H), 11.96 (s, 1H), 8.66 (d, 1H, J = 8 Hz), 8.51 (d, 1H, J = 4 Hz) 8.34 (m, 1H), 7.84 (d, 2H), 7.81 (s, 1H), 7.67 (m, 2H), 7.56 (m, 2H), 7.29 (m, 1H), 7.02 (m, 2H), 2.67 (3, 3H)
231		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazo[4-yl]-[6-(2-trifluoromethyl-pyridin-4-yl)-1H-indol-2-yl]-methanone	502	12.69 (bs, 1H), 11.98 (s, 1H), 8.83 (d, 1H, J = 4 Hz), 8.31 (m, 1H), 8.16 (m, 1H), 8.05 (d, 1H, J = 4 Hz), 7.94 (s, 1H), 7.86 (d, 1H, J = 8 Hz), 7.62 (m, 3H), 7.54 (m, 1H), 7.31 (d, 1H, J = 8 Hz), 7.07 (bs, 2H), 2.55 (s, 3H)

TABLE 3-continued

Example	Structure	Compound name	m/z	1H-NMR
232		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazo-4-yl]-[5-(3,3-difluoro-pyrrolidine-1-carbonyl)-1H-indol-2-yl]-methanone	490	8.33 (bs, 1H), 8.03 (bs, 2H), 7.81 (m, 2H), 7.56 (m, 2H), 7.50 (m, 2H), 4.24 (t, 4H, J = 12 Hz), 2.66 (s, 3H), 1.49 (m, 1H), 1.39 (m, 3H), 1.28 (m, 4H)
233		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazo-4-yl]-[5-(2,6-dimethyl-nmorpholine-4-carbonyl)-1H-indol-2-yl]-methanone	498	12.46 (d, 1H, J = 4 Hz), 11.91 (s, 1H), 8.32 (m, 1H), 7.77 (m, 1H), 7.65 (m, 1H), 7.56 (m, 1H), 7.51 (m, 1H), 7.27 (m, 2H), 7.05 (s, 1H), 7.0 (s, 1H), 3.55 (bs, 2H), 2.62 (s, 3H), 1.23 (m, 5H), 1.07 (bs, 3H)
234		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazo-4-yl]-[5-[(1,4-bipiperidinyl)-1'-carbonyl]-1H-indol-2-yl]-methanone	551	8.28 (s, 1H), 7.83 (s, 1H), 7.63 (m, 2H), 7.55 (m, 1H), 7.45 (s, 1H), 7.32 (d, 2H, 7.05 (s, 1H, J = 8 Hz), 2.60 (m, 8H), 1.88 (m, 2H), 1.62 (m, 4H)

TABLE 3-continued

Exam- ple	Structure	Compound name	m/z	1H-NMR
235		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazo-4-yl-[5'-14-(2,2-trifluoro-ethyl)-piperazine-1-carbonyl]-1H-indol-2-yl]-methanone	551	8.28 (s, 1H), 7.84 (s, 1H), 7.64 (d, 2H, $J = 8$ Hz), 7.55 (d, 1H, $J = 1$ H, $J = 8$ Hz), 7.45 (s, 1H), 7.35 (t, 1H, $J = 8$ Hz), 3.67 (bs, 4H), 3.17 (t, 2H, $J = 8$ Hz), 2.74 (m, 4H), 2.36 (s, 3H),
236		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazo-4-yl-[5'-14-(2-hydroxy-ethyl)-piperazine-1-carbonyl]-1H-indol-2-yl]-methanone	513	8.28 (s, 1H), 7.84 (s, 1H), 7.65 (m, 2H), 7.55 (d, 1H, $J = 8$ Hz), 7.46 (s, 1H), 7.35 (m, 2H), 3.69 (m, 6H), 6.82 (m, 3H), 3.33 (s, 1H), 2.64 (s, 3H), 2.56 (m, 6H)
237		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazo-4-yl-[45-(3,3,4,4-tetrafluoro-pyrrolidine-1-carbonyl)-1H-indol-2-yl]-methanone	526	8.289 (s, 1H), 7.99 (m, 1H), 7.65 (m, 2H), 7.55 (m, 1H), 7.47 (m, 2H), 7.39 (d, 1H, $J = 8$ Hz), 3.95 (t, 2H, $J = 12$ Hz), 3.87 (t, 2H, $J = 8$ Hz), 2.61 (s, 3H), 2.45 (bs, 2H)


TABLE 3-continued

Exam- ple	Structure	Compound name	m/z	1H-NMR
238		[5-amino-1-(2-methyl-1H-benzimidazo[5,1-b]pyrazo[4,3-y]-[5-(R)-3-fluoro-pyrolidine-1-carbonyl]-1H-indol-2-yl]-methanone	472	8.29 (s, 1H), 7.97 (d, 1H, J = 12 Hz), 7.67 (m, 2H), 7.55 (m, 1H), 7.47 (m, 2H), 7.37 (d, 2H, J = 8 Hz), 5.3 (m, 1H), 3.84 (m, 6H), 2.61 (s, 3H)
239		[5-amino-1-(2-methyl-1H-benzimidazo[5,1-b]pyrazo[4,3-y]-[5-(S)-3-fluoro-pyrolidine-1-carbonyl]-1H-indol-2-yl]-methanone	472	8.29 (s, 1H), 7.97 (d, 1H), 7.65 (m, 2H), 7.55 (m, 1H), 7.47 (m, 2H), 7.35 (d, 1H, J = 8 Hz), 5.3 (m, 1H), 3.77 (m, 4H), 2.61 (s, 3H), 2.2 (bs, 2H)

161

Example 90

Synthesis of [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[3-fluoro-1H-indol-2-yl]-methanone



[5-Amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[3-fluoro-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone (25.0 mg, 0.041 mmol) was dissolved in methane

162

sulfonic acid (0.25 ml), and stirred at room temperature for one hour. The pH of the reaction mixture was adjusted to 6 using an aqueous solution of 1 M sodium hydroxide. After extraction with ethyl acetate, the extract was dried over anhydrous sodium sulfate. The desiccant was removed by filtration. The filtrate was concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (dichloromethane/methanol=60/1 to 40/1) to give [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[3-fluoro-1H-indol-2-yl]-methanone was obtained as a pale yellow solid (8.7 g, with a yield of 55%).

¹H-NMR (DMSO-D₆) δ 12.48 (1H, s), 11.50 (1H, s), 8.03 (1H, d, J=3.1 Hz), 7.69 (1H, d, J=8.5 Hz), 7.62 (2H, s), 7.45 (1H, d, J=8.5 Hz), 7.25-7.35 (2H, m), 7.15 (1H, t, J=7.3 Hz), 7.05 (2H, s), 2.53 (3H, s)

ESI (LC-MS positive mode) m/z 375 [(M+H)⁺]

The compounds of Examples 91 to 131 listed in Table 4 were synthesized by the same method as in Example 90.

TABLE 4

Exam- ple	Structure	Compound name	m/z	¹ H-NMR
91		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(1-isopropyl-piperidin-4-yl)-6-trifluoromethyl-1H-indol-2-yl]-methanone	550	¹ H-NMR (DMSO-D ₆) δ: 12.48 (1H, s), 11.99 (1H, s), 8.30 (1H, s), 7.87 (1H, s), 7.79 (1H, s), 7.66-7.55 (2H, br m), 7.45 (1H, s), 7.29 (1H, d, J = 8.5 Hz), 7.06 (2H, br s), 7.96-2.89 (2H, m), 2.84-2.70 (2H, m), 2.53 (3H, s), 2.25-2.19 (2H, m), 1.81-1.71 (4H, m), 1.01 (8H, d, J = 6.7 Hz).
92		2-[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazole-4-carbonyl]-1H-indole-6-carbonitrile	382	¹ H-NMR (DMSO-D ₆) δ: 12.47 (1H, s), 12.24 (1H, s), 8.33 (1H, s), 7.93-7.86 (2H, m), 7.67-7.55 (3H, m), 7.42 (1H, dd, J = 8.5, 1.2 Hz), 7.29 (1H, dd, J = 8.5, 1.8 Hz), 7.10 (2H, s), 2.54 (3H, s).
93		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5(1,2,3,6-tetrahydro-pyridin-4-yl)-1H-indol-2-yl]-methanone	438	¹ H-NMR (DMSO-D ₆) δ: 12.45 (1H, s), 11.65 (1H, s), 8.28 (1H, s), 7.57-7.54 (3H, m), 7.44-7.39 (3H, m), 7.29 (1H, d, J = 8.5 Hz), 6.99 (2H, br s), 6.16 (1H, s), 3.41-3.39 (2H, m), 2.95 (2H, t, J = 5.5 Hz), 2.53 (3H, s), 2.43-2.41 (2H, m).

TABLE 4-continued

Exam- ple	Structure	Compound name	m/z	1H-NMR
94		[5-amino-1-(2-methyl-1H-benzimidazo[5,1-f]indol-2-yl)-5-piperidin-4-yl]methanone	440	1H-NMR (DMSO-D6) δ: 12.44 (1H, s), 11.55 (1H, s), 8.28 (1H, s), 7.66-7.55 (2H, br m), 7.48 (1H, s), 7.40 (1H, d, J = 8.5 Hz), 7.37 (1H, d, J = 1.2 Hz), 7.29 (1H, d, J = 8.5 Hz), 7.15 (1H, dd, J = 8.5, 1.2 Hz), 8.97 (2H, br s), 3.05-3.02 (2H, m), 2.67-2.58 (3H, m), 2.53 (3H, s), 1.75-1.72 (2H, m), 1.61-1.50 (2H, m),
95		[5-amino-1-(2-methyl-1H-benzimidazo[5,1-f]indol-2-yl)-5-(R)-3-fluoro-pyridin-1-ylmethyl)-1H-indol-2-yl]methanone	458	1H-NMR (DMSO-D6) δ: 12.46 (1H, d, J = 4.9 Hz), 11.66 (1H, d, J = 1.2 Hz), 8.30 (1H, d, J = 4.9 Hz), 7.65 (1H, dd, J = 5.2, 3.4 Hz), 7.59-7.57 (2H, m), 7.44-7.42 (2H, m), 7.32-7.27 (1H, m), 7.23 (1H, dd, J = 8.2, 1.5 Hz), 6.99 (2H, d, J = 22.0 Hz), 5.20 (1H, dt, J = 5.5, 9.5, 5.6 Hz), 3.57 (2H, s), 2.81-2.75 (2H, m), 2.65-2.58 (1H, m), 2.54 (3H, s), 2.34-2.32 (1H, m), 2.18-2.13 (1H, m), 1.90-1.84 (1H, m).
96		[5-amino-1-(2-methyl-1H-benzimidazo[5,1-f]indol-2-yl)-5-(6-fluoro-5-piperidin-4-yl)-1H-indol-2-yl]methanone	458	1H-NMR (DMSO-D6) δ: 12.45 (1H, s), 11.63 (1H, s), 8.27 (1H, s), 7.62-7.59 (2H, br m), 7.55 (1H, d, J = 7.3 Hz), 7.43 (1H, s), 7.28 (1H, dd, J = 8.5, 2.4 Hz), 7.14 (1H, d, J = 11.0 Hz), 8.97 (2H, br s), 3.06-3.03 (2H, m), 2.91-2.85 (1H, m), 2.68-2.59 (2H, m), 2.53 (3H, s), 1.75-1.72 (2H, m), 1.63-1.53 (2H, m),
97		[5-amino-1-(2-methyl-1H-benzimidazo[5,1-f]indol-2-yl)-5-(6-fluoro-5-(1-methyl-piperidin-4-yl)-1H-indol-2-yl)]methanone	472	1H-NMR (DMSO-D6) δ: 12.45 (1H, s), 11.64 (1H, d, J = 1.5 Hz), 8.27 (1H, s), 7.65-7.62 (1H, br m), 7.59-7.53 (1H, br m), 7.57 (1H, d, J = 7.3 Hz), 7.42 (1H, d, J = 1.5 Hz), 7.28 (1H, d, J = 9.8 Hz), 7.14 (1H, d, J = 11.6 Hz), 6.97 (2H, br s), 2.92-2.87 (2H, m), 2.79-2.72 (1H, m), 2.63 (3H, s), 2.21 (3H, s), 2.04-1.97 (2H, m), 1.78-1.69 (4H, m).

TABLE 4-continued

Exam- ple	Structure	Compound name	m/z	1H-NMR
98		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(1-isopropyl-piperidin-4-yl)-1H-indol-2-yl]-methanone	482	1H-NMR (DMSO-D6) δ: 12.45 (1H, s), 11.55 (1H, d, J = 1.8 Hz), 8.28 (1H, s), 7.65-7.63 (1H, br m), 7.59-7.56 (1H, br m), 7.49 (1H, s), 7.39 (1H, d, J = 8.5 Hz), 7.36 (1H, d, J = 1.5 Hz), 7.29 (1H, d, J = 9.1 Hz), 7.16 (1H, dd, J = 8.5, 1.5 Hz), 7.00 (1H, br s), 6.95 (1H, br s), 2.92-2.87 (2H, m), 2.76-2.68 (1H, m), 2.55-2.57 (1H, m), 2.53 (3H, s), 2.27-2.20 (2H, m), 1.83-1.77 (2H, m), 1.71-1.60 (2H, m), 1.00 (6H, d, J = 6.7 Hz).
99		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-fluoro-5-(1-isopropyl-piperidin-4-yl)-1H-indol-2-yl]-methanone	500	1H-NMR (DMSO-D6) δ: 12.45 (1H, s), 11.64 (1H, d, J = 1.5 Hz), 8.27 (1H, s), 7.66-7.61 (1H, br m), 7.59-7.55 (1H, br m), 7.57 (1H, d, J = 7.3 Hz), 7.41 (1H, d, J = 1.5 Hz), 7.28 (1H, d, J = 7.9 Hz), 7.14 (1H, d, J = 11.6 Hz), 7.00 (1H, br s), 6.95 (1H, br s), 2.93-2.88 (2H, m), 2.77-2.69 (2H, m), 2.53 (3H, s), 2.30-2.22 (2H, m), 1.84-1.78 (2H, m), 1.75-1.65 (2H, m), 1.01 (6H, d, J = 8.7 Hz),
100		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-pyridin-3-yl-1H-indol-2-yl]-methanone	434	1H-NMR (DMSO-D6) δ: 12.47 (1H, s), 11.86 (1H, s), 8.90 (1H, d, J = 2.4 Hz), 8.55 (1H, d, J = 4.9 Hz), 8.34 (1H, s), 8.08 (1H, d, J = 7.9 Hz), 7.83 (1H, d, J = 7.9 Hz), 7.73 (1H, s), 7.62 (2H, s), 7.53-7.43 (3H, m), 7.30 (2H, dd, J = 8.2, 1.5 Hz), 7.03 (3H, s), 2.54 (3H, s).

TABLE 4-continued

Exam- ple	Structure	Compound name	m/z	1H-NMR
101		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(6-norpholin-4-yl-pyridin-3-yl)-1H-indol-2-yl]-methanone	519	1H-NMR (DMSO-D6) δ: 12.47 (1H, d, J = 1.2 Hz), 8.49 (1H, 4, 3 = 2.4 Hz), 8.32 (1H, s), 7.91-7.90 (2H, m), 7.66-7.47 (5H, m), 7.30 (1H, d, J = 8.5 Hz), 7.02 (2H, d, J = 19.5 Hz), 6.94 (1H, d, J = 9.2 Hz), 3.73 (4H, dd, J = 4.6, 2.3 Hz), 3.49 (4H, dd, J = 4.9, 2.4 Hz), 2.54 (3H, s).
102		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(6-pyridin-3-yl-1H-indol-2-yl)-methanone]	434	1H-NMR (DMSO-D6) δ: 12.47 (1H, s), 11.85 (1H, d, J = 1.8 Hz), 8.93 (1H, d, 3 = 2.4 Hz), 8.54 (1H, dd, J = 4.9, 1.2 Hz), 8.33 (1H, s), 8.10 (1H, dt, J = 8.1, 1.8 Hz), 8.03 (1H, s), 7.64-7.60 (4H, m), 7.52 (1H, d, J = 1.8 Hz), 7.49 (1H, dd, J = 7.6, 4.6 Hz), 7.31 (1H, d, J = 8.5 Hz), 7.03 (2H, d, J = 20.1 Hz), 2.54 (3H, s).
103		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(6-piperazin-1-yl-pyridin-3-yl)-1H-indol-2-yl]-methanone	518	1H-NMR (DMSO-D6) δ: 12.48 (1H, s), 11.74 (1H, s), 8.45 (1H, d, J = 3.1 Hz), 8.32 (1H, s), 7.87-7.85 (2H, m), 7.69-7.49 (5H, m), 7.47 (1H, s), 7.30 (1H, dd, J = 8.5, 1.8 Hz), 7.02 (2H, s), 6.89 (1H, d, J = 9.2 Hz), 3.44 (4H, t, J = 5.1 Hz), 2.80 (4H, t, J = 5.1 Hz), 2.54 (3H, s).

TABLE 4-continued






Example	Structure	Compound name	m/z	1H-NMR
104		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(6-hydroxy-pyridin-3-yl)-1H-indol-2-yl]-methane	450	1H-NMR (DMSO-D6) δ: 12.89 (1H, s), 11.76 (1H, s), 8.38 (1H, s), 8.00 (1H, d, J = 9.2 Hz), 7.95 (1H, d, J = 9.2 Hz), 7.88 (1H, dd, J = 9.7, 2.5 Hz), 7.82 (1H, s), 7.73 (1H, dd, J = 8.5, 1.8 Hz), 7.67 (1H, d, J = 2.5 Hz), 7.52-7.48 (4H, m), 7.25 (2H, s), 6.47 (1H, 4, J = 9.7 Hz), 2.84 (3H, s).
105		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-fluoro-5-(4-methyl-1-piperazin-1-ylmethyl)-1H-indol-2-yl]-methane	487	1H-NMR (DMSO-D6) δ: 12.47 (1H, s), 11.71 (1H, s), 8.29 (1H, s), 7.65 (1H, d, J = 7.3 Hz), 7.62-7.57 (2H, br m), 7.46 (1H, s), 7.28 (1H, dd, J = 8.5, 1.8 Hz), 7.15 (1H, d, J = 11.0 Hz), 8.99 (2H, br s), 3.56 (2H, s), 2.53 (3H, s), 2.47-2.38 (4H, br m), 2.35-2.28 (4H, br m), 2.14 (3H, s).
106		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-fluoro-5-(pyrrolidin-1-ylmethyl)-1H-indol-2-yl]-methane	458	1H-NMR (DMSO-D6) δ: 12.48 (1H, s), 11.69 (1H, s), 8.29 (1H, s), 7.67 (1H, d, J = 7.3 Hz), 7.62-7.58 (2H, br m), 7.45 (1H, s), 7.28 (1H, dd, J = 8.6, 1.8 Hz), 7.14 (1H, d, J = 11.0 Hz), 6.99 (2H, br s), 3.68 (2H, s), 2.53 (3H, s), 2.52-2.45 (4H, m), 1.72-1.67 (4H, m).
107		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(1-methyl-1H-indol-2-yl)-1H-indol-2-yl]-methane	454	1H-NMR (DMSO-D6) δ: 12.47 (1H, s), 11.56 (1H, s), 8.28 (1H, s), 7.63-7.57 (2H, br m), 7.60 (1H, d, J = 8.5 Hz), 7.39 (1H, d, J = 1.8 Hz), 7.30 (1H, s), 7.28 (1H, dd, J = 8.5, 1.8 Hz), 6.99 (1H, dd, J = 8.5, 1.8 Hz), 6.98 (2H, br s), 2.91-2.86 (2H, br m), 2.55-2.51 (1H, br m), 2.53 (3H, s), 2.20 (3H, s), 2.02-1.96 (2H, m), 1.79-1.64 (4H, m).
108		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(4-norpholin-4-yl-phenyl)-1H-indol-2-yl]-methane	518	1H-NMR (DMSO-D6) δ: 12.47 (1H, s), 11.69 (1H, s), 8.32 (1H, d, J = 1.8 Hz), 7.73 (1H, d, J = 6.7 Hz), 7.64-7.56 (6H, m), 7.46 (1H, s), 7.37 (1H, d, J = 8.6 Hz), 7.30 (1H, d, J = 8.5 Hz), 7.09-6.97 (4H, m), 3.80-3.73 (4H, m), 3.19-3.14 (4H, m), 2.53 (3H, s).

TABLE 4-continued





Example	Structure	Compound name	m/z	1H-NMR
109		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(3,4,5,6-tetrahydro-2H-[1,2]bipyridin-5'-yl)-1H-indol-2-yl]-methanone	517	1H-NMR (DMSO-D6) δ: 11.70 (1H, d, J = 2.4 Hz), 8.33 (1H, s), 7.83 (1H, dd, J = 8.9, 2.7 Hz), 7.74 (1H, d, J = 8.5 Hz), 7.64-7.59 (4H, d, J = 8.5 Hz), 7.47 (1H, s) 7.36 (1H, d, J = 8.5 Hz), 7.30 (1H, dd, J = 8.5, 1.8 Hz), 7.01 (2H, s), 6.92 (1H, d, J = 9.2 Hz), 3.68 (4H, t, J = 5.2 Hz), 2.54 (3H, s), 1.64-1.57 (6H, m).
110		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(6-piperazin-1-yl-pyridin-3-yl)-1H-indol-2-yl]-methanone	518	1H-NMR (DMSO-D6) δ: 12.47 (1H, s), 11.71 (1H, s), 8.46 (1H, d, J = 2.4 Hz), 8.33 (1H, s), 7.85 (1H, dd, J = 8.6, 2.4 Hz), 7.76 (1H, d, J = 8.5 Hz), 7.65-7.58 (3H, m), 7.47 (1H, s), 7.36 (1H, d, J = 7.9 Hz), 7.30 (1H, dd, J = 8.5, 1.8 Hz), 7.01 (2H, s), 6.91 (1H, d, J = 9.2 Hz), 3.48 (4H, t, J = 4.9 Hz), 2.80 (4H, t, J = 4.9 Hz), 2.54 (3H, s).
111		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(6-methoxy-n-methoxy-3-yl)-1H-indol-2-yl]-methanone	464	1H-NMR (DMSO-D6) δ: 12.47 (1H, s), 11.79 (1H, s), 8.49 (1H, d, J = 2.4 Hz), 8.32 (1H, s), 8.03 (1H, dd, J = 8.9, 2.7 Hz), 7.93 (1H, s), 7.62-7.54 (4H, m), 7.49 (1H, s) 7.30 (1H, d, J = 8.2, 2.1 Hz), 7.02 (2H, s), 6.92 (1H, d, J = 9.2 Hz), 3.91 (3H, s), 2.54 (3H, s).
112		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(S)-3-methyl-1-morpholin-4-ylmethyl-1H-indol-2-yl]-methanone	470	1H-NMR (DMSO-D6) δ: 12.46 (1H, s), 11.65 (1H, s), 8.30 (1H, s), 7.60-7.59 (3H, m), 7.44-7.42 (2H, m), 7.30 (1H, d, J = 8.5 Hz), 7.22 (1H, d, J = 8.5 Hz), 6.99 (2H, s), 4.08 (1H, d, J = 12.8 Hz), 3.64-3.61 (2H, m), 3.43-3.40 (2H, m), 3.17-3.14 (2H, m), 2.53 (3H, s) 2.42-2.40 (1H, m), 2.12-2.08 (1H, m), 1.06 (3H, d, J = 5.7 Hz).

TABLE 4-continued

Exam- ple	Structure	Compound name	m/z	1H-NMR
113		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-((R)-3-fluoro-pyridin-1-ylmethyl)-1H-indol-2-yl]-methanone	458	1H-NMR (DMSO-D6) δ: 12.48 (1H, s), 11.64 (1H, s), 8.29 (1H, s), 7.61-7.58 (3H, m), 7.42-7.40 (2H, m), 7.28 (1H, dd, J = 8.5, 2.1 Hz), 7.04 (1H, dd, J = 8.2, 1.2 Hz), 8.98 (2H, br s), 5.28-5.11 (1H, m), 3.68 (2H, s), 2.82-2.75 (2H, m), 2.67-2.65 (1H, m), 2.52 (3H, s), 2.22-2.30 (1H, m), 2.28-2.08 (1H, m), 1.94-1.78 (1H, m).
114		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(2,5-dimethyl-pyrrolidin-1-ylmethyl)-1H-indol-2-yl]-methanone	468	1H-NMR (DMSO-D6) δ: 12.44 (1H, d, J = 4.3 Hz), 11.80 (1H, s), 8.30 (1H, d, J = 4.3 Hz), 7.65-7.55 (3H, m), 7.41-7.40 (2H, m), 7.28-7.21 (2H, m), 6.98 (2H, d, J = 22.0 Hz), 3.90-3.52 (2H, m), 2.97-2.95 (1H, m), 2.61 (1H, dd, J = 11.0, 5.5 Hz), 2.53 (3H, s), 1.99-1.93 (1H, m), 1.80-1.74 (1H, m), 1.32-1.27 (2H, m), 0.97 (6H, t, J = 6.1 Hz).
115		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(3-fluoro-piperidin-1-ylmethyl)-1H-indol-2-yl]-methanone	472	1H-NMR (DMSO-D6) δ: 12.45 (1H, s), 11.64 (1H, s), 8.29 (1H, s), 7.63-7.56 (3H, m), 7.44-7.41 (2H, m), 7.29 (1H, d, J = 8.5 Hz), 7.20 (1H, d, J = 8.5 Hz), 6.98 (2H, s), 4.62 (1H, d, J = 48.2 Hz), 3.57 (2H, s), 2.75-2.21 (4H, m), 2.53 (3H, s), 1.80-1.74 (2H, m), 1.52-4.43 (2H, m).

TABLE 4-continued

Exam- ple	Structure	Compound name	m/z	1H-NMR
116		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-{5-(3,3-difluoro-piperidin-1-ylmethyl)-1H-indol-2-yl}-methanone	490	1H-NMR (DMSO-D6) δ: 12.46 (1H, s), 11.68 (1H, s), 8.30 (1H, s) 7.61-7.58 (3H, m), 7.46-7.42 (2H, m), 7.29 (1H, dd, J = 8.5, 1.8 Hz), 7.20 (1H, d, J = 8.5 Hz) 6.99 (2H, s) 3.64 (2H, s), 2.51 (4H, m), 2.53 (3H, s) 1.88-1.86 (2H, m), 1.66-1.64 (2H, m).
117		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-{6-[2-(4-methyl-methyl)-1H-pyridin-4-yl]-pyridin-4-yl}-1H-indol-2-yl]-methanone	532	1H-NMR (DMSO-D6) δ: 12.47 (1H, s), 11.72m (1H, d, J = 1.2 Hz), 8.46 (1H, d, J = 3.1 Hz) 8.33 (1H, s) 7.86 (1H, dd, J = 8.9, 2.7 Hz), 7.76 (1H, d, J = 8.5 Hz) 7.68-7.55 (3H, m), 7.48 (1H, d, J = 1.2 Hz), 7.36 (1H, dd, J = 8.2, 1.5 Hz), 7.30 (1H, d, J = 7.9 Hz), 7.07-6.93 (3H, dd, m), 3.57-3.52 (4H, m), 2.63 (3H, s), 2.44-2.39 (4H, m), 2.23 (3H, s),
118		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-{6-pyridin-4-yl-1H-indol-2-yl}-methanone	434	1H-NMR (DMSO-D6) δ: 8.65 (2H, dd, J = 4.6, 1.5 Hz), 8.34 (1H, s), 7.84 (2H, d, J = 9.2 Hz) 7.72 (2H, dd, J = 4.6, 1.5 Hz), 7.61 (2H, t, J = 4.6 Hz) 7.55-7.50 (2H, m), 7.29 (1H, dd, J = 8.2, 2.1 Hz), 7.06 (2H, s) 2.55 (3H, s),
119		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-{5-(4-fluoropiperidin-1-ylmethyl)-1H-indol-2-yl}-methanone	472	1H-NMR (DMSO-D6) δ: 12.46 (1H, d, J = 4.9 Hz), 11.66 (1H, d, J = 1.8 Hz), 8.30 (1H, d, J = 4.9 Hz), 7.65 (1H, dd, J = 5.2, 3.4 Hz), 7.58-7.56 (2H, m), 7.44-7.42 (2H, m), 7.32-7.27 (1H, m), 7.21 (1H, d, J = 4.9 Hz), 7.00 (2H, d, J = 22.6 Hz), 4.72-4.65 (1H, m), 3.54 (2H, s) 2.53 (3H, s), 2.51-2.48 (2H, m), 2.32-2.31 (2H, m), 1.89-1.83 (2H, m), 1.73-1.71 (2H, m),

TABLE 4-continued

Exam- ple	Structure	Compound name	m/z	1H-NMR
120		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(4,4-difluoro-piperidin-1-ylmethyl)-1H-indol-2-yl]-methanone	490	1H-NMR (DMSO-D6) δ: 12.45 (1H, s), 11.66 (1H, s), 8.29 (1H, s), 7.61-7.58 (3H, m), 7.43-7.42 (2H, m), 7.29 (1H, dd, J = 8.4, 2.1 Hz), 7.22 (1H, dd, J = 8.4, 1.8 Hz), 6.99 (2H, s), 3.61 (2H, s), 3.34-3.30 (4H, m), 2.53 (3H, s), 1.99-1.90 (4H, m).
121		[5-amino-1-(2-difluoromethyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(1-methyl-piperidin-4-yl)-1H-indol-2-yl]-methanone	490	1H-NMR (DMSO-D6) δ: 13.60 (1H, br s), 11.58 (1H, d, J = 1.8 Hz), 8.31 (1H, s), 7.83-7.80 (2H, m), 7.51-7.46 (2H, m), 7.45-7.38 (2H, m), 7.32-7.14 (2H, br m), 7.08 (2H, br s), 2.93-2.85 (2H, m), 2.36-2.50 (1H, m), 2.21 (3H, s), 2.04-1.96 (2H, m), 1.81-1.65 (4H, br m).
122		[5-amino-1-(2-difluoromethyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1H-indol-2-yl]-methanone	393	1H-NMR (DMSO-D6) δ: 13.60 (1H, br s), 11.69 (1H, s), 8.34 (1H, s), 7.84-7.80 (2H, m), 7.70 (1H, d, J = 7.9 Hz), 7.51-7.45 (3H, m), 7.32-7.19 (2H, m), 7.12-7.06 (3H, m).
123		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(3,3-difluoro-pyrrolidin-1-ylmethyl)-1H-indol-2-yl]-methanone	476	1H-NMR (DMSO-D6) δ: 12.47 (1H, s), 11.68 (1H, s), 8.30 (1H, d, J = 4.91 Hz), 7.85 (1H, dd, J = 5.0, 3.4 Hz), 7.61-7.55 (2H, m), 7.44-7.41 (2H, m), 7.30 (1H, t, J = 6.4 Hz), 7.22 (1H, d, J = 8.5 Hz), 7.00 (2H, dd, J = 21.4 Hz), 3.69 (2H, s), 2.86 (2H, t, J = 13.5 Hz), 2.66-2.42 (2H, m), 2.61 (3H, s), 2.29-2.22 (2H, m).

TABLE 4-continued

Exam- ple	Structure	Compound name	m/z	1H-NMR
124		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(1-cyclohexyl-piperidin-4-yl)-1H-indol-2-yl]-methanone	508	1H-NMR (DMSO-D6) δ: 12.47 (1H, s) 11.57 (1H, d, J = 1.2 Hz), 8.29 (1H, d, J = 3.7 Hz), 7.66-7.56 (2H, m), 7.50 (1H, s), 7.43-7.37 (2H, m), 7.29 (1H, t, J = 6.1 Hz), 7.17 (1H, dd, J = 8.5, 1.2 Hz), 6.99 (2H, d, J = 22.0 Hz), 3.06 (2H, d, J = 11.0 Hz), 2.64 (3H, s), 2.02 (2H, t, J = 10.7 Hz), 1.64-1.48 (14H, m).
125		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(1-cyclohexyl-piperidin-4-yl)-1H-indol-2-yl]-methanone	522	1H-NMR (DMSO-D6) δ: 12.46 (1H, s), 11.57 (1H, d, J = 1.8 Hz), 8.29 (1H, s), 7.62-7.58 (2H, m), 7.49 (1H, s), 7.40-7.37 (2H, m), 7.29 (1H, d, J = 7.9 Hz), 7.16 (1H, dd, J = 8.5, 1.2 Hz), 6.98 (2H, d, J = 20.8 Hz), 2.93 (2H, d, J = 11.6 Hz), 2.53 (3H, s), 2.36-2.31 (3H, m), 1.80-1.57 (9H, m), 1.22-1.14 (6H, m).
126		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-bromo-1H-pyrrol-2-yl]-methanone	388, 387	1H-NMR (DMSO-D6) δ: 12.47 (1H, s), 12.04 (1H, s), 8.20 (1H, s), 7.61-7.57 (1H, m), 7.27 (1H, dd, J = 8.5, 1.7 Hz), 7.19-7.18 (2H, m), 6.93-6.90 (3H, m), 2.53 (3H, s).

TABLE 4-continued

Exam- ple	Structure	Compound name	m/z	1H-NMR
127		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]- (1H-pyrrol-2-yl)-methanone	307	1H-NMR (DMSO-D6) δ: 12.46 (1H, s), 11.71 (1H, s), 8.16 (1H, d, J = 5.0 Hz), 7.59 (2H, dd, J = 23.6, 7.1 Hz), 7.29 (1H, d, J = 10.0 Hz), 7.08 (1H, d, J = 15.4 Hz), 6.85 (2H, d, J = 14.8 Hz), 6.24-6.22 (2H, m), 2.53 (3H, s).
128		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]- (4-phenyl-1H-pyrrol-2-yl)-methanone	383	1H-NMR (CD3OD) δ: 8.54 (1H, s), 8.25 (1H, s), 7.94 (1H, d, J = 1.5 Hz), 7.91 (1H, d, J = 1.8 Hz), 7.67-7.63 (2H, m), 7.44-7.31 (6H, m), 2.81 (3H, s).
129		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]- [4-(3-chloro-phenyl)-1H-pyrrol-2-yl]-methanone	417	1H-NMR (CD3OD) δ: 8.30-8.26 (1H, m), 7.66 (2H, dt, J = 5.4, 2.4 Hz), 7.58 (1H, dq, J = 7.8, 0.9 Hz), 7.48 (1H, d, J = 1.6 Hz), 7.42 (1H, d, J = 1.5 Hz), 7.39 (1H, d, J = 2.0 Hz), 7.36 (1H, d, J = 1.8 Hz), 7.31 (1H, d, J = 7.9 Hz), 7.17 (1H, dq, J = 8.0, 1.0 Hz), 2.61 (3H, s).


TABLE 4-continued

Example	Structure	Compound name	m/z	1H-NMR
130		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-(4-fluoro-phenyl)-1H-pyrrol-2-yl]-methanone	401	1H-NMR (CD3OD) δ: 8.26 (1H, s), 7.66-7.63 (3H, m), 7.40 (1H, dd, J = 3.7, 1.7 Hz), 7.36 (1H, dd, J = 3.0, 1.8 Hz), 7.11 (1H, d, J = 2.1 Hz), 7.08 (2H, t, J = 2.1 Hz), 7.05 (1H, d, J = 2.1 Hz), 2.61 (3H, s).
131		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-(3-fluoro-phenyl)-1H-pyrrol-2-yl]-methanone	401	1H-NMR (CD3OD) δ: 8.27 (1H, s), 7.66-7.65 (2H, m), 7.47 (1H, d, J = 1.5 Hz), 7.45 (1H, t, J = 1.2 Hz), 7.42 (1H, d, J = 1.6 Hz), 7.39-7.35 (2H, m), 7.33-7.31 (1H, m), 6.94-6.86 (1H, m), 2.61 (3H, s).

187

Example 132

Synthesis of [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-morpholin-4-ylmethyl-1H-indol-2-yl]-methanone



[5-Amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1-benzenesulfonyl-6-morpholin-4-ylmethyl-1H-

188

indol-2-yl)-methanone (132 mg, 0.22 mmol) was dissolved in tetrahydrofuran (THF) (1.0 ml), and then a tetrahydrofuran (THF) solution of 1 M tetrabutylammonium fluoride (0.46 ml, 0.46 mmol) was added thereto. The mixture was heated at 5 65° C. with stirring for 22 hours. The reaction mixture was then cooled to room temperature, and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (dichloromethane/methanol=100/10) to give [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-morpholin-4-ylmethyl-1H-indol-2-yl]-methanone as a yellow solid (74 mg, 75%).

¹H-NMR (DMSO-D₆) δ: 12.48 (1.0H, brs), 11.64 (1.0H, brs), 8.30 (1.0H, s), 7.64-7.60 (3.0H, m), 7.42-7.41 (2.0H, m), 7.29 (1.0H, dd, J=8.5, 2.2 Hz), 7.06 (1.0H, dd, J=8.3, 1.0 Hz), 6.99 (2.0H, brs), 3.58 (4.0H, t, J=4.4 Hz), 3.55 (2.0H, s), 2.53 (3.0H, s), 2.39-2.37 (4.0H, brm)

ESI (LC-MS positive mode) m/z 456 [(M+H)⁺]

The compounds of Examples 133 to 143 listed in Table 5 were synthesized by the same method as in Example 132.

TABLE 5

Exam- ple	Structure	Compound name	m/z 1H-NMR
133		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl-[4-(2-morpholin-4-ylethyl)amino]-1H-indol-2-yl]-methanone	485 1H-NMR (CD3OD) δ: 8.32 (1.0H, s), 7.73-7.61 (2.0H, s), 7.68 (1.0H, d, J = 1.0 Hz), 7.38 (1H, dd, J = 8.8, 2.0 Hz), 7.11 (1H, t, J = 7.8 Hz), 6.79 (1H, d, J = 8.3 Hz), 6.21 (1H, d, J = 7.3 Hz), 3.77-3.72 (4H, m), 3.46 (2H, q, J = 6.0 Hz), 2.76 (2H, t, J = 6.0 Hz), 2.61 (3H, s), 2.55-2.63 (4H, m).
134		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl-[5-(4-methyl-piperazine-1-carbonyl)-1H-indol-2-yl]-methanone	483 1H-NMR (DMSO-D6) δ: 12.47 (1.0H, s), 11.91 (1.0H, s), 8.31 (1.0H, d, J = 4.4 Hz), 7.75 (1.0H, s), 7.66 (1.0H, m), 7.67 (1.0H, m), 7.52 (2.0H, m), 7.29 (2.0H, m), 7.10-7.00 (2.0H, m), 3.56-3.51 (4.0H, m), 2.53 (3.0H, s), 2.40-2.25 (4.0H, m), 2.21 (3.0H, s).
135		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl-[6-(2-morpholin-4-ylethyl)amino]-1H-indol-2-yl]-methanone	485 1H-NMR (DMSO-D6) δ: 12.45 (1.0H, br s), 11.50 (1.0H, br s), 8.27 (1.0H, s), 7.60-7.55 (3.0H, m), 7.40 (1.0H, br s), 7.32-7.28 (1.0H, m), 6.93 (3.0H, br s), 6.75 (1.0H, dd, J = 8.8, 2.4 Hz), 4.11 (2.0H, t, J = 5.9 Hz), 3.60 (4.0H, t, J = 4.6 Hz), 3.34-3.28 (4.0H, m), 2.73 (2.0H, t, J = 5.9 Hz), 2.53 (3.0H, s).

TABLE 5-continued

Exam- ple	Structure	Compound name	m/z 1H-NMR
136		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(piperazine-1-carbonyl)-1H-indole-3-yl]-methanone	469 ¹ H-NMR (CD ₃ OD) δ: 8.28 (1.0H, s), 7.88 (1.0H, s), 7.68-7.64 (2.0H, m), 7.58 (1.0H, d, J = 8.3 Hz), 7.46 (1.0H, m), 7.40-7.35 (2.0H, m), 3.75 (4.0H, m), 3.01 (4.0H, m), 2.61 (3.0H, s).
137		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-(2-methoxy-ethylamino)-1H-indol-2-yl]-methanone	430 ¹ H-NMR (CD ₃ OD) δ: 8.33 (1H, s), 7.66-7.69 (3H, m), 7.37 (1H, dd, J = 8.8, 2.0 Hz), 7.10 (1H, t, J = 7.8 Hz), 6.78 (1H, d, J = 8.3 Hz), 6.21 (1H, d, J = 7.3 Hz), 3.70 (2H, t, J = 5.8 Hz), 3.46 (2H, t, J = 5.8 Hz), 2.60 (3.0H, s).
138		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-(2-hydroxy-1-hydroxymethyl-ethylamino)-1H-indol-2-yl]-methanone	446 ¹ H-NMR (CD ₃ OD) δ: 8.36 (1H, s), 7.72-7.61 (3H, m), 7.37 (1H, dd, J = 8.8, 2.0 Hz), 7.10 (1H, t, J = 8.1 Hz), 6.78 (1H, d, J = 8.3 Hz), 6.29 (1H, d, J = 7.8 Hz), 3.85-3.71 (6H, m), 2.61 (3H, s).
139		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-(2-pyridin-4-yl-ethylamino)-1H-indol-2-yl]-methanone	477 ¹ H-NMR (CD ₃ OD) δ: 8.43 (2H, dd, J = 4.4, 1.6 Hz), 8.30 (1H, s), 7.74-7.61 (2H, s), 7.57 (1H, s), 7.40-7.35 (3H, m), 7.13 (1H, t, J = 8.1 Hz), 6.79 (1H, d, J = 8.3 Hz), 6.26 (1H, d, J = 7.8 Hz), 3.61 (2H, t, J = 7.1 Hz), 3.09 (2H, t, J = 7.1 Hz), 2.62 (3H, s).


TABLE 5-continued

Example	Structure	Compound name	m/z 1H-NMR
140		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(2-methoxyethylamino)-1H-indol-2-yl]-methanone	430 $^1\text{H-NMR}$ (CD_3OD) δ : 8.23 (1.0H, s), 7.67 (2.0H, br s), 7.46-7.44 (1.0H, m), 7.38 (1.0H, dd, J = 8.8, 2.0 Hz), 7.27 (1.0H, s), 6.63-6.60 (2.0H, m), 3.65 (2.0H, t, J = 6.4 Hz), 3.41 (3.0H, s), 3.34 (2.0H, t, J = 5.4 Hz), 2.62 (3.0H, s).
141		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(4-morpholin-4-yl-1H-indol-2-yl)-methanone	442 $^1\text{H-NMR}$ (DMSO-D_6) δ : 12.48 (1.0H, br s), 11.39 (1.0H, br s), 8.27 (1.0H, s), 7.61 (2.0H, br s), 7.54 (1.0H, d, J = 8.8 Hz), 7.35 (1.0H, d, J = 2.0 Hz), 7.29 (1.0H, dd, J = 8.3, 2.0 Hz), 6.93-6.91 (3.0H, m), 6.84 (1.0H, br s), 3.78 (4.0H, t, J = 4.8 Hz), 3.12 (4.0H, t, J = 4.8 Hz), 2.53 (3.0H, s).
142		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-morpholin-4-yl-1H-indol-2-yl]-methanone	442 $^1\text{H-NMR}$ (CD_3OD) δ : 8.23 (1H, s), 7.67 (2H, s), 7.38 (1H, dd, J = 8.8, 2.0 Hz), 7.29 (1H, s), 7.23-7.14 (2H, m), 6.63-6.60 (1H, m), 3.99-3.94 (4H, m), 3.27-3.22 (4H, m), 2.61 (3H, s).
143		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-(4-morpholin-4-ylmethyl)-1H-indol-2-yl]-methanone	456 $^1\text{H-NMR}$ (CD_3OD) δ : 8.31 (1H, s), 7.75-7.62 (2H, m), 7.39 (1H, s), 7.45-7.37 (2H, m), 7.25 (1H, t, J = 7.8 Hz), 7.10-7.06 (1H, m), 3.88 (2H, s), 3.75-3.69 (4H, m), 2.62 (3H, s), 2.80-2.53 (4H, m).

195

Example 144

Synthesis of [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(5-morpholin-4-ylmethyl-1H-indol-2-yl)-methanone



Cesium carbonate (1.29 g) was added to a methanol solution (20 ml) of [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(1-benzenesulfonyl-5-morpholin-4-ylmethyl-1H-indol-2-yl)-methanone (110 mg), and stirred at room temperature for 16 hours. Then, water (5 ml) and

196

ammonia water (3 ml) were added to the reaction mixture and stirred for three hours. The reaction mixture was concentrated under reduced pressure. Water was added to the resulting residue. After ethyl acetate extraction, the extract was washed with a saturated aqueous solution of sodium chloride, and then dried over anhydrous sodium sulfate. The desiccant was removed by filtration. The filtrate was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (methanol/dichloromethane=0/10 to 20/100) to give [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-(5-morpholin-4-ylmethyl-1H-indol-2-yl)-methanone (33 mg).

¹H-NMR (DMSO-D₆) δ: 12.47 (1.0H, s), 11.67 (1.0H, s), 8.30 (1.0H, s), 7.60 (3.0H, m), 7.44 (2.0H, m), 7.30 (1.0H, dd, J=8.4, 2.1 Hz), 7.23 (1.0H, dd, J=8.4, 1.5 Hz), 7.01 (2.0H, m), 3.58 (4.0H, t, J=4.4 Hz), 3.54 (2.0H, s), 2.55 (3.0H, s), 2.38 (4.0H, m)

ESI (LC-MS positive mode) m/z 456 [(M+H)⁺]

The compounds of Examples 145 to 164 listed in Table 6 were synthesized by the same method as in Example 144.

TABLE 6

Exam- ple	Structure	Compound name	m/z $^1\text{H-NMR}$
145		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(morpholine-4-carbonyl)-1H-indole-2-yl]-methanone	470 $^1\text{H-NMR}$ (DMSO-D ₆) δ : 12.47 (1.0H, s), 11.92 (1.0H, s), 8.31 (1.0H, s), 7.79 (1.0H, s), 7.61 (2.0H, m), 7.53 (2.0H, m), 7.32-7.29 (1.0H, m), 7.32 (1.0H, m), 7.30 (1.0H, dd, J = 8.8, 1.5 Hz), 7.10-6.95 (2.0H, m), 3.82-3.51 (8.0H, m), 2.54 (3.0H, s).
146		[5-amino-1-(2-isopropyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1H-indole-2-yl]-methanone	385 $^1\text{H-NMR}$ (CD3OD) δ : 8.28 (1H, s), 7.73-7.67 (3H, m), 7.50-7.47 (1H, m), 7.40-7.37 (2H, m), 7.29-7.24 (1H, m), 7.12-7.07 (1H, m), 3.30-3.24 (7.2H, m), 1.46 (6H, d, J = 7.6 Hz).
147		[5-amino-1-(2-propyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1H-indole-2-yl]-methanone	385 $^1\text{H-NMR}$ (DMSO-D ₆) δ : 12.46 (1H, s), 11.70 (1H, s), 8.31 (1H, s), 7.71-7.66 (2H, m), 7.59-7.57 (1H, m), 7.50-7.46 (2H, m), 7.32-7.23 (2H, m), 7.10-6.98 (3H, m), 2.83 (2H, t, J = 7.4 Hz), 1.85-1.79 (2H, m), 0.96 (3H, t, J = 7.3 Hz).
148		[5-amino-1-(1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1H-indol-2-yl]-methanone	343 $^1\text{H-NMR}$ (CD3OD) δ : 8.32 (1H, s), 8.29 (1H, s), 7.83-7.86 (2H, m), 7.72 (1H, d, d = 8.1 Hz), 7.50-7.46 (2H, m), 7.38 (1H, s), 7.27 (1H, t, J = 7.2 Hz), 7.09 (1H, t, J = 7.2 Hz).
149		[5-amino-1-(2-trifluoromethyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1H-indol-2-yl]-methanone	411 $^1\text{H-NMR}$ (DMSO-D ₆) δ : 12.58 (1H, s), 11.71 (1H, s), 8.35 (1H, s), 7.89-7.81 (2H, m), 7.70 (1H, d, d = 7.4 Hz), 7.50-7.46 (3H, m), 7.27-7.23 (1H, m), 7.10-7.06 (3H, m).

TABLE 6-continued

Example	Structure	Compound name	m/z 1H-NMR
150		[5-amino-1-(2-ethyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1H-indol-2-yl]-methanone	371 ¹ H-NMR (DMSO-D ₆) δ: 12.40 (1H, s), 11.68 (1H, s), 8.26 (1H, s), 7.66-7.64 (1H, m), 7.61-7.52 (2H, m), 7.46-7.40 (2H, m), 7.18 (2H, m), 7.05-7.01 (1H, m), 6.90 (1.1H, s), 2.83 (2H, d, J = 7.6 Hz), 1.29 (3H, t, J = 7.5 Hz).
151		[5-amino-1-(2-benzyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1H-indol-2-yl]-methanone	433 ¹ H-NMR (DMSO-D ₆) δ: 12.60 (1H, s), 11.70 (1H, s), 8.31 (1H, s), 7.69 (1H, d, J = 8.2 Hz), 7.67-7.59 (2H, m), 7.49-7.45 (2H, m), 7.31-7.23 (2H, m), 7.10-7.08 (1H, m), 7.03-6.97 (2H, m), 4.22 (2H, s).
152		1-(4-[{2-[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-carbonyl]-1H-indol-5-ylmethyl}-]piperazin-1-yl)-ethanone	497 ¹ H-NMR (CD3OD) δ: 8.27 (1.0H, s), 7.66 (3.0H, m), 7.46 (1.0H, d, J = 8.3 Hz), 7.38 (1.0H, dd, J = 8.8, 2.0 Hz), 7.35 (1.0H, s), 7.30 (1.0H, dd, J = 8.5, 1.7 Hz), 3.64 (2.0H, s), 3.56 (2H, dt, J = 21.6, 4.9 Hz), 2.61 (3.0H, s), 2.49 (4.0H, td, J = 10.5, 5.5 Hz), 2.07 (3.0H, s).
153		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(4-methanesulfonyl-1H-indole-2-yl)-methanone]	533 ¹ H-NMR (CD3OD) δ: 8.27 (1.0H, s), 7.67 (3.0H, m), 7.46 (1.0H, d, J = 8.3 Hz), 7.38 (1.0H, dd, J = 8.3, 2.0 Hz), 7.35 (1.0H, s), 7.30 (1.0H, dd, J = 8.3, 1.5 Hz), 3.67 (2.0H, s), 3.23 (4.0H, s), 2.83 (3.0H, s), 2.66-2.65 (4.0H, m), 2.61 (3.0H, s).
154		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-piperazin-1-yl]-[5-piperazin-1-ylmethyl-1H-indole-2-yl]-methanone	455 ¹ H-NMR (CD3OD) δ: 8.28 (1.0H, s), 7.70-7.62 (3.0H, m), 7.47 (1.1H, d, J = 8.8 Hz), 7.39 (1.0H, dd, J = 8.3, 2.0 Hz), 7.36 (1.0H, d, J = 1.0 Hz), 7.30 (1.0H, dd, J = 8.8, 1.5 Hz), 3.67-3.60 (2.0H, m), 2.95-2.85 (4.0H, m), 2.62 (3.0H, s), 2.60-2.50 (2.0H, s).

TABLE 6-continued

Example	Structure	Compound name	n/z 1H-NMR
155		1-(4-[2-[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-carbonyl]-1H-indol-6-ylmethyl)-piperazin-1-yl)-ethanone	497 1H-NMR (DMSO-D ₆) δ : 12.49 (1.0H, br s), 11.66 (1.0H, br s), 8.30 (1.0H, s), 7.65-7.60 (3.0H, m), 7.43-7.41 (2.0H, m), 7.29 (1.0H, dd, J = 8.3, 2.0 Hz), 7.06 (1.0H, dd, J = 8.3, 1.0 Hz), 6.99 (2.0H, br s), 3.58 (2.0H, s), 3.45-3.41 (4.0H, m), 2.53 (3.0H, s), 2.39 (2.0H, t, J = 4.6 Hz), 2.33 (2.0H, t, J = 4.9 Hz), 1.98 (3.0H, s).
156		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(4-methyl-piperazin-1-ylmethyl)-1H-indol-2-yl]-methanone	469 1H-NMR (CD3OD) δ : 12.47 (1.0H, br s), 11.63 (1.0H, br s), 8.30 (1.0H, s), 7.66-7.56 (3.0H, m), 7.42-7.40 (2.0H, m), 7.30-7.28 (1.0H, m), 7.04-6.97 (3.0H, m), 3.53 (2.0H, s), 3.36-3.30 (4.0H, m), 2.53 (3.0H, s), 2.46-2.33 (4.0H, m), 2.15 (3.0H, s).
157		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(4-methyl-piperazin-1-ylmethyl)-1H-indol-2-yl]-methanone	469 1H-NMR (CD3OD) δ : 8.27 (1.0H, s), 7.66 (3.0H, m), 7.45 (1.0H, d, J = 8.3 Hz), 7.40-7.33 (2.0H, m), 7.31-7.25 (1.0H, m), 3.64 (2.0H, s), 2.70-2.40 (8H, m), 2.61 (3.0H, s), 2.28 (3.0H, s).
158		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-pyrrolidine-1-ylmethyl]-1H-indol-2-yl]-methanone	440 1H-NMR (CD3OD) δ : 8.27 (1.0H, s), 7.66 (3.0H, m), 7.46 (1.0H, d, J = 8.3 Hz), 7.38 (1.0H, dd, J = 8.3, 2.0 Hz), 7.35 (1.0H, s), 7.30 (1.0H, dd, J = 8.5, 1.7 Hz), 3.75 (2.0H, s), 2.85-2.55 (4.0H, m), 2.61 (3.0H, s), 1.82 (4.0H, s).
159		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-fluoro-1H-indol-2-yl]-methanone	375 1H-NMR (DMSO-D ₆) δ : 12.48 (1H, s), 12.04 (1H, s), 8.38 (1H, s), 7.68-7.55 (2H, m), 7.46 (1H, s), 7.34-7.20 (3H, m), 7.09-6.97 (2H, m), 6.88-6.84 (1H, m), 2.53 (3H, s).

TABLE 6-continued


Example	Structure	Compound name	m/z 1H-NMR
160		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]- (5-thiophen-2-yl)-methanone	375 $^1\text{H-NMR}$ (DMSO-D ₆) δ : 12.48 (1H, s), 11.81 (1H, s), 8.29 (1H, s), 7.69-7.53 (2H, m), 7.50-7.47 (1H, m), 7.44-7.41 (2H, m), 7.29 (1H, dd, J = 8.4, 2.0 Hz), 7.15-7.10 (1H, m), 7.07-6.97 (2H, s), 2.53 (3H, s).
161		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]- (6-fluoro-1H-indol-2-yl)-methanone	375 $^1\text{H-NMR}$ (DMSO-D ₆) δ : 12.48 (1H, s), 11.78 (1H, s), 8.30 (1H, s), 7.73-7.70 (1H, m), 7.64-7.58 (2H, m), 7.49 (1H, s), 7.30-7.27 (1H, m), 7.20-7.17 (1H, m), 7.00-6.94 (3H, m), 2.53 (3H, s),
162		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]- (1H-pyrrolo[2,3-b]pyridin-4-yl)- methanone	358 $^1\text{H-NMR}$ (DMSO-D ₆) δ : 12.48 (1H, s), 12.23 (1H, s), 8.40 (1H, dd, J = 4.6, 1.7 Hz), 8.27 (1H, s), 8.13 (1H, dd, J = 8.0, 1.8 Hz), 7.61 (2H, m), 7.41 (1H, s), 7.29 (1H, dd, J = 8.5, 2.1 Hz), 7.18- 7.15 (1H, m), 7.04 (2H, s), 2.53 (3.6H, s),

TABLE 6-continued

Example	Structure	Compound name	m/z 1H-NMR
163		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazolo[4,3-j]-[5-hydro-6-morpholin-4-yl]methyl-1H-indol-2-yl)methanone	474 ¹ H-NMR (DMSO-D ₆) δ: 12.46 (1H, m), 11.74 (1H, s), 8.28 (1H, d, J = 5.1 Hz), 7.67-7.63 (1H, m), 7.58-7.56 (1H, m), 7.49 (1H, d, J = 6.3 Hz), 7.42-7.39 (2H, m), 7.31-7.27 (1H, m), 7.05-6.99 (2H, m), 3.62-3.56 (6H, m), 2.53 (3H, s), 2.47-2.39 (4, m).
164		2-[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazolo[4,3-j]-[5-hydro-6-morpholin-4-yl]methyl-1H-indol-2-yl)methanone	401 ¹ H-NMR (DMSO-D ₆) δ: 12.57 (1.0H, s), 12.47 (1.0H, d, J = 5.4 Hz), 12.04 (1.0H, s), 8.40 (1.0H, t, J = 4.6 Hz), 7.84 (1.0H, dd, J = 8.5, 1.7 Hz), 7.68-7.62 (2.0H, m), 7.67 (1.0H, d, J = 8.3 Hz), 7.53 (1.0H, d, J = 8.3 Hz), 7.29 (1.0H, m), 7.10-6.95 (2.0H, m), 2.54 (3.0H, s).

207

Step 1: Synthesis of [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1-benzenesulfonyl-1H-indol-2-yl]-methanone (1001)

**208**

(2-Methyl-1H-benzimidazol-5-yl)-hydrazine dihydrochloride (830 mg) was added to an ethanol solution (15 ml) of crude 2-(1-benzenesulfonyl-1H-indole-2-carbonyl)-3-dimethylamino acrylonitrile (1.17 g). The reaction mixture was heated with stirring under reflux for four hours. After cooling to room temperature, the mixture was allowed to stand at room temperature. The precipitated solid was collected by filtration, and washed with ethanol to give [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1-benzenesulfonyl-1H-indol-2-yl]-methanone was obtained as a yellow solid (1.5 g, with a two-step yield of 91%).

¹H-NMR (DMSO-D₆) δ: 8.15-8.13 (2H, m), 8.02 (1H, dd, J=8.4, 0.8 Hz), 7.97 (1H, d, J=2.0 Hz), 7.92 (1H, d, J=8.8 Hz), 7.87 (1H, s), 7.76-7.62 (5H, m), 7.49-7.45 (1H, m), 7.36-7.26 (4H, m), 2.82 (3H, m)

ESI (LC-MS positive mode) m/z 497 [(M+H)⁺]

The compounds of numbers 1002 to 1082, and 1511 to 1527 listed in Table 7 were synthesized by the same method as in Step 1.

TABLE 7

Com- ound No.	Structure	Compound name	m/z
1002		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1-benzenesulfonyl-6-morpholin-4-ylmethyl-1H-indol-2-yl]-methanone	595
1003		2-[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-carbonyl]-1-(toluene-4-sulfonyl)-1H-indole-5-carboxylic acid	555

TABLE 7-continued

Com- ound No.	Structure	Compound name	m/z
1004		[5-amino-1-(2-isopropyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	539
1005		[5-amino-1-(2-propyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[2-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	539
1006		[5-amino-1-(1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	497

TABLE 7-continued





Compound No.	Structure	Compound name	m/z
1007		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1-benzenesulfonyl-5-morpholin-4-ylmethyl-1H-indol-2-yl]-methanone	596
1008		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1-benzenesulfonyl-4-morpholin-4-yl-1H-indol-2-yl]-methanone	582
1009		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1-benzenesulfonyl-4-morpholin-4-ylmethyl-1H-indole-2-yl]-methanone	596
1010		[5-amino-1-(2-trifluoromethyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	565

TABLE 7-continued

Com- ound No.	Structure	Compound name	m/z
1011		[5-amino-1-(2-ethyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	525
1012		[5-amino-1-(2-benzyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	587
1013		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1-benzenesulfonyl-5-piperazin-1-ylmethyl-1H-indol-2-yl]-methanone	595

TABLE 7-continued

Com- ound No.	Structure	Compound name	m/z
1014		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1-benzenesulfonyl-4-fluoro-1H-indol-2-yl]-methanone	515
1015		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1-benzenesulfonyl-5-fluoro-1H-indol-2-yl]-methanone	515
1016		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1-benzenesulfonyl-6-fluoro-1H-indol-2-yl]-methanone	515
1017		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1-benzenesulfonyl-1H-pyrrolo[2,3-b]pyridin-2-yl]-methanone	498

TABLE 7-continued

Compound No.	Structure	Compound name	m/z
1018		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1-benzenesulfonyl-1H-pyrrolc[3,2-e]pyridin-2-yl]-methanone	498
1019		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1-benzenesulfonyl-5-fluoro-6-morpholin-4-ylmethyl-1H-indol-2-yl]-methanone	614
1020		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1-benzenesulfonyl-6-(2-morpholin-4-ylethoxy)-1H-indol-2-yl]-methanone	626
1021		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1-benzenesulfonyl-6-tetrahydropyran-4-yloxy-1H-indol-2-yl]-methanone	597

TABLE 7-continued

Com- ound No.	Structure	Compound name	m/z
1022		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-chloro-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	545, 547
1023		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[3-fluoro-1-(toluene-4-sulfonyl)-1H-indole-2-yl]-methanone	529
1024		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(1-methylpiperidin-4-yl)-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	608

TABLE 7-continued




Com- ound No.	Structure	Compound name	m/z
1025		4-[2-[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazole-4-carbonyl]-1-(toluene-4-sulfonyl)-1H-indol-5-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester	692
1026		4-[2-[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazole-4-carbonyl]-1-(toluene-4-sulfonyl)-1H-indol-5-yl]-piperidine-1-carboxylic acid tert-butyl ester	694
1027		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-((R)-3-fluoro-pyrrolidin-1-ylmethyl)-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	612

TABLE 7-continued




Com- ound No.	Structure	Compound name	m/z
1028		4-[2-[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazole-4-carbonyl]-6-fluoro-1-(toluene-4-sulfonyl)-1H-indol-5-yl]-piperidine-1-carboxylic acid tert-butyl ester	712
1029		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-fluoro-5-(1-methyl-piperidin-4-yl)-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	626
1030		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1-benzenesulfonyl-6-(tert-butyl-diphenyl-silyloxyethyl)-1H-indol-2-yl]methanone	765

TABLE 7-continued

Com- ound No.	Structure	Compound name	m/z
1031		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(1-isopropyl-piperidin-4-yl)-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	636
1032		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-fluoro-5-(1-isopropyl-piperidin-4-yl)-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	654
1033		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-{1-benzenesulfonyl)-6-[2-(4-methyl-piperidin-1-yl)-ethoxy]-1H-indol-2-yl}-methanone	639

TABLE 7-continued

Com- ound No.	Structure	Compound name	m/z
1034		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-fluoro-5-(4-methyl-piperidin-1-ylmethyl)-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	641
1035		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-fluoro-5-(pyrrolidin-1-ylmethyl)-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	612
1036		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(1-methyl-piperidin-4-yl)-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	608

TABLE 7-continued

Com- ound No.	Structure	Compound name	m/z
1037		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl-[5-(4-fluoropiperidin-1-ylmethyl)-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone]	626
1038		[5-amino-1-(2-difluoromethyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl-[5-(1-methylpiperidin-4-yl)-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone]	644
1039		[5-amino-1-(2-difluoromethyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl-[1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone]	547

TABLE 7-continued

Compound No.	Structure	Compound name	m/z
1040		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(1-cyclopentyl-piperidin-4-yl)-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	662
1041		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(1-cyclohexyl-piperidin-4-yl)-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	676
1042		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-bromo-1-(toluene-4-sulfonyl)-1H-pyrrol-2-yl]-methanone	539, 541
1043		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1-(toluene-4-sulfonyl)-1H-pyrrol-2-yl]-methanone	461

TABLE 7-continued

Com- ound No.	Structure	Compound name	m/z
1044		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-butyl-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	567
1045		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(1-isopropyl-piperidin-4-yl)-1-(toluene-4-sulfonyl)-6-trifluoromethyl-1H-indol-2-yl]-methanone	704
1046		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-6-bromo-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	589, 591

TABLE 7-continued

Com- ound No.	Structure	Compound name	m/z
1047		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-cyclopropyl-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	551
1048		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-bromo-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	589, 591
1049		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-iodo-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	637

TABLE 7-continued

Com- ound No.	Structure	Compound name	m/z
1050		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-isopropyl-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	553
1051		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1-benzenesulfonyl-1H-pyrrolo[3,4-b]pyridin-2-yl]-methanone	498
1052		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-bromo-1-(toluene-4-sulfonyl)-6-trifluoromethyl-1H-indol-2-yl]-methanone	657, 659

TABLE 7-continued

Com- ound No.	Structure	Compound name	m/z
1053		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-bromo-5-fluoro-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	609, 609
1054		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-pyridin-2-yl-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	588
1055		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-cyclopropyl-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	551

TABLE 7-continued

Com- ound No.	Structure	Compound name	m/z
1056		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-pyridazin-3-yl-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	589
1057		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-methylsulfanyl-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	557
1058		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-bromo-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	589, 591

TABLE 7-continued

Com- ound No.	Structure	Compound name	m/z
1059		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-butoxy-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	583
1060		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-isopropoxy-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	569
1061		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(2-methoxy-ethoxy)-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	585

TABLE 7-continued

Com- ound No.	Structure	Compound name	m/z
1062		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1-benzenesulfonyl-4-methyl-1H-indol-2-yl]-methanone	511
1063		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1-trimethylsilyl-4-ethynyl-1H-indol-2-yl]-methanone	593
1064		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(toluene-4-sulfonyl)-5H-[1,3]dioxolo[4,5-f]indol-6-yl]-methanone	555

TABLE 7-continued




Com- ound No.	Structure	Compound name	m/z
1065		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-cyclopropylmethoxy-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	581
1066		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[(1-benzenesulfonyl-4-bromo-1H-indol-2-yl)-methanone]	575, 577
1067		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[2,2-difluoro-5-(toluene-4-sulfonyl)-5H-[1,3]dioxolo[4,5-f]indol-6-yl]-methanone	591

TABLE 7-continued

Compound No.	Structure	Compound name	m/z
1068		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(3-chloropyridin-2-yl)-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	622
1069		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(3-fluoropyridin-2-yl)-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	606
1070		[5-amino-1-(7-fluoro-2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1-benzenesulfonyl-1H-indol-2-yl]-methanone	515

TABLE 7-continued

Com- ound No.	Structure	Compound name	m/z
1071		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-methyl-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	525
1072		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(5-fluoro-pyridin-2-yl)-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	606
1073		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(6-morpholin-4-yl-pyridazin-3-yl)-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	674

TABLE 7-continued

Com- ound No.	Structure	Compound name	m/z
1074		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-chloro-6-cyclopropylmethoxy-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	615, 617
1075		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1-(toluene-4-sulfonyl)-6-(5-trifluoromethyl-pyridin-2-yl)-1H-indol-2-yl]-methanone	656
1076		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1-(toluene-4-sulfonyl)-6-(6-trifluoromethyl-pyridin-2-yl)-1H-indol-2-yl]-methanone	656

TABLE 7-continued

Com- ound No.	Structure	Compound name	m/z
1077		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(5-chloropyridin-2-yl)-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	621, 623
1078		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4,5-dibromo-1-(4-methoxybenzyl)-1H-pyrrol-2-yl]-methanone	583, 585, 587
1079		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1-(toluene-4-sulfonyl)-6-(5-trifluoromethylpyridin-2-yl)-1H-indol-2-yl]-methanone	656

TABLE 7-continued




Com- ound No.	Structure	Compound name	m/z
1080		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1-(toluene-4-sulfonyl)-6-(4-trifluoromethyl-pyridin-2-yl)-1H-indol-2-yl]-methanone	656
1081		[5-amino-1-(7-fluoro-2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1-(benzenesulfonyl-1H-indol-2-yl)-methanone]	515
1082		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1-(benzenesulfonyl-4-isopropyl-1H-indol-2-yl)-methanone]	539

TABLE 7-continued

Com- ound No.	Structure	Compound name	m/z
1511		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-chloro-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	545
1512		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	545
1513		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1-(toluene-4-sulfonyl)-1H-indol-3-yl]-methanone	511
1514		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1-(toluene-4-sulfonyl)-1H-indol-6-yl]-methanone	511

TABLE 7-continued

Com- ound No.	Structure	Compound name	m/z
1515		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-bromo-6-fluoro-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	607
1516		[5-amino-1-(2-ethyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-bromo-6-fluoro-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	621
1517		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1-(toluene-4-sulfonyl)-5-trifluoromethyl-1H-indol-2-yl]-methanone	579

TABLE 7-continued

Com- ound No.	Structure	Compound name	m/z
1518		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1-(toluene-4-sulfonyl)-5-trifluoromethoxy-1H-indol-2-yl]-methanone	595
1519		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4,6-dichloro-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	579
1520		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-bromo-4-fluoro-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	607

TABLE 7-continued

Com- ound No.	Structure	Compound name	m/z
1521		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1-(toluene-4-sulfonyl)-6-trifluoromethoxy-1H-indol-2-yl]-methanone	595
1522		[5-amino-1-(2-ethyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1-(toluene-4-sulfonyl)-5-trifluoromethoxy-1H-indol-2-yl]-methanone	609
1523		[5-amino-1-(2-ethyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1-(toluene-4-sulfonyl)-5-trifluoromethyl-1H-indol-2-yl]-methanone	593

TABLE 7-continued

Com- ound No.	Structure	Compound name	m/z
1524		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5,6-dichloro-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	579
1525		[5-amino-1-(2-ethyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-bromo-5-fluoro-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	621
1526		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4,5-dichloro-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	579

TABLE 7-continued

Compound No.	Structure	Compound name	m/z
1527		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4,6-difluoro-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	547

Examples 165 to 195, and 247 to 254

25

The compounds of Examples 165 to 195, and 247 to 254 listed in Table 8 were synthesized using compounds having indole ring with unprotected nitrogen atoms by the same method as in Step 1.

TABLE 8

Exam- ple	Structure	Compound name	m/z	1H-NMR
165		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]- (5-methoxy-1H-indol-2-yl)-methanone	387	1H-NMR (DMSO-D6) δ: 12.47 (1H, s), 11.56 (1H, s), 8.27 (1H, s), 7.62 (2H, s), 7.39-7.35 (2H, m), 7.29 (1H, dd, J = 1.8 Hz), 7.13 (1H, d, J = 2.4 Hz), 6.99 (2H, s), 6.91 (1H, dd, J = 8.5, 2.4 Hz), 3.78 (3H, s), 2.53 (3H, s).
166		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]- (4,6-dimethoxy-1H-indol-2-yl)-methanone	417	1H-NMR (DMSO-D6) δ: 12.46 (1H, s), 11.56 (1H, d, J = 1.8 Hz), 8.22 (1H, s), 7.82-7.57 (2H, m), 7.31-7.28 (1H, m), 7.25 (1H, q, J = 1.8 Hz), 6.92 (2H, d, J = 22.0 Hz), 6.53 (1H, s), 6.21 (1H, d, J = 1.8 Hz), 3.88 (3H, s), 3.79 (3H, s), 2.53 (3H, s).
167		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]- (4-methoxy-1H-indol-2-yl)-methanone	387	1H-NMR (DMSO-D6) δ: 12.47 (1H, s), 11.73 (1H, s), 8.26 (1H, s), 7.62-7.60 (2H, m), 7.32-7.28 (2H, m), 7.18 (1H, dd, J = 7.9, 4.0 Hz), 7.07 (1H, d, J = 8.5 Hz), 6.98 (2H, s), 8.55 (1H, d, J = 7.3 Hz), 3.92 (3H, s), 2.53 (3H, s).
168		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]- (6-methoxy-1H-indol-2-yl)-methanone	387	1H-NMR (DMSO-D6) δ: 12.46 (1H, s), 11.53 (1H, s), 8.28 (1H, s), 7.60-7.57 (3H, m), 7.41 (1H, d, J = 1.8 Hz), 7.29 (1H, dd, J = 8.5, 1.8 Hz), 6.95-6.93 (3H, m), 6.75 (1H, dd, J = 8.9, 2.1 Hz), 3.80 (3H, s), 2.53 (3H, s).

TABLE 8-continued

Exam- ple	Structure	Compound name	m/z	1H-NMR
169		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]- (4,6-dimethyl-1H-indol-2-yl)methanone	385	1H-NMR (DMSO-D6) δ: 12.46 (1H, s), 11.51 (1H, s), 8.37 (1H, s), 7.85-7.67 (2H, br m), 7.40 (1H, br s), 7.29 (1H, d, J = 8.5 Hz), 7.07 (1H, br s), 6.96 (2H, br s), 6.70 (1H, br s), 2.53 (3H, s), 2.53 (3H, s), 2.37 (3H, s).
170		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]- (5-tert-butyl-1H-indol-2-yl)methanone	413	1H-NMR (DMSO-D6) δ: 12.46 (1H, s), 11.55 (1H, s), 8.27 (1H, s), 7.64-7.58 (2H, br m), 7.63 (1H, d, J = 1.5 Hz), 7.41 (1H, d, J = 8.5 Hz), 7.40 (1H, s), 7.36 (1H, dd, J = 8.5, 1.5 Hz), 7.29 (1H, dd, J = 8.5, 1.8 Hz), 6.99 (2H, br s), 2.53 (3H, d, J = 4.3 Hz), 1.35 (9H, s).
171		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]- (5-isopropyl-1H-indol-2-yl)methanone	399	1H-NMR (DMSO-D6) δ: 12.46 (1H, s), 11.56 (1H, s), 8.28 (1H, s), 7.64-7.56 (2H, br m), 7.50 (1H, s), 7.40 (1H, d, J = 8.5 Hz), 7.37 (1H, d, J = 1.5 Hz), 7.29 (1H, dd, J = 8.5, 1.9 Hz), 7.17 (1H, dd, J = 8.5, 1.5 Hz), 6.98 (2H, br s), 3.01-2.94 (1H, m), 2.53 (3H, s), 1.26 (6H, d, J = 6.7 Hz).

TABLE 8-continued

Example	Structure	Compound name	m/z	1H-NMR
172		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]methane	463	1H-NMR (DMSO-D6) δ: 12.46 (1H, s), 11.58 (1H, d, J = 1.8 Hz), 8.27 (1H, d, J = 3.0 Hz), 7.65-7.55 (2H, m), 7.49-7.47 (2H, m), 7.42-7.38 (3H, m), 7.33-7.29 (3H, m), 7.21 (1H, d, J = 2.4 Hz), 7.01-6.98 (3H, m), 5.12 (2H, s), 2.53 (3H, s).
173		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-benzyloxy-1H-indol-2-yl]methane	463	1H-NMR (DMSO-D6) δ: 12.46 (1H, s), 11.75 (1H, d, J = 1.8 Hz), 8.27 (1H, s), 7.62-7.58 (4H, m), 7.42 (2H, t, J = 10.4 Hz), 7.35-7.30 (3H, m), 7.15 (1H, dd, J = 7.9, 4.0 Hz), 7.08 (1H, d, J = 8.5 Hz), 6.97 (2H, d, J = 19.5 Hz), 6.64 (1H, d, J = 7.9 Hz), 5.29 (2H, s), 2.53 (3H, s).
174		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5,6-dimethoxy-1H-indol-2-yl]methane	417	1H-NMR (DMSO-D6) δ: 12.45 (1H, s), 11.43 (1H, d, J = 1.6 Hz), 8.24 (1H, d, J = 4.4 Hz), 7.66-7.55 (2H, m), 7.32-7.27 (2H, m), 7.12 (1H, s), 6.94-6.91 (3H, m), 3.81 (3H, s), 3.79 (3H, s), 2.53 (3H, s).

TABLE 8-continued

Exam- ple	Structure	Compound name	m/z	1H-NMR
175		[5-amino-1-(2-methyl-1H-benzimidazo[5,1-b]1H-pyrazol-4-yl)-6-(tert-butyl-1H-indol-2-yl)methanone	413	1H-NMR (DMSO-D6) δ: 12.45 (1H, s), 11.53 (1H, s), 8.28 (1H, s), 7.62-7.58 (2H, br m), 7.61 (1H, d, J = 8.5 Hz), 7.44 (1H, s), 7.38 (1H, d, J = 1.2 Hz), 7.28 (1H, dd, J = 8.5, 1.8 Hz), 7.19 (1H, dd, J = 8.5, 1.2 Hz), 6.98 (2H, br s), 2.53 (3H, s), 1.35 (9H, s).
176		[5-amino-1-(2-methyl-1H-benzimidazo[5,1-b]1H-pyrazol-4-yl)-6-(5-fluoro-4-trifluoromethyl-1H-indol-2-yl)methanone	443	1H-NMR (DMSO-D6) δ: 12.48 (1.0H, br s), 12.38 (1.0H, br s), 8.22 (1.0H, s), 7.82 (1.0H, dd, J = 9.0, 4.2 Hz), 7.64-7.59 (2.0H, m), 7.38-7.28 (3.0H, m), 7.10-7.07 (2.0H, br m), 2.54 (3.0H, s).
177		[5-amino-1-(2-methyl-1H-benzimidazo[5,1-b]1H-pyrazol-4-yl)-(5-phenoxy-1H-indol-2-yl)methanone	449	1H-NMR (DMSO-D6) δ: 12.46 (1H, s), 11.77 (1H, s), 8.27 (1H, s), 7.68-7.55 (2H, br m), 7.51 (1H, d, J = 8.8 Hz), 7.41 (1H, s), 7.37-7.33 (2H, m), 7.30-7.27 (2H, m), 7.08 (1H, d, J = 7.5 Hz), 7.06-7.00 (2H, m), 7.03 (1H, dd, J = 8.8, 2.4 Hz), 8.98 (2H, d, J = 7.5 Hz), 2.53 (3H, s).

TABLE 8-continued

Exam- ple	Structure	Compound name	m/z	1H-NMR
178		[5-amino-1-(2-methyl-1H-benzimidazo[5,1-f]1H-pyrazol-4-yl)-6-methylsulfanyl-1H-indol-2-yl)methane	403	1H-NMR (DMSO-D6) δ: 12.45 (1H, s), 11.62 (1H, d, J = 1.8 Hz), 8.29 (1H, d, J = 5.5 Hz), 7.65-7.61 (2H, m), 7.56 (1H, d, J = 8.5 Hz), 7.43 (1H, s), 7.33 (1H, s), 7.36-7.26 (1H, m), 7.02-7.00 (2H, m), 6.97 (1H, s), 2.53 (3H, d, J = 1.8 Hz), 2.52 (3H, s).
179		[5-amino-1-(2-methyl-1H-benzimidazo[5,1-f]1H-pyrazol-4-yl)-(4-tert-butyl-1H-indol-2-yl)methane	413	1H-NMR (DMSO-D6) δ: 12.46 (1H, br s), 11.76 (1H, s), 8.19 (1H, s), 7.63-7.58 (2H, br m), 7.42 (1H, s), 7.36 (1H, d, J = 7.9 Hz), 7.29 (1H, dd, J = 8.5, 1.8 Hz), 7.17 (1H, t, J = 7.9 Hz), 6.97 (2H, br s), 6.95 (1H, d, J = 7.9 Hz), 2.54 (3H, s), 1.51 (9H, s).
180		[5-amino-1-(2-methyl-1H-benzimidazo[5,1-f]1H-pyrazol-4-yl)-(5-methyl-1H-indol-2-yl)methanone	371	1H-NMR (DMSO-D6) δ: 12.46 (1H, br s), 11.55 (1H, s), 8.27 (1H, s), 7.60-7.58 (2H, m), 7.45 (1H, s), 7.36 (1H, d, J = 8.4 Hz), 7.33 (1H, s), 7.27 (1H, dd, J = 8.4, 2.0 Hz), 7.07 (1H, dd, J = 8.3, 1.5 Hz), 6.98 (2H, br s), 2.52 (3H, s), 2.38 (3H, s).
181		[5-amino-1-(2-methyl-1H-benzimidazo[5,1-f]1H-pyrazol-4-yl)-(5-ethyl-1H-indol-2-yl)methanone	385	1H-NMR (DMSO-D6) δ: 12.46 (1H, s), 11.56 (1H, s), 8.27 (1H, s), 7.60-7.58 (2H, m), 7.47 (1H, s), 7.38 (1H, d, J = 8.5 Hz), 7.36-7.35 (1H, m), 7.28 (1H, dd, J = 8.5, 2.1 Hz), 7.11 (1H, dd, J = 8.5, 1.7 Hz), 6.96 (2H, s), 2.69-2.66 (2H, m), 2.52 (3H, s), 1.22 (3H, t, J = 7.6 Hz).

TABLE 8-continued

Exam- ple	Structure	Compound name	m/z	1H-NMR
182		[5-amino-1-(2-methyl-1H-benzimidazo[5,1-f]indol-4-yl)-1H-pyrazol-4-yl]methane	443	1H-NMR (DMSO-D6) δ: 12.48 (1.0H, br s), 12.24 (1.0H, br s), 8.31 (1.0H, s), 7.82 (1.0H, d, J = 5.9 Hz), 7.73 (1.0H, d, J = 11.2 Hz), 7.65-7.54 (3.0H, m), 7.29 (1.0H, d, J = 8.3 Hz), 7.13-7.09 (2.0H, br m), 2.54 (3.0H, s).
183		[5-amino-1-(2-methyl-1H-benzimidazo[5,1-f]indol-4-yl)-1H-pyrazol-4-yl]methane	405	1H-NMR (DMSO-D6) δ: 12.46 (1H, s), 11.64 (1H, s), 8.26 (1H, s), 7.64-7.57 (2H, br m), 7.38 (1H, s), 7.32 (1H, d, J = 9.1 Hz), 7.28 (1H, dd, J = 8.5, 2.4 Hz), 7.23 (1H, d, J = 11.6 Hz), 6.98 (2H, br s), 3.86 (3H, s), 2.53 (3H, s).
184		[5-amino-1-(2-methyl-1H-benzimidazo[5,1-f]indol-4-yl)-1H-pyrazol-4-yl]methane	421, 423	1H-NMR (DMSO-D6) δ: 12.46 (1H, s), 11.65 (1H, s), 8.26 (1H, s), 7.65-7.55 (2H, br m), 7.51 (1H, s), 7.38 (1H, s), 7.31 (1H, s), 7.28 (1H, dd, J = 8.5, 2.4 Hz), 7.01 (2H, br s), 3.87 (3H, s), 2.53 (3H, s).

TABLE 8-continued

Exam- ple	Structure	Compound name	m/z	1H-NMR
185		[5-amino-1-(2-methyl-1H-benzimidazo[5,1-b]pyrazol-4-yl)-6-chloro-6-methoxy-1H-indol-2-yl)methanone	421	1H-NMR (DMSO-D6) δ: 12.45 (1H, s), 11.70 (1H, s), 8.25 (1H, s), 7.73 (1H, s), 7.64-7.55 (2, br m), 7.38 (1H, s), 7.28 (1H, dd, J = 8.5, 2.4 Hz), 7.06 (1H, s), 6.97 (2H, br s), 3.89 (3H, s), 2.53 (3H, s).
186		[5-amino-1-(2-methyl-1H-benzimidazo[5,1-b]pyrazol-4-yl)-6-propoxy-1H-indol-2-yl)methanone	415	1H-NMR (DMSO-D6) δ: 12.43 (1.0H, s), 11.41 (2.0H, s), 8.27 (1.0H, s), 7.7-7.50 (3.0H, m), 7.38 (1.0H, s), 7.29 (1.0H, dd, J = 8.5, 1.7 Hz), 6.95-6.90 (2.0H, m), 6.72 (1.0H, dd, J = 8.7, 2.2 Hz), 4.62-4.56 (1.0H, m), 2.53 (3.0H, s), 1.31 (8.0H, d, J = 6.1 Hz).
187		[5-amino-1-(2-methyl-1H-benzimidazo[5,1-b]pyrazol-4-yl)-6-(benzyloxy)-1H-indol-2-yl)methanone	463	1H-NMR (DMSO-D6) δ: 12.45 (1H, s), 11.52 (1H, s), 8.27 (1H, d, J = 4.9 Hz), 7.64 (1H, dd, J = 4.9, 3.3 Hz), 7.57 (2H, dd, J = 8.5, 4.3 Hz), 7.50-7.49 (2H, m), 7.42-7.39 (3H, m), 7.36-7.26 (2H, m), 7.00-6.94 (3H, m), 6.82 (1H, dd, J = 8.8, 2.2 Hz), 5.14 (2H, s), 2.53 (3H, s).

TABLE 8-continued

Example	Structure	Compound name	m/z	1H-NMR
188		[5-amino-1-(2-methyl-1H-benzimidazo[5,1-b]indol-5-yl)-1H-pyrazol-4-yl]methane	415	1H-NMR (DMSO-D6) δ: 12.47 (1.0H, br s), 11.69 (1.0H, br s), 8.23 (1.0H, s), 7.64-7.59 (2.0H, m), 7.29 (1.0H, dd, J = 8.3, 1.5 Hz), 7.25-7.25 (1.0H, br m), 7.15 (1.0H, dd, J = 8.0, 8.0 Hz), 7.04-6.97 (3.0H, m), 6.55 (1.0H, d, J = 8.0 Hz), 4.79-4.73 (1.0H, m), 2.53 (3.0H, s), 1.38 (6.0H, d, J = 5.9 Hz).
189		[5-amino-1-(2-methyl-1H-benzimidazo[5,1-b]indol-5-yl)-1H-pyrazol-4-yl-(2,3-dihydro-6H-[1,4]dioxinol-2,3-yl)methane	415	1H-NMR (DMSO-D6) δ: 12.44 (1.0H, s), 11.27 (1.0H, d, J = 1.6 Hz), 8.24 (1.0H, s), 7.64-7.62 (1.0H, br m), 7.58-7.54 (1.0H, br m), 7.30-7.26 (1.0H, br m), 7.28 (1.0H, d, J = 1.6 Hz), 7.08 (1H, s), 6.97 (1H, br s), 6.91 (1H, br s), 6.87 (1H, s), 4.27-4.22 (4H, m), 2.53 (3H, s).
190		[5-amino-1-(2-methyl-1H-benzimidazo[5,1-b]indol-5-yl)-1H-pyrazol-4-yl-(4,6-di-tert-butyl-1H-indol-2-yl)methane	469	1H-NMR (DMSO-D6) δ: 12.47 (1.0H, br s), 11.61 (1.0H, br s), 8.19 (1.0H, s), 7.62 (2.0H, br s), 7.37 (1.0H, s), 7.32-7.28 (2.0H, m), 7.05 (1.0H, s), 6.96 (2.0H, br s), 2.63 (3.0H, s), 1.51 (9.0H, s), 1.34 (9.0H, s).

TABLE 8-continued

Example	Structure	Compound name	m/z	1H-NMR
191		2-[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazole-4-carbonyl]-1H-indole-4-carbonitrile	382	1H-NMR (DMSO-D6) δ: 12.44 (1.0H, s), 12.33 (1.0H, s), 8.36 (1.0H, s), 7.84 (1.0H, d, J = 8.2 Hz), 7.70-7.60 (3.0H, m), 7.45-7.35 (2.0H, m), 7.29 (1.0H, dd, J = 8.5, 1.9 Hz), 7.06 (1.0H, m), 2.53 (3.0H, s).
192		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-imidazol-1-yl-1H-indol-2-yl]-methanone	423	1H-NMR (DMSO-D6) δ: 8.31 (1H, s), 8.17 (1H, s), 7.86 (1H, d, J = 2.0 Hz), 7.70 (1H, s), 7.60-7.59 (3H, m), 7.50-7.47 (2H, m), 7.27 (1H, dd, J = 8.6, 2.0 Hz), 7.11 (1H, d, J = 0.8 Hz), 7.09 (2H, br s), 2.53 (3H, s).
193		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-trifluoromethylsulfonyl-1H-indol-2-yl]-methanone	457	1H-NMR (DMSO-D6) δ: 12.31 (1H, br s), 8.32 (1H, s), 8.09 (1H, s), 7.62 (1H, d, J = 2.0 Hz), 7.61-7.59 (2H, m), 7.54 (1H, s), 7.48 (1H, d, J = 8.4 Hz), 7.28 (1H, dd, J = 8.6, 2.0 Hz), 7.14 (2H, br s), 2.53 (3H, s).

TABLE 8-continued


Example	Structure	Compound name	m/z	1H-NMR
194		[5-amino-1-(2-methyl-1H-benzimidazo[5,1-b]pyrazol-4-yl)-5-methylsulfanyl-1H-indol-3-yl)methane	403	1H-NMR (DMSO-D6) δ: 12.48 (1H, s), 11.76 (1H, s), 8.29 (1H, s), 7.62-7.62 (3H, m), 7.44 (1H, d, J = 8.6 Hz), 7.39 (1H, s), 7.29 (1H, dd, J = 8.6, 2.0 Hz), 7.23 (1H, dd, J = 8.6, 1.8 Hz), 7.02 (2H, br s), 3.34 (3H, s), 2.54 (3H, s).
247		[5-amino-1-(2-methyl-1H-benzimidazo[5,1-b]pyrazol-4-yl)-1-benzofuran-2-ylmethane	358	9.21 (m, 1H), 8.52 (s, 1H), 7.73 (d, J = 7.8 Hz, 1H), 7.64 (d, J = 8.4 Hz, 1H), 7.61 (s, 1H), 7.47 (t, J = 8 Hz, 1H), 7.40 (m, 1H), 7.32 (t, J = 7.6 Hz, 1H), 6.17 (m, 2H), 2.66 (s, 3H)
248		[5-amino-1-(2-methyl-1H-benzimidazo[5,1-b]pyrazol-4-yl)-1-benzo[b]thiophen-2-ylmethane	374	12.46 (s, 1H), 8.42 (s, 1H), 8.35 (m, 1H), 8.05 (m, 2H), 7.65 (m, 1H), 7.56 (m, 1H), 7.51 (m, 2H), 7.28 (m, 1H), 7.09 (s, 1H), 7.03 (s, 1H), 2.54 (s, 3H)
249		[5-amino-1-(2-methyl-1H-benzimidazo[5,1-b]pyrazol-4-yl)-1-benzothiazol-2-ylmethane	375	8.83 (s, 1H), 8.27 (m, 2H), 7.86 (m, 2H), 7.64 (m, 2H), 7.57 (m, 1H), 7.44 (s, 2H), 2.73 (s, 3H)

TABLE 8-continued

Example	Structure	Compound name	m/z	1H-NMR
250		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazo[4-yl]-[4-fluorophenyl]-methanone	336	7.88 (m, 4H), 7.55 (d, J = 8.4 Hz, 1H), 7.36 (t, J = 8.7 Hz, 2H), 7.28 (s, 1H), 7.21 (s, 2H), 7.15 (s, 1H), 7.03 (s, 1H), 2.73 (s, 3H).
251		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazo[4-yl]-[3-chlorophenyl]-methanone	352	7.77 (m, 1H), 7.74 (m, 1H), 7.65 (m, 1H), 7.57 (m, 3H), 7.24 (d, J = 8.6 Hz, 2H), 7.03 (br s, 2H), 2.51 (m, 3H).
252		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazo[4-yl]-[3-yl-methanone]	369	9.21 (s, 1H), 8.85 (s, 1H), 8.23 (d, J = 8.1 Hz, 1H), 8.12 (d, J = 8.4 Hz, 1H), 8.06 (s, 1H), 7.91 (m, 3H), 7.73 (t, J = 6.2 Hz, 1H), 7.64 (d, J = 8.4 Hz, 1H), 7.33 (s, 2H), 2.74 (s, 3H).
253		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazo[4-yl]-[7-yl-methanone]	369	9.05 (m, 1H), 8.52 (d, J = 8.2 Hz, 1H), 8.38 (s, 1H), 8.17 (d, J = 8.4 Hz, 1H), 7.93 (n, 4H), 7.69 (m, 2H), 7.32 (s, 2H), 2.79 (s, 3H).
254		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazo[4-yl]-[6-yl-methanone]	369	9.02 (d, J = 5.1 Hz, 1H), 8.51 (d, J = 8.4 Hz, 1H), 8.37 (s, 1H), 8.16 (d, J = 8.3 Hz, 1H), 7.92 (m, 4H), 7.66 (m, 2H), 7.32 (m, 2H), 2.74 (s, 3H).

293

Step 2: Synthesis of 2-(1-benzenesulfonyl-1H-indole-2-carbonyl)-3-dimethylamino-acrylonitrile (1083)

**294**

N,N-Dimethylformamide dimethylacetal (620 μ l) was added at room temperature to a tetrahydrofuran (THF) solution (8.5 ml) of 3-(1-benzenesulfonyl-1H-indol-2-yl)-3-oxo-propionitrile (1.0 g, 3.08 mmol), and stirred for ten minutes. The reaction mixture was then concentrated under reduced pressure to give crude 2-(1-benzenesulfonyl-1H-indole-2-carbonyl)-3-dimethylamino-acrylonitrile as yellow amorphous material. The obtained crude product was used in subsequent reactions without purification.

ESI (LC-MS positive mode) m/z 380 [(M+H)⁺]

¹⁵ The compounds of numbers 1084 to 1184, and 1528 to 1549 listed in Table 9 were synthesized by the same method as in Step 2.

TABLE 9

Com- ound No.	Structure	Compound name	m/z
1084		2-(1-benzenesulfonyl-6-morpholin-4-ylmethyl-1H-indole-2-carbonyl)-3-dimethylamino-acrylonitrile	479
1085		2-(1-benzenesulfonyl-5-morpholin-4-ylmethyl-1H-indole-2-carbonyl)-3-dimethylamino-acrylonitrile	479




TABLE 9-continued

Compound No.	Structure	Compound name	m/z
1086		2-(1-benzenesulfonyl-4-morpholin-4-yl-1H-indole-2-carbonyl)-3-dimethylamino-acrylonitrile	465
1087		2-(1-benzenesulfonyl-4-morpholin-4-ylmethyl-1H-indole-2-carbonyl)-3-dimethylamino-acrylonitrile	479
1088		4-[1-benzenesulfonyl-2-(2-cyano-3-dimethylamino-acryloyl)-1H-indol-5-ylmethyl]-piperazine-1-carboxylic acid tert-butyl ester	578
1089		2-(1-benzenesulfonyl-4-fluoro-1H-indole-2-carbonyl)-3-dimethylamino-acrylonitrile	398

TABLE 9-continued





Com- ound No.	Structure	Compound name	m/z
1090		2-(1-benzenesulfonyl-5-fluoro-1H-indole-2-carbonyl)-3-dimethylaminoacrylonitrile	398
1091		2-(1-benzenesulfonyl-6-fluoro-1H-indole-2-carbonyl)-3-dimethylaminoacrylonitrile	398
1092		2-(1-benzenesulfonyl-1H-pyrrolo[2,3-b]pyridine-2-carbonyl)-3-dimethylaminoacrylonitrile	381
1093		2-(1-benzenesulfonyl-1H-pyrrolo[3,4-c]pyridine-2-carbonyl)-3-dimethylaminoacrylonitrile	381

TABLE 9-continued

Com- ound No.	Structure	Compound name	m/z
1094		2-(1-benzenesulfonyl-5-fluoro-6-morpholin-4-ylmethyl-1H-indole-2-carbonyl)-3-dimethylamino-acrylonitrile	497
1095		2-[1-benzenesulfonyl-6-(2-morpholin-4-yl-ethoxy)-1H-indole-2-carbonyl]-dimethylamino-acrylonitrile	509
1096		2-[1-benzenesulfonyl-6-(tetrahydro-pyran-4-yloxy)-1H-indole-2-carbonyl]-3-dimethylamino-acrylonitrile	480
1097		2-[4-chloro-1-(toluene-4-sulfonyl)-1H-indole-2-carbonyl]-3-dimethylamino-acrylonitrile	428, 430

TABLE 9-continued




Com- ound No.	Structure	Compound name	m/z
1098		3-dimethylamino-2-[3-fluoro-1-(toluene-4-sulfonyl)-1H-indol-2-carbonyl]-acrylonitrile	412
1099		3-dimethylamino-2-[5-(1-methyl-piperidin-4-yl)-1-(toluene-4-sulfonyl)-1H-indole-2-carbonyl]-acrylonitrile	491
1100		4-[2-(2-cyano-3-dimethylamino-acryloyl)-1-(toluene-4-sulfonyl)-1H-indol-5-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester	575

TABLE 9-continued

Com- ound No.	Structure	Compound name	m/z
1101		4-[2-(2-cyano-3-dimethylamino-acryloyl)-1-(toluene-4-sulfonyl)-1H-indol-5-yl]-piperidine-1-carboxylic acid tert-butyl ester	577
1102		3-dimethylamino-2-[4-((R)-3-fluoro-pyrrolidin-1-ylmethyl)-1-(toluene-4-sulfonyl)-1H-indole-2-carbonyl]-acrylonitrile	495
1103		4-[2-(2-cyano-3-dimethylamino-acryloyl)-6-fluoro-1-(toluene-4-sulfonyl)-1H-indol-5-yl]-piperidine-1-carboxylic acid tert-butyl ester	595

TABLE 9-continued

Com- ound No.	Structure	Compound name	m/z
1104		3-dimethylamino-2-[6-fluoro-5-(1-methylpiperidin-4-yl)-1-(toluene-4-sulfonyl)-1H-indole-2-carbonyl]-acrylonitrile	509
1105		2-[1-benzenesulfonyl-6-(tert-butyldiphenylsilanyloxymethyl)-1H-indole-2-carbonyl]-3-dimethylamino-acrylonitrile	648
1106		3-dimethylamino-2-[5-(1-isopropylpiperidin-4-yl)-1-(toluene-4-sulfonyl)-1H-indole-2-carbonyl]-acrylonitrile	519

TABLE 9-continued

Com- ound No.	Structure	Compound name	m/z
1107		3-dimethylamino-2-[6-fluoro-5-(1-isopropyl-piperidin-4-yl)-1-(toluene-4-sulfonyl)-1H-indole-2-carbonyl]-acrylonitrile	537
1108		2-(1-benzenesulfonyl-6-[2-(4-methylpiperidin-1-yl)-ethoxy]-1H-indole-2-carbonyl)-3-dimethylaminoacrylonitrile	522
1109		3-dimethylamino-2-[6-fluoro-5-(4-methyl-piperazin-1-ylmethyl)-1-(toluene-4-sulfonyl)-1H-indole-2-carbonyl]-acrylonitrile	524

TABLE 9-continued

Com- ound No.	Structure	Compound name	m/z
1110		3-dimethylamino-2-[6-fluoro-5-pyrrolidin-1-ylmethyl-1-(toluene-4-sulfonyl)-1H-indole-2-carbonyl]-acrylonitrile	495
1111		3-dimethylamino-2-[6-(1-methyl-piperidin-4-yl)-1-(toluene-4-sulfonyl)-1H-indole-2-carbonyl]-acrylonitrile	491
1112		2-[5-(1-cyclopentyl-piperidin-4-yl)-1-(toluene-4-sulfonyl)-1H-indole-2-carbonyl]-3-dimethylamino-acrylonitrile	545

TABLE 9-continued

Com- ound No.	Structure	Compound name	m/z
1113		2-[5-(1-cyclohexyl-piperidin-4-yl)-1-(toluene-4-sulfonyl)-1H-indole-2-carbonyl]-3-dimethylamino-acrylonitrile	559
1114		2-[5-bromo-1-(toluene-4-sulfonyl)-1H-pyrrol-2-carbonyl]-3-dimethylamino-acrylonitrile	422, 424
1115		3-dimethylamino-2-(1-(toluene-4-sulfonyl)-1H-pyrrol-2-carbonyl)-acrylonitrile	344
1116		2-(6-benzyloxy-1H-indole-2-carbonyl)-3-dimethylamino-acrylonitrile	346

TABLE 9-continued

Compound No.	Structure	Compound name	m/z
1117		3-dimethylamino-2-(5-methoxy-1H-indole-2-carbonyl)-acrylonitrile	270
1118		2-[6-butyl-1-(toluene-4-sulfonyl)-1H-indole-2-carbonyl]-3-dimethylaminoacrylonitrile	450
1119		3-dimethylamino-2-[5-(1-isopropyl-piperidin-4-yl)-1-(toluene-4-sulfonyl)-6-trifluoromethyl-1H-indole-2-carbonyl]-acrylonitrile	587
1120		2-(4,6-dimethoxy-1H-indole-2-carbonyl)-3-dimethylaminoacrylonitrile	300
1121		3-dimethylamino-2-(4-methoxy-1H-indole-2-carbonyl)-acrylonitrile	270

TABLE 9-continued

Compound No.	Structure	Compound name	m/z
1122		3-dimethylamino-2-(6-methoxy-1H-indole-2-carbonyl)-acrylonitrile	270
1123		3-dimethylamino-2-(4,6-dimethyl-1H-indole-2-carbonyl)-acrylonitrile	268
1124		2-[6-bromo-1-(toluene-4-sulfonyl)-1H-indole-2-carbonyl]-3-dimethylaminoacrylonitrile	472, 474
1125		2-[6-cyclopropyl-1-(toluene-4-sulfonyl)-1H-indole-2-carbonyl]-3-dimethylaminoacrylonitrile	434
1126		2-(5-tert-butyl-1H-indole-2-carbonyl)-3-dimethylaminoacrylonitrile	296

TABLE 9-continued

Com- ound No.	Structure	Compound name	m/z
1127		3-dimethylamino-2-(5-isopropyl-1H-indole-2-carbonyl)-acrylonitrile	282
1128		2-(5-benzyloxy-1H-indole-2-carbonyl)-3-dimethylamino-acrylonitrile	346
1129		2-(4-benzyloxy-1H-indole-2-carbonyl)-3-dimethylamino-acrylonitrile	346
1130		2-[5-bromo-1-(toluene-4-sulfonyl)-1H-indole-2-carbonyl]-3-dimethylamino-acrylonitrile	472, 474
1131		2-(5,6-dimethoxy-1H-indole-2-carbonyl)-3-dimethylamino-acrylonitrile	300

TABLE 9-continued

Compound No.	Structure	Compound name	m/z
1132		2-(1-benzenesulfonyl-4-iodo-1H-indole-2-carbonyl)-3-dimethylaminoacrylonitrile	506
1133		3-dimethylamino-2-[6-isopropyl-1-(toluene-4-sulfonyl)-1H-indole-2-carbonyl]-acrylonitrile	436
1134		2-(1-benzenesulfonyl-1H-pyrrolo[3,2-b]pyridine-2-carbonyl)-3-dimethylaminoacrylonitrile	381
1135		2-[5-bromo-1-(toluene-4-sulfonyl)-6-trifluoromethyl-1H-indole-2-carbonyl]-3-dimethylaminoacrylonitrile	542, 542

TABLE 9-continued

Compound No.	Structure	Compound name	m/z
1136		2-[6-bromo-5-fluoro-1-(toluene-4-sulfonyl)-1H-indole-2-carbonyl]-3-dimethylamino-acrylonitrile	490, 492
1137		3-dimethylamino-2-[6-pyridin-2-yl-1-(toluene-4-sulfonyl)-1H-indole-2-carbonyl]-acrylonitrile	471
1138		2-[5-cyclopropyl-1-(toluene-4-sulfonyl)-1H-indole-2-carbonyl]-3-dimethylamino-acrylonitrile	434
1139		2-(6-tert-butyl-1H-indole-2-carbonyl)-3-dimethylamino-acrylonitrile	296

TABLE 9-continued

Compound No.	Structure	Compound name	m/z
1140		3-dimethylamino-2-[6-pyridazin-3-yl-1-(toluene-4-sulfonyl)-1H-indole-2-carbonyl]-acrylonitrile	472
1141		3-dimethylamino-2-(5-fluoro-4-trifluoromethyl-1H-indole-2-carbonyl)-acrylonitrile	324 [M - H]
1142		3-dimethylamino-2-(5-phenoxy-1H-indole-2-carbonyl)-acrylonitrile	332
1143		3-dimethylamino-2-[6-methylsulfonyl]-1-(toluene-4-sulfonyl)-1H-indole-2-carbonyl)-acrylonitrile	440
1144		3-dimethylamino-2-(5-imidazol-1-yl-1H-indole-2-carbonyl)-acrylonitrile	306

TABLE 9-continued

Compound No.	Structure	Compound name	m/z
1145		3-dimethylamino-2-(5-trifluoromethylsulfanyl-1H-indole-2-carbonyl)-acrylonitrile	340
1146		3-dimethylamino-2-(6-iodo-1H-indole-2-carbonyl)-acrylonitrile	M not detected
1147		(2-(4-tert-butyl-1H-indole-2-carbonyl)-3-dimethylamino-acrylonitrile	296
1148		3-dimethylamino-2-(5-methyl-1H-indole-2-carbonyl)-acrylonitrile	254
1149		3-dimethylamino-2-(5-ethyl-1H-indole-2-carbonyl)-acrylonitrile	268
1150		2-[5-butoxy-1-(toluene-4-sulfonyl)-1H-indole-2-carbonyl]-3-dimethylamino-acrylonitrile	466

TABLE 9-continued

Com- ound No.	Structure	Compound name	m/z
1151		3-dimethylamino-2-[5-isopropoxy-1-(toluene-4-sulfonyl)-1H-indole-2-carbonyl]-acrylonitrile	452
1152		3-dimethylamino-2-[5-(2-methoxyethoxy)-1-(toluene-4-sulfonyl)-1H-indole-2-carbonyl]-acrylonitrile	467.99
1153		2-(1-benzenesulfonyl-4-methyl-1H-indole-2-carbonyl)-3-dimethylaminoacrylonitrile	394
1154		3-dimethylamino-2-(5-fluoro-6-trifluoromethyl-1H-indole-2-carbonyl)-acrylonitrile	324 [M - H]

TABLE 9-continued

Compound No.	Structure	Compound name	m/z
1155		3-dimethylamino-2-(6-fluoro-5-methoxy-1H-indole-2-carbonyl)-acrylonitrile	288
1156		2-[5-benzyl-1-(toluene-4-sulfonyl)-1H-indole-2-carbonyl]-3-dimethylamino-acrylonitrile	484
1157		2-(6-chloro-5-methoxy-1H-indole-2-carbonyl)-3-dimethylamino-acrylonitrile	304, 306
1158		2-(5-chloro-6-methoxy-1H-indole-2-carbonyl)-3-dimethylamino-acrylonitrile	304, 306
1159		3-dimethylamino-2-(6-isopropoxy-1H-indole-2-carbonyl)-acrylonitrile	298

TABLE 9-continued

Compound No.	Structure	Compound name	m/z
1160		2-(1-benzenesulfonyl-4-trimethylsilylethynyl)-1H-indole-2-carbonyl-3-dimethylamino-acrylonitrile	476
1161		2-[5-bromo-6-methoxy-1-(toluene-4-sulfonyl)-1H-indole-2-carbonyl]-3-dimethylamino-acrylonitrile	502, 504
1162		3-dimethylamino-2-[5-(toluene-4-sulfonyl)-5H-[1,3]dioxolo[4,5-f]indole-6-carbonyl]-acrylonitrile	438
1163		2-(6-benzyloxy-1H-indole-2-carbonyl)-3-dimethylamino-acrylonitrile	346

TABLE 9-continued

Com- ound No.	Structure	Compound name	m/z
1164		2-[5-cyclopropylmethoxy-1-(toluene-4-sulfonyl)-1H-indole-2-carbonyl]-3-dimethylamino-acrylonitrile	464
1165		3-dimethylamino-2-(4-isopropoxy-1H-indole-2-carbonyl)-acrylonitrile	298
1166		2-(1-benzenesulfonyl-4-bromo-1H-indole-2-carbonyl)-3-dimethylamino-acrylonitrile	458, 460
1167		2-[2,2-difluoro-5-(toluene-4-sulfonyl)-5H-[1,3]dioxolo[4,5-f]indole-6-carbonyl]-3-dimethylamino-acrylonitrile	474

TABLE 9-continued

Com- ound No.	Structure	Compound name	m/z
1168		2-[6-(3-chloro-pyridin-2-yl)-1-(toluene-4-sulfonyl)-1H-indole-2-carbonyl]-3-dimethylamino-acrylonitrile	505, 507
1169		3-dimethylamino-2-[6-(3-fluoropyridin-2-yl)-1-(toluene-4-sulfonyl)-1H-indole-2-carbonyl]-acrylonitrile	489
1170		3-dimethylamino-2-[6-methyl-1-(toluene-4-sulfonyl)-1H-indole-2-carbonyl]-acrylonitrile	408

TABLE 9-continued

Compound No.	Structure	Compound name	m/z
1171		3-dimethylamino-2-[6-(5-fluoro-pyridin-2-yl)-1-(toluene-4-sulfonyl)-1H-indole-2-carbonyl]-acrylonitrile	489
1172		2-(2,3-dihydro-6H-[1,4]dioxino[2,3-f]indole-7-carbonyl)-3-dimethylaminoacrylonitrile	298
1173		3-dimethylamino-2-[6-(6-morpholin-4-yl-pyridazin-3-yl)-1-(toluene-4-sulfonyl)-1H-indole-2-carbonyl]-acrylonitrile	557
1174		2-[5-chloro-6-cyclopropylmethoxy-1-(toluene-4-sulfonyl)-1H-indole-2-carbonyl]-3-dimethylaminoacrylonitrile	498, 500

TABLE 9-continued

Com- ound No.	Structure	Compound name	m/z
1175		2-(4,6-di-tert-butyl-1H-indole-2-carbonyl)-3-dimethylamino-acrylonitrile	352
1176		3-dimethylamino-2-[1-(toluene-4-sulfonyl)-6-(5-trifluoromethylpyridin-2-yl)-1H-indole-2-carbonyl]-acrylonitrile	539
1177		3-dimethylamino-2-[1-(toluene-4-sulfonyl)-6-(6-trifluoromethylpyridin-2-yl)-1H-indole-2-carbonyl]-acrylonitrile	539
1178		2-[6-(5-chloropyridin-2-yl)-1-(toluene-4-sulfonyl)-1H-indole-2-carbonyl]-3-dimethylamino-acrylonitrile	505, 507

TABLE 9-continued

Com- ound No.	Structure	Compound name	m/z
1179		2-[4,5-dibromo-1-(4-methoxybenzyl)-1H-pyrrol-2-carbonyl]-3-dimethylaminoacrylonitrile	466, 468, 470
1180		3-dimethylamino-2-[1-(toluene-4-sulfonyl)-6-(3-trifluoromethylpyridin-2-yl)-1H-indole-2-carbonyl]acrylonitrile	539
1181		3-dimethylamino-2-[1-(toluene-4-sulfonyl)-6-(4-trifluoromethylpyridin-2-yl)-1H-indole-2-carbonyl]acrylonitrile	539
1182		3-dimethylamino-2-(5-methylsulfonyl-1H-indole-2-carbonyl)acrylonitrile	286

TABLE 9-continued

Compound No.	Structure	Compound name	m/z
1183		3-dimethylamino-2-(5-methanesulfonyl-1H-indole-2-carbonyl)-acrylonitrile	318
1184		2-(1-benzenesulfonyl-4-isopropyl-1H-indole-2-carbonyl)-3-dimethylamino-acrylonitrile	422
1528		2-[6-chloro-1-(toluene-4-sulfonyl)-1H-indole-2-carbonyl]-3-dimethylamino-acrylonitrile	428
1529		2-[5-chloro-1-(toluene-4-sulfonyl)-1H-indole-2-carbonyl]-3-dimethylamino-acrylonitrile	428

TABLE 9-continued

Compound No.	Structure	Compound name	m/z
1530		3-dimethylamino-2-[1-(toluene-4-sulfonyl)-1H-indole-3-carbonyl]-acrylonitrile	394
1531		3-dimethylamino-2-[1-(toluene-4-sulfonyl)-1H-indole-6-carbonyl]-acrylonitrile	394
1532		2-[5-bromo-6-fluoro-1-(toluene-4-sulfonyl)-1H-indole-2-carbonyl]-3-dimethylamino-acrylonitrile	490, 492
1533		3-dimethylamino-2-[1-(toluene-4-sulfonyl)-5-trifluoromethyl-1H-indole-2-carbonyl]-acrylonitrile	462

TABLE 9-continued

Com- ound No.	Structure	Compound name	m/z
1534		3-dimethylamino-2-[1-(toluene-4-sulfonyl)-5-trifluoromethoxy-1H-indole-2-carbonyl]-acrylonitrile	478
1535		2-[4,6-dichloro-1-(toluene-4-sulfonyl)-1H-indole-2-carbonyl]-3-dimethylamino-acrylonitrile	462
1536		2-[6-bromo-4-fluoro-1-(toluene-4-sulfonyl)-1H-indole-2-carbonyl]-3-dimethylamino-acrylonitrile	490

TABLE 9-continued

Com- ound No.	Structure	Compound name	m/z
1537		3-dimethylamino-2-[1-(toluene-4-sulfonyl)-6-trifluoromethoxy-1H-indole-2-carbonyl]-acrylonitrile	478
1538		2-[5,6-dichloro-1-(toluene-4-sulfonyl)-1H-indole-2-carbonyl]-3-dimethylamino-acrylonitrile	462
1539		2-[4,5-dichloro-1-(toluene-4-sulfonyl)-1H-indole-2-carbonyl]-3-dimethylamino-acrylonitrile	462


TABLE 9-continued

Com- ound No.	Structure	Compound name	m/z
1540		2-[4,6-difluoro-1-(toluene-4-sulfonyl)-1H-indole-2-carbonyl]-3-dimethylamino-acrylonitrile	430
1541		2-(benzofuran-2-carbonyl)-3-dimethylamino-acrylonitrile	241
1542		2-(benzo[b]thiophene-2-carbonyl)-3-dimethylamino-acrylonitrile	257
1543		2-(benzothiazole-2-carbonyl)-3-dimethylamino-acrylonitrile	258
1544		3-dimethylamino-2-(4-fluorobenzoyl)-acrylonitrile	219
1545		2-(3-chlorobenzoyl)-3-dimethylamino-acrylonitrile	235

TABLE 9-continued

Compound No.	Structure	Compound name	m/z
1546		3-dimethylamino-2-(quinoline-3-carbonyl)-acrylonitrile	252
1547		3-dimethylamino-2-(quinoline-7-carbonyl)-acrylonitrile	252
1548		3-dimethylamino-2-(quinoline-6-carbonyl)-acrylonitrile	252
1549		3-dimethylamino-2-(1H-indole-2-carbonyl)-acrylonitrile	240

Step 3: Synthesis of 3-(1-benzenesulfonyl-1H-indol-2-yl)-3-oxo-propionitrile (1185)



Acetonitrile (10.6 g, 0.202 mol) was added to a tetrahydrofuran (THF) solution (135 ml) of 1-benzenesulfonyl-1H-indole-2-carboxylic acid ethyl ester (33.4 g, 0.101 mol), and cooled to -78° C. A tetrahydrofuran (THF) solution of 1 M lithium bis(trimethylsilyl) amide (213 ml, 0.213 mol) was

added dropwise thereto, and stirred for 30 minutes. A saturated aqueous solution (83 ml) of ammonium chloride was added to the reaction mixture, and stirred for 10 minutes. Water (50 ml) was added to the mixture and warmed to room temperature. The solvent was distilled off under reduced pressure, and the resulting residue was extracted with ethyl acetate. The extract was washed with a saturated aqueous solution of sodium chloride and dried over anhydrous sodium sulfate. The desiccant was removed by filtration. The filtrate was concentrated under reduced pressure. The resulting crude product was washed with ethanol to give 3-(1-benzenesulfonyl-1H-indol-2-yl)-3-oxo-propionitrile (47.3 g, 70%).

¹H-NMR (CDCl₃) δ: 8.12 (1.0H, dq, J=8.5, 0.8 Hz), 7.79-7.76 (2.0H, m), 7.56-7.48 (3.0H, m), 7.42-7.38 (2.0H, m), 7.32-7.28 (1.0H, m), 7.20 (1.0H, d, J=0.8 Hz), 4.16 (2.0H, s) ESI (LC-MS positive mode) m/z 325 [(M+H)⁺] The compounds of numbers 1186 to 1284, and 1550 to 1571 listed in Table 10 were synthesized by the same method as in Step 3.

TABLE 10

Compound No.	Structure	Compound name	m/z
1186		3-(1-benzenesulfonyl-6-morpholin-4-ylmethyl-1H-indol-2-yl)-3-oxo-propionitrile	424
1187		3-(1-benzenesulfonyl-5-morpholin-4-ylmethyl-1H-indol-2-yl)-3-oxo-propionitrile	424
1188		3-(1-benzenesulfonyl-4-morpholin-4-yl-1H-indol-2-yl)-3-oxo-propionitrile	410
1189		3-(1-benzenesulfonyl-4-morpholin-4-ylmethyl-1H-indol-2-yl)-3-oxo-propionitrile	424

TABLE 10-continued

Compound No.	Structure	Compound name	m/z
1190		4-[1-benzenesulfonyl-2-(2-cyanoacetyl)-1H-indol-5-ylmethyl]-piperazine-1-carboxylic acid tert-butyl ester	523
1191		3-(1-benzenesulfonyl-4-fluoro-1H-indol-2-yl)-3-oxo-propionitrile	343
1192		3-(1-benzenesulfonyl-5-fluoro-1H-indol-2-yl)-3-oxo-propionitrile	343
1193		3-(1-benzenesulfonyl-6-fluoro-1H-indol-2-yl)-3-oxo-propionitrile	343
1194		3-(1-benzenesulfonyl-1H-pyrrolo[2,3-b]pyridin-2-yl)-3-oxo-propionitrile	340

TABLE 10-continued

Compound No.	Structure	Compound name	m/z
1195		3-(1-benzenesulfonyl-1H-pyrrolo[3,2-c]pyridin-2-yl)-3-oxo-propionitrile	326
1196		3-(1-benzenesulfonyl-5-fluoro-6-morpholin-4-ylmethyl-1H-indol-2-yl)-3-oxo-propionitrile	442
1197		3-[1-benzenesulfonyl-6-(2-morpholin-4-yl-ethoxy)-1H-indol-2-yl]-3-oxo-propionitrile	454
1198		3-[1-benzenesulfonyl-6-(tetrahydro-pyran-4-yloxy)-1H-indol-2-yl]-3-oxo-propionitrile	425
1199		3-[4-chloro-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-3-oxo-propionitrile	373, 375

TABLE 10-continued

Compound No.	Structure	Compound name	m/z
1200		3-[3-fluoro-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-3-oxo-propionitrile	357
1201		3-[5-(1-methyl-piperidin-4-yl)-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-3-oxo-propionitrile	436
1202		4-[2-(2-cyano-acetyl)-6-fluoro-1-(toluene-4-sulfonyl)-1H-indol-5-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester	538
1203		4-[2-(2-cyano-acetyl)-1-(toluene-4-sulfonyl)-1H-indol-5-yl]-piperidine-1-carboxylic acid tert-butyl ester	466 [M - tBu]

TABLE 10-continued

Compound No.	Structure	Compound name	m/z
1204		3-[5-((R)-3-fluoro-pyrrolidin-1-ylmethyl)-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-3-oxo-propionitrile	440
1205		4-[2-(2-cyano-acetyl)-6-fluoro-1-(toluene-4-sulfonyl)-1H-indol-5-yl]-piperidine-1-carboxylic acid tert-butyl ester	540
1206		3-[6-fluoro-5-(1-methyl-piperidin-4-yl)-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-3-oxo-propionitrile	454
1207		3-[1-benzenesulfonyl-6-(tert-butyl-diphenyl-silyloxymethyl)-1H-indol-2-yl]-3-oxo-propionitrile	593

TABLE 10-continued

Compound No.	Structure	Compound name	m/z
1208		3-[5-(1-isopropyl-piperidin-4-yl)-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-3-oxo-propionitrile	464
1209		3-[6-fluoro-5-(1-isopropyl-piperidin-4-yl)-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-3-oxo-propionitrile	482
1210		3-{1-benzenesulfonyl-6-[2-(4-methyl-piperidin-1-yl)-ethoxy]-1H-indol-2-yl}-3-oxo-pr	467
1211		3-[6-fluoro-5-(4-methyl-piperidin-1-ylmethyl)-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-3-oxo-propionitrile	469

TABLE 10-continued

Compound No.	Structure	Compound name	m/z
1212		3-[6-fluoro-5-pyrrolidin-1-ylmethyl]-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-3-oxo-propionitrile	440
1213		3-[6-(1-methyl-piperidin-4-yl)-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-3-oxo-propionitrile	436
1214		3-[5-(1-cyclopentyl-piperidin-4-yl)-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-3-oxo-propionitrile	490
1215		3-[5-(1-cyclohexyl-piperidin-4-yl)-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-3-oxo-propionitrile	504

TABLE 10-continued

Compound No.	Structure	Compound name	m/z
1216		3-[4-bromo-1-(toluene-4-sulfonyl)-1H-pyrrol-2-yl]-3-oxo-propionitrile	367, 369
1217		3-oxo-3-[1-(toluene-4-sulfonyl)-1H-pyrrol-2-yl]-propionitrile	289
1218		3-(5-methoxy-1H-indol-2-yl)-3-oxo-propionitrile	215
1219		3-[6-butyl-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-3-oxo-propionitrile	395
1220		3-[5-(1-isopropyl-piperidin-4-yl)-1-(toluene-4-sulfonyl)-6-trifluoromethyl-1H-indol-2-yl]-3-oxo-propionitrile	532

TABLE 10-continued

Compound No.	Structure	Compound name	m/z
1221		3-(4,6-dimethoxy-1H-indol-2-yl)-3-oxo-propionitrile	245
1222		3-(4-methoxy-1H-indol-2-yl)-3-oxo-propionitrile	215
1223		3-(6-methoxy-1H-indol-2-yl)-3-oxo-propionitrile	215
1224		3-(4,6-dimethyl-1H-indol-2-yl)-3-oxo-propionitrile	213
1225		3-[6-bromo-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-3-oxo-propionitrile	417, 419
1226		3-[6-cyclopropyl-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-3-oxo-propionitrile	379
1227		3-(5-tert-butyl-1H-indol-2-yl)-3-oxo-propionitrile	241
1228		3-(5-isopropyl-1H-indol-2-yl)-3-oxo-propionitrile	227

TABLE 10-continued

Compound No.	Structure	Compound name	m/z
1229		3-(5-benzyloxy-1H-indol-2-yl)-3-oxo-propionitrile	291
1230		3-(4-benzyloxy-1H-indol-2-yl)-3-oxo-propionitrile	291
1231		3-[5-bromo-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-3-oxo-propionitrile	417, 419
1232		3-(5,6-dimethoxy-1H-indol-2-yl)-3-oxo-propionitrile	245
1233		3-(4-iodo-1H-indol-2-yl)-3-oxo-propionitrile	309 [M - H]
1234		3-[6-isopropyl-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-3-oxo-propionitrile	381
1235		3-(1-benzenesulfonyl-1H-pyrrolo[3,2-b]pyridin-2-yl)-3-oxo-propionitrile	326

TABLE 10-continued

Compound No.	Structure	Compound name	m/z
1236		3-[5-bromo-1-(toluene-4-sulfonyl)-6-trifluoromethyl-1H-indol-2-yl]-3-oxo-propionitrile	483, 485 [M - H]
1237		3-[6-bromo-5-fluoro-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-3-oxo-propionitrile	435, 437
1238		3-oxo-3-[6-pyridin-2-yl-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-propionitrile	416
1239		3-[5-cyclopropyl-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-3-oxo-propionitrile	379
1240		3-(-(6-tert-butyl-1H-indol-2-yl)-3-oxo-propionitrile	241

TABLE 10-continued

Compound No.	Structure	Compound name	m/z
1241		3-oxo-3-[6-pyridazin-3-yl-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-propionitrile	417
1242		3-(5-fluoro-4-trifluoromethyl-1H-indol-2-yl)-3-oxo-propionitrile	269 [M - H]
1243		3-oxo-3-(5-phenoxy-1H-indol-2-yl)-propionitrile	277
1244		3-[6-methylsulfanyl-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-3-oxo-propionitrile	385
1245		3-(5-imidazol-1-yl-1H-indol-2-yl)-3-oxo-propionitrile	251
1246		3-oxo-3-(5-trifluoromethylsulfanyl-1H-indol-2-yl)-propionitrile	285
1247		3-(4-tert-butyl-1H-indol-2-yl)-3-oxo-propionitrile	241

TABLE 10-continued

Compound No.	Structure	Compound name	m/z
1248		3-(5-methyl-1H-indol-2-yl)-3-oxo-propionitrile	199
1249		3-(5-ethyl-1H-indol-2-yl)-3-oxo-propionitrile	213
1250		3-[5-butoxy-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-3-oxo-propionitrile	411
1251		3-[5-isopropoxy-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-3-oxo-propionitrile	397
1252		3-[5-(2-methoxy-ethoxy)-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-3-oxo-propionitrile	413
1253		3-(1-benzenesulfonyl-4-methyl-1H-indol-2-yl)-3-oxo-propionitrile	337 [M - H]

TABLE 10-continued

Compound No.	Structure	Compound name	m/z
1254		3-(5-fluoro-6-trifluoromethyl-1H-indol-2-yl)-3-oxo-propionitrile	269 [M - H]
1255		3-(5-methylsulfanyl-1H-indol-2-yl)-3-oxo-propionitrile	231
1256		3-(6-fluoro-5-methoxy-1H-indol-2-yl)-3-oxo-propionitrile	233
1257		3-[5-benzyl-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-3-oxo-propionitrile	429
1258		3-(6-chloro-5-methoxy-1H-indol-2-yl)-3-oxo-propionitrile	249, 251
1259		3-(5-chloro-6-methoxy-1H-indol-2-yl)-3-oxo-propionitrile	249, 251
1260		3-(6-isopropoxy-1H-indol-2-yl)-3-oxo-propionitrile	243
1261		3-(1-benzenesulfonyl-4-trimethylsilyl-1H-indol-2-yl)-3-oxo-propionitrile	421

TABLE 10-continued

Compound No.	Structure	Compound name	m/z
1262		3-[5-bromo-6-methoxy-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-3-oxo-propionitrile	447, 449
1263		3-oxo-3-[5-(toluene-4-sulfonyl)-5H-[1,3]dioxolo[4,5-f]indol-6-yl]-propionitrile	383
1264		3-(6-benzyloxy-1H-indol-2-yl)-3-oxo-propionitrile	291
1265		3-[5-cyclopropylmethoxy-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-3-oxo-propionitrile	409
1266		3-(4-isopropoxy-1H-indol-2-yl)-3-oxo-propionitrile	243

TABLE 10-continued

Compound No.	Structure	Compound name	m/z
1267		3-(1-benzenesulfonyl-4-bromo-1H-indol-2-yl)-3-oxo-propionitrile	403, 405
1268		3-[2,2-difluoro-5-(toluene-4-sulfonyl)-5H-[1,3]dioxolo[4,5-f]indol-6-yl]-3-oxo-propionitrile	419
1269		3-[6-(3-chloro-pyridin-2-yl)-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-3-oxo-propionitrile	450, 452
1270		3-[6-(3-fluoro-pyridin-2-yl)-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-3-oxo-propionitrile	434
1271		3-[6-methyl-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-3-oxo-propionitrile	353

TABLE 10-continued

Compound No.	Structure	Compound name	m/z
1272		3-[6-(5-fluoro-pyridin-2-yl)-1H-indol-2-yl]-3-oxo-propionitrile	434
1273		3-{2,3-dihydro-6H-[1,4]dioxino[2,3-f]indol-7-yl}-3-oxo-propionitrile	243
1274		3-[6-(6-morpholin-4-yl-pyridazin-3-yl)-1H-indol-2-yl]-3-oxo-propionitrile	502
1275		3-[5-chloro-6-cyclopropylmethoxy-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-3-oxo-propionitrile	443, 445
1276		3-(4,6-di-tert-butyl-1H-indole-2-yl)-3-oxopropionitrile	352
1277		3-oxo-3-[1-(toluene-4-sulfonyl)-6-(5-trifluoromethyl-pyridin-2-yl)-1H-indol-2-yl]-propionitrile	484

TABLE 10-continued

Compound No.	Structure	Compound name	m/z
1278		3-oxo-3-[1-(toluene-4-sulfonyl)-6-(6-trifluoromethyl-pyridin-2-yl)-1H-indol-2-yl]-propionitrile	484
1279		3-[6-(5-chloro-pyridin-2-yl)-1H-indol-2-yl]-3-oxo-propionitrile	450, 452
1280		3-[4,5-dibromo-1-(4-methoxy-benzyl)-1H-pyrrol-2-yl]-3-oxo-propionitrile	411, 413, 415
1281		3-oxo-3-[1-(toluene-4-sulfonyl)-6-(3-trifluoromethyl-pyridin-2-yl)-1H-indol-2-yl]-propionitrile	484
1282		3-oxo-3-[1-(toluene-4-sulfonyl)-6-(4-trifluoromethyl-pyridin-2-yl)-1H-indol-2-yl]-propionitrile	484

TABLE 10-continued

Compound No.	Structure	Compound name	m/z
1283		3-(5-methanesulfonyl-1H-indol-2-yl)-3-oxo-propionitrile	263
1284		3-(1-benzenesulfonyl-4-isopropyl-1H-indol-2-yl)-3-oxo-propionitrile	367
1550		3-[6-chloro-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-3-oxo-propionitrile	373
1551		3-[5-chloro-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-3-oxo-propionitrile	373
1552		3-oxo-3-[1-(toluene-4-sulfonyl)-1H-indol-3-yl]-propionitrile	339

TABLE 10-continued

Compound No.	Structure	Compound name	m/z
1553		3-oxo-3-[1-(toluene-4-sulfonyl)-1H-indol-6-yl]-propionitrile	339
1554		3-[5-bromo-6-fluoro-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-3-oxo-propionitrile	435
1555		3-oxo-3-[1-(toluene-4-sulfonyl)-5-trifluoromethyl-1H-indol-2-yl]-propionitrile	407
1556		3-oxo-3-[1-(toluene-4-sulfonyl)-5-trifluoromethoxy-1H-indol-2-yl]-propionitrile	423
1557		3-[4,6-dichloro-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-3-oxo-propionitrile	407

TABLE 10-continued


Compound No.	Structure	Compound name	m/z
1558		3-[6-bromo-4-fluoro-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-3-oxo-propionitrile	435
1559		3-oxo-3-[1-(toluene-4-sulfonyl)-6-trifluoromethoxy-1H-indol-2-yl]-3-oxo-propionitrile	423
1560		3-[5,6-dichloro-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-3-oxo-propionitrile	407
1561		3-[4,5-dichloro-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-3-oxo-propionitrile	407

TABLE 10-continued

Compound No.	Structure	Compound name	m/z
1562		3-[4,6-difluoro-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-3-oxo-propionitrile	375
1563		3-benzofuran-2-yl-3-oxo-propionitrile	186
1564		3-benzo[b]thiophen-2-yl-3-oxo-propionitrile	202
1565		3-benzothiazol-2-yl-3-oxo-propionitrile	203
1566		3-(4-fluoro-phenyl)-3-oxo-propionitrile	164
1567		3-(3-chloro-phenyl)-3-oxo-propionitrile	180
1568		3-oxo-3-quinolin-3-yl-propionitrile	197
1569		3-oxo-3-quinolin-7-yl-propionitrile	197
1570		3-oxo-3-quinolin-6-yl-propionitrile	197
1571		3-(1H-indol-2-yl)-3-oxo-propionitrile	185

399

Step 4: Synthesis of
1-benzenesulfonyl-1H-indole-2-carboxylic acid ethyl
ester (1285)



With cooling on ice, an anhydrous N,N-dimethylformamide (DMF) solution (70 ml) of 1H-indole-2-carboxylic acid ethyl ester (45 g, 0.238 mol) was added dropwise to a solution of 50% sodium hydride (13.7 g, 0.286 mol) in anhydrous N,N-dimethylformamide (DMF) (90 ml). After one and half hour of stirring with cooling on ice, the reaction mixture was warmed to room temperature, and then stirred for one hour.

400

After cooling on ice, an anhydrous N,N-dimethylformamide (DMF) solution of benzenesulfonyl chloride (50.4 g) was added dropwise, and the resulting mixture was stirred for one hour. An aqueous solution of 0.5 N hydrochloric acid was added dropwise to the reaction mixture, and then water was added thereto. The mixture was stirred for 30 minutes. The resulting solid was collected by filtration, and washed with water and then with n-hexane. The solid was dissolved in ethyl acetate, and washed with a saturated aqueous solution of sodium bicarbonate and then with a saturated aqueous solution of sodium chloride. The organic layer was dried over anhydrous sodium sulfate. The desiccant was removed by filtration. The filtrate was concentrated under reduced pressure to give crude 1-benzenesulfonyl-1H-indole-2-carboxylic acid ethyl ester. The obtained crude product was recrystallized (ethyl acetate/hexane) to give 1-benzenesulfonyl-1H-indole-2-carboxylic acid ethyl ester (68.9 g, 79%).

¹H-NMR (CDCl_3) δ : 8.12 (1H, d, $J=8.3$ Hz), 8.04 (2H, d, $J=7.8$ Hz), 7.60-7.52 (2H, m), 7.51-7.40 (3H, m), 7.31-7.21 (1H, m), 7.17 (1H, s), 4.40 (2H, q, $J=7.0$ Hz), 1.39 (3H, t, $J=7.0$ Hz)

ESI (LC-MS positive mode) m/z 330 [(M+H)⁺]

The compounds of numbers 1286 to 1312 listed in Table 11 were synthesized by the same method as in Step 4.

TABLE 11

Compound No.	Structure	Compound name	m/z
1286		6-morpholin-4-ylmethyl-1-(benzenesulfonyl)-1H-indole-2-carboxylic acid ethyl ester	429
1287		5-morpholin-4-ylmethyl-1-(benzenesulfonyl)-1H-indole-2-carboxylic acid ethyl ester	429
1288		1-benzenesulfonyl-4-morpholin-4-yl-1H-indole-2-carboxylic acid ethyl ester	415

401**402**

TABLE 11-continued

Compound No.	Structure	Compound name	m/z
1289		1-benzenesulfonyl-4-morpholin-4-ylmethyl-1H-indole-2-carboxylic acid ethyl ester	429
1290		1-benzenesulfonyl-4-fluoro-1H-indole-2-carboxylic acid ethyl ester	348
1291		1-benzenesulfonyl-5-fluoro-1H-indole-2-carboxylic acid ethyl ester	348
1292		1-benzenesulfonyl-6-fluoro-1H-indole-2-carboxylic acid ethyl ester	348
1293		1-benzenesulfonyl-1H-pyrrolo[2,3-b]pyridine-2-carboxylic acid ethyl ester	331

TABLE 11-continued

Compound No.	Structure	Compound name	m/z
1294		1-benzenesulfonyl-1H-pyrrolo[3,2-c]pyridine-2-carboxylic acid ethyl ester	331
1295		1-benzenesulfonyl-5-fluoro-6-morpholin-4-ylmethyl-1H-indole-2-carboxylic acid ethyl ester	447
1296		1-benzenesulfonyl-6-(2-morpholin-4-yl-ethoxy)-1H-indole-2-carboxylic acid methyl ester	445
1297		1-benzenesulfonyl-6-(tetrahydro-pyran-4-yloxy)-1H-indole-2-carboxylic acid methyl ester	416
1298		4-chloro-1-(toluene-4-sulfonyl)-1H-indole	306, 308

TABLE 11-continued

Compound No.	Structure	Compound name	m/z
1299		5-((R)-3-fluoro-pyrrolidin-1-ylmethyl)-1-(toluene-4-sulfonyl)-1H-indole-2-carboxylic acid ethyl ester	445
1300		6-bromo-1-(toluene-4-sulfonyl)-1H-indole-2-carboxylic acid ethyl ester	422, 424
1301		5-bromo-1-(toluene-4-sulfonyl)-1H-indole-2-carboxylic acid ethyl ester	422, 424
1302		1-benzenesulfonyl-4-iodo-1H-indole-2-carboxylic acid ethyl ester	456

TABLE 11-continued

Compound No.	Structure	Compound name	m/z
1303		6-isopropyl-1-(toluene-4-sulfonyl)-1H-indole-2-carboxylic acid methyl ester	372
1304		1-(toluene-4-sulfonyl)-1H-pyrrolo[3,2-b]pyridine-2-carboxylic acid ethyl ester	345
1305		6-methylsulfanyl-1-(toluene-4-sulfonyl)-1H-indole-2-carboxylic acid methyl ester	376
1306		4-methyl-1-(toluene-4-sulfonyl)-1H-indole-2-carboxylic acid methyl ester	344
1307		5-(toluene-4-sulfonyl)-5H-[1,3]dioxolo[4,5-f]indol-6-carboxylic acid methyl ester	374

409**410**


TABLE 11-continued

Compound No.	Structure	Compound name	m/z
1308		1-benzenesulfonyl-4-bromo-1H-indole-2-carboxylic acid ethyl ester	408, 410
1309		6-methyl-1-(toluene-4-sulfonyl)-1H-indole-2-carboxylic acid methyl ester	344
1310		4-bromo-1-(toluene-4-sulfonyl)-1H-pyrrole-2-carboxylic acid ethyl ester	372, 374
1311		1-(toluene-4-sulfonyl)-1H-pyrrole-2-carboxylic acid ethyl ester	294

TABLE 11-continued

Compound No.	Structure	Compound name	m/z
1312		1-benzenesulfonyl-4-isopropyl-1H-indole-2-carboxylic acid ethyl ester	372

Step 5: Synthesis of [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-(2-methoxyethylamino)-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone (1313)



Copper (I) iodide (16 mg, 0.086 mmol), L-proline (37 mg, 0.32 mmol), and [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-iodo-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone (1313)

20 dol-2-yl]-methanone (104 mg) were dissolved in anhydrous dimethylsulfoxide (DMSO), and then 1,8-diazabicyclo [5.4.0]undec-7-ene (49 μ l) and 2-methoxyethylamine (43 μ l) were added thereto. The mixture was heated at 80° C. with stirring under a nitrogen atmosphere for 18 hours. After the reaction mixture was cooled to room temperature, 25% ammonia water was added thereto. The resulting mixture was extracted with ethyl acetate. The organic layer was isolated, washed with an aqueous solution of 1 M hydrochloric acid and then with a saturated aqueous solution of sodium chloride, and dried over anhydrous magnesium sulfate. After the desiccant was removed by filtration, the solvent was distilled off under reduced pressure. The resulting residue was purified by chromatography (dichloromethane/methanol=100/5) using a small amount of silica gel to give crude product of 25 [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-(2-methoxyethylamino)-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone. The obtained crude product was used in subsequent reactions without purification.

30 ESI (LC-MS positive mode) m/z 584 [(M+H)⁺]

35 The compounds of numbers 1314 to 1320 listed in Table 12 were synthesized by the same method as in Step 5.

TABLE 12

Compound No.	Structure	Compound name	m/z
1314		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-(2-morpholin-4-yl-ethylamino)-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	639

TABLE 12-continued


Compound No.	Structure	Compound name	m/z
1315		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(2-morpholin-4-ylethylamino)-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	639
1316		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-(2-methoxyethylamino)-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	584
1317		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-(2-hydroxymethyl-ethylamino)-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	600

TABLE 12-continued

Compound No.	Structure	Compound name	m/z
1318		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-(2-pyridin-4-ylethylamino)-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	631
1319		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-morpholin-4-yl-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	596
1320		1-benzenesulfonyl-4-morpholin-4-yl-1H-indole-2-carboxylic acid ethyl ester	415

417

Step 6: Synthesis of [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(morpholine-4-carbonyl)-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone (1321)



2-[5-Amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazole-4-carbonyl]-1-(toluene-4-sulfonyl)-1H-indole-5-

418

carboxylic acid (113 mg) was dissolved in water (5 ml) and tetrahydrofuran (THF) (10 ml), and then morpholine (53.5 µl) and N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (WSC-HCl) (43 mg) were added thereto. The mixture was stirred at room temperature for 24 hours. The reaction mixture was then concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (methanol/dichloromethane=0/100 to 17/100) to give [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(morpholine-4-carbonyl)-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone (59 mg).

¹H-NMR (DMSO-D₆) δ: 12.49 (1.0H, d, J=9.3 Hz), 8.08 (3.0H, m), 7.82-7.74 (2.0H, m), 7.70-7.64 (1.0H, m), 7.58 (1.0H, d, J=8.3 Hz), 7.53-7.42 (3.0H, m), 7.35-7.25 (2.0H, m), 7.13-6.89 (2.0H, m), 3.69-3.51 (4.0H, m), 3.40-3.28 (4.0H, m), 2.54 (3.0H, s), 2.38 (3.0H, s)

ESI (LC-MS positive mode) m/z 624 [(M+H)⁺]

The compounds of numbers 1322 to 1326, 1572 to 1579 listed in Table 13 were synthesized by the same method as in Step 6.

TABLE 13

Compound No.	Structure	Compound name	m/z
1322		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(4-methylpiperidine-1-carbonyl)-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	637
1323		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(piperidine-1-carbonyl)-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	623

TABLE 13-continued





Compound No.	Structure	Compound name	m/z
1324		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(4,4-difluoro-piperidine-1-carbonyl)-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	658
1325		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(3,3-difluoro-piperidine-1-carbonyl)-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	658
1326		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-carbonyl]-1-(toluene-4-sulfonyl)-1H-indol-5-carboxylic acid (2,2,2-trifluoroethyl)-amide	636
1572		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(3,3-difluoro-pyrrolidine-1-carbonyl)-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	644

TABLE 13-continued




Compound No.	Structure	Compound name	m/z
1573		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(2,6-dimethylmorpholine-4-carbonyl)-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	652
1574		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-([1,4']bipiperidinyl-1'-carbonyl)-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	705
1575		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-{1-(toluene-4-sulfonyl)-5-[4-(2,2,2-trifluoroethyl)piperazine-1-carbonyl]-1H-indol-2-yl}-methanone	705

TABLE 13-continued


Compound No.	Structure	Compound name	m/z
1576		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-[4-(2-hydroxy-ethyl)-piperazine-1-carbonyl]-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	667
1577		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(3,3,4,4-tetrafluoro-pyrrolidine-1-carbonyl)-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	680
1578		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-((R)-3-fluoro-pyrrolidine-1-carbonyl)-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	626

TABLE 13-continued

Compound No.	Structure	Compound name	m/z
1579		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(S)-3-fluoro-pyrrolidine-1-carbonyl]-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	626

Step 7: Synthesis of 2-[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazole-4-carbonyl]-1-(toluene-4-sulfonyl)-1H-indole-6-carbaldehyde (1327)

25



In a pressure-proof container, palladium acetate (1.0 mg, 0.0044 mmol), 1,3-bis(diphenylphosphino)propane (1.8 mg, 0.0044 mmol), [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-iodo-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone (100 mg, 0.16 mmol), and sodium carbonate (18 mg, 0.17 mmol) were dissolved in anhydrous N,N-dimethylformamide (DMF) (0.22 ml). After triethylsilane (52 μ l, 0.33 mmol) was added, the air inside the container was replaced with carbon monoxide. Then, the reaction mixture was heated at 60° C. with stirring under pressure with carbon monoxide (3 atm) for 24 hours. After the reaction mixture was cooled to room temperature, the pressure was released to ambient pressure. The reaction mixture was diluted with ethyl acetate. The sodium carbonate was removed by filtration. The filtrate was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (dichloromethane/methanol=100/5) to give 2-[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazole-4-carbonyl]-1-(toluene-4-sulfonyl)-1H-indole-6-carbaldehyde as a yellow solid (80 mg, 85%).

¹H-NMR (CDCl_3) δ : 10.14 (1.0H, s), 9.81-9.40 (1.0H, brm), 8.61 (1.0H, d, J =3.9 Hz), 8.09 (2.0H, d, J =7.3 Hz), 7.86-7.72 (4.0H, m), 7.52-7.30 (4.0H, m), 7.02 (1.0H, s), 6.07 (1.0H, brs), 6.04 (1.0H, brs), 2.67 (3.0H, s), 2.40 (3.0H, s)

ESI (LC-MS positive mode) m/z 539 [(M+H)⁺]

Synthesis of 2-[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazole-4-carbonyl]-1-(toluene-4-sulfonyl)-1H-indole-5-carbaldehyde (1328)

25

30

35

40


45

50

55

60


65



2-[5-Amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazole-4-carbonyl]-1-(toluene-4-sulfonyl)-1H-indole-5-carbaldehyde was synthesized by the same method as in Step 7.

ESI (LC-MS positive mode) m/z 539 [(M+H)⁺]

Step 8: Synthesis of 2-[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazole-4-carbonyl]-1H-indole-6-carbaldehyde (1329)



427

2-[5-Amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazole-4-carbonyl]-1-(toluene-4-sulfonyl)-1H-indole-6-carbaldehyde (29 mg, 0.054 mmol), 1-methylpiperazine (7 μ L, 0.066 mmol), and sodium triacetoxyborohydride (17 mg, 0.083 mmol) were dissolved in anhydrous dichloromethane (0.5 mL) and stirred at room temperature under a nitrogen atmosphere for 14 hours. A saturated aqueous solution of sodium bicarbonate was added to the reaction mixture. Then, the mixture was extracted with ethyl acetate. The organic layer was isolated, washed with a saturated aqueous solution of sodium chloride, and dried over anhydrous magnesium sulfate.

428

The desiccant was removed by filtration. The filtrate was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (dichloromethane/methanol=100/15) to give [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(4-methyl-piperazin-1-ylmethyl)-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone as a yellow solid (29 mg, 86%).

ESI (LC-MS positive mode) m/z 623 [(M+H)⁺]

The compounds of numbers 1330 to 1358 listed in Table 14 were synthesized by the same method as in Step 8.

TABLE 14

Com- ound No.	Structure	Compound name	m/z
1330		6-morpholin-4-ylmethyl-1-(toluene-4-sulfonyl)-1H-indole-2-carboxylic acid ethyl ester	443
1331		5-morpholin-4-ylmethyl-1-benzenesulfonyl-1H-indole-2-carboxylic acid ethyl ester	429
1332		1-benzenesulfonyl-4-morpholin-4-ylmethyl-1H-indole-2-carboxylic acid ethyl ester	429

TABLE 14-continued

Compound No.	Structure	Compound name	m/z
1333		5-((R)-3-fluoro-pyrrolidin-1-ylmethyl)-1-(toluene-4-sulfonyl)-1H-indole-2-carboxylic acid ethyl ester	445
1334		6-fluoro-5-(4-methyl-piperazin-1-ylmethyl)-1-(toluene-4-sulfonyl)-1H-indole-2-carboxylic acid ethyl ester	474
1335		6-fluoro-5-pyrrolidin-1-ylmethyl-1-(toluene-4-sulfonyl)-1H-indole-2-carboxylic acid ethyl ester	445
1336		1-benzenesulfonyl-5-fluoro-6-morpholin-4-ylmethyl-1H-indole	375
1337		4-(1-benzenesulfonyl-1H-indol-5-ylmethyl)-piperadin-1-carboxylic acid tert-butyl ester	456

TABLE 14-continued




Com- ound No.	Structure	Compound name	m/z
1338		1-[4-[2-[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-carbonyl]-1-(toluene-4-sulfonyl)-1H-indol-6-ylmethyl]-piperizin-1-yl]-ethanone	651
1339		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1-benzenesulfonyl-5-(4-methyl-piperazin-1-ylmethyl)-1H-indol-2-yl]-methanone	609
1340		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1-benzenesulfonyl-5-pyrrolidin-1-ylmethyl-1H-indol-2-yl]-methanone	580

TABLE 14-continued




Compound No.	Structure	Compound name	m/z
1341		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-pyrrolidin-1-ylmethyl-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	594
1342		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(4-hydroxy-piperidin-1-ylmethyl)-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	624
1343		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-piperidin-1-ylmethyl)-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	609

TABLE 14-continued




Com- ound No.	Structure	Compound name	m/z
1344		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-((R)-3-methyl-morpholin-4-ylmethyl)-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	624
1345		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-((R)-3-fluoro-pyrrolidin-1-ylmethyl)-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	612
1346		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(2,5-dimethyl-pyrrolidin-1-ylmethyl)-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	622

TABLE 14-continued

Com- ound No.	Structure	Compound name	m/z
1347		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(3-fluoropiperidin-1-ylmethyl)-1-(toluenesulfonyl)-1H-indol-2-yl]-methanone	626
1348		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(3,3-difluoropiperidin-1-ylmethyl)-1-(toluenesulfonyl)-1H-indol-2-yl]-methanone	644
1349		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(4-fluoropiperidin-1-ylmethyl)-1-(toluenesulfonyl)-1H-indol-2-yl]-methanone	626

TABLE 14-continued







Com- ound No.	Structure	Compound name	m/z
1350		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(4,4-difluoro-piperidin-1-ylmethyl)-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	644
1351		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(3-fluoro-piperidin-1-ylmethyl)-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	626
1352		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-{{[bis-(2-methoxy-ethyl)-amino]-methyl}-1-(toluene-4-sulfonyl)-1H-indol-2-yl}-methanone	656

TABLE 14-continued

Com- ound No.	Structure	Compound name	m/z
1353		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(3,3-difluoro-pyrrolidin-1-ylmethyl)-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	630
1354		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-{6-[(methyl-prop-2-ynyl-amino)methyl]-1-(toluene-4-sulfonyl)-1H-indol-2-yl}-methanone	592
1355		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(3,3-difluoro-pyrrolidin-1-ylmethyl)-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	630

TABLE 14-continued

Compound No.	Structure	Compound name	m/z
1356		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(2,5-dimethyl-pyrrolidin-1-ylmethyl)-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	622
1357		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(3,3-difluoro-piperidin-1-ylmethyl)-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	644
1358		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-((S)-3-methyl-morpholin-4-ylmethyl)-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	624

445

Examples 196 and 197

The compounds of Examples 196 and 197 listed in Table 15 were synthesized by the same method as in Step 8.

446

s), 6.03 (2.0H, m), 3.62 (2.0H, t, J=5.0 Hz), 3.58 (2.0H, s), 3.45 (2.0H, t, J=5.0 Hz), 2.64 (3.0H, s), 2.42 (4.0H, m), 2.07 (3.0H, s)

ESI (LC-MS positive mode) m/z 637 [(M+H)+]


TABLE 15

Ex- ample	Structure	Compound name	m/z NMR
196		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(4,4-difluoropiperidin-1-ylmethyl)-1H-indol-2-yl]-methanone	490 1H-NMR (DMSO-D6) δ: 12.46 (1.0H, s), 11.65 (1.0H, s), 8.30 (1.0H, s), 7.64 (3.0H, m), 7.42 (2.0H, t, J = 2.4 Hz), 7.30 (1.0H, dd, J = 8.3, 2.0 Hz), 7.07 (1.0H, dd, J = 8.3, 1.0 Hz), 7.00 (2.0H, m), 3.64 (3.0H, s), 2.55-2.48 (4.2H, m), 2.54 (2.5H, s), 2.01-1.91 (4.2H, m).
197		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(4-fluoropiperidin-1-ylmethyl)-1H-indol-2-yl]-methanone	472 1H-NMR (DMSO-D6) δ: 12.46 (1.0H, s), 11.63 (1.0H, s), 8.30 (1.0H, s), 7.62 (3.0H, m), 7.41 (2.0H, d, J = 6.9 Hz), 7.30 (1.0H, dd, J = 8.5, 2.2 Hz), 7.05 (1.0H, dd, J = 8.3, 1.0 Hz), 7.00 (2.0H, m), 4.69 (1.0H, m), 3.56 (2.0H, s), 2.60-2.50 (2.0H, m), 2.54 (3H, s), 2.37-2.26 (2.0H, m), 1.94-1.78 (2.0H, m), 1.78-1.85 (2.0H, m).


Step 9: Synthesis of 1-(4-{2-[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazole-4-carbonyl]-1-benzenesulfonyl-1-indol-5-ylmethyl}-piperazin-1-yl)-ethanone (1359)

35

Step 10: Synthesis of 5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1-benzenesulfonyl-5-(4-methanesulfonylpiperazin-1-ylmethyl)-1H-indol-2-yl]-methanone (1360)



40



50

[5-Amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-piperazin-1-ylmethyl-1H-indol-2-yl]-methanone (103 mg) was dissolved in a saturated aqueous solution of sodium bicarbonate (25 ml) containing dichloromethane (20 ml) and methanol (3 ml), and cooled to 0° C. Then, acetyl chloride (326 µl) was added thereto in three parts, and stirred for 1.5 hour. The reaction mixture was extracted with dichloromethane. The extract was dried over anhydrous sodium sulfate. The desiccant was removed by filtration, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (methanol/dichloromethane=0/100 to 10/100) to give 1-(4-{2-[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazole-4-carbonyl]-1-benzenesulfonyl-1-indol-5-ylmethyl}-piperazin-1-yl)-ethanone (32 mg).

¹H-NMR (CDCl₃) δ: 8.18-8.14 (2.0H, m), 8.05 (1.0H, d, J=8.8 Hz), 7.78 (1.1H, s), 7.60-7.56 (1.0H, m), 7.50 (3.0H, m), 7.40 (1.0H, dd, J=8.8, 1.5 Hz), 7.35 (1.0H, m), 6.98 (1.0H,

55


[5-Amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-piperazin-1-ylmethyl-1H-indol-2-yl]-methanone (94 mg) was dissolved in tetrahydrofuran (THF) (5 ml) and a saturated aqueous solution of sodium bicarbonate (5 ml), and cooled to 0° C. Then methanesulfonyl chloride (94 µl) was added thereto and stirred at 0° C. for 1.5 hour. Then ammonia water (5 ml) was added thereto, and stirred at 0° C. for two hours. The reaction mixture was extracted with ethyl acetate, and the extract was washed with a saturated sodium chloride solution and dried over anhydrous sodium sulfate. The desiccant was removed by filtration. The filtrate was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (methanol/dichloromethane=0/100 to 15/100) to give 5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1-benzenesulfonyl-5-(4-methanesulfonylpiperazin-1-ylmethyl)-1H-indol-2-yl]-methanone (1360) (32 mg).

447

sulfonyl-5-(4-methanesulfonylpiperazin-1-ylmethyl)-1H-indol-2-yl]-methanone (39 mg).

¹H-NMR (CD₃OD) δ: 8.09 (2.0H, m), 7.98 (2.0H, m), 7.84 (1.0H, m), 7.75 (1.0H, m), 7.65-7.57 (3.0H, m), 7.53-7.40 (3.0H, m), 7.12 (1.0H, d, J=3.9 Hz), 3.64 (2.0H, m), 3.25-3.15 (4.0H, m), 2.86 (3.0H, s), 2.82 (3.0H, s), 2.54 (4.0H, m)
ESI (LC-MS positive mode) m/z 673 [(M+H)⁺]

Step 11: Synthesis of 5-isopropoxy-1-(toluene-4-sulfonyl)-1H-indole-2-carboxylic acid ethyl ester
(1361)

**448**

Diisopropyl azodicarboxylate (0.15 ml, 0.75 mmol) was added to an anhydrous tetrahydrofuran (THF) solution (2.5 ml) of 5-hydroxy-1-(toluene-4-sulfonyl)-1H-indole-2-carboxylic acid ethyl ester (175 mg, 0.48 mmol), triphenylphosphine (197 mg, 0.75 mmol), and 2-propanol (0.2 ml, 4.0 mmol), and stirred at room temperature for one hour. The reaction mixture was concentrated under reduced pressure.
The resulting residue was purified by silica gel column chromatography to give 5-isopropoxy-1-(toluene-4-sulfonyl)-1H-indole-2-carboxylic acid ethyl ester as a colorless gum-like material (166.7 mg, 87%).

¹H-NMR (DMSO-D₆) δ: 7.86 (1H, d, J=9.1 Hz), 7.79 (2H, d, J=8.5 Hz), 7.39 (2H, d, J=8.5 Hz), 7.25 (1H, s), 7.15 (1H, d, J=2.4 Hz), 7.04 (1H, dd, J=9.1, 2.4 Hz), 4.62-4.53 (1H, m), 4.34 (2H, q, J=7.1 Hz), 2.34 (3H, s), 1.31 (3H, t, J=7.1 Hz), 1.25 (6H, d, J=6.1 Hz)

ESI (LC-MS positive mode) m/z 402 [(M+H)⁺]

The compounds of numbers 1362 to 1367 listed in Table 16 were synthesized by the same method as in Step 11.

TABLE 16


Com- ound No.	Structure	Compound name	m/z
1362		6-(2-morpholin-4-yl-ethoxy)-1-(toluene-4-sulfonyl)-1H-indole-2-carboxylic acid methyl ester	459
1363		6-(tetrahydro-pyran-4-yloxy)-1-(toluene-4-sulfonyl)-1H-indole-2-carboxylic acid methyl ester	430

TABLE 16-continued

Compound No.	Structure	Compound name	m/z
1364		1-benzenesulfonyl-6[2-(4-methyl-piperadin-1-yl)-ethoxy]-1H-indole-2-carboxylic acid methyl ester	458
1365		4-isopropoxy-1H-indole-2-carboxylic acid methyl ester	234
1366		5-(2-methoxy-ethoxy)-1-(toluene-4-sulfonyl)-1H-indole-2-carboxylic acid ethyl ester	416
1367		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(3-methyl-oxetan-3-ylmethoxy)-1-(toluene-4-sulfonyl)-1H-indol-2-yl]methanone	611

451

Step 12: Synthesis of 5-cyclopropylmethoxy-1-(toluene-4-sulfonyl)-1H-indole-2-carboxylic acid ethyl ester (1368)




Cyclopropylmethyl bromide (0.072 ml, 0.75 mmol) was added to a suspension (5.0 ml) of 5-hydroxy-1-(toluene-4-sulfonyl)-1H-indole-2-carboxylic acid ethyl ester (173 mg, 0.48 mmol) and potassium carbonate (276 mg, 1.0 mmol) in acetonitrile, and stirred at 80° C. for five hours. After cooling to room temperature, the reaction mixture was combined with ethyl acetate and water and extracted with ethyl acetate. The extract was washed with water and a saturated aqueous solution of sodium chloride, and dried over anhydrous sodium sulfate. The desiccant was removed by filtration. The filtrate was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography to give 5-cyclopropylmethoxy-1-(toluene-4-sulfonyl)-1H-indole-2-carboxylic acid ethyl ester as a colorless gum-like material (112.5 mg, 56%).

¹H-NMR (DMSO-D₆) δ: 7.87 (1H, d, J=9.2 Hz), 7.76 (2H, d, J=8.2 Hz), 7.38 (2H, d, J=8.2 Hz), 7.25 (1H, s), 7.11 (1H, d, J=2.6 Hz), 7.07 (1H, dd, J=9.2, 2.6 Hz), 4.33 (2H, q, J=8.1 Hz), 3.80 (2H, d, J=6.6 Hz), 2.33 (3H, s), 1.32 (3H, t, J=8.1 Hz), 1.25-1.19 (1H, m), 0.58-0.52 (2H, m), 0.33-0.28 (2H, m)

ESI (LC-MS positive mode) m/z 414 [(M+H)⁺]

Example 198

Synthesis of [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(oxetan-3-yloxy)-1H-indol-2-yl]-methanone



[5-Amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-hydroxy-1H-indol-2-yl]-methanone (21 mg, 0.056 mmol), toluene-4-sulfonic acid oxetan-3-yl ester (19 mg, 0.084 mmol), and potassium carbonate (13 mg, 0.095 mmol) were dissolved in anhydrous N,N-dimethylformamide (DMF), and heated at 80° C. with stirring under a nitrogen atmosphere for six days. After cooling to room tem-

452


perature, the reaction mixture was combined with water, and extracted with an ethyl acetate/methanol (10/1) solution. The organic layer was isolated, washed with water, and dried over anhydrous magnesium sulfate. The desiccant was removed by filtration. The filtrate was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (dichloromethane/methanol=100/3) to give [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(oxetan-3-yloxy)-1H-indol-2-yl]-methanone as a yellow solid (6.9 mg, 29%).

¹H-NMR (DMSO-D₆) δ: 12.48 (1.0H, brs), 11.48 (1.0H, brs), 8.28 (1.0H, s), 7.62-7.60 (3.0H, m), 7.41 (1.0H, brs), 7.28 (1.0H, dd, J=8.3, 2.0 Hz), 6.96 (1.0H, brs), 6.94 (1.0H, brs), 6.71 (1.0H, dd, J=8.5, 2.2 Hz), 6.67 (1.0H, brs), 5.34-5.29 (1.0H, m), 4.94 (2.0H, dd, J=6.8, 6.8 Hz), 4.60 (2.0H, dd, J=6.8, 5.1 Hz), 2.53 (3.0H, s)

ESI (LC-MS positive mode) m/z 429 [(M+H)⁺]

Example 199

Synthesis of [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-hydroxy-1H-indol-2-yl]-methanone



2-[5-Amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazole-4-carbonyl]-1-(toluene-4-sulfonyl)-1H-indole-6-carbaldehyde (650 mg, 1.0 mmol), 1,1'-bis(diphenylphosphino)ferrocene palladium(II) dichloride (42 mg, 0.051 mmol), bis(pinacolato)diboron (312 mg, 1.23 mmol), and potassium acetate (323 mg, 3.3 mmol) were dissolved in anhydrous N,N-dimethylformamide (DMF) (4.1 ml). After deaeration, the mixture was heated at 100° C. with stirring under a nitrogen atmosphere for eight hours. The reaction mixture was cooled to room temperature, and then water was added thereto. The precipitated solid was collected by filtration, washed with water, and then dried to give a brown solid (538 mg). The obtained crude product was used in subsequent reactions without purification.


The obtained brown solid crude product of 4-methylmorpholine N-oxide (256 mg, 2.2 mmol) was dissolved in tetrahydrofuran (THF) (7.0 ml), and heated at 70° C. with stirring under a nitrogen atmosphere for three and half hours. After the reaction mixture was cooled to room temperature, water and ethyl acetate were added thereto. The mixture was filtered through Celite®, and the filtrate was divided into organic and aqueous layers. The organic layer was concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (amino silica; dichloromethane/methanol=100/5 to 100/10) to give [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-hydroxy-1H-indol-2-yl]-methanone as a yellow amorphous material (123 mg, with a two-step yield of 23%).

¹H-NMR (DMSO-D₆) δ: 12.51 (1.0H, brs), 11.30 (1.0H, brs), 9.40 (1.0H, brs), 8.26 (1.0H, s), 7.61-7.59 (2.0H, m), 7.47 (1.0H, d, J=8.8 Hz), 7.34 (1.0H, s), 7.28 (1.0H, d, J=8.8 Hz), 6.91 (2.0H, brs), 6.82 (1.0H, s), 6.62 (1.0H, d, J=8.8 Hz), 2.53 (3.0H, s)

ESI (LC-MS positive mode) m/z 373 [(M+H)⁺]

453

Step 13: Synthesis of [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-iodo-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone (1369)



A mixture consisting of [5-amino-1-(2-methyl-3H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-bromo-1-(toluene-4-

454

sulfonyl)-1H-indol-2-yl]-methanone (1 g), copper (I) iodide (161 mg), sodium iodide (508 mg), trans-N,N'-dimethylcyclohexane-1,2-diamine (267 μ l), and anhydrous dioxane (5 ml) was stirred in a pressure-proof container at 105 to 112°C. under a nitrogen atmosphere for 20 hours. The reaction mixture was poured into an aqueous solution of 2 M ammonia, and the mixture was extracted with ethyl acetate. The organic layer was washed with a saturated aqueous solution of sodium chloride, and dried over anhydrous sodium sulfate. The desiccant was removed by filtration. The filtrate was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (methanol/dichloromethane=0/100 to 20/100) to give [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-iodo-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone (0.67 g, 62%).

¹H-NMR (DMSO-D₆) δ : 12.44 (1.0H, s), 8.30 (1.0H, d, J=0.6 Hz), 7.98 (2.0H, d, J=8.5 Hz), 7.75 (1.0H, s), 7.66 (1.0H, dd, J=8.2, 1.4 Hz), 7.51 (1.0H, d, J=8.0 Hz), 7.46 (2.0H, d, J=8.5 Hz), 7.28 (1.0H, d, J=7.6 Hz), 7.23 (1.0H, d, J=0.4 Hz), 7.10-6.92 (2.0H, m), 2.53 (3.0H, s), 2.37 (3.0H, s) ESI (LC-MS positive mode) m/z 637 [(M+H)⁺]


The compounds of numbers 1370 and 1371 listed in Table 17 were synthesized by the same method as in Step 13.

TABLE 17

Com- ound No.	Structure	Compound name	m/z
1370		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-iodo-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	637
1371		1-benzenesulfonyl-4-iodo-1H-indole-2-carboxylic acid ethyl ester	456

455

Step 14: Synthesis of 2-[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazole-4-carbonyl]-1-(benzenesulfonyl)-1H-indole-5-carbonitrile (1372)



A mixture of 2-[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazole-4-carbonyl]-1-(benzenesulfonyl)-5-iodo-

456

1H-indole (117 mg), copper (I) cyanide (84 mg), and 1-methyl-2-pyrrolidinone was reacted in a microwave reactor (190° C., 20 minutes). The reaction mixture was poured into a mixed solution of 2 M ammonia water (40 ml), ethyl acetate (60 ml), and methanol (7 ml), and sonicated for five minutes. After ethyl acetate extraction, the extract was washed with water and then dried over anhydrous sodium sulfate. The desiccant was removed by filtration. The filtrate was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (methanol/dichloromethane=0/100 to 20/100) to give 2-[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazole-4-carbonyl]-1-(benzenesulfonyl)-1H-indole-5-carbonitrile (87 mg, 89%).

¹H-NMR (DMSO-D₆) δ: 12.47 (1.0H, d, J=8.4 Hz), 8.27-8.21 (4.0H, m), 7.86 (1.0H, dd, J=8.8, 1.8 Hz), 7.80-7.76 (2.0H, m), 7.72-7.64 (3.0H, m), 7.60-7.55 (1.0H, m), 7.35-7.25 (2.0H, m), 7.12-7.02 (2.0H, m), 2.54 (3.0H, s)

ESI (LC-MS positive mode) m/z 522 [(M+H)⁺]


The compounds of numbers 1373 and 1374 listed in Table 18 were synthesized by the same method as in Step 14.

TABLE 18

Com- ound No.	Structure	Compound name	m/z
1373		2-[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazole-4-carbonyl]-1-(benzenesulfonyl)-1H-indole-5-carbonitrile	522
1374		2-[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazole-4-carbonyl]-1-(toluene-4-sulfonyl)-1H-indole-6-carbonitrile	536

457

Step 15: Synthesis of 1-(toluene-4-sulfonyl)-1H-indole-2,5-dicarboxylic acid 2-ethyl ester (1375)




A mixture of 5-bromo-1-(toluene-4-sulfonyl)-1H-indole-2-carboxylic acid ethyl ester (948.4 mg, 2.24 mmol), Tris (dibenzylideneacetone)dipalladium (0) (0.112 mmol, 103 mg), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (Xantphos) (0.225 mmol, 130 mg), lithium formate monohydrate (5.6 mmol, 394 mg), lithium chloride (286 mg, 6.75 mmol), and anhydrous N,N-dimethylformamide (DMF) (5.9 ml) was evacuated, and backfilled with argon. Then, N,N-diisopropylethyl amine (4.5 mmol, 0.78 ml) and acetic anhydride (4.5 mmol, 0.43 ml) were added to the mixture, and deaeration and argon replacement was performed again. The reaction container was placed in a reaction device preheated at 80° C. and the reaction mixture was stirred for 20 hours. After cooling to room temperature, the reaction mixture was diluted with ethyl acetate and an aqueous solution of 1 M hydrochloric acid, and filtered through Celite. The resulting filtrate was washed with 1 M hydrochloric acid, water, and a saturated aqueous solution of sodium chloride, and then dried over anhydrous sodium sulfate. The desiccant was removed by filtration. The filtrate was concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (hexane/ethyl acetate=5/1 to 1/3, and finally ethyl acetate/methanol=15/1) to give 1-(toluene-4-sulfonyl)-1H-indole-2,5-dicarboxylic acid 2-ethyl ester as a yellow amorphous material (930 mg).

¹H-NMR (DMSO-D₆) δ: 8.32 (1H, d, J=1.5 Hz), 8.13 (1H, d, J=8.8 Hz), 8.05 (1H, dd, J=8.8, 1.5 Hz), 7.93 (2H, d, J=8.2 Hz), 7.50 (1H, s), 7.46 (2H, d, J=8.2 Hz), 4.38 (2H, q, J=7.1 Hz), 2.37 (3H, s), 1.34 (3H, t, J=7.1 Hz)

ESI (LC-MS positive mode) m/z 388 [(M+H)⁺]

Synthesis of 2-[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazole-4-carbonyl]-1-(toluene-4-sulfonyl)-1H-indole-6-carboxylic acid (1376)




2-[5-Amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazole-4-carbonyl]-1H-indole-6-carboxylic acid was synthesized by the same method as in Step 15.

ESI (LC-MS positive mode) m/z 555 [(M+H)⁺]

458

Step 16: Synthesis of 1-(toluene-4-sulfonyl)-1H-indole-2,5-dicarboxylic acid 5-tert-butyl ester 2-ethyl ester (1377)




1-(Toluene-4-sulfonyl)-1H-indole-2,5-dicarboxylic acid 2-ethyl ester (690 mg, 1.85 mmol) was dissolved in N,N-dimethylformamide di-tert-butyl acetal (3.0 ml), and stirred at 80° C. for two and half hours. N,N-dimethylformamide di-tert-butyl acetal (2.0 ml) was further added thereto and stirred at 80° C. for three hours. After cooling to room temperature, the reaction mixture was diluted with ethyl acetate (150 ml) and water (75 ml). The organic layer was isolated, washed with water and a saturated aqueous solution of sodium chloride, and then dried over anhydrous sodium sulfate. The desiccant was removed by filtration. The filtrate was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (hexane/ethyl acetate=25/1 to 5/1) to give 1-(toluene-4-sulfonyl)-1H-indole-2,5-dicarboxylic acid 5-tert-butyl ester 2-ethyl ester (551 mg, 69%).

¹H-NMR (DMSO-D₆) δ: 8.25 (1H, d, J=1.4 Hz), 8.12 (1H, d, J=8.8 Hz), 8.00 (1H, dd, J=8.8, 1.4 Hz), 7.88 (2H, d, J=8.0 Hz), 7.48 (1H, s), 7.43 (2H, d, J=8.0 Hz), 4.37 (2H, q, J=7.2 Hz), 2.37 (3H, s), 1.56 (9H, s), 1.34 (3H, t, J=7.2 Hz)

ESI (LC-MS positive mode) m/z 444 [(M+H)⁺]

Step 17: Synthesis of [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1-(toluene-4-sulfonyl)-5-trimethyl-silyl-ethynyl-1H-indol-2-yl]methanone (1378)




459

[5-Amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-bromo-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone (150 mg), dichloro-bis(triphenylphosphine)palladium (11)(54 mg), copper (I) iodide (10 mg), triethylamine (0.7 ml), and anhydrous N,N-dimethylformamide (DMF) (0.7 ml) were combined together in a pressure-proof container, and trimethylsilyl acetylene (150 mg) was added thereto. The mixture was stirred at 80 to 85° C. under nitrogen for 15 hours. After cooling to room temperature, the reaction mixture was diluted with ethyl acetate, washed with a saturated aqueous solution of sodium chloride, and dried over anhydrous sodium sulfate. The desiccant was removed by filtration. The filtrate was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (methanol/dichloromethane=0/100 to 20/100) to give [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1-(toluene-4-sulfonyl)-5-trimethyl-silanylethynyl-1H-indol-2-yl]-methanone (65 mg, 42%).

¹H-NMR (DMSO-D₆) δ: 12.48 (1H, d, J=8.4 Hz), 8.04-7.95 (3H, m), 7.80 (1H, s), 7.75 (1H, d, J=3.7 Hz), 7.69-7.62 (1H, m), 7.62-7.54 (1H, m), 7.50 (1H, dd, J=8.7, 1.7 Hz), 7.44 (2H, d, J=8.6 Hz), 7.29 (1H, t, J=7.9 Hz), 7.20 (1H, s), 7.09-6.97 (2H, m), 2.54 (3H, s), 2.36 (3.0H, s), 0.23 (9.0H, s), ESI (LC-MS positive mode) m/z 607 [(M+H)⁺]


Synthesis of 1-benzenesulfonyl-4-trimethyl-silanyl-ethynyl-1H-indole-2-carboxylic acid ethyl ester
(1379)



1-Benzenesulfonyl-4-trimethyl-silanyl-ethynyl-1H-indole-2-carboxylic acid ethyl ester was synthesized by the same method as in Step 17.

ESI (LC-MS positive mode) m/z 426 [(M+H)⁺]

Step 18: Synthesis of N-[2-[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazole-4-carbonyl]-1-(toluene-4-sulfonyl)-1H-indol-6-yl]-methanesulfonamide (1380)


**460**

[5-Amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-iodo-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone (80.3 mg, 0.126 mmol), copper (I) iodide (37.5 mg, 0.197 mmol), methanesulfonamide (37.5 mg, 0.394 mmol), sarcosine (36.2 mg, 0.406 mmol), and tripotassium phosphate (86.0 mg, 9.405 mmol) were dissolved in anhydrous 1-methyl-2-pyrrolidinone (0.36 ml), and heated at 140° C. with stirring under an argon atmosphere for 30 minutes. The reaction mixture was added dropwise to an aqueous solution (20 ml) of 20% ammonium chloride, and extracted with ethyl acetate, the organic layer was washed with an aqueous solution of 20% sodium chloride and dried over anhydrous sodium sulfate. The desiccant was removed by filtration. The filtrate was concentrated under reduced pressure, and the resulting residue was purified by amino gel column chromatography (dichloromethane/methanol=15/1) to give N-[2-[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazole-4-carbonyl]-1-(toluene-4-sulfonyl)-1H-indol-6-yl]-methanesulfonamide as a yellow amorphous material (17.9 mg with a yield of 24%).

¹H-NMR (DMSO-D₆) δ: 12.47 (1H, s), 9.93 (1H, brs), 7.97 (1H, s), 7.94 (2H, d, J=7.9 Hz), 7.77 (1H, s), 7.64-7.59 (3H, m), 7.43 (2H, d, J=6.7 Hz), 7.29 (1H, d, J=7.9 Hz), 7.22-7.15 (2H, t, J=5.2 Hz), 7.01 (2H, brs), 2.97 (3H, s), 2.53 (3H, s), 2.35 (3H, s), ESI (LC-MS positive mode) m/z 604 [(M+H)⁺]

Example 200

Synthesis of [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-methanesulfonyl-1H-indol-2-yl]-methanone




[5-Amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-methanesulfonyl-1H-indol-2-yl]-methanone (23 mg, 0.057 mmol) was dissolved in trifluoroethanol (5 ml), and an aqueous solution (0.5 ml) of oxone (105 mg, 0.171 mmol) was added thereto. The mixture was stirred at room temperature under a nitrogen atmosphere for 1.75 hours. The reaction mixture was filtered, and the filtrate was concentrated. The resulting residue was purified by amino gel column chromatography (dichloromethane/methanol=99/1 to 92/8). Thus, [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-methanesulfonyl-1H-indol-2-yl]-methanone was obtained as a pale yellow solid (8 mg, 32%).

¹H-NMR (DMSO-D₆) δ: 12.48 (1H, d, J=4.9 Hz), 12.33 (1H, s), 8.35 (1H, d, J=4.9 Hz), 8.05 (1H, s), 7.94 (1H, d, J=8.5 Hz), 7.65-7.59 (4H, m), 7.31-7.27 (1H, m), 7.11 (2H, d, J=21.4 Hz), 3.22 (3H, s), 2.54 (3H, s), ESI (LC-MS positive mode) m/z 435 [(M+H)⁺]

461

Step 19: Synthesis of 6-cyclopropyl-1-(toluene-4-sulfonyl)-1H-indole-2-carboxylic acid methyl ester (1381)



Predetermined amounts of 6-bromo-1-(toluene-4-sulfonyl)-1H-indole-2-carboxylic acid methyl ester (300 mg, 0.73

462

mmol), palladium acetate (16.5 mg, 0.07 mmol), bis(1,1-dimethylethyl)phenylphosphine (0.028 ml, 0.12 mmol), potassium cyclopropyl trifluoro borate (163 mg, 1.1 mmol), and cesium carbonate (718 mg, 2.2 mmol) were placed in a reaction container, and toluene (5 ml) and water (0.5 ml) were added thereto. The resulting mixture was then stirred at 100° C. for 14 hours. After cooling it to room temperature, the mixture was diluted with ethyl acetate, and washed twice with water, and then dried over anhydrous sodium sulfate. The desiccant was removed by filtration, and concentration was performed. Then, the residue obtained by concentration under reduced pressure was purified by silica gel column chromatography (hexane/ethyl acetate=97/3 to 7/3). Thus, a yellow solid was obtained (208 mg, 77%).

¹⁵ ¹H-NMR (DMSO-D₆) δ: 7.82-7.80 (2H, m), 7.68 (1H, brs), 7.52 (1H, d, J=8.2 Hz), 7.42-7.39 (2H, m), 7.32 (1H, d, J=0.8 Hz), 7.00 (1H, dd, J=8.3, 1.5 Hz), 3.83 (3H, s), 2.33 (3H, s), 2.11-2.09 (1H, m), 1.03 (2H, ddd, J=9.6, 5.2, 3.1 Hz), 0.73-0.70 (2H, m)

²⁰ ESI (LC-MS positive mode) m/z 370 [(M+H)⁺]


The compounds of numbers 1382 to 1384 listed in Table 19 were synthesized as described in Step 19.

TABLE 19

Compound No.	Structure	Compound name	m/z
1382		6-butyl-1-(toluene-4-sulfonyl)-1H-indole-2-carboxylic acid methyl ester	386
1383		5-cyclopropyl-1-(toluene-4-sulfonyl)-1H-indole-2-carboxylic acid ethyl ester	384
1384		5-benzyl-1-(toluene-4-sulfonyl)-1H-indole-2-carboxylic acid ethyl ester	434

463

Step 20: Synthesis of
5-imidazol-1-yl-1H-indole-2-carboxylic acid ethyl
ester (1385)



Hydrazone-Based Synthesis Method

Synthesis of

2-[*(E*)-4-imidazol-1-yl-phenylimino]-propionic acid
ethyl ester

4-imidazol-1-yl-phenyl amine (637 mg) was dissolved in 2 M hydrochloric acid/MeOH (3 ml), and this was concentrated under reduced pressure. The residue was suspended in concentrated hydrochloric acid (1 ml), and an aqueous solution of sodium nitrite (304 mg, 2.5 ml) was added dropwise thereto over 30 minutes at 0° C. on ice. The reaction mixture was slowly added dropwise to an aqueous solution prepared in advance from aqueous solutions of sodium hydrosulfite (2.3 g, 13 ml) and 5 M sodium hydroxide (400 µl), while keeping the temperature of the reaction mixture at 5° C. or lower. Then, the mixture was stirred at 25° C. for one hour. An

464

ethanol solution (5 ml) of ethyl pyruvate (465 µl) was added dropwise to the reaction mixture. After stirring at 50° C. for 30 minutes, the mixture was further stirred at 25° C. for 10 hours. The pH of the mixture was adjusted to 11 using an aqueous solution (about 10 ml) of 20% potassium phosphate. The resulting precipitate was collected by filtration, and dried. Thus, 2-[*(E*)-4-imidazol-1-yl-phenylimino]-propionic acid ethyl ester was obtained as a pale yellow powder (1.1 g, 99%).

10

Indole-Based Synthesis Method

Synthesis of 5-imidazol-1-yl-1H-indole-2-carboxylic
acid ethyl ester

15

2-[*(E*)-4-Imidazol-1-yl-phenylimino]-propionic acid ethyl ester (842 mg) was added to an Eaton's reagent (4 ml), and this was stirred at 100° C. for one hour. After adjusting the pH of the reaction mixture to 11 using an aqueous solution (about 10 ml) of 20% potassium phosphate, the mixture was extracted with ethyl acetate (30 ml). The organic layer was washed with an aqueous solution saturated with sodium chloride (20 ml), and the organic layer was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (dichloromethane/methanol). Thus, 5-imidazol-1-yl-1H-indole-2-carboxylic acid ethyl ester was obtained as a yellow amorphous material (370 mg, 47%).

ESI (LC-MS positive mode) m/z 256 [(M+H)⁺]

The compounds of numbers 1386 to 1394 listed in Table 20 were synthesized as described in Step 20.

TABLE 20

Com- ound No.	Structure	Compound name	m/z
1386		4-tert-butyl-1H-indole-2-carboxylic acid ethyl ester	246
1387		5-trifluoromethylsulfonyl- 1H-indole-2-carboxylic acid ethyl ester	290
1388		5-trifluoromethylsulfonyl- 1H-indole-2-carboxylic acid ethyl ester [M - H]	274
1389		5-fluoro-4-trifluoromethyl- 1H-indole-2-carboxylic acid ethyl ester [M - H]	274

465


TABLE 20-continued

Compound No.	Structure	Compound name	m/z
1390		6-tert-butyl-1H-indole-2-carboxylic acid ethyl ester	246
1391		4,6-dimethyl-1H-indole-2-carboxylic acid ethyl ester	218
1392		5-tert-butyl-1H-indole-2-carboxylic acid ethyl ester	246
1393		5-isopropyl-1H-indole-2-carboxylic acid ethyl ester	232
1394		5-phenoxy-1H-indole-2-carboxylic acid ethyl ester	282

Step 21: Synthesis of
1-chloro-2-cyclopropylmethoxy-4-nitro-benzene
(1395)

40 $^1\text{H-NMR}$ (DMSO- D_6) δ : 7.84 (1H, dd, $J=8.4, 2.5$ Hz), 7.81 (1H, d, $J=2.5$ Hz), 7.74 (1H, d, $J=8.4$ Hz), 4.08 (2H, d, $J=7.1$ Hz), 1.33-1.23 (1H, m), 0.63-0.59 (2H, m), 0.41-0.37 (2H, m)


45 Step 22: Synthesis of
4-chloro-3-cyclopropylmethoxy-phenylamine (1396)



Cyclopropylmethyl bromide (2.0 ml, 20 mmol, 2.0 eq.) was added to a mixture solution of 2-chloro-5-nitro-phenol (1.7 g, 10 mmol), potassium carbonate (2.7 g, 20 mmol), and anhydrous acetonitrile (20 ml). This was stirred at 80° C. for eight hours. After cooling it to room temperature, the reaction mixture was filtered through Celite, and washed with ethyl acetate. The filtrate was concentrated under reduced pressure. This yielded crude 1-chloro-2-cyclopropyl-methoxy-4-nitro-benzene as a pale red solid. The crude product was used in subsequent reactions without being purified.

55 1-chloro-2-cyclopropylmethoxy-4-nitro-benzene (2.3 g, 10 mmol) was dissolved in ethanol (30 ml) and water (30 ml), and then sodium dithionite was gradually added thereto. This was stirred at 80° C. for four and half hours. After cooling it to room temperature, an aqueous solution of 5 M hydrochloride (40 ml) was added to the reaction mixture. This was stirred at room temperature for one hour. Then, an aqueous solution (42 ml) of 5 M sodium hydroxide was added, and the solution was alkalized and extracted with ethyl acetate. The extract was washed with water and an aqueous solution saturated with sodium chloride, and dried over anhydrous sodium sulfate. The desiccant was removed by filtration, and concen-

60
65



467

tration was performed. Then, the residue obtained by concentration under reduced pressure was purified by silica gel column chromatography. Thus, 4-chloro-3-cyclopropylmethoxy-phenylamine was obtained as a pale yellow gum-like material (1.4 g).

¹H-NMR (DMSO-D₆) δ: 6.95 (1H, d, J=8.3 Hz), 6.28 (1H, d, J=2.4 Hz), 6.11 (1H, dd, J=8.3, 2.4 Hz), 5.19 (2H, s), 3.76 (2H, d, J=7.1 Hz), 1.24-1.18 (1H, m), 0.59-0.54 (2H, m), 0.35-0.30 (2H, m)

ESI (LC-MS positive mode) m/z 198, 200 [(M+H)⁺]

468

tion was performed. Crude solid 4-bromo-2-iodo-5-trifluoromethyl-phenylamine was obtained by concentration under reduced pressure. The resulting crude product was used in subsequent reactions without being purified.

5 ¹H-NMR (DMSO-D₆) δ: 7.94 (1H, s), 7.15 (1H, s), 5.86 (2H, s)

ESI (LC-MS positive mode) m/z 366, 368 [(M+H)⁺]


The compounds of numbers 1398 to 1402 listed in Table 21 were synthesized as described in Step 23.

TABLE 21

Compound No.	Structure	Compound name	m/z
1398		5-bromo-4-fluoro-2-iodophenylamine	316, 318
1399		4-bromo-5-fluoro-2-iodophenylamine	316, 318
1400		2,2-difluoro-6-iodo-benzo[1,3]dioxol-5-ylamine	300
1401		4-chloro-5-cyclopropylmethoxy-2-iodophenylamine	324, 326
1402		4-bromo-2-iodo-5-methoxyphenylamine	3281, 330

Step 23: Synthesis of
4-bromo-2-iodo-5-trifluoromethyl-phenylamine
(1397)

45




Iodine (1.4 g, 5.5 mmol, 1.1 eq.) was gradually added to a mixture solution of 4-bromo-3-trifluoromethyl aniline (1.2 g, 1.0 mmol), silver sulfate (1.72 g, 5.5 mmol, 1.1 eq.), and anhydrous ethanol (35 ml). This was stirred at room temperature for two and half hours. The reaction mixture was filtered through Celite, and washed with ethyl acetate. The wash solution was washed with aqueous solutions of 10% sodium thiosulfate, saturated sodium bicarbonate, and saturated sodium chloride, and then dried over anhydrous sodium sulfate. The desiccant was removed by filtration, and concentra-

Step 24: Synthesis of N-(4-bromo-2-iodo-5-trifluoromethyl-phenyl)-4-methyl benzenesulfonamide
(1403)

50

55

60



65 4-Bromo-2-iodo-5-trifluoromethyl-phenylamine (366 mg, 1.0 mmol) and p-toluene sulfonyl chloride (286 mg, 1.5 mmol, 1.5 eq.) were dissolved in anhydrous pyridine (2.5 ml). This was stirred at room temperature for 16 hours. An aqueous solution of 1 M sodium hydroxide was added to the reaction mixture, and this was stirred for five minutes. The reaction mixture was diluted with ethyl acetate. The organic

469

layer was isolated, and washed with an aqueous solution of 1 M hydrochloric acid and an aqueous solution saturated with sodium chloride, and dried over anhydrous sodium sulfate. The desiccant was removed by filtration, and concentration was performed. Then, the residue obtained by concentration under reduced pressure was dissolved in tetrahydrofuran (THF) (2.5 mL), and then a tetrahydrofuran (THF) solution of 1 M tetrabutylammonium fluoride was added thereto. This was stirred at room temperature for 17 hours. The reaction mixture was diluted with ethyl acetate. The organic layer was isolated, and washed with water and an aqueous solution saturated with sodium chloride, and then dried over anhydrous sodium sulfate. The desiccant was removed by filtration

470

and concentration was performed. Then, the residue obtained by concentration under reduced pressure was purified by silica gel column chromatography. Thus, N-(4-bromo-2-iodo-5-trifluoromethyl-phenyl)-4-methyl benzenesulfonamide was obtained as a pale brown solid (494 mg, three-step yield of 95%).

¹H-NMR (DMSO-D₆) δ: 10.10 (1H, s), 8.34 (1H, s), 7.58 (2H, d, J=8.2 Hz), 7.39 (2H, d, J=8.2 Hz), 7.27 (1H, s), 2.38 (3H, s)

ESI (LC-MS positive mode) m/z 520, 522 [(M+H)⁺]

The compounds of numbers 1404 to 1408 listed in Table 22 were synthesized as described in Step 24.

TABLE 22

Compound No.	Structure	Compound name	m/z
1404		N-(5-bromo-4-fluoro-2-iodophenyl)-4-methylbenzenesulfonamide	470, 472
1405		N-(4-bromo-5-fluoro-2-iodophenyl)-4-methylbenzenesulfonamide	Not observed
1406		N-(2,2-difluoro-6-iodobenzodioxol-5-yl)-4-methylbenzenesulfonamide	454

471

TABLE 22-continued

472

Compound No.	Structure	Compound name	m/z
1407		N-(4-chloro-5-cyclopropylmethoxy-2-iodophenyl)-4-methylbenzenesulfonamide	478, 480
1408		N-(4-bromo-2-iodo-5-methoxy-phenyl)-4-methylbenzenesulfonamide	482, 484

Step 25: Synthesis of 5-bromo-1-(toluene-4-sulfonyl)-6-trifluoromethyl-1H-indole-2-carboxylic acid ethyl ester (1409)

drous tetrahydrofuran (THF) solution (3.2 ml) containing N-(4-bromo-2-iodo-5-trifluoromethyl-phenyl)-4-methylbenzenesulfonamide (208 mg, 0.4 mmol) and zinc bromide (270 mg, 1.2 mmol). Then, the mixture was evacuated, and backfilled with argon. This was stirred at 80° C. for 13 hours. After cooling it to room temperature, the reaction mixture was filtered through Celite, and washed with ethyl acetate. The wash solution was washed with an aqueous solution saturated with sodium bicarbonate and an aqueous solution saturated with sodium chloride, and dried over anhydrous sodium sulfate. The desiccant was removed by filtration, and concentration was performed. Then, the residue obtained by concentration under reduced pressure was purified by silica gel column chromatography. Thus, 5-bromo-1-(toluene-4-sulfonyl)-6-trifluoromethyl-1H-indole-2-carboxylic acid ethyl ester was obtained as a pale brown solid (195 mg, 50%).

¹H-NMR (DMSO-D₆) δ: 8.37 (1H, s), 8.29 (1H, s), 7.89 (2H, d, J=8.2 Hz), 7.47 (2H, d, J=8.2 Hz), 7.43 (1H, s), 4.36 (2H, q, J=7.1 Hz), 2.38 (3H, s), 1.30 (3H, t, J=7.1 Hz)

ESI (LC-MS positive mode) m/z 490, 492 [(M+H)⁺]

N,N-diisopropylethyl amine (0.42 ml, 2.4 mmol), ethyl propionate (0.12 ml, 1.2 mmol), and tetrakis(triphenylphosphine)palladium (46 mg, 0.04 mmol) were added to an anhy-

The compounds of numbers 1410 to 1414 listed in Table 23 were synthesized as described in Step 25.





TABLE 23

Compound No.	Structure	Compound name	m/z
1410		6-bromo-5-fluoro-1-(toluene-4-sulfonyl)-1H-indole-2-carboxylic acid ethyl ester	440, 442
1411		5-bromo-6-fluoro-1-(toluene-4-sulfonyl)-1H-indole-2-carboxylic acid ethyl ester	Not observed
1412		5-bromo-1-(toluene-4-sulfonyl)-6-trifluoromethyl-1H-indole-2-carboxylic acid ethyl ester	490, 492
1413		2,2-difluoro-5-(toluene-4-sulfonyl)-5H-[1,3]dioxolo[4,5-f]indole-6-carboxylic acid ethyl ester	424


475

TABLE 23-continued

Compound No.	Structure	Compound name	m/z
1414		5-chloro-6-(cyclopropylmethoxy)-1-(toluene-4-sulfonyl)-1H-indole-2-carboxylic acid ethyl ester	448, 450


Step 26: Synthesis of N-benzhydrylidene-N'-(3,5-di-tert-butyl-phenyl)-hydrazine (1415)

25



Step 27: Synthesis of 4,6-di-tert-butyl-1H-indole-2-carboxylic acid ethyl ester (1416)

4



Palladium acetate (8.4 mg, 0.037 mmol) and 2-dicyclohexylphosphino-2',4',6'-tri-i-propyl-1,1'-biphenyl (X-PHOS) (35.6 mg, 0.074 mmol) were dissolved in tert-amyl alcohol (10 μ l, 0.093 mmol) and anhydrous ethylene glycol dimethyl ether (0.25 ml). The mixture was heated and stirred at 60° C. for five minutes under a nitrogen atmosphere to prepare a catalyst. In a separate reaction container under a nitrogen atmosphere, 1-bromo-3,5-di-t-butyl benzene (501 mg, 1.9 mmol), lithium bis(trimethylsilyl) amide (475 mg, 2.8 mmol), and benzophenone hydrazone (401 mg, 2.0 mmol) were dissolved in anhydrous ethylene glycol dimethyl ether (2.5 ml). Then, a solution containing the prepared catalyst was added thereto. After deaeration, this was heated and stirred at 90° C. for two hours under a nitrogen atmosphere. The reaction mixture was cooled to room temperature, and then concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (hexane/ethyl acetate=100/5). Thus, N-benzhydrylidene-N'-(3,5-di-tert-butyl-phenyl)-hydrazine was obtained as a yellow amorphous material (699 mg, 97.7%).

¹H-NMR (DMSO-D₆) δ : 8.72 (1.0H, s), 7.63-7.53 (3.0H, m), 7.42-7.25 (7.0H, m), 7.11 (2.0H, s), 6.83 (1.0H, s), 1.26 (18.0H, s)

ESI (LC-MS positive mode) m/z 385 [(M+H)⁺]

30

40

45

50

55

60

65

N-Benzhydrylidene-N'-(3,5-di-tert-butyl-phenyl)-hydrazine (617 mg, 1.6 mmol) was dissolved in ethanol (12 ml). Then, ethyl pyruvate (212 μ l, 1.9 mmol) and p-toluene sulfonic acid monohydrate (914 mg, 4.8 mmol) were added thereto. This was heated and stirred at 150° C. by microwave under a nitrogen atmosphere for one hour. After cooling it to room temperature, the reaction mixture was combined with water and an aqueous solution saturated with sodium bicarbonate. The product was extracted into ethyl acetate. The organic layer was isolated, and washed with an aqueous solution saturated with sodium chloride, and dried over magnesium sulfate. The desiccant was removed by filtration, and concentration was performed. Then, the residue obtained by concentration under reduced pressure was purified by silica gel column chromatography (hexane/ethyl acetate=100/5). Thus, 4,6-di-tert-butyl-1H-indole-2-carboxylic acid ethyl ester was obtained as a brown solid (268 mg, 56%).


¹H-NMR (DMSO-D₆) δ : 11.76 (1.0H, brs), 7.27 (1.0H, s), 7.22-7.22 (1.0H, brm), 7.04-7.03 (1.0H, brm), 4.33 (2.0H, q, J=7.2 Hz), 1.44 (9.0H, s), 1.36-1.32 (12.0H, m)

ESI (LC-MS positive mode) m/z 302 [(M+H)⁺]

476

477

Step 28: Synthesis of 6-(5-fluoro-pyridin-2-yl)-1-(toluene-4-sulfonyl)-1H-indole-2-carboxylic acid methyl ester (1417)



6-Bromo-1-(toluene-4-sulfonyl)-1H-indole-2-carboxylic acid methyl ester (202.0 mg, 0.495 mmol), dichlorobis(triphenylphosphine)palladium (II) (35.6 mg, 0.051 mmol), bis (pinacol)borane (189.3 mg, 0.745 mmol), potassium acetate (147.3 mg, 1.51 mmol), and dioxane (1.6 ml) were

478

mixed. The air was replaced three times with argon under reduced pressure. The mixture was microwaved at 120° C. for 30 minutes. Dichlorobis(triphenylphosphine)palladium (II) (35.6 mg, 0.051 mmol) and 2-bromo-5-fluoro-pyridine (206.9 mg, 1.48 mmol) were added to the reaction mixture. After deaeration, the air was replaced three times with argon. This was heated and stirred at 100° C. for three hours. The reaction mixture was extracted with ethyl acetate, and the extract was dried over anhydrous sodium sulfate. The desiccant was removed by filtration, and concentration was performed. Then, the residue obtained by concentration under reduced pressure was purified by amino gel column chromatography (n-hexane/ethyl acetate=7/100 to 63/100). Thus, 6-(5-fluoro-pyridin-2-yl)-1-(toluene-4-sulfonyl)-1H-indole-2-carboxylic acid methyl ester was obtained as a pale yellow amorphous material (150.5 mg, yield of 72%).

¹H-NMR (CDCl₃) δ: 8.70 (1H, s), 8.59 (1H, d, J=2.7 Hz), 7.93 (3H, d, J=8.2 Hz), 7.83 (1H, dd, J=8.8, 3.8 Hz), 7.65 (1H, d, J=8.2 Hz), 7.53 (1H, td, J=8.4, 2.9 Hz), 7.29-7.25 (2H, m), 7.19 (1H, s), 3.95 (3H, s), 2.37 (3H, s)
ESI (LC-MS positive mode) m/z 425 [(M+H)⁺]

The compounds of numbers 1418 to 1427 listed in Table 24 were synthesized as described in Step 28.

TABLE 24

Com- ound No.	Structure	Compound name	m/z
1418		6-pyridin-2-yl-1-(toluene-4-sulfonyl)-1H-indole-2-carboxylic acid methyl ester	407
1419		6-pyridazin-3-yl-1-(toluene-4-sulfonyl)-1H-indole-2-carboxylic acid methyl ester	408
1420		1-(toluene-4-sulfonyl)-6-(5-trifluoromethyl-pyridin-2-yl)-1H-indole-2-carboxylic acid methyl ester	475

TABLE 24-continued

Compound No.	Structure	Compound name	m/z
1421		1-(toluene-4-sulfonyl)-6-(6-trifluoromethyl-pyridin-2-yl)-1H-indole-2-carboxylic acid methyl ester	475
1422		6-(5-chloro-pyridin-2-yl)-1-(toluene-4-sulfonyl)-1H-indole-2-carboxylic acid methyl ester	441
1423		1-(toluene-4-sulfonyl)-6-(3-trifluoromethyl-pyridin-2-yl)-1H-indole-2-carboxylic acid methyl ester	475
1424		1-(toluene-4-sulfonyl)-6-(4-trifluoromethyl-pyridin-2-yl)-1H-indole-2-carboxylic acid methyl ester	475
1425		6-(3-chloro-pyridin-2-yl)-1-(toluene-4-sulfonyl)-1H-indole-2-carboxylic acid methyl ester	441, 443

TABLE 24-continued


Compound No.	Structure	Compound name	m/z
1426		6-(3-fluoro-pyridin-2-yl)-1-(toluene-4-sulfonyl)-1H-indole-2-carboxylic acid methyl ester	425
1427		6-(6-morpholin-4-yl-pyridazin-3-yl)-1-(toluene-4-sulfonyl)-1H-indole-2-carboxylic acid methyl ester	493

Step 29: Synthesis of [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(6-methoxy-pyridin-3-yl)-1-(toluene-4-sulfonyl)-1H-indol-2-yl]methanone (1428)

dichlorobis(triphenylphosphine)palladium (II) (14 mg, 0.020 mmol), 2-methoxy-5-pyridine boronic acid (39 mg, 0.255 mmol), and an aqueous solution of 2 M sodium bicarbonate (0.255 mL, 0.51 mmol) was stirred at 140° C. for six minutes in a microwave reactor. The reaction mixture was filtered through Celite, and washed with ethyl acetate and then with methanol. The filtrate was dried over anhydrous sodium sulfate. The desiccant was removed by filtration and concentration was performed. The residue obtained was purified by amino gel chromatography (dichloromethane/methanol=99/1 to 92/8). Thus, [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(6-methoxy-pyridin-3-yl)-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone was obtained as a pale yellow solid (54 mg, 85%).

⁵⁵ ¹H-NMR (DMSO-D₆) δ: 12.50 (1H, s), 8.50 (1H, d, J=2.4 Hz), 8.08-8.04 (4H, m), 7.94 (1H, d, J=1.8 Hz), 7.77 (1H, s), 7.74 (1H, dd, J=9.1, 1.8 Hz), 7.63-7.61 (2H, m), 7.46-7.40 (2H, m), 7.30 (1H, dd, J=8.5, 1.8 Hz), 7.25 (1H, s), 7.06 (2H, s), 6.93 (1H, d, J=8.5 Hz), 3.90 (3H, s), 2.54 (3H, s), 2.37 (3H, s)

ESI (LC-MS positive mode) m/z 618 [(M+H)⁺]



A mixture of dioxane (0.6 ml), [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-bromo-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone (60 mg, 0.102 mmol),

⁶⁵ The compounds of numbers 1429 to 1462, and 1580 to 1590 listed in Table 25 were synthesized as described in Step 29.

TABLE 25

Com- ound No.	Structure	Compound name	m/z
1429		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(morpholin-4-ylpyridin-3-yl)-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	673
1430		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-pyridin-3-yl)-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	588
1431		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(morpholin-4-ylpyridin-3-yl)-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	673
1432		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-pyridin-3-yl-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	588

TABLE 25-continued





Compound No.	Structure	Compound name	m/z
1433		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(6-piperadin-1-yl-pyridin-3-yl)-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	672
1434		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(6-hydroxy-pyridin-3-yl)-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	604
1435		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(3,4,5,6-tetrahydro-2H-[1,2']bipyridin-5'-yl)-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	671
1436		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(6-piperadin-1-yl-pyridin-3-yl)-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	672

TABLE 25-continued

Com- ound No.	Structure	Compound name	m/z
1437		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-[2-(4-methyl-piperazin-1-yl)-pyridin-4-yl]-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	686
1438		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-pyridin-4-yl-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	588
1439		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(1-methyl-1H-pyrazol-4-yl)-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	591

TABLE 25-continued

Com- ound No.	Structure	Compound name	m/z
1440		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(5-methoxy-pyridin-3-yl)-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	618
1441		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(2-methoxy-pyridin-3-yl)-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	618
1442		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(5-methanesulfonyl-pyridin-3-yl)-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	666

TABLE 25-continued

Com- ound No.	Structure	Compound name	m/z
1443		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(4-methyl-pyridin-2-yl)-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	602
1444		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(4-morpholin-4-yl-phenyl)-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	672
1445		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(2-methoxy-phenyl)-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	617

TABLE 25-continued

Com- ound No.	Structure	Compound name	m/z
1446		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-phenyl-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	587
1447		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(2-fluoro-phenyl)-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	605
1448		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1-(toluene-4-sulfonyl)-5-(2-trifluoromethyl-phenyl)-1H-indol-2-yl]-methanone	655

TABLE 25-continued

Com- ound No.	Structure	Compound name	m/z
1449		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(3-fluoro-phenyl)-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	605
1450		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1-(toluene-4-sulfonyl)-5-(3-trifluoromethyl-phenyl)-1H-indol-2-yl]-methanone	655
1451		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(2-fluoro-phenyl)-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	605

TABLE 25-continued

Com- ound No.	Structure	Compound name	m/z
1452		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(3-fluoro-phenyl)-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	605
1453		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(4-fluoro-phenyl)-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	605
1454		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(2-chloro-phenyl)-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	621, 623

TABLE 25-continued

Com- ound No.	Structure	Compound name	m/z
1455		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(3-chlorophenyl)-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	621, 623
1456		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(4-chlorophenyl)-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	621, 623
1457		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1-(toluene-4-sulfonyl)-6-(2-trifluoromethyl-phenyl)-1H-indol-2-yl]-methanone	655

TABLE 25-continued

Com- ound No.	Structure	Compound name	m/z
1458		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1-(toluene-4-sulfonyl)-6-(3-trifluoromethylphenyl)-1H-indol-2-yl]-methanone	655
1459		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1-(toluene-4-sulfonyl)-6-(4-trifluoromethyl-phenyl)-1H-indol-2-yl]-methanone	655
1460		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1-(toluene-4-sulfonyl)-5-(4-trifluoromethyl-phenyl)-1H-indol-2-yl]-methanone	655

TABLE 25-continued

Com- ound No.	Structure	Compound name	m/z
1461		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(2,4-difluoro-phenyl)-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	623
1462		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(3-chloro-4-fluoro-phenyl)-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	640, 642
1580		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(3-chloropyridin-4-yl)-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	622

TABLE 25-continued

Com- ound No.	Structure	Compound name	m/z
1581		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(6-methylpyridin-3-yl)-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	602
1582		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(5-fluoropyridin-3-yl)-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	606
1583		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1-(toluene-4-sulfonyl)-6-(2-trifluoromethyl-pyridin-3-yl)-1H-indol-2-yl]-methanone	656

TABLE 25-continued


Compound No.	Structure	Compound name	m/z
1584		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(5-chloro-2-methoxy-pyridin-3-yl)-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	652
1585		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(5-chloro-pyridin-3-yl)-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	622
1586		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-thiophen-3-yl-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	593
1587		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(4-chloropyridin-3-yl)-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	622

TABLE 25-continued

Com- ound No.	Structure	Compound name	m/z
1588		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-thiophen-2-yl-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	593
1589		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(3-fluoro-pyridin-4-yl)-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone	606
1590		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1-(toluene-4-sulfonyl)-6-(2-trifluoromethyl-pyridin-4-yl)-1H-indol-2-yl]-methanone	656

511


Step 30: Synthesis of [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-pyridazin-4-yl-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone (1463)



A mixture of [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-iodo-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone (194.9 mg, 0.306 mmol), [1,1'-bis(diphenylphosphino)ferrocene]dichloro-palladium (II)/²⁵ dichloromethane adduct (14.4 mg, 0.015 mmol) bis(pinacol) borane (100.9 mg, 0.397 mmol), potassium acetate (132.3 mg, 1.35 mmol), and anhydrous dimethylsulfoxide (DMSO) (1.5 ml) was deaerated. Then, the air was replaced three times with argon, and was heated and stirred at 110° C. for six hours. Then, the reaction mixture was extracted with ethyl acetate. The extract was dried over anhydrous sodium sulfate. The desiccant was removed by filtration, and concentration was performed. Then, the residue obtained by concentration under reduced pressure was subjected to silica gel column chromatography (dichloromethane/methanol=15/1). The resulting crude product was mixed with 4-bromo-pyridazine (78.0 mg, 0.491 mol), dichlorobis(triphenylphosphine)palladium (II) (17.2 mg, 0.025 mmol), an aqueous solution of 2 M sodium bicarbonate (0.325 mmol), and dioxane (0.4 ml). After deaeration, the air was replaced three times with argon, and this was microwaved at 150° C. for five minutes. Then, the reaction mixture was extracted with ethyl acetate. The extract was dried over anhydrous sodium sulfate. The desiccant was removed by filtration, and concentration was performed. Then, the residue obtained by concentration under reduced pressure was purified by silica gel column chromatography (dichloromethane/methanol=1% to 12%). Thus, [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-pyridazin-4-yl-1-(toluene-4-sulfonyl)-1H-indol-2-yl]-methanone was obtained as a pale yellow amorphous material (20.0 mg, yield of 11%).

ESI (LC-MS positive mode) m/z 589 [(M+H)⁺]


Step 31: Synthesis of (1-benzenesulfonyl-1H-indol-6-yl) methanol (1464)

**512**

A predetermined amount of lithium aluminum hydride (167 mg, 4.42 mmol) was placed into a reaction container, and anhydrous tetrahydrofuran (THF) (15 ml) was added thereto, and this was cooled to 0° C. An anhydrous tetrahydrofuran (THF) solution (5 ml) of 1-benzenesulfonyl-1H-indole-6-carboxylic acid methyl ester (930 mg, 2.95 mmol) was added to the mixture. This was stirred at 0° C. for 30 minutes. An aqueous solution saturated with ammonium chloride (1 ml) was added to the mixture. After Celite filtration, the Celite was washed with dichloromethane. The filtrate was dried over anhydrous sodium sulfate. The desiccant was removed by filtration, and concentration was performed. Then, by concentration under reduced pressure, (1-benzenesulfonyl-1H-indol-6-yl)-methanol was obtained as an oily brown material (859 mg, 100%).

¹⁵ ¹H-NMR (DMSO-D₆) δ: 7.96-7.92 (3H, m), 7.74 (1H, d, J=3.7 Hz), 7.68-7.67 (1H, m), 7.60-7.55 (2H, m), 7.52 (1H, d, J=8.0 Hz), 7.19-7.17 (1H, m), 6.80 (1H, dd, J=3.7, 0.8 Hz), 5.30 (1H, t, J=5.7 Hz), 4.59 (2H, d, J=5.7 Hz)
ESI (LC-MS positive mode) m/z 288 [(M+H)⁺]


Step 32: Synthesis of 1-benzenesulfonyl-6-(tert-butyl-diphenyl-silyloxymethyl)-1H-indole (1465)



Predetermined amounts of 1-benzenesulfonyl-1H-indol-6-yl-methanol (859 mg, 2.99 mmol), tert-butyl diphenyl chlorosilane (2.3 ml, 8.97 mmol), and imidazole (1.2 g, 17.9 mmol) were placed into a reaction container, and dimethylformamide (30 ml) was added thereto. This was stirred at room temperature for 20 hours. The reaction mixture was diluted with ethyl acetate (60 ml). This was washed twice with water, and dried over anhydrous sodium sulfate. The desiccant was removed by filtration, and concentration was performed. The resulting crude product was used in subsequent reactions.

ESI (LC-MS positive mode) m/z 526 [(M+H)⁺]

Step 33: Synthesis of 1-benzenesulfonyl-6-(tert-butyl-diphenyl-silyloxy methyl)-1H-indole-2-carboxylic acid methyl ester (1466)




A tetrahydrofuran (THF) solution of lithium diisopropyl amide (LDA) was prepared by adding a hexane solution of 1.0 M n-butylium (2.8 ml, 4.49 mmol) dropwise to a pre-cooled (0° C.) anhydrous tetrahydrofuran (THF) solution (5 ml) of N,N-diisopropyl amine (0.64 ml, 4.49 mmol).

513

An anhydrous tetrahydrofuran (THF) solution (20 ml) of crude 1-benzenesulfonyl-6-(tert-butyl-diphenyl-silyloxy)methyl)-1H-indole was cooled to -78°C., and a prepared tetrahydrofuran (THF) solution of lithium diisopropyl amide (LDA) was added thereto. This was stirred at -78°C. for 30 minutes. Methyl chloroformate (0.43 ml, 5.98 mmol) was added thereto, and this was stirred at -78°C. for 30 minutes. An aqueous solution saturated with ammonium chloride was added to the reaction mixture, and this was warmed to room temperature. After ethyl acetate extraction, the organic layer was dried over anhydrous sodium sulfate. The desiccant was removed by filtration and concentration was performed. Then, the residue obtained by concentration under reduced pressure was purified by silica gel column chromatography (hexane/ethyl acetate=98/2 to 4/1). Thus, 1-benzenesulfonyl-6-(tert-butyl-diphenyl-silyloxy)methyl)-1H-indole-2-carboxylic acid methyl ester was obtained as a brown amorphous material (882 mg, 51%).

ESI (LC-MS positive mode) m/z 584 [(M+H)⁺]

Step 34: Synthesis of 5-(1-tert-butoxycarbonyl-1,2,3,6-tetrahydro-pyridin-4-yl)-1-(toluene-4-sulfonyl)-1H-indole-2-carboxylic acid ethyl ester (1467)

**514**

5-Bromo-1-(toluene-4-sulfonyl)-1H-indole-2-carboxylic acid ethyl ester (844 mg, 2.0 mmol), 4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester (742 mg, 2.4 mmol), potassium phosphate (848 mg, 4.0 mmol), and tetrakis(triphenylphosphine) palladium (116 mg, 0.1 mmol) were placed into a flask. After deaeration, the air was replaced with nitrogen. Anhydrous dioxane (16 ml) and water (4 ml) were added to the flask, and this was stirred at 80°C. for 15 hours. After cooling it to room temperature, the reaction mixture was filtered through Celite, and then washed with ethyl acetate. The filtrate was concentrated, and the residue obtained by concentration under reduced pressure was purified by silica gel column chromatography. Thus, 5-(1-tert-butoxycarbonyl-1,2,3,6-tetrahydro-pyridin-4-yl)-1-(toluene-4-sulfonyl)-1H-indole-2-carboxylic acid ethyl ester was obtained as a colorless amorphous material (1.0 g, 97.2%).

¹H-NMR (DMSO-D₆) δ: 7.96 (1H, d, J=9.1 Hz), 7.84 (2H, d, J=8.2 Hz), 7.68 (1H, d, J=1.8 Hz), 7.60 (1H, dd, J=9.1, 1.8 Hz), 7.41 (2H, d, J=8.2 Hz), 7.34 (1H, s), 6.17 (1H, s), 4.34 (2H, q, J=7.0 Hz), 4.02-3.98 (2H, m), 3.57-3.51 (2H, m), 2.51-2.45 (1H, m), 2.34 (3H, s), 1.42 (9H, s), 1.32 (3H, t, J=7.0 Hz)

ESI (LC-MS positive mode) m/z 525 [(M+H)⁺]

The compounds of numbers 1468 and 1469 listed in Table 26 were synthesized as described in Step 34.


TABLE 26

Compound No.	Structure	Compound name	m/z
1468		5-(1-tert-butoxycarbonyl-1,2,3,6-tetrahydro-pyridin-4-yl)-6-fluoro-1-(toluene-4-sulfonyl)-1H-indole-2-carboxylic acid ethyl ester	543

TABLE 26-continued

Compound No.	Structure	Compound name	m/z
1469		5-(1-tert-butoxycarbonyl-1,2,3,6-tetrahydro-pyridin-4-yl)-1-(toluene-4-sulfonyl)-6-trifluoromethyl-1H-indole-2-carboxylic acid ethyl ester	593

Step 35: Synthesis of 5-(1-tert-butoxycarbonyl-piperidin-4-yl)-1-(toluene-4-sulfonyl)-1H-indole-2-carboxylic acid ethyl ester (1470)



A mixture of 5-(1-tert-butoxycarbonyl-1,2,3,6-tetrahydro-pyridin-4-yl)-1-(toluene-4-sulfonyl)-1H-indole-2-carboxylic acid ethyl ester (495 mg, 0.9 mmol), 5% palladium carbon (100 mg), and methanol (20 ml) was stirred under a hydrogen atmosphere for 13 hours. The reaction mixture was filtered through Celite, and washed with ethyl acetate, and the filtrate was concentrated. The residue obtained by concentration under reduced pressure was purified by silica gel column chromatography. Thus, 5-(1-tert-butoxycarbonyl-piperidin-4-yl)-1-(toluene-4-sulfonyl)-1H-indole-2-carboxylic acid ethyl ester was obtained as a colorless amorphous material (315.9 mg, 64%).

¹H-NMR (DMSO-D₆) δ: 7.92 (1H, d, J=8.8 Hz), 7.87 (2H, d, J=7.9 Hz), 7.53 (1H, d, J=1.5 Hz), 7.42 (2H, d, J=7.9 Hz), 7.39 (1H, dd, J=8.8, 1.5 Hz), 7.30 (1H, s), 4.33 (2H, q, J=7.0 Hz), 4.12-4.00 (2H, m), 2.85-2.70 (3H, m), 2.35 (3H, s), 1.78-1.70 (2H, m), 1.54-1.44 (2H, m), 1.41 (9H, s), 1.31 (3H, t, J=7.0 Hz)

ESI (LC-MS positive mode) m/z 527 [(M+H)⁺]

The compounds of numbers 1471 and 1472 listed in Table 27 were synthesized as described in Step 35.


TABLE 27

Compound No.	Structure	Compound name	m/z
1471		5-(1-tert-butoxycarbonyl-piperidin-4-yl)-6-fluoro-1-(toluene-4-sulfonyl)-1H-indole-2-carboxylic acid ethyl ester	489 [M-tert-Bu]

TABLE 27-continued

Compound No.	Structure	Compound name	m/z
1472		5-(1-tert-butoxycarbonyl-piperidin-4-yl)-1-(toluene-4-sulfonyl)-6-trifluoromethyl-1H-indole-2-carboxylic acid ethyl ester	595

Step 36: Synthesis of 5-piperidin-4-yl-1-(toluene-4-sulfonyl)-1H-indole-2-carboxylic acid ethyl ester (1473)



25 5-(1-tert-Butoxycarbonyl-piperidin-4-yl)-1-(toluene-4-sulfonyl)-1H-indole-2-carboxylic acid ethyl ester (362 mg, 0.687 mmol) was dissolved in a mixture solution of ethyl acetate (4 ml) and 4 M hydrochloric acid/ethyl acetate (8 ml). This was stirred at room temperature under a nitrogen atmosphere for 1.5 hours. The reaction mixture was concentrated under reduced pressure. Thus, 5-piperidin-4-yl-1-(toluene-4-sulfonyl)-1H-indole-2-carboxylic acid ethyl ester hydrochloride was obtained as a colorless amorphous material (332 mg).

30 35 ¹H-NMR (DMSO-D₆) δ: 8.78 (1H, brs), 7.98 (1H, d, J=8.5 Hz), 7.90 (2H, d, J=8.5 Hz), 7.51 (1H, s), 7.44 (2H, d, J=8.5 Hz), 7.38-7.36 (2H, m), 4.34 (2H, q, J=7.1 Hz), 3.02-2.90 (4H, m), 2.36 (3H, s), 1.95-1.78 (5H, m), 1.31 (3H, t, J=7.1 Hz)

40 ESI (LC-MS positive mode) m/z 427 [(M+H)⁺]

The compounds of numbers 1474 and 1475 listed in Table 28 were synthesized as described in Step 36.

TABLE 28

Compound No.	Structure	Compound name	m/z
1474		6-fluoro-5-piperidin-4-yl-1-(toluene-4-sulfonyl)-1H-indole-2-carboxylic acid ethyl ester	445


519

520

TABLE 28-continued

Compound No.	Structure	Compound name	m/z
1475		5-piperidin-4-yl-1-(toluene-4-sulfonyl)-6-trifluoromethyl-1H-indole-2-carboxylic acid ethyl ester	495

Step 37: Synthesis of 5-(1-isopropyl-piperidin-4-yl)-1-(toluene-4-sulfonyl)-1H-indole-2-carboxylic acid ethyl ester (1476)



A mixture of 5-piperidin-4-yl-1-(toluene-4-sulfonyl)-1H-indole-2-carboxylic acid ethyl ester hydrochloride (253 mg, 0.592 mmol) in dichloroethane (4 ml), triethylamine (0.17 ml, 1.18 mmol), acetone (1.44 ml, 19.6 mmol), acetic acid

(0.28 ml, 4.89 mmol), and sodium triacetoxyborohydride (318 mg, 1.50 mmol) was stirred at room temperature for 14.5 hours. The pH of the reaction mixture was adjusted to 9 (basic) using an aqueous solution saturated with sodium bicarbonate. The mixture was extracted with ethyl acetate. The extract was washed with an aqueous solution saturated with sodium chloride, and then dried over anhydrous sodium sulfate. The desiccant was removed by filtration, and concentration was performed. The resulting residue was purified by amino gel column chromatography (hexane/ethyl acetate=92/8 to 35/65). Thus, 5-(1-isopropyl-piperidin-4-yl)-1-(toluene-4-sulfonyl)-1H-indole-2-carboxylic acid ethyl ester was obtained as a colorless gum-like material (191 mg, 69%).

¹H-NMR (DMSO-D₆) δ: 7.91 (1H, d, J=8.5 Hz), 7.87 (2H, d, J=8.5 Hz), 7.52 (1H, d, J=1.8 Hz), 7.42 (2H, d, J=8.5 Hz), 7.39 (1H, dd, J=9.2, 1.8 Hz), 7.31 (1H, s), 4.34 (2H, q, J=7.1 Hz), 2.87 (2H, d, J=11.6 Hz), 2.74-2.67 (1H, m), 2.56-2.53 (1H, m), 2.35 (3H, s), 2.21 (2H, dd, J=11.6, 5.8 Hz), 1.77-1.74 (2H, m), 1.63-1.57 (2H, m), 1.31 (3H, t, J=7.1 Hz), 0.98 (6H, d, J=6.7 Hz)

ESI (LC-MS positive mode) m/z 469 [(M+H)⁺]

The compounds of numbers 1477 to 1480 listed in Table 29 were synthesized as described in Step 37.

TABLE 29


Compound No.	Structure	Compound name	m/z
1477		6-fluoro-5-(1-isopropyl-piperidin-4-yl)-1-(toluene-4-sulfonyl)-1H-indole-2-carboxylic acid ethyl ester	487

TABLE 29-continued

Com- ound No.	Structure	Compound name	m/z
1478		5-(1-cyclopentyl-piperidin-4-yl)-1-(toluene-4-sulfonyl)-1H-indole-2-carboxylic acid ethyl ester	495
1479		5-(1-cyclohexyl-piperidin-4-yl)-1-(toluene-4-sulfonyl)-1H-indole-2-carboxylic acid ethyl ester	509
1480		5-(1-isopropyl-piperidin-4-yl)-1-(toluene-4-sulfonyl)-6-trifluoromethyl-1H-indole-2-carboxylic acid ethyl ester	537

523

Step 38: Synthesis of 6-(1-methyl-piperidin-4-yl)-1-(toluene-4-sulfonyl)-1H-indole (1481)



Preparation of Zinc Reagent:

An anhydrous tetrahydrofuran (THF) solution (3.5 ml) of 4-chloro-1-methyl-piperidine (8.56 mmol, 1.1 ml) was added at 80° C. to a suspension (0.5 ml) of magnesium (234 mg, 9.6 mmol) in anhydrous tetrahydrofuran (THF). This was stirred for one hour. After cooling it to room temperature, the reaction mixture was added dropwise to a mixed solution of zinc bromide (1.1 g, 4.8 mmol) in anhydrous tetrahydrofuran (THF) (2.0 ml) and anhydrous 1-methyl-2-pyrrolidinone (0.6 ml). This was stirred for 30 minutes.

524

Coupling Reaction:

6-Bromo-1-(toluene-4-sulfonyl)-1H-indole (340 mg, 0.97 mmol), Tris(dibenzylideneacetone)dipalladium (0) (23 mg, 0.025 mmol), and (3-diethoxyphosphinothioylsulfanyl-1,4-dioxan-2-yl)sulfanyl-diethoxy-sulfanylidene-phosphorane (Ruphos) (47 mg, 0.1 mmol) were placed into a reaction container. After deaeration, the air was replaced with nitrogen. Anhydrous tetrahydrofuran (THF) (5.0 ml) and a prepared zinc reagent suspension were added thereto, and this was stirred at 70° C. for 17 hours. After cooling it to room temperature, the reaction mixture was alkalized with an aqueous solution saturated with sodium bicarbonate. The precipitated solid was removed by filtration. The filtrate was extracted with ethyl acetate. The extract was washed with water and an aqueous solution saturated with sodium chloride, and dried over anhydrous sodium sulfate. The desiccant was removed by filtration and concentration was performed. The residue obtained by concentration under reduced pressure was purified by silica gel column chromatography. Thus, 6-(1-methyl-piperidin-4-yl)-1-(toluene-4-sulfonyl)-1H-indole was obtained as a wax-like solid (293.7 mg, 82%).

¹H-NMR (DMSO-D₆) δ: 7.83 (2H, d, J=8.2 Hz), 7.75 (1H, d, J=1.5 Hz), 7.71 (1H, d, J=3.7 Hz), 7.48 (1H, d, J=8.1 Hz), 7.38 (2H, d, J=8.2 Hz), 7.14 (1H, dd, J=8.1, 1.5 Hz), 6.76 (1H, d, J=3.7 Hz), 2.89-2.87 (2H, m), 2.61-2.52 (1H, m), 2.31 (3H, s), 2.21 (3H, s), 1.99 (2H, td, J=11.4, 5.7 Hz), 1.76-1.62 (4H, m)

ESI (LC-MS positive mode) m/z 369 [(M+H)⁺]


The compounds of numbers 1482 and 1483 listed in Table 30 were synthesized as described in Step 38.

TABLE 30

Com- ound No.	Structure	Compound name	m/z
1482		6-fluoro-5-(1-methyl-piperidin-4-yl)-1-(toluene-4-sulfonyl)-1H-indole-2-carboxylic acid ethyl ester	459
1483		5-(1-methyl-piperidin-4-yl)-1-(toluene-4-sulfonyl)-1H-indole-2-carboxylic acid ethyl ester	441

525

Step 40: Synthesis of 4-chloro-1-(toluene-4-sulfonyl)-1H-indole-2-carboxylic acid methyl ester
(1484)

**526**

A lithium diisopropyl amide solution was prepared by adding, at -78°C., a hexane solution of 1.0 M n-butyl lithium to an anhydrous tetrahydrofuran (THF) solution (1.5 ml) of diisopropyl amine (370 µl). The prepared solution was added at -78°C. to a tetrahydrofuran (THF) solution (6 ml) of 4-chloro-1-(toluene-4-sulfonyl)-1H-indole. This was stirred for 15 minutes. After adding methyl chloroformate (169 µl) thereto, the reaction mixture was stirred at -78°C. for 15 minutes, and then an aqueous solution (4 ml) of 1 M hydrochloric acid was added thereto at -78°C. After warming it to room temperature, the reaction mixture was extracted with ethyl acetate (10 ml). The organic layer was washed with an aqueous solution saturated with sodium chloride, and the organic layer was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (hexane/ethyl acetate). Thus, 4-chloro-1-(toluene-4-sulfonyl)-1H-indole-2-carboxylic acid methyl ester was obtained as a colorless solid (591 mg, 82%).

ESI (LC-MS positive mode) m/z 364, 366 [(M+H)⁺]

The compounds of numbers 1485 to 1490 listed in Table 31 were synthesized as described in Step 39.


TABLE 31

Com- ound No.	Structure	Compound name	m/z
1485		3-fluoro-1-(toluene-4-sulfonyl)-1H-indole-2-carboxylic acid methyl ester	348
1486		6-(1-methyl-piperidin-4-yl)-1-(toluene-4-sulfonyl)-1H-indole-2-carboxylic acid methyl ester	427
1487		1-benzenesulfonyl-5-fluoro-6-morpholin-4-ylmethyl-1H-indole-2-carboxylic acid ethyl ester	447

TABLE 31-continued

Com- ound No.	Structure	Compound name	m/z
1488		1-benzenesulfonyl-5-(4-tert-butoxycarbonyl-piperidin-1-ylmethyl)-1H-indole-2-carboxylic acid ethyl ester	528
1489		1-benzenesulfonyl-6-(tert-butyl-diphenyl-silyloxy)methyl-1H-indole-2-carboxylic acid methyl ester	584
1490		1-benzenesulfonyl-5-(4-tert-butoxycarbonyl-piperidin-1-ylmethyl)-1H-indole-2-carboxylic acid ethyl ester	528

Step 40: Synthesis of
(2-methyl-1H-benzimidazol-5-yl)-hydrazine
dihydrochloride (1491)



5-Amino-2-methyl-1H-benzimidazol hydrochloride (16.51 g) was dissolved in concentrated hydrochloric acid

40 (200 ml), and this was cooled to 0° C. An aqueous solution (15 ml) of sodium nitrite (7.59 g) was added dropwise thereto at 0° C. over 20 minutes. This was stirred for 20 minutes. Then, a concentrated hydrochloric acid solution (20 ml) of tin (II) 45 chloride dihydrate (55.7 g) was added dropwise thereto at 0° C. over one hour, and then this was stirred for 30 minutes. The precipitated solid was collected by filtration, and washed with water, and dried. Thus, crude (2-methyl-1H-benzimidazol-5-yl)-hydrazine dihydrochloride was obtained.
50 ESI (LC-MS positive mode) m/z 163 [(M+H)⁺]
The compounds of numbers 1492 to 1496 listed in Table 32 were synthesized as described in Step 40.


TABLE 32

Com- ound No.	Structure	Compound name	m/z
1492		(2-ethyl-1H-benzimidazol-5-yl)-hydrazine dihydrochloride	177

TABLE 32-continued

Com- ound No.	Structure	Compound name	m/z
1493		(2-isopropyl-1H-benzimidazol-5-yl)-hydrazine dihydrochloride	191
1494		(2-propyl-1H-benzimidazol-5-yl)-hydrazine dihydrochloride	191
1495		(2-trifluoromethyl-1H-benzimidazol-5-yl)-hydrazine dihydrochloride	217
1496		(2-benzyl-1H-benzimidazol-5-yl)-hydrazine dihydrochloride	239

Step 41: Synthesis of (7-fluoro-2-methyl-1H-benzimidazol-5-yl)-hydrazine dihydrochloride (1497)



A catalyst was prepared as follows. Palladium acetate (1.2 mg, 0.0052 mmol) and 2-dicyclohexyl phosphino-2',4',6'-tri-i-propyl-1,1'-biphenyl (X-PHOS) (4.2 mg, 0.0088 mmol) were dissolved in tert-amyl alcohol (2.4 µl, 0.022 mmol) and N-methyl-morpholine (0.05 ml). The resulting solution was heated and stirred at 60° C. under a nitrogen atmosphere for five minutes.

In a separate reaction container, 7-fluoro-2-methyl-3H-benzimidazol-5-yl amine (100 mg, 0.44 mmol), lithium bis(trimethylsilyl) amide (190 mg, 1.1 mmol), and benzophenone hydrazone (94.3 mg, 0.48 mmol) were dissolved in N-methyl-morpholine (0.5 ml) under a nitrogen atmosphere. Then, the prepared solution containing the catalyst was added thereto. After deaeration, this was heated and stirred at 100° C. under a nitrogen atmosphere for two hours. The reaction mixture was cooled to room temperature, and then an aqueous solution of 6 M hydrochloric acid (0.5 ml) was added thereto. The organic layer was isolated, and concentrated under

reduced pressure. Thus, crude N-benzhydrylidene-N'-(7-fluoro-2-methyl-1H-benzimidazol-5-yl)-hydrazine was obtained. The obtained crude product was used in subsequent reactions without being purified.


Concentrated hydrochloric acid (0.7 ml) was added to a mixture of the crude N-benzhydrylidene-N'-(7-fluoro-2-methyl-1H-benzimidazol-5-yl)-hydrazine (325 mg) and ethanol (0.7 ml). This was stirred at 59 to 64° C. for one hour, and the reaction mixture was cooled to room temperature. Then, the precipitated solid was collected by filtration and dried. Thus, 7-fluoro-2-methyl-1H-benzimidazol-5-yl-hydrazine dihydrochloride (90 mg, 80%) was obtained.

¹H-NMR (DMSO-D₆) δ: 7.11 (1.0H, d, J=1.8 Hz), 6.99 (1.0H, dd, J=12.4, 1.8 Hz), 2.69 (3.1H, s)

ESI (LC-MS positive mode) m/z 181 [(M+H)⁺]

6-Fluoro-2-methyl-1H-benzimidazol-5-yl-hydrazine dihydrochloride (1498) was synthesized as described in Step 41.


55



ESI (LC-MS positive mode) m/z 181 [(M+H)⁺]

531

Step 42: Synthesis of
6-bromo-2-difluoromethyl-1H-benzimidazole (1499)




4-Bromophenylene diamine (935 mg, 5.0 mmol) and difluoroacetic acid (0.47 ml, 7.5 mmol, 1.5 eq.) were dissolved in an aqueous solution (10 ml) of 5 M hydrochloric acid. This was stirred at 100° C. for 24 hours. After cooling it to room temperature, the reaction mixture was alkalinized by adding an aqueous solution (10 ml) of 5 M sodium hydroxide thereto. After ethyl acetate extraction, the extract was dried over anhydrous sodium sulfate. The desiccant was removed by filtration and concentration was performed. The residue obtained by concentration under reduced pressure was purified by silica gel column chromatography. Thus, 6-bromo-2-difluoromethyl-1H-benzimidazole was obtained as a pale yellow solid (1.0 g, 85.4%).

¹H-NMR (DMSO-D₆) δ: 13.51 (1H, brs), 7.86 (1H, d, J=1.8 Hz), 7.62 (1H, d, J=8.5 Hz), 7.44 (1H, dd, J=8.5, 1.8 Hz), 7.41-7.14 (1H, m)

ESI (LC-MS positive mode) m/z 247, 249 [(M+H)⁺]

Step 43: Synthesis of 6-bromo-2-difluoromethyl-1-(2-trimethylsilyl-ethoxymethyl)-1H-benzimidazole (1500)




(2-Chloro-methoxy-ethyl)-trimethyl-silane (1.1 ml, 6.4 mmol, 1.5 eq.) was added to an anhydrous dichloromethane solution (22 ml) of 6-bromo-2-difluoromethyl-1H-benzimidazole (1.0 g, 4.27 mmol) and N,N-diisopropyl ethyl amine (1.9 ml, 10.6 mmol, 2.5 eq.). This was stirred at room temperature for 18 hours. The reaction mixture was concentrated. The residue obtained by concentration under reduced pressure was purified by silica gel column chromatography. Thus, 6-bromo-2-difluoromethyl-1-(2-trimethylsilyl-ethoxymethyl)-1H-benzimidazole was obtained as a yellow solid (1.37 g, 85%).

¹H-NMR (DMSO-D₆) δ: 8.07-8.02 (1H, m), 7.78-7.74 (1H, m), 7.60-7.28 (2H, m), 5.76 (2H, s), 3.52 (2H, td, J=8.4, 2.6 Hz), 0.83 (2H, td, J=8.4, 2.6 Hz), -0.10 (9H, s)

ESI (LC-MS positive mode) m/z 377, 379 [(M+H)⁺]

532


Step 44: Synthesis of 2-difluoromethyl-3-(2-trimethylsilyl-ethoxymethyl)-3H-benzimidazol-5-yl-hydrazine hydrochloride (1501)



6-Bromo-2-difluoromethyl-1-(2-trimethylsilyl-ethoxymethyl)-1H-benzimidazole (754 mg, 2.0 mmol), Tris (dibenzylideneacetone)dipalladium (0) (92 mg, 0.1 mmol), 2-dicyclohexylphosphino-2',4',6'-tri-i-propyl-1,1'-biphenyl (X-PHOS) (143 mg, 0.3 mmol), cesium carbonate (1.3 g, 4.0 mmol), and tert-butyl carbazate (794 mg, 6.0 mmol) were placed into a flask. After deaeration, the air was replaced with argon. Anhydrous toluene (8.0 ml) was added thereto, and this was stirred at 100° C. for 20 hours. After cooling it to room temperature, the reaction mixture was filtered through Celite, and washed with ethyl acetate. The filtrate was concentrated. The residue obtained by concentration under reduced pressure was purified by silica gel column chromatography. Thus, tert-butoxycarbonylated hydrazine was obtained as a pale yellow gum-like material (220 mg, 26%). A 4 M hydrochloric acid/ethyl acetate solution (6.0 ml) was added to an ethyl acetate solution (3.0 ml) of the prepared tert-butoxycarbonylated hydrazine. This was stirred at room temperature for one and a half hours. The precipitated solid was collected by filtration, washed with ethyl acetate, and dried. Thus, crude [2-difluoromethyl-3-(2-trimethylsilyl-ethoxymethyl)-3H-benzimidazol-5-yl]-hydrazine hydrochloride was obtained as a yellow solid. The crude product was used in subsequent reactions without being purified.

ESI (LC-MS positive mode) m/z 329 [(M+H)⁺]

Synthesis of 1-(2-methyl-1H-benzo[d]imidazol-5-yl)-hydrazine-1,2-dicarboxylic acid di-tert-butyl mesilate



533

Step A

A mixture solution of 5-iodo-2-methyl-1H-benzimidazole (10 g, 39 mmol), trimethoxy-methane (200 ml), and chlorotrimethylsilane (0.075 ml, 0.59 mmol) was heated and stirred at 100° C. for five hours under a nitrogen atmosphere while distilling off the solvent (a reaction conversion rate of 97%). The reaction mixture was cooled to 40° C., and then a tetrahydrofuran solution (0.87 ml, 0.87 mmol) of potassium tert-butoxide was added thereto. This was concentrated under reduced pressure to provide crude 1-dimethoxymethyl-5-iodo-2-methyl-1H-benzimidazole.

Step B

A tetrahydrofuran solution (44 ml, 47 mmol) of 1.06 M cyclohexyl magnesium chloride was added to a mixed solution of crude 1-dimethoxymethyl-5-iodo-2-methyl-1H-benzimidazole and tetrahydrofuran (79 ml). This was stirred at -20° C. under a nitrogen atmosphere for two hours. A toluene solution (40 ml) of di-tert-butyl azodicarboxylate (10.7 g, 46 mmol) was added to the reaction mixture, and this was stirred under a nitrogen atmosphere at -20° C. for one hour and at 0° C. for another one hour (a reaction conversion rate of 96%). An aqueous solution (60 ml) of 15% ammonium chloride was added to the reaction mixture. After extraction with a solution of isopropyl acetate/heptane (1/1; 50 ml), the organic layer was washed with an aqueous solution (50 ml) of 2% sodium bicarbonate. Then, 1-methyl-pyrrolidin-2-one (15 ml) was added thereto, and this was concentrated under reduced pressure to provide a 1-methyl-pyrrolidin-2-one solution (48 ml) of crude 1-(1-(dimethoxymethyl)-2-methyl-1H-benzo[d]imidazol-5-yl)hydrazine-1,2-dicarboxylic acid di-tert-butyl mesilate.

Isopropyl acetate (61 ml), water (0.2 ml), and mesylic acid (0.87 ml) were added to the 1-methyl-pyrrolidin-2-one solution (16 ml) of crude 1-(1-(dimethoxymethyl)-2-methyl-1H-benzo[d]imidazol-5-yl)hydrazine-1,2-dicarboxylic acid di-tert-butyl. This was stirred at 40° C. for two hours. After cooling it to 5° C., the precipitated solid was collected by filtration, and dried to provide 1-(2-methyl-1H-benzo[d]imidazol-5-yl)hydrazine-1,2-dicarboxylic acid di-tert-butyl mesilate (4.3 g, 73%).

¹H-NMR (CD₃OD) δ: 7.87 (1.0H, m), 7.69-7.53 (2.0H, m), 2.84 (3.0H, s), 2.70 (3.0H, s), 1.52-1.47 (18H, m)

Crude 1-dimethoxymethyl-5-iodo-2-methyl-1H-benzimidazole was prepared using magnesium chloride instead of chlorotrimethylsilane in step A (a reaction conversion rate of 98%).


Crude 1-dimethoxymethyl-5-iodo-2-methyl-1H-benzimidazole was prepared using lithium chloride instead of chlorotrimethylsilane in step A (a reaction conversion rate of 98%).

Crude 1-dimethoxymethyl-5-iodo-2-methyl-1H-benzimidazole was prepared using benzoic acid instead of chlorotrimethylsilane in step A (a reaction conversion rate of 97%).

Crude 1-(1-(dimethoxymethyl)-2-methyl-1H-benzo[d]imidazol-5-yl)hydrazine-1,2-dicarboxylic acid di-tert-butyl was prepared using a tetrahydrofuran solution of isopropyl magnesium chloride instead of a tetrahydrofuran solution of cyclohexyl magnesium chloride in step B (a reaction conversion rate of 96%).

534


Synthesis of 1-(2-methyl-1H-benzo[d]imidazol-5-yl)hydrazine-1,2-dicarboxylic acid di-tert-butyl malate tetrahydrofuran solvate



1-(2-Methyl-1H-benzo[d]imidazol-5-yl)hydrazine-1,2-dicarboxylic acid di-tert-butyl malate tetrahydrofuran solvate was prepared using tetrahydrofuran, maleic acid, and heptane instead of mesylic acid and isopropyl acetate in step B (a yield of 62%).

¹H-NMR (CD₃OD) δ: 7.77 (1.0H, m), 7.64-7.53 (2.0H, m), 6.26 (2.0H, s), 3.74-3.71 (4.0H, m), 2.80 (3.0H, s), 1.90-1.85 (4.0H, m), 1.51-1.48 (18H, m)

Step 45: Synthesis of 1-(4-methoxy-benzyl)-1H-pyrrole-2-carboxylic acid ethyl ester (1502)




60% Oily sodium hydride (362 mg) was washed with hexane, and this was suspended in anhydrous N,N-dimethylformamide (DMF) (5 ml). An N,N-dimethylformamide (DMF) solution (15 ml) of 1H-pyrrole-2-carboxylic acid ethyl ester (1.05 g) was added dropwise to the suspension at 0° C. with argon flow. The reaction mixture was stirred at 25° C. for one hour, and then 4-methoxybenzyl chloride (1.5 ml) was added thereto at 0° C. The reaction mixture was stirred at 25° C. for 10 hours. Then, ice (about 10 g) was added to the reaction mixture, and this was extracted with ethyl acetate (20 ml). The organic layer was washed with an aqueous solution (60 ml) saturated with sodium chloride, and then concentrated. The residue obtained by concentration under reduced pressure was purified by silica gel column chromatography (hexane/ethyl acetate). Thus, a yellow oily material was obtained (1.64 g, 83%).

ESI (LC-MS positive mode) m/z 260 [(M+H)⁺]

535


Step 46: Synthesis of
4-bromo-1H-pyrrole-2-carboxylic acid ethyl ester
(1503)



1H-Pyrrole-2-carboxylic acid ethyl ester (10 g) was dissolved in carbon tetrachloride (50 ml). A carbon tetrachloride solution (50 ml) of bromine was added dropwise thereto on ice over 30 minutes. The reaction mixture was stirred at 25° C. for one hour. The suspension of reaction mixture was added dropwise to an ethanol solution (100 ml) of 10% sodium ethoxide on ice over 20 minutes. The solvent was concentrated under reduced pressure. The resulting residue was diluted with ethyl acetate (40 ml) and water (20 ml). The organic layer was washed with an aqueous solution saturated with sodium chloride (10 ml), and then concentrated. The residue obtained by concentration under reduced pressure was purified by silica gel column chromatography (hexane/ethyl acetate). Thus, a brown solid was obtained (10 g, 99%).

ESI (LC-MS positive mode) m/z 218, 220 [(M+H)⁺]

Step 47: Synthesis of 4,5-dibromo-1-(4-methoxy-benzyl)-1H-pyrrole-2-carboxylic acid ethyl ester
(1504)




An anhydrous N,N-dimethylformamide (DMF) solution (9 ml) of N-bromosuccinimide (2.7 g) was added dropwise to an anhydrous N,N-dimethylformamide (DMF) solution (8 ml) of 1-(4-methoxy-benzyl)-1H-pyrrole-2-carboxylic acid ethyl ester (2 g) at 0° C. with argon flow. The reaction mixture was stirred at 0° C., and then water (20 ml) was added thereto.

536

After extraction with ethyl acetate (30 ml), the organic layer was washed with an aqueous solution saturated with sodium chloride (70 ml), and the organic layer was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (hexane/ethyl acetate). Thus, 4,5-dibromo-1-(4-methoxy-benzyl)-1H-pyrrole-2-carboxylic acid ethyl ester was obtained as an oily pale brown material (2.99 g, 92%).

ESI (LC-MS positive mode) m/z 416, 418, 420 [(M+H)⁺]

15 Step 48: Synthesis of [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-phenyl-1-toluene-4-sulfonyl]-1H-pyrrol-2-yl]-methanone
(1505)



45 Dioxane (1.5 ml) and an aqueous solution (1.5 ml) of 1 M sodium bicarbonate were added to [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-bromo-1-(toluene-4-sulfonyl)-1H-pyrrol-2-yl]-methanone (57 mg), palladium chloride bis-triphenylphosphine complex (10 mg), and 50 phenylboronic acid (37 mg). The mixture was reacted at 140° C. in a microwave reactor for ten minutes. The reaction mixture was diluted with water (5 ml), and then extracted with ethyl acetate. The organic layers were combined, and concentrated under reduced pressure. After HPLC purification, the eluate was desalting using PLHCO3 cartridge (PolymerLabs), and then concentrated under reduced pressure. Thus, [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-phenyl-1-(toluene-4-sulfonyl)-1H-pyrrol-2-yl]-methanone was obtained as a yellow powder (15 mg, 26%).

60 ESI (LC-MS positive mode) m/z 537 [(M+H)⁺]

The compounds of numbers 1506 to 1510, and 1591 to 65 1598 listed in Table 33 were synthesized as described in Step 48.

TABLE 33




Com- ound No.	Structure	Compound name	m/z
1506		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1-(4-methoxy-benzyl)-4,5-diphenyl-1H-pyrrol-2-yl]-methanone	579
1507		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1-(4-methoxy-benzyl)-4,5-diphenyl-1H-pyrrol-2-yl]-methanone	581
1508		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-(3-chloro-phenyl)-1-(toluene-4-sulfonyl)-1H-pyrrol-2-yl]-methanone	571, 573

TABLE 33-continued

Com- ound No.	Structure	Compound name	m/z
1509		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-4-(4-fluoro-phenyl)-1-(toluene-4-sulfonyl)-1H-pyrrol-2-yl]-methanone	555
1510		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-4-(3-fluoro-phenyl)-1-(toluene-4-sulfonyl)-1H-pyrrol-2-yl]-methanone	555
1591		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1-(4-methoxy-benzyl)-4-(4-methoxy-phenyl)-1H-pyrrol-2-yl]-methanone	533

TABLE 33-continued

Com- ound No.	Structure	Compound name	m/z
1592		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1-(4-methoxy-benzyl)-4-(3-methoxy-phenyl)-1H-pyrrol-2-yl]-methanone	533
1593		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4,5-bis-(3-fluoro-phenyl)-1-(4-methoxy-benzyl)-1H-pyrrol-2-yl]-methanone	615
1594		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-(5-fluoro-2-methoxy-phenyl)-1-(4-methoxy-benzyl)-1H-pyrrol-2-yl]-methanone	551

TABLE 33-continued


Com- ound No.	Structure	Compound name	m/z
1595		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1-(4-methoxy-benzyl)-4-bis-(4-methoxy-phenyl)-1H-pyrrol-2-yl]-methanone	639
1596		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-(2,4-difluoro-phenyl)-1-(4-methoxy-benzyl)-1H-pyrrol-2-yl]-methanone	539
1597		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1-(4-methoxy-benzyl)-4-(4-trifluoromethoxy-phenyl)-1H-pyrrol-2-yl]-methanone	589

TABLE 33-continued

Com- ound No.	Structure	Compound name	m/z
1598		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1-(4-methoxy-benzyl)-4,5-bis-(3-methoxy-phenyl)-1H-pyrrol-2-yl]-methanone	439

Examples 201

Synthesis of [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4,5-dibromo-1H-pyrrol-2-yl]-methanone



[5-Amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4,5-dibromo-1-(4-methoxy-benzyl)-1H-pyrrol-2-yl]-methanone (317 mg) was dissolved in ethyl acetate/sul-

furic acid (4/1; 5 ml). This was stirred at 80° C. for four hours. The pH of the reaction mixture was adjusted to 11 (basic) using an aqueous solution of 5 M sodium hydroxide while cooling it on ice. The reaction mixture was extracted with ethyl acetate/tetrahydrofuran (THF) (10 ml). The organic layer was washed with an aqueous solution saturated with sodium chloride (5 ml), and the organic layer was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (dichloromethane/methanol). Thus, a brown solid was obtained (135 mg, 54%).
¹H-NMR (DMSO-D₆) δ: 12.88 (1H, s), 12.46 (1H, s), 8.19 (1H, s), 7.63 (1H, d, J=8.7 Hz), 7.56-7.54 (1H, m), 7.27-7.26 (3H, m), 6.90 (1H, t, J=14.2 Hz), 2.53 (3H, s)
ESI (LC-MS positive mode) m/z 463, 465, 467 [(M+H)⁺]

Examples 202 and 203

The compounds of Examples 202, 203, and 240-246 listed in Table 34 were synthesized as described in Example 201.

TABLE 34

Ex- ample	Structure	Compound name	m/z	¹ H-NMR
202		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4,5-diphenyl-1H-pyrrol-2-yl]-methanone	458	¹ H-NMR (CD3OD) δ: 8.22 (1H, s), 7.73-7.64 (3H, m), 7.60-7.51 (2H, m), 7.45-7.38 (3H, m), 7.37-7.18 (9H, m), 2.61 (3H, s).

TABLE 34-continued

Ex- ample	Structure	Compound name	m/z	1H-NMR
203		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4,5-dipyridin-3-yl-1H-pyrrol-2-yl]-methanone	461	1H-NMR (DMSO-D6) δ: 12.39 (1H, s), 8.56 (1H, dd, J = 7.9, 2.1 Hz), 8.52 (1H, dd, J = 4.7, 1.1 Hz), 8.43 (1H, dd, J = 4.7, 1.6 Hz), 8.38 (1H, s), 7.81 (1H, dt, J = 7.9, 1.9 Hz), 7.72 (1H, dt, J = 8.0, 2.0 Hz), 7.63-7.59 (2H, m), 7.42 (1H, t, J = 3.7 Hz), 7.36 (1H, dd, J = 8.5, 3.7 Hz), 7.30 (1H, dd, J = 8.6, 2.0 Hz), 6.98 (2H, br s), 2.54 (3H, s).
240		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-(4-methoxy-phenyl)-1H-pyrrol-2-yl]-methanone	413	11.9 (1H, br s), 7.64-7.62 (2H, m), 7.56 (1H, m), 7.51 (1H, m), 7.33-7.31 (3H, m), 7.27-7.23 (1H, m), 6.96 (1H, m), 6.90 (2H, m), 6.75-6.73 (1H, m), 3.82 (3H, s), 2.60 (3H, s)
241		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-(3-methoxy-phenyl)-1H-pyrrol-2-yl]-methanone	413	11.9 (1H, br s), 7.69-7.62 (2H, m), 7.56 (1H, m), 7.51 (1H, m), 7.33-7.31 (3H, m), 7.27-7.23 (1H, m), 6.96 (1H, m), 6.90 (2H, m), 6.75-6.73 (1H, m), 3.82 (3H, s), 2.60 (3H, s)
242		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4,5-bis(3-fluoro-phenyl)-1H-pyrrol-2-yl]-methanone	495	7.67 (1H, m), 7.41-7.28 (3H, m), 7.25-7.23 (2H, m), 7.16-7.14 (2H, m), 7.10-7.05 (2H, m), 6.99-6.95 (1H, m), 2.65 (3H, s)
243		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4,5-bis(4-methoxy-phenyl)-1H-pyrrol-2-yl]-methanone	519	8.19 (1H, m), 7.66-7.64 (2H, m), 7.38-7.34 (3H, m), 7.25-7.23 (2H, m), 7.14 (1H, m), 6.91-6.84 (4H, s), 3.80 (3H, s), 3.76 (3H, s), 2.61 (3H, s)

TABLE 34-continued

Ex- ample	Structure	Compound name	m/z	1H-NMR
244		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-(2,4-difluoro-phenyl)-1H-pyrrol-2-yl]-methanone	419	8.30 (1H, m), 7.96-7.89 (1H, m), 7.69 (2H, m), 7.47-7.45 (2H, m), 7.42-7.39 (1H, m), 7.26-7.21 (1H, m), 7.12-7.08 (1H, m), 2.60 (3H, s)
245		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-(4-trifluoromethoxy-phenyl)-1H-pyrrol-2-yl]-methanone	467	12.5 (1H, br s), 11.9 (1H, br s), 8.39 (1H, m), 7.89-7.87 (2H, m), 7.64-7.55 (4H, m), 7.33-7.31 (3H, m), 6.91-6.85 (2H, m), 2.54 (3H, s)
246		[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4,5-bis-(3-methoxy-phenyl)-1H-pyrrol-2-yl]-methanone	519	12.5 (1H, br s), 11.9 (1H, br s), 7.65-7.63 (1H, m), 7.58-7.55 (1H, m), 7.31-7.28 (1H, m), 7.25-7.18 (3H, m), 7.07 (1H, m), 6.96-6.86 (6H, m), 6.80-6.78 (1H, m), 3.73 (3H, s), 3.69 (3H, s), 2.53 (3H, s)

Pharmacological Test Methods

1. Inhibitory Activity Against the FGFR1 Enzyme

The FGFR1-inhibiting activity was measured based on the activity to inhibit phosphorylation of the biotinylated peptide EGPWLEEEEAYGWMDF (SEQ ID NO:1) by the human FGFR1 enzyme (Carna Biosciences, cat. 08-133). Phosphorylated biotinylated peptides were detected by the time-resolved fluorescent measurement using a europium cryptate-linked anti-phophotyrosine antibody and a streptavidin to which XL665, a derivative of allophycocyanine, is linked. The 50% inhibitory concentration (IC_{50}) was calculated based on the inhibitory rate against the control group without test substances.

2. Inhibitory Activity Against the FGFR2 Enzyme

The FGFR2-inhibiting activity was measured based on the activity to inhibit phosphorylation of the biotinylated peptide EGPWLEEEEAYGWMDF (SEQ ID NO:1) by the human FGFR2 enzyme prepared using a baculovirus expression system. Phosphorylated biotinylated peptides were detected by the time-resolved fluorescent measurement using a europium cryptate-linked anti-phophotyrosine antibody and a streptavidin to which XL665, a derivative of allophycocyanine, is linked. The 50% inhibitory concentration (IC_{50}) was calculated based on the inhibitory rate against the control group without test substances.

3. Inhibitory Activity Against the FGFR3 Enzyme

The FGFR3-inhibiting activity was measured based on the activity to inhibit phosphorylation of the biotinylated peptide

EGPWLEEEEAYGWMDF (SEQ ID NO:1) by the human FGFR3 enzyme (Carna Biosciences, cat. 08-135). Phosphorylated biotinylated peptides were detected by the time-re-

40 solved fluorescent measurement using a europium cryptate-linked anti-phophotyrosine antibody and a streptavidin to which XL665, a derivative of allophycocyanine, is linked.

45 The 50% inhibitory concentration (IC_{50}) was calculated based on the inhibitory rate against the control group without test substances.

Test Results

50 Compounds that have an activity of inhibiting FGFR1 (IC_{50} of 0.3 μ M or less):

Examples 1-14, 16-18, 23-25, 27-32, 35-62, 64-87, 89-108, 110, 112-125, 130-161, 163-175, 177-191, and 192-201

55 Compounds that have an activity of inhibiting FGFR2 (IC_{50} of 0.3 μ M or less):

Examples 1-14, 16-62, 64-108, 110, 112-126, 128-150, 152-161, 163-191, and 192-201

60 Compounds that have an activity of inhibiting FGFR3 (IC_{50} of 0.3 μ M or less):

Examples 1-3, 5-9, 12-13, 25, 27-29, 32, 36, 38-50, 52-54, 56, 61, 64-67, 69-72, 74-81, 85-87, 89, 91-100, 102-108, 110, 112-121, 123-125, 132-150, 152-161, 163-169, 174-176, 178, 180-187, 189-191, 192, and 194-200

551

TABLE 35

Example	FGFR1	FGFR2	FGFR3
1	0.0050	0.023	0.018
3	0.0053	0.0055	0.013
5	0.028	0.0056	0.038
6	0.0027	0.0032	0.0054
7	0.0030	0.0043	0.0067
12	0.031	0.0085	0.50
16	0.042	0.031	0.36
21	0.46	0.064	50
27	0.030	0.0054	0.0031
28	0.099	0.021	0.21
29	0.093	0.019	0.35
38	0.015	0.023	0.077
39	0.010	0.015	0.046
40	0.00081	0.012	0.0037
42	0.0096	0.023	0.034
43	0.017	0.017	0.070
47	0.0027	0.0043	0.0054
48	0.030	0.0089	0.11
50	0.042	0.026	0.15
52	0.016	0.0086	0.21
53	0.043	0.021	0.15
54	0.089	0.042	0.19
56	0.051	0.034	0.18
57	0.26	0.086	0.58
60	0.077	0.022	0.32
62	0.035	0.016	0.36
64	0.022	0.012	0.16
66	0.025	0.048	0.043
67	0.029	0.025	0.082
68	0.23	0.20	0.40
69	0.023	0.016	0.060
71	0.060	0.027	0.13
72	0.045	0.021	0.082
73	0.076	0.036	0.80
74	0.050	0.026	0.23
75	0.043	0.022	0.086
79	0.018	0.010	0.027
81	0.018	0.012	0.045
82	0.024	0.0083	0.37
83	0.057	0.014	0.67
85	0.022	0.0055	0.094
87	0.062	0.014	0.090
90	0.075	0.040	0.38
91	0.039	0.018	0.077
92	0.009	0.0062	0.032
93	0.043	0.039	0.015
96	0.033	0.038	0.068
98	0.011	0.017	0.065
102	0.048	0.039	0.16
104	0.036	0.031	0.14
107	0.0069	0.0084	0.018
114	0.00032	0.012	0.012
115	0.00067	0.0085	0.030
121	0.087	0.11	0.13
124	0.011	0.012	0.041
126	0.39	0.26	2.1
127	0.98	0.51	5.5
131	0.21	0.067	9.8
132	0.0014	0.0034	0.0035
133	0.0051	0.026	0.19
134	0.0020	0.012	0.035
137	0.0064	0.019	0.026
138	0.0042	0.006	0.0056
139	0.0085	0.029	0.018
141	0.0025	0.0040	0.0016
145	0.0038	0.0091	0.010
149	0.024	0.20	0.28
150	0.0029	0.065	0.079
151	0.082	0.32	0.92
153	0.0079	0.011	0.036
154	0.066	0.038	0.13
155	0.0018	0.0063	0.0012
157	0.0016	0.0048	0.012
158	0.0014	0.0046	0.010

552

TABLE 35-continued

Example	FGFR1	FGFR2	FGFR3
5			
159	0.070	0.028	0.19
163	0.018	0.0036	0.019
164	0.0030	0.010	0.0084
166	0.040	0.015	0.080
168	0.048	0.021	0.079
169	0.03	0.015	0.14
170	0.15	0.056	0.95
177	0.12	0.11	0.38
178	0.033	0.020	0.077
182	0.060	0.029	0.18
185	0.0055	0.0040	0.029
187	0.046	0.016	0.25
188	0.091	0.026	1.3
189	0.038	0.0076	0.10
190	0.034	0.0055	0.094
192	0.031	0.020	0.11
193	0.14	0.078	0.37
196	0.0029	0.0094	0.13
198	0.021	0.020	0.090
199	0.027	0.018	0.12
200	0.056	0.021	0.068
201	0.26	0.066	1.4
203	1.7	0.393	1.8
204	0.091	0.057	0.37
207	3.6	1.9	7.9
210	0.092	0.037	0.33
213	0.045	0.026	0.15
222	0.053	0.017	0.21
225	0.053	0.028	0.26
229	0.036	0.010	0.35
232	0.056	0.22	0.26
233	0.210	0.35	0.88
239	2.8	0.538	4.0
240	0.85	0.18	3.18
249	0.038	0.022	0.082
250	0.095	0.040	0.32
251	0.077	0.032	0.23
50			
55			
60			
65			

INDUSTRIAL APPLICABILITY

The present invention provides compounds having an activity of inhibiting FGFR family kinases. Furthermore, the present invention provides pharmaceutical agents for preventing and/or treating cancers (for example, breast cancer, acute myelocytic leukemia, pancreatic cancer, bladder cancer, prostatic cancer, esophageal cancer, angiogenesis, stomach cancer, uterine body cancer, ovarian cancer, brain tumor including glioblastoma, colon cancer, multiple myeloma, hepatocellular carcinoma, pulmonary cancer including small cell and non-small cell lung cancers, and thyroid cancer).

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 1

<210> SEQ ID NO 1
<211> LENGTH: 17
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: An artificially synthesized peptide sequence


<400> SEQUENCE: 1

Glu Gly Pro Trp Leu Glu Glu Glu Ala Tyr Gly Trp Met Asp
1 5 10 15

Phe

The invention claimed is:

1. A method for treating a disorder, comprising administering a pharmaceutically effective amount of a composition comprising a compound represented by formula (I), or a pharmaceutically acceptable salt thereof to a patient in need of treatment of the disorder;



wherein R₁, R₂, R₃, and R₄ each independently represents the group listed below:

R₁ represents hydrogen, hydroxy, halogen, cyano, nitro, C₁₋₄ haloalkyl, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, C₆₋₁₀ aryl C₁₋₄ alkyl, —OR₅, —NR₆R₇, —(CR₈R₉)_nZ₁, —C(O)NR₁₂R₁₃, —SR₁₄, —SOR₁₅, —SO₂R₁₆, —NR₁₇SO₂R₁₈, COOH, C₆₋₁₀ aryl which is optionally substituted by one or more groups independently selected from group P, 5- to 10-membered heteroaryl or 3- to 10-membered heterocycl which is optionally substituted by one or more groups independently selected from group Q, —COR₁₉, —COOR₂₀, —OC(O)R₂₁, —NR₂₂C(O)R₂₃, —NR₂₄C(S)R₂₅, —C(S)NR₂₆R₂₇, —SO₂NR₂₈R₂₉, —OSO₂R₃₀, —SO₃R₃₁, or —Si(R₃₂)₃;

R₂ represents hydrogen, hydroxy, halogen, cyano, nitro, C₁₋₄ haloalkyl, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, C₆₋₁₀ aryl C₁₋₄ alkyl, —OR₅, —NR₆R₇, —(CR₈R₉)_nZ₁, —C(O)NR₁₂R₁₃, —SR₁₄, —SOR₁₅, —SO₂R₁₆, —NR₁₇SO₂R₁₈, COOH, C₆₋₁₀ aryl which is optionally substituted by one or more groups independently selected from group P, 5- to 10-membered heteroaryl or 3- to 10-membered heterocycl which is optionally substituted by one or more groups independently selected from group Q, —COR₁₉, —COOR₂₀, —OC(O)R₂₁, —NR₂₂C(O)R₂₃, —NR₂₄C(S)R₂₅, —C(S)NR₂₆R₂₇, —SO₂NR₂₈R₂₉, —OSO₂R₃₀, —SO₃R₃₁, or —Si(R₃₂)₃;

R₁ and R₂, together with an atom linked thereto, form 3- to 10-membered heterocycl or 5- to 10-membered heteroaryl, wherein the heterocycl or heteroaryl is optionally substituted by halogen;

R₃ represents hydrogen, C₁₋₅ alkyl, C₆₋₁₀ aryl C₁₋₆ alkyl, or C₁₋₄ haloalkyl;

R₄ represents hydrogen, halogen, C₁₋₃ alkyl, C₁₋₄ haloalkyl, hydroxy, cyano, nitro, C₁₋₄ alkoxy, —(CH₂)_nZ₁, —NR₆R₇, —OR₅, —C(O)NR₁₂R₁₃, —SR₁₄, —SOR₁₅, —SO₂R₁₆, —NR₁₇SO₂R₁₈, COOH, —COR₁₉, —COOR₂₀, —OC(O)R₂₁, —NR₂₂C(O)R₂₃, —NR₂₄C(S)R₂₅, —C(S)NR₂₆R₂₇, —SO₂NR₂₈R₂₉, —OSO₂R₃₀, —SO₃R₃₁, or —Si(R₃₂)₃;

A represents a 5- to 10-membered heteroaryl ring or C₆₋₁₀ aryl ring;

R₅ represents C₁₋₅ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkyl C₁₋₃ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₄ haloalkyl, C₁₋₃ alkoxy C₁₋₄ alkyl, C₁₋₃ alkoxy C₁₋₄ alkoxy C₁₋₄ alkyl, C₁₋₄ aminoalkyl, C₁₋₄ alkylamino C₁₋₄ alkyl, di(C₁₋₄ alkyl)amino C₁₋₄ alkyl, C₆₋₁₀ aryl, C₆₋₁₀ aryl C₁₋₃ alkyl, or 3- to 10-membered heterocycl C₁₋₃ alkyl, 3- to 10-membered heterocycl, 5- to 10-membered heteroaryl, 5- to 10-membered heteroaryl C₁₋₃ alkyl, C₁₋₆ monohydroxy alkyl, C₁₋₆ dihydroxy alkyl, or C₁₋₆ trihydroxy alkyl which is optionally substituted by one or more groups independently selected from group Q;

R₆ and R₇, which are the same or different, each represents hydrogen, C₁₋₄ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₄ haloalkyl, C₁₋₃ alkoxy C₁₋₄ alkyl, C₆₋₁₀ aryl C₁₋₃ alkyl, 3- to 10-membered heterocycl C₁₋₃ alkyl, 5- to 10-membered heteroaryl C₁₋₃ alkyl, C₁₋₆ monohydroxy alkyl, C₁₋₆ dihydroxy alkyl, C₁₋₆ trihydroxy alkyl, 3- to 10-membered heterocycl, C₁₋₄ aminoalkyl, C₁₋₄ alkylamino C₁₋₄ alkyl, di(C₁₋₄ alkyl)amino C₁₋₄ alkyl, or cyano(C₁₋₃ alkyl); or R₆ and R₇, together with a nitrogen atom linked thereto, form 3- to 10-membered heterocycl or 5- to 10-membered heteroaryl;

n represents 1 to 3;

R₈ and R₉, which are the same or different, each represents hydrogen, C₁₋₄ alkyl, or halogen; or alternatively, R₈ and R₉, together with a carbon atom linked thereto, form a cycloaliphatic ring;

Z₁ represents hydrogen, NR₁₀R₁₁, —OH, or 3- to 10-membered heterocycl or 5- to 10-membered heteroaryl which is optionally substituted by one or more groups independently selected from group Q;

R₁₀ and R₁₁, which are the same or different, each represents C₁₋₄ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₄ haloalkyl, C₁₋₃ alkoxy C₁₋₄ alkyl, cyano(C₁₋₃ alkyl), or

555

C_{1-3} alkylsulfonyl C_{1-4} alkyl; or alternatively, R_{10} and R_{11} , together with a nitrogen atom linked thereto, form 3- to 10-membered heterocycl or 5- to 10-membered heteroaryl;

R_{12} and R_{13} , which are the same or different, each represents hydrogen, C_{1-4} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-4} haloalkyl, C_{1-3} alkoxy C_{1-4} alkyl, C_{6-10} aryl, 5- to 10-membered heteroaryl, 3- to 10-membered heterocycl, C_{6-10} aryl C_{1-4} alkyl, 3- to 10-membered heterocycl C_{1-3} alkyl, 5- to 10-membered heteroaryl C_{1-3} alkyl, cyano(C_{1-3} alkyl), C_{1-3} alkylsulfonyl C_{1-4} alkyl, 3- to 10-membered cycloaliphatic ring, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocycl; or alternatively, R_{12} and R_{13} , together with a nitrogen atom linked thereto, form 3- to 10-membered heterocycl or 5- to 10-membered heteroaryl which is optionally substituted by one or more groups independently selected from group Q;

R_{14} represents C_{1-4} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-4} haloalkyl, C_{6-10} aryl which is optionally substituted by one or more groups independently selected from group P, or 5- to 10-membered heteroaryl or 3- to 10-membered heterocycl which is optionally substituted by one or more groups independently selected from group Q;

R_{15} represents C_{1-4} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-4} haloalkyl, C_{6-10} aryl which is optionally substituted by one or more groups independently selected from group P, or 5- to 10-membered heteroaryl or 3- to 10-membered heterocycl which is optionally substituted by one or more groups independently selected from group Q;

R_{16} represents C_{1-4} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-4} haloalkyl, C_{6-10} aryl which is optionally substituted by one or more groups independently selected from group P, or 5- to 10-membered heteroaryl or 3- to 10-membered heterocycl which is optionally substituted by one or more groups independently selected from group Q;

R_{17} represents hydrogen or C_{1-4} alkyl;

R_{18} represents C_{1-4} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-4} haloalkyl, C_{6-10} aryl which is optionally substituted by one or more groups independently selected from group P, or 5- to 10-membered heteroaryl or 3- to 10-membered heterocycl which is optionally substituted by one or more groups independently selected from group Q;

R_{19} represents hydrogen, C_{1-4} alkyl, C_{3-7} cycloalkyl, C_{1-4} haloalkyl, C_{6-10} aryl, or 5- to 10-membered heteroaryl or 3- to 10-membered heterocycl which is optionally substituted by one or more groups independently selected from group Q;

R_{20} represents C_{1-4} alkyl, C_{3-7} cycloalkyl, C_{1-4} haloalkyl, C_{6-10} aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocycl;

R_{21} represents C_{1-4} alkyl, C_{3-7} cycloalkyl, C_{1-4} haloalkyl, C_{6-10} aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocycl;

R_{22} represents hydrogen, C_{1-4} alkyl, or C_{1-4} haloalkyl;

R_{23} represents hydrogen, C_{1-4} alkyl, C_{3-7} cycloalkyl, C_{1-4} haloalkyl, C_{6-10} aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocycl;

R_{24} represents hydrogen, C_{1-4} alkyl, or C_{1-4} haloalkyl;

R_{25} represents C_{1-4} alkyl, C_{3-7} cycloalkyl, C_{1-4} haloalkyl, C_{6-10} aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocycl;

556

R_{26} and R_{27} , which are the same or different, each represents hydrogen, C_{1-4} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-4} haloalkyl, C_{1-3} alkoxy C_{1-4} alkyl, C_{6-10} aryl, 5- to 10-membered heteroaryl, 3- to 10-membered heterocycl, C_{6-10} aryl C_{1-4} alkyl, 3- to 10-membered heterocycl C_{1-3} alkyl, cyano(C_{1-3} alkyl), C_{1-3} alkylsulfonyl C_{1-4} alkyl, or 3- to 10-membered cycloaliphatic ring; or alternatively, R_{26} and R_{27} , together with a nitrogen atom linked thereto, form 3- to 10-membered heterocycl or 5- to 10-membered heteroaryl;

R_{28} and R_{29} , which are the same or different, each represents hydrogen, C_{1-4} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-4} haloalkyl, C_{1-3} alkoxy C_{1-4} alkyl, C_{6-10} aryl, 5- to 10-membered heteroaryl, 3- to 10-membered heterocycl, C_{6-10} aryl C_{1-4} alkyl, 3- to 10-membered heterocycl C_{1-3} alkyl, cyano(C_{1-3} alkyl), C_{1-3} alkylsulfonyl C_{1-4} alkyl, or 3- to 10-membered cycloaliphatic ring; or alternatively, R_{28} and R_{29} , together with a nitrogen atom linked thereto, form 3- to 10-membered heterocycl or 5- to 10-membered heteroaryl;

R_{30} represents C_{1-4} alkyl, C_{3-7} cycloalkyl, C_{1-4} haloalkyl, C_{6-10} aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocycl;

R_{31} represents C_{1-4} alkyl, C_{3-7} cycloalkyl, C_{1-4} haloalkyl, C_{6-10} aryl, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocycl;

R_{32} represents C_{1-4} alkyl or C_{6-10} aryl; group P is a halogen, C_{1-4} alkyl, C_{1-4} haloalkyl, —OH, C_{1-3} alkoxy, C_{1-3} haloalkoxy, 3- to 10-membered heterocyclamino, — SO_2R_{16} , —CN, —NO₂, or 3- to 10-membered heterocycl; and

group Q is a halogen, C_{1-4} alkyl, C_{1-4} haloalkyl, —OH, C_{1-3} alkoxy, C_{1-6} monohydroxy alkyl, C_{1-6} dihydroxy alkyl, C_{1-6} trihydroxy alkyl, 3- to 10-membered heterocycl amine, — SO_2R_{16} , —CN, —NO₂, C_{3-7} cycloalkyl, —COR₁₉, or 3- to 10-membered heterocycl which is optionally substituted by C_{1-4} alkyl;

wherein the disorder is breast cancer, acute myelocytic leukemia, pancreatic cancer, bladder cancer, prostatic cancer, esophageal cancer, angiogenesis, stomach cancer, uterine body cancer, ovarian cancer, brain tumor, colon cancer, multiple myeloma, hepatocarcinoma, pulmonary cancer, or thyroid cancer.

2. The method of claim 1, wherein A represents benzene, indole, azaindole, benzofuran, benzothiophene, benzothiazole, quinoline, or pyrrole.

3. The method of claim 1, wherein R₃ represents hydrogen, C_{1-4} alkyl, C_{6-10} aryl C_{1-4} alkyl, or C_{1-3} perfluoroalkyl.

4. The method of claim 1 or a pharmaceutically acceptable salt thereof, wherein R₄ represents hydrogen, halogen, C_{1-3} alkyl, C_{1-3} perfluoroalkyl, cyano, methanesulfonyl, hydroxyl, alkoxy, or amino.

5. The method of claim 1, wherein the compound is selected from the group consisting of:

(1) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1H-indol-2-yl]-methanone;

(2) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-pyrrolidin-1-ylmethyl-1H-indol-2-yl]-methanone;

(3) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(4-hydroxy-piperidin-1-ylmethyl)-1H-indol-2-yl]-methanone;

(4) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1H-pyrrolo[3,2-c]pyridin-2-yl]-methanone;

557

- (5) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-piperazin-1-ylmethyl-1H-indol-2-yl]-methanone;
 (6) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(2-morpholin-4-yl-ethoxy)-1H-indol-2-yl]-methanone;
 (7) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(tetrahydro-pyran-4-yloxy)-1H-indol-2-yl]-methanone;
 (8) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-chloro-1H-indol-2-yl]-methanone;
 (9) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-bromo-1H-indol-2-yl]-methanone;
 (10) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-iodo-1H-indol-2-yl]-methanone;
 (11) 2-[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazole-4-carbonyl]-1H-indole-5-carbonitrile;
 (12) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-bromo-5-fluoro-1H-indol-2-yl]-methanone;
 (13) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-ethynyl-1H-indol-2-yl]-methanone;
 (14) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(2-fluoro-phenyl)-1H-indol-2-yl]-methanone;
 (15) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(3-fluoro-phenyl)-1H-indol-2-yl]-methanone;
 (16) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(4-fluoro-phenyl)-1H-indol-2-yl]-methanone;
 (17) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(2-chloro-phenyl)-1H-indol-2-yl]-methanone;
 (18) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(3-chloro-phenyl)-1H-indol-2-yl]-methanone;
 (19) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(4-chloro-phenyl)-1H-indol-2-yl]-methanone;
 (20) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(2-trifluoromethyl-phenyl)-1H-indol-2-yl]-methanone;
 (21) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(3-trifluoromethyl-phenyl)-1H-indol-2-yl]-methanone;
 (22) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(4-trifluoromethyl-phenyl)-1H-indol-2-yl]-methanone;
 (23) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-bromo-1H-indol-2-yl]-methanone;
 (24) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(3-fluoro-pyridin-2-yl)-1H-indol-2-yl]-methanone;
 (25) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-methyl-1H-indol-2-yl]-methanone;
 (26) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(4,4-difluoro-piperidine-1-carbonyl)-1H-indol-2-yl]-methanone;
 (27) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(3,3-difluoro-piperidine-1-carbonyl)-1H-indol-2-yl]-methanone;
 (28) 2-[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazole-4-carbonyl]-1H-indole-5-carboxylic acid (2,2,2-trifluoro-ethyl)-amide;

558

- (29) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(5-trifluoromethyl-pyridin-2-yl)-1H-indol-2-yl]-methanone;
 (30) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(6-trifluoromethyl-pyridin-2-yl)-1H-indol-2-yl]-methanone;
 (31) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(5-chloro-pyridin-2-yl)-1H-indol-2-yl]-methanone;
 (32) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(4-methyl-pyridin-2-yl)-1H-indol-2-yl]-methanone;
 (33) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(3-chloro-4-fluoro-phenyl)-1H-indol-2-yl]-methanone;
 (34) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(3-trifluoromethyl-pyridin-2-yl)-1H-indol-2-yl]-methanone;
 (35) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(4-trifluoromethyl-pyridin-2-yl)-1H-indol-2-yl]-methanone;
 (36) [5-amino-1-(6-fluoro-2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1H-indol-2-yl]-methanone;
 (37) 2-[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazole-4-carbonyl]-1H-indole-6-carboxylic acid;
 (38) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-hydroxymethyl-1H-indol-2-yl]-methanone;
 (39) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-{2-(4-methyl-piperazin-1-yl)-ethoxy}-1H-indol-2-yl]-methanone;
 (40) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(3-methyl-oxetan-3-ylmethoxy)-1H-indol-2-yl]-methanone;
 (41) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(3-fluoro-piperidin-1-ylmethyl)-1H-indol-2-yl]-methanone;
 (42) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-{[(bis(2-methoxy-ethyl)amino)methyl]-1H-indol-2-yl}-methanone;
 (43) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-{(methyl-prop-2-ynyl-amino)methyl}-1H-indol-2-yl]-methanone;
 (44) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(3,3-difluoro-pyrrolidin-1-ylmethyl)-1H-indol-2-yl]-methanone;
 (45) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(2,5-dimethyl-pyrrolidin-1-ylmethyl)-1H-indol-2-yl]-methanone;
 (46) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(3,3-difluoro-piperidin-1-ylmethyl)-1H-indol-2-yl]-methanone;
 (47) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-((S)-3-methyl-morpholin-4-ylmethyl)-1H-indol-2-yl]-methanone;
 (48) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-bromo-1H-indol-2-yl]-methanone;
 (49) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-iodo-1H-indol-2-yl]-methanone;
 (50) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1H-pyrrolo[3,2-b]pyridin-2-yl]-methanone;
 (51) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-bromo-6-trifluoromethyl-1H-indol-2-yl]-methanone;
 (52) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-iodo-1H-indol-2-yl]-methanone;

559

- (53) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-methyl-1H-indol-2-yl]-methanone;
 (54) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-isopropyl-1H-indol-2-yl]-methanone;
 (55) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(2-fluoro-phenyl)-1H-indol-2-yl]-methanone; 5
 (56) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-benzyl-1H-indol-2-yl]-methanone;
 (57) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(2-trifluoromethyl-phenyl)-1H-indol-2-yl]-methanone; 10
 (58) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(3-fluorophenyl)-1H-indol-2-yl]-methanone; 15
 (59) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(3-trifluoromethyl-phenyl)-1H-indol-2-yl]-methanone;
 (60) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-ethynyl-1H-indol-2-yl]-methanone; 20
 (61) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5H-[1,3]dioxolo[4,5-f]indol-6-yl]-methanone;
 (62) [5-amino-1-(7-fluoro-2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1H-indol-2-yl]-methanone; 25
 (63) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(4-trifluoromethyl-phenyl)-1H-indol-2-yl]-methanone;
 (64) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-butoxy-1H-indol-2-yl]-methanone; 30
 (65) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(1-methyl-piperidin-4-yl)-1H-indol-2-yl]-methanone;
 (66) N-[2-[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazole-4-carbonyl]-1H-indol-6-yl]-methane-35 sulfonamide;
 (67) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(6-morpholin-4-yl-pyridin-3-yl)-1H-indol-2-yl]-methanone; 40
 (68) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-butyl-1H-indol-2-yl]-methanone;
 (69) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(1-methyl-1H-pyrazol-4-yl)-1H-indol-2-yl]-methanone; 45
 (70) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(5-methoxy-pyridin-3-yl)-1H-indol-2-yl]-methanone;
 (71) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(2-methoxy-pyridin-3-yl)-1H-indol-2-yl]-methanone; 50
 (72) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-cyclopropyl-1H-indol-2-yl]-methanone;
 (73) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(2-methoxy-phenyl)-1H-indol-2-yl]-methanone; 55
 (74) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-phenyl-1H-indol-2-yl]-methanone;
 (75) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(5-methanesulfonyl-pyridin-3-yl)-1H-indol-2-yl]-methanone; 60
 (76) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-isopropyl-1H-indol-2-yl]-methanone;
 (77) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-pyridin-2-yl-1H-indol-2-yl]-methanone; 65

560

- (78) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-cyclopropyl-1H-indol-2-yl]-methanone;
 (79) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-pyridazin-3-yl-1H-indol-2-yl]-methanone;
 (80) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-isopropoxy-1H-indol-2-yl]-methanone;
 (81) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(2-methoxy-ethoxy)-1H-indol-2-yl]-methanone;
 (82) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-cyclopropylmethoxy-1H-indol-2-yl]-methanone; 10
 (83) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[2,2-difluoro-5H-[1,3]dioxolo[4,5-f]indol-6-yl]-methanone;
 (84) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(3-chloro-pyridin-2-yl)-1H-indol-2-yl]-methanone;
 (85) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(5-fluoro-pyridin-2-yl)-1H-indol-2-yl]-methanone;
 (86) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(6-morpholin-4-yl-pyridazin-3-yl)-1H-indol-2-yl]-methanone; 20
 (87) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-chloro-6-cyclopropylmethoxy-1H-indol-2-yl]-methanone;
 (88) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(2,4-difluoro-phenyl)-1H-indol-2-yl]-methanone;
 (89) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-pyridazin-4-yl-1H-indol-2-yl]-methanone; 30
 (90) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[3-fluoro-1H-indol-2-yl]-methanone;
 (91) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(1-isopropyl-piperidin-4-yl)-6-trifluoromethyl-1H-indol-2-yl]-methanone;
 (92) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazole-4-carbonyl]-1H-indole-6-carbonitrile;
 (93) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(1,2,3,6-tetrahydro-pyridin-4-yl)-1H-indol-2-yl]-methanone; 40
 (94) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-piperidin-4-yl-1H-indol-2-yl]-methanone;
 (95) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-((R)-3-fluoro-pyrrolidin-1-ylmethyl)-1H-indol-2-yl]-methanone; 50
 (96) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-fluoro-5-piperidin-4-yl-1H-indol-2-yl]-methanone;
 (97) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-fluoro-5-(1-methyl-piperidin-4-yl)-1H-indol-2-yl]-methanone; 60
 (98) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(1-isopropyl-piperidin-4-yl)-1H-indol-2-yl]-methanone;
 (99) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-fluoro-5-(1-isopropyl-piperidin-4-yl)-1H-indol-2-yl]-methanone; 70
 (100) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-pyridin-3-yl-1H-indol-2-yl]-methanone; 80

561

- (101) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(6-morpholin-4-ylpyridin-3-yl)-1H-indol-2-yl]-methanone;
- (102) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-pyridin-3-yl-1H-indol-2-yl]-methanone; 5
- (103) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(6-piperazin-1-yl-pyridin-3-yl)-1H-indol-2-yl]-methanone;
- (104) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(6-hydroxy-pyridin-3-yl)-1H-indol-2-yl]-methanone; 10
- (105) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-fluoro-5-(4-methyl-piperazin-1-ylmethyl)-1H-indol-2-yl]-methanone; 15
- (106) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-fluoro-5-pyrrolidin-1-ylmethyl-1H-indol-2-yl]-methanone;
- (107) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(1-methyl-piperidin-4-yl)-1H-indol-2-yl]-methanone; 20
- (108) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(4-morpholin-4-yl-phenyl)-1H-indol-2-yl]-methanone; 25
- (109) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(3,4,5,6-tetrahydro-2H-[1,2']bipyridin-5-yl)-1H-indol-2-yl]-methanone;
- (110) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(6-piperazin-1-yl-pyridin-3-yl)-1H-indol-2-yl]-methanone; 30
- (111) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(6-methoxy-pyridin-3-yl)-1H-indol-2-yl]-methanone;
- (112) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-((S)-3-methyl-morpholin-4-ylmethyl)-1H-indol-2-yl]-methanone; 35
- (113) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(*R*)-3-fluoro-pyrrolidin-1-ylmethyl)-1H-indol-2-yl]-methanone;
- (114) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(2,5-dimethyl-pyrrolidin-1-ylmethyl)-1H-indol-2-yl]-methanone; 40
- (115) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(3-fluoro-piperidin-1-ylmethyl)-1H-indol-2-yl]-methanone;
- (116) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(3,3-difluoro-piperidin-1-ylmethyl)-1H-indol-2-yl]-methanone; 45
- (117) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-[2-(4-methyl-piperazin-1-yl)pyridin-4-yl]-1H-indol-2-yl]-methanone;
- (118) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-pyridin-4-yl-1H-indol-2-yl]-methanone; 50
- (119) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(4-fluoropiperidin-1-ylmethyl)-1H-indol-2-yl]-methanone;
- (120) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(4,4-difluoro-piperidin-1-ylmethyl)-1H-indol-2-yl]-methanone; 60
- (121) [5-amino-1-(2-difluoromethyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(1-methyl-piperidin-4-yl)-1H-indol-2-yl]-methanone;
- (122) [5-amino-1-(2-difluoromethyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1H-indol-2-yl]-methanone; 65

562

- (123) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(3,3-difluoro-pyrrolidin-1-ylmethyl)-1H-indol-2-yl]-methanone;
- (124) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(1-cyclopentyl-piperidin-4-yl)-1H-indol-2-yl]-methanone;
- (125) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(1-cyclohexyl-piperidin-4-yl)-1H-indol-2-yl]-methanone;
- (126) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-bromo-1H-pyrrol-2-yl]-methanone;
- (127) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1H-pyrrol-2-yl]-methanone;
- (128) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-phenyl-1H-pyrrol-2-yl]-methanone;
- (129) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-(3-chloro-phenyl)-1H-pyrrol-2-yl]-methanone;
- (130) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-(4-fluoro-phenyl)-1H-pyrrol-2-yl]-methanone;
- (131) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-(3-fluoro-phenyl)-1H-pyrrol-2-yl]-methanone;
- (132) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-morpholin-4-ylmethyl-1H-indol-2-yl]-methanone;
- (133) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-(2-morpholin-4-yl-ethylamino)-1H-indol-2-yl]-methanone;
- (134) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(4-methyl-piperazine-1-carbonyl)-1H-indol-2-yl]-methanone;
- (135) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(2-morpholin-4-yl-ethylamino)-1H-indol-2-yl]-methanone;
- (136) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(piperazine-1-carbonyl)-1H-indol-2-yl]-methanone;
- (137) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-(2-methoxy-ethylamino)-1H-indol-2-yl]-methanone;
- (138) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-(2-hydroxy-1-hydroxymethyl-ethylamino)-1H-indol-2-yl]-methanone;
- (139) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-(2-pyridin-4-yl-ethylamino)-1H-indol-2-yl]-methanone;
- (140) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(2-methoxy-ethylamino)-1H-indol-2-yl]-methanone;
- (141) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-morpholin-4-yl-1H-indol-2-yl]-methanone;
- (142) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-morpholin-4-yl-1H-indol-2-yl]-methanone;
- (143) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-morpholin-4-ylmethyl-1H-indol-2-yl]-methanone;
- (144) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-morpholin-4-ylmethyl-1H-indol-2-yl]-methanone;
- (145) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(morpholine-4-carbonyl)-1H-indol-2-yl]-methanone;

563

- (146) [5-amino-1-(2-isopropyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1H-indol-2-yl]-methanone;
 (147) [5-amino-1-(2-propyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1H-indol-2-yl]-methanone;
 (148) [5-amino-1-(1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1H-indol-2-yl]-methanone; 5
 (149) [5-amino-1-(2-trifluoromethyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1H-indol-2-yl]-methanone;
 (150) [5-amino-1-(2-ethyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1H-indol-2-yl]-methanone; 10
 (151) [5-amino-1-(2-benzyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1H-indol-2-yl]-methanone;
 (152) 1-[4-{2-[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazole-4-carbonyl]-1H-indol-5-ylmethyl}]-15
 piperazin-1-yl)-ethanone;
 (153) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(4-methanesulfonyl-piperazin-1-ylmethyl)-1H-indol-2-yl]-methanone;
 (154) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-piperazin-1-ylmethyl-1H-indol-2-yl]-methanone; 20
 (155) 1-[4-{2-[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazole-4-carbonyl]-1H-indol-6-ylmethyl}]-piperazin-1-yl)-ethanone;
 (156) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(4-methyl-piperazin-1-ylmethyl)-1H-indol-2-yl]-methanone; 25
 (157) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(4-methyl-piperazin-1-ylmethyl)-1H-indol-2-yl]-methanone; 30
 (158) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-pyrrolidin-1-ylmethyl-1H-indol-2-yl]-methanone;
 (159) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-fluoro-1H-indol-2-yl]-methanone; 35
 (160) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-fluoro-1H-indol-2-yl]-methanone;
 (161) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-fluoro-1H-indol-2-yl]-methanone; 40
 (162) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1H-pyrrolo[2,3-b]pyridin-2-yl]-methanone;
 (163) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-fluoro-6-morpholin-4-ylmethyl-1H-indol-2-yl]-methanone; 45
 (164) 2-[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazole-4-carbonyl]-1H-indole-5-carboxylic acid;
 (165) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-methoxy-1H-indol-2-yl]-methanone; 50
 (166) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4,6-dimethoxy-1H-indol-2-yl]-methanone;
 (167) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-methoxy-1H-indol-2-yl]-methanone; 55
 (168) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-methoxy-1H-indol-2-yl]-methanone;
 (169) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4,6-dimethyl-1H-indol-2-yl]-methanone; 60
 (170) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-tert-butyl-1H-indol-2-yl]-methanone;
 (171) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-isopropyl-1H-indol-2-yl]-methanone;
 (172) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-benzyloxy-1H-indol-2-yl]-methanone; 65

564

- (173) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-benzyloxy-1H-indol-2-yl]-methanone;
 (174) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5,6-dimethoxy-1H-indol-2-yl]-methanone;
 (175) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-tert-butyl-1H-indol-2-yl]-methanone;
 (176) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-fluoro-4-trifluoromethyl-1H-indol-2-yl]-methanone;
 (177) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-phenoxy-1H-indol-2-yl]-methanone;
 (178) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-methylsulfanyl-1H-indol-2-yl]-methanone;
 (179) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-tert-butyl-1H-indol-2-yl]-methanone;
 (180) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-methyl-1H-indol-2-yl]-methanone;
 (181) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-ethyl-1H-indol-2-yl]-methanone;
 (182) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-fluoro-6-trifluoromethyl-1H-indol-2-yl]-methanone;
 (183) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-fluoro-5-methoxy-1H-indol-2-yl]-methanone;
 (184) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-chloro-5-methoxy-1H-indol-2-yl]-methanone;
 (185) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-chloro-6-methoxy-1H-indol-2-yl]-methanone;
 (186) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-isopropoxy-1H-indol-2-yl]-methanone;
 (187) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-benzyloxy-1H-indol-2-yl]-methanone;
 (188) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-isopropoxy-1H-indol-2-yl]-methanone;
 (189) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[2,3-dihydro-6H-[1,4]dioxino[2,3-f]indol-7-yl]-methanone;
 (190) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4,6-di-tert-butyl-1H-indol-2-yl]-methanone;
 (191) 2-[5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazole-4-carbonyl]-1H-indole-4-carbonitrile;
 (192) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-imidazol-1-yl-1H-indol-2-yl]-methanone;
 (193) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-trifluoromethylsulfanyl-1H-indol-2-yl]-methanone;
 (194) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-methylsulfanyl-1H-indol-2-yl]-methanone;
 (195) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-methanesulfonyl-1H-indol-2-yl]-methanone;
 (196) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(4,4-difluoro-piperidin-1-ylmethyl)-1H-indol-2-yl]-methanone;

565

- (197) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(4-fluoro-piperidin-1-ylmethyl)-1H-indol-2-yl]-methanone;
- (198) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(oxetan-3-yloxy)-1H-indol-2-yl]-methanone; 5
- (199) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-hydroxy-1H-indol-2-yl]-methanone;
- (200) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-methanesulfonyl-1H-indol-2-yl]-methanone; 10
- (201) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4,5-dibromo-1H-pyrrol-2-yl]-methanone;
- (202) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4,5-diphenyl-1H-pyrrol-2-yl]-methanone; 15
- (203) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4,5-dipyridin-3-yl-1H-pyrrol-2-yl]-methanone;
- (204) [5-amino-1-(2-methyl-3H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-chloro-1H-indol-2-yl]-methanone;
- (205) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-chloro-1H-indol-2-yl]-methanone; 20
- (206) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1H-indol-3-yl]-methanone;
- (207) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1H-indol-6-yl]-methanone; 25
- (208) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-bromo-6-fluoro-1H-indol-2-yl]-methanone;
- (209) [5-amino-1-(2-ethyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-bromo-6-fluoro-1H-indol-2-yl]-methanone; 30
- (210) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-trifluoromethyl-1H-indol-2-yl]-methanone;
- (211) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-trifluoromethoxy-1H-indol-2-yl]-methanone; 35
- (212) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4,6-dichloro-1H-indol-2-yl]-methanone;
- (213) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-bromo-4-fluoro-1H-indol-2-yl]-methanone; 40
- (214) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-trifluoromethoxy-1H-indol-2-yl]-methanone;
- (215) [5-amino-1-(2-ethyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-trifluoromethoxy-1H-indol-2-yl]-methanone; 45
- (216) [5-amino-1-(2-ethyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-trifluoromethyl-1H-indol-2-yl]-methanone;
- (217) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5,6-dichloro-1H-indol-2-yl]-methanone; 50
- (218) [5-amino-1-(2-ethyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-bromo-5-fluoro-1H-indol-2-yl]-methanone;
- (219) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4,5-dichloro-1H-indol-2-yl]-methanone; 55
- (220) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4,6-difluoro-1H-indol-2-yl]-methanone;

566

- (221) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(3-chloro-pyridin-4-yl)-1H-indol-2-yl]-methanone;
- (222) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(6-methyl-pyridine-3-yl)-1H-indol-2-yl]-methanone;
- (223) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(5-fluoro-pyridin-3-yl)-1H-indol-2-yl]-methanone;
- (224) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(2-trifluoromethyl-pyridin-3-yl)-1H-indol-2-yl]-methanone;
- (225) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(5-chloro-2-methoxy-pyridin-3-yl)-1H-indol-2-yl]-methanone;
- (226) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(5-chloro-pyridin-3-yl)-1H-indol-2-yl]-methanone;
- (227) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-thiophen-3-yl-1H-indol-2-yl]-methanone;
- (228) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(4-chloropyridin-3-yl)-1H-indol-2-yl]-methanone;
- (229) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-thiophen-2-yl-1H-indol-2-yl]-methanone;
- (230) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(3-fluoro-pyridin-4-yl)-1H-indol-2-yl]-methanone;
- (231) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[6-(2-trifluoromethyl-pyridin-4-yl)-1H-indol-2-yl]-methanone;
- (232) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(3,3-difluoro-pyrrolidine-1-carbonyl)-1H-indol-2-yl]-methanone;
- (233) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(2,6-dimethyl-morpholine-4-carbonyl)-1H-indol-2-yl]-methanone;
- (234) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-[(1,4'bipiperidinyl-1'-carbonyl)-1H-indol-2-yl]-methanone;
- (235) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-[4-(2,2,2-trifluoro-ethyl)-piperazine-1-carbonyl]-1H-indol-2-yl]-methanone;
- (236) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-[4-(2-hydroxy-ethyl)-piperazine-1-carbonyl]-1H-indol-2-yl]-methanone;
- (237) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-(3,3,4,4-tetrafluoro-pyrrolidine-1-carbonyl)-1H-indol-2-yl]-methanone;
- (238) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-((R)-3-fluoro-pyrrolidine-1-carbonyl)-1H-indol-2-yl]-methanone;
- (239) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[5-((S)-3-fluoro-pyrrolidine-1-carbonyl)-1H-indol-2-yl]-methanone;
- (240) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-(4-methoxy-phenyl)-1H-pyrrol-2-yl]-methanone;
- (241) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-(3-methoxy-phenyl)-1H-pyrrol-2-yl]-methanone;
- (242) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4,5-bis-(3-fluoro-phenyl)-1H-pyrrol-2-yl]-methanone;

567

- (243) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4,5-bis-(4-methoxy-phenyl)-1H-pyrrol-2-yl]-methanone;
- (244) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-(2,4-difluoro-phenyl)-1H-pyrrol-2-yl]-methanone;
- (245) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-(4-trifluoromethoxy-phenyl)-1H-pyrrol-2-yl]-methanone;
- (246) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4,5-bis-(3-methoxy-phenyl)-1H-pyrrol-2-yl]-methanone;
- (247) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-benzofuran-2-yl-methanone;
- (248) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-benzo[b]thiophen-2-yl-methanone;
- (249) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-benzothiazol-2-yl-methanone;

5 10

568

- (250) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[4-fluoro-phenyl]-methanone;
 - (251) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[3-chloro-phenyl]-methanone;
 - (252) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-quinolin-3-yl-methanone;
 - (253) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-quinolin-7-yl-methanone; and
 - (254) [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-quinolin-6-yl-methanone,
- or a pharmaceutically acceptable salt thereof.
- 6.** The method of claim **5**, wherein the compound is [5-amino-1-(2-methyl-1H-benzimidazol-5-yl)-1H-pyrazol-4-yl]-[1H-indol-2-yl]-methanone or a pharmaceutically acceptable salt thereof.

* * * * *

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 9,102,692 B2
APPLICATION NO. : 14/297790
DATED : August 11, 2015
INVENTOR(S) : Naoki Taka et al.

Page 1 of 2


It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Specification


Column 28, Line 46: Delete “C₃₋₇ cycloalkylC₁₋₃ alkyl,” and insert

-- C₃₋₇ cycloalkyl C₁₋₃ alkyl, --, therefor.

Column 51, Line 32 (approx.): Delete “substituent” and insert -- substituent --, therefor.



Column 78, Line 40 (approx.): Delete “Pro” and



insert -- --, therefor.

Column 81, Line 49 (approx.): Delete “10-1” and insert -- 10-I --, therefor.

Column 81, Line 53: Delete “10-1” and insert -- 10-I --, therefor.

Signed and Sealed this
Second Day of February, 2016

Michelle K. Lee
Director of the United States Patent and Trademark Office

CERTIFICATE OF CORRECTION (continued)
U.S. Pat. No. 9,102,692 B2

Page 2 of 2

Specification

Column 82, Lines 42-43 (approx.): Delete “methanone 1-methanesulfonate” and insert
-- methanone-1-methanesulfonate --, therefor.

Column 83, Lines 7-8: Delete “methanone 1-methanesulfonate” and insert
-- methanone-1-methanesulfonate --, therefor.

Column 470, Lines 4-5: Delete “benzynesulfonamide” and insert -- benzenesulfonamide --, therefor.

Column 528, Line 49: Delete “dihydrochlide” and insert -- dihydrochloride --, therefor.

Column 546, Line 49 (approx.): Under “m/z” in Table 34, delete “458” and insert -- 459 --, therefor.

Column 549, Line 46: Delete “anti-phophotyrosine” and insert -- anti-phosphotyrosine --, therefor.

Column 549, Line 59: Delete “anti-phophotyrosine” and insert -- anti-phosphotyrosine --, therefor.

Column 550, Line 42 (approx.): Delete “anti-phophotyrosine” and insert
-- anti-phosphotyrosine --, therefor.

Claims

Column 561, Line 28, Claim 5 (approx.): Delete “din-5-yl)” and insert -- din-5'-yl) --, therefor.